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 Abstract 
This thesis describes the design, preparation and study of synthetic peptides 
dimerised with polypyridine linkers. Their conformational transitions, which result 
from the coordination of metal-ions, are proposed to trigger the orientation of their 
peptide substituents, thus allowing for the design of conjugates incorporating artificial 
regulation sites. To test this hypothesis, different polypyridine linkers were designed, 
such that the substituents orientation is either dependent or independent of the 
polypyridine conformations.  The approach developed herein includes a detailed 
conformational study of low-molecular weight species (model conjugates) and the 
preparation of conjugates mimicking a natural protein, for which dimerisation is 
essential for its bioactivity. For the latter conjugates, which are based on the GCN4 
transcription factor, the influence of metal addition on sequence-specific DNA 
binding was tested using a combination of spectroscopic and electrophoretic 
techniques. The results presented herein indicate that metal addition can influence the 
interaction of the polypyridine peptide conjugates with DNA, depending on the 
peptides and linkers design, and that this can be partly attributed to a conformational 
transition of the polypyridine linker. As an extension, the potential of these conjugates 
as sequence-specific DNA sensors or nuclease agents was partly investigated. 
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List of Abbreviations 
All abbreviations found in the text are summarised below. Non-common or specific 
abbreviations are displayed in bold. Proteinogenic amino-acids, variables and their respective 
units are not included in this list, however, they were abbreviated according to IUPAC norms. 
Compounds are sometimes referred to by their chemical formula.  
(GCN4bd2)2 = dimer designed in this 
work 
[G28TS]2Fe = conjugate complex designed 
by Schepartz et al. 
A = adenine 
Aib = α-methylalnine 
aPP = avian Pancreatic polypeptide 
Bcl = B-cell leukemia 
bd = basic domain 
bHLH = basic helix-loop-helix proteins 
bHLHZ = basic helix-loop-helix zipper 
proteins 
bipy = 2,2’-bipyridine 
bipy(GCN4bd1)2 = conjugate designed in 
this work 
bipy(GCN4bd2)2 = conjugate designed in 
this work 
bipy-Br2 = 5,5’-dimethyl-2,2’-bipyridine 
bipy-GS2 = 5,5’-bis(methyl-S-
glutathionyl)-2,2’-bipyridine 
bp = base-pair 
bz = basic-zipper 
bZIP = basic zipper proteins 
C = cytosine 
CD = circular dichroism 
COSY = correlation spectroscopy 
cys2bipy = 5,5’-bis(methyl-S-cysteinyl)-
2,2’-bipyridine 
cys2pyr = 2,6-bis(methyl-S-
cysteinyl)pyridine 
cys2terpy = 6,6’’-bis(methyl-S-cysteinyl)-
2,2’:6’,2’’-terpyridine 
DIEA = diisopropylethylamine 
DMF = dimethylformamide 
DMSO-d6 = deuterated dimethylsulfoxide 
DNA = deoxyribonucleic acid 
DQF-COSY = double quantum filtered 
correlation spectroscopy  
DTT = dithiotreithiol 
EDTA = ethylenediaminetetraacetic acid 
EI = electronic impact 
EMSA = electrophoretic mobility shift 
assay 
eq. = equivalent 
ESI = electrospray ionisation 
EtOH = ethanol 
exc. = excitation 
Fmoc- = fluorenylmethyloxycarbonyl- 
group 
FT = Fourier transform 
G = guanine 
G28 = peptide designed by Schepartz et al. 
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G28-bipy-G28 = conjugate designed by 
Schepartz et al. 
G28
SS
 = peptide dimer designed by 
Schepartz et al. 
GCN4bd1 = peptide designed in this work  
GCN4bd2 = peptide designed in this work 
GCN4br5
SS
 = conjugate designed by Kim 
et al. 
GCN4br6
SS
 = conjugate designed by Kim 
et al. 
GSH = glutathione 
HBTU = (O-(benzotriazol-1-yl)-
NN,N’,N’-tetramethyluronium) 
hexafluorophosphate 
HOHAHA = homonuclear Hartman Hahn 
HOMO = highest occupied molecular 
orbital 
HPLC = high-performance liquid 
chromatography 
HRES = high-resolution electrospray 
HTH = helix-turn-helix proteins 
Ida = iminodiacetic acid 
LUMO = lowest unoccupied molecular 
orbital 
MALDI = matrice-assisted laser desorption 
MBHA = 4-methylbenzhydrylamine 
MCS = multiple cloning site 
Me2bipy = 5,5’dimethyl-2,2’-bipyridine 
Me2pyr = 2,6-dimethylpyridine 
Me2terpy = 6,6’’-dimethyl-2,2’:6’,2’’-
terpyridine 
MeOH = methanol 
MLCT = metal-to-ligand charge transfer 
MPA = 3-mercaptopropionic acid 
MS = mass spectrometry 
NMR = nuclear magnetic resonance 
NOE = nuclear Overhauser effect 
NOESY = nuclear Overhauser effect 
spectroscopy 
pD = deuterium ion potential 
pdb = protein data bank 
pH = hydrogen ion potential 
phen = 1,10-phenanthroline 
phen’ = 5-(amidoglutaryl)-1,10-
phenanthroline 
phen-IA = N-iodoacetyl-5-amino-1,10-
phenanthroline 
phin = 9,10-phenanthrenequinone diimine 
pKa = acid dissociation constant potential  
pyr(GCN4bd1)2 = conjugate designed in 
this work 
pyr-Br2 = 2,6-bis(bromomethyl)pyridine 
pyr-GS2 = 2,6-bis(methyl-S-
glutathionyl)pyridine 
RNA = ribonucleic acid 
ROS = reactive oxygen species 
RP-HPLC = reversed-phase high 
performance liquid chromatography 
Rt = retention time 
SPPS = solid-phase peptide synthesis 
T = thymine 
TBE = Tris-borate-EDTA buffer 
TCEP = tris(2-carboxyethyl)phosphine 
TCNQ = 7,7’,8,8’-
tetracyanoquinodimethane 
terpy = 2,2:6’,2’’-terpyridine 
terpy(GCN4bd1) = impurity observed in 
this work 
terpy(GCN4bd1)2 = conjugate designed in 
this work 
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terpy(GCN4bd2)2 = conjugate designed in 
this work 
terpy-Br2 = 6,6’’-bis(bromomethyl)- 
2,2’:6’,2’’-terpyridine 
terpy-GS2 = 6,6’’-bis(methyl-S-
glutathionyl)-2,2’:6’,2’’-terpyridine 
TFA = trifluoroacetic acid 
TG = Tris:Glycine buffer 
THF = tetrahydrofuran 
TOF = time-of-flight 
TPPI = time proportional phase 
incrementation 
Tris = 2-amino-2-hydroxymethyl-propane-
1,3-diol 
UV = ultraviolet 
vis = visible 
Ac- = acetyl- group 
Pbf = 2,2,4,6,7-
pentamethyldihydrobenzofuran-5-
sulfonyl- group 
Trt = trityl- group 
wt = wild type
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1.1 – Introduction 
Artificial regulation of biomolecular activity is a biochemist’s fantasy. Biomolecular 
recognition or activity of protein is often dictated by their three-dimensional arrangement. In 
order to reach their functional folded states, proteins may use templating proteins (ca 
chaperones [1]), and the structure may vary with the conditions (pH,[2] temperature [3,4]) or 
following contact with other entities (proteins,[5] metal ions,[6] light,[7] or DNA (see section 
1.3)). Artificial stabilisation, or introduction of stimuli-responsive elements able to control the 
structure, therefore represents an opportunity to control the activity of biomolecules. The first 
part of this chapter introduces the research done so far towards the stabilisation of α-helices, 
which are particularly relevant to biomolecular recognition and to this work, and other 
secondary and super-secondary structures are briefly introduced with a focus on model 
mimics which include polypyridine units. Next, some larger assemblies (tertiary and 
quaternary structures), based on stabilised secondary structure elements will be introduced. 
DNA is often regarded as a genetic encyclopedia owning the code for protein 
transcription, in which case transcription factor proteins serve to act as a set of bookmarks, 
marking off the reading frame for the messenger RNA. Considering their ability to bind DNA 
at specific sites, transcription factors are the last links in large signalling chains.[8] Indeed, 
they often function as multi-protein complexes and their activity, which consists of either 
promoting or inhibiting transcription, is often regulated by co-factors such as amino-acids,[9] 
metal ions,[10] hormones,[11] and/or by post-translational modification such as 
phosphorylation.[12] There exists a wide variety of quaternary and tertiary protein structures 
which mainly relies on α-helices to bind DNA at distinct recognition sites. As has previously 
been done in many reviews,[13,14] we chose to categorise transcription factors based on a 
similar structural motif within their DNA binding domains, rather than the more general 
structural classification of the proteins database (SCOP).[15] 
Chapter 1 – Literature review 
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The second part of this chapter will introduce some natural examples of transcription 
factors, for which DNA binding is well-understood, and then focus on their miniaturisation 
and the preparation of peptide based artificial mimics with enhanced or regulated binding to 
specific DNA sequences (often based on α-helix stabilisation or turn insertion). It is worth 
mentioning that this can alternatively be achieved by some natural non-proteinogenic 
molecules[16] and their synthetic derivatives.[17] Some aromatic molecules, including 
polypyridine complexes, can efficiently intercalate into DNA, but their selectivity is usually 
based on shape rather than sequence.[18-20] This concept will be briefly introduced in 
Chapter 6, but will not be expanded on here. 
The third part describes the coordination chemistry of 2,2’-bipyridine (bipy) and 
2,2’:6’,2’’-terpyridine (terpy). A large range of complexes containing bipy/terpy and 
transition metals have been previously reported and studied. However here the discussion will 
be limited to the dication from the second half of the 1st row of transition metals: Fe(II), 
Co(II), Ni(II), Cu(II) and Zn(II). The stoichiometry and structure of the resulting M(II)Ln 
complexes in aqueous solution are particularly relevant to this work and will be described. 
 
1.2 – Stabilisation of peptide secondary structure in natural peptides and their 
derivatives  
1.2.1 – α-Helices 
The α-helix is the most common peptide secondary structure for which the backbone 
organisation is stabilised by a repeated hydrogen bonding pattern between carboxyl oxygens 
from residues (i), with the amino hydrogens of others located 4 residues later in the sequence 
(i+4), affording a helix with 3.6 residues per turn (often noted as a heptad repeat of two α-
helical turns) (see Figure 1.1A).[21] The propensity of a given peptide chain to form an α-
helix depends largely on the primary structure, which corresponds to the nature of the residue 
Chapter 1 – Literature review 
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side-chains.[22] Among the 23 proteinogenic L-amino-acids, two have been shown to 
disfavour α-helix formation due to their great (glycine) or too restricted flexibility (proline). 
In contrast, conformational restrictions in non-proteinogenic dialkylated residues such as α-
methylalanine (Aib) are compatible with α-helices, and therefore promote their formation.[23] 
α-Helices are among the most common peptide recognition motif, and are for example, 
involved in the apoptosis activation by B-cell leukemia peptides (Bcl),[24] or the inhibition of 
p53 transcription activation by the MDM2 oncoprotein.[25] However, short peptide fragments 
(less than 20 residues) rarely form α-helices,[26,27] and chemist have explored strategies to 
stabilise them.[28] The most straightforward approach for stabilisation of α-helices involves 
constraining residues at position i → i+3, i → i+4 , or i → i+7 in similar orientations, thus 
stabilising the 3.6 residues per turn helical motif (see Figure 1.1B). This can be achieved 
through diverse types of interaction/linkage, the presentation of which will start from those 
with the lowest bond energy. 
 
Figure 1.1 – Two representations of the α-helix and associated residue positions: (A) three-
dimensional representation of a polyalanine α-helix and the i → i+4 hydrogen bond pattern 
(green = carbon; blue = nitrogen; red = oxygen; hydrogen atoms are omitted for clarity); (B) 
top-down view of a helical wheel diagram displaying the proximity of i, i+3, i+4 and i+7 
residues (backbone is displayed in black, circles represents α-carbons) and the possibility of 
helix stabilisation by enhancing i → i+3, i → i+4, or i → i+7 interactions between side-
chains, is indicated. 
 
Based on the observation that a salt bridge can stabilise a short RNase A peptide mimic 
in a partial α-helical conformation,[27,29] Baldwin and co-workers first introduced the 
Chapter 1 – Literature review 
 
12 
 
glutamic acid-lysine salt pair at position i → i+4  of a 17-mer polyalanine synthetic peptide 
(see Figure 1.2A). Interestingly, the resulting model peptide displayed higher helical content 
at neutral pH (~97% folded in the presence of 0.01 M NaCl and 274 K, calculation based on 
reference 30), associated with glutamic acid and lysine side chains being charged, compared 
to data recorded at lower or higher pH (~87 % in both cases).[31] By extension, similar α-
helical stabilisation was obtained upon shortening,[32] or elongation of the propanoate side-
chain.[33] Intermolecular electrostatic interaction with spermine [34,35] or guanidinium [36] 
is also an efficient strategy to stabilise the α-helix conformation of aspartate and glutamate 
bearing peptides (see Figure 1.2B). 
 
Figure 1.2 – Two examples of α-helix stabilisation at neutral pH by electrostatic interactions: 
(A) top-down view helical wheel diagram representing helices stabilised by intramolecular i 
→ i+4 interactions between glutamate and lysine side-chains, designed by Baldwin et al.; (B) 
side view of a α-helix bearing glutamate residues at positions i and i+4, stabilised by 
intermolecular interactions with spermine as shown by Sasaki et al (side-chains of other 
residues are omitted for clarity). 
 
A variant of this strategy involves α-helix stabilisation with coordination bonds, by 
careful positioning of residues able to bind metal ions. Ghadiri and co-workers introduced a 
cysteine and/or histidines at positions i → i+4 of synthetic peptides and reported an increases 
in helicity upon addition of Cd(II), Zn(II), Cu(II), Ni(II),[37] or cis-Ru
III
(NH3)4.[38] In 
contrast, the helicity decreased upon addition of Pd(II) or Pt(II), which were proposed to 
either adopt a different geometry or to coordinate different heteroatoms.[37] The strategy was 
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expanded to other residues bearing side-chains with metal coordination ability, such as 
methionines [39] or unnatural residues with iminodiacetic acids (Ida),[40] or pyridyl side-
chains,[41] allowing the binding of a larger variety of metal ions (see Figure 1.3A). Increased 
helical stability as a result of metal addition was used to enhance biomolecular recognition of 
short peptides, such as antimicrobial peptide mimics [42,43], but also in the construction of 
haemic models [44,45], or higher order structures (see section 1.2.3). Conversely, Futaki and 
co-workers have shown that metal-complexation could lead to destabilisation of a α-helical 
motif when Ida residues are introduced at i → i+2 positions (see Figure 1.3B).[46] Synthetic 
peptides have also been stabilised in helical conformations using electrostatic dipole-dipole 
(host-guest systems),[47,48] cation-π,[49, 50] and π-π interactions.[51]  
 
Figure 1.3 – (A) Helix stabilisation by transition metal ions (MII) upon coordination to side-
chains of histidines at positions i and i+4 of a de novo peptide designed by Ghadiri et al. (B) 
Fe(II) (red sphere) coordination to iminodiacetic acid side-chains of Ida residues (highlighted 
in orange) at positions i and i+2 results in α-helix destabilisation (relative to Futaki et al. 
studies). 
 
α-Helices were also stabilised using artificial covalent linkages between side-chains 
with increasing biological lifetimes: from cystine,[52,53] to lactam (cyclic amide) [54,55] and 
hydrocarbon linkage (use of non-natural residues).[56,57] Aside from the atoms directly 
involved, the size and the chirality of the linkage are important features to afford efficient 
stabilisation, and numerous cross-linkers have been evaluated, including unmetallated 5,5’-
dimethyl-3,3’-bipyridine.[58] A recent report by Greenbaum and co-workers describes a 
cross-linker screening method for determining the most suitable one (molecule and position), 
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to achieve stabilisation of a decapeptide derived from the minimal active domain of 
calpastatin into the bioactive two-turn long α-helix motif (see Figure 1.4).[59] Unlike 
uncrosslinked analogues, the most helical crosslinked decapeptide studied was shown to 
efficiently inhibit calpain-1 protease activity, while remaining selective with respect to other 
enzymes from the papain protease family. 
 
Figure 1.4 – Cartoon representation of the decapeptide prepared by Greenbaum et al. derived 
from the calpastatin fragment alone (A) before and (B) after cross-linking with 1,3-bis-
(bromomethyl)benzene, and (C) when bound to the surface of the calpain protein. (D) Crystal 
structure of the calapastatin protein bound to calpain; adapted with permission from reference 
59. Copyright 2012 American Chemical Society. 
 
Schepartz and co-workers developed a general residue grafting strategy (see section 
1.3.3) that involves identifying the nature and relative positionning of residues essential to a 
specific function, such as those from the Bak protein which is involved in apoptosis activation 
upon binding to Bcl-xL, and to incorporate them onto a well folded scaffold such as the avian 
pancreatic polypeptide (aPP), which consists of an α-helix stabilised by hydrophobic 
interactions with a polyproline motif. The PPBH3-1 mutant that incorporates 6 key residues 
from the Bak72-87 peptide onto the aPP scaffold, displays a higher affinity for Bcl-2 and Bcl-xL 
than the Bak72-87 peptide alone.[60,61] The same strategy was also applied, among others, to 
the design of helical peptides capable of inhibiting p53-hDM2 interactions.[62]  
The α-helical content of short peptides can be controlled by side-chain crosslinking 
through stimuli-responsive units. Woolley and co-workers introduced an azobenzene 
photoswitchable unit as a side-chain crosslink at positions i → i+4 [63] and i → i+7 [64] of 
two similar 17 residues synthetic peptides, through alkylation of cysteine residues. Irradiation 
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at 380 nm resulted in 38% and 36% increase of α-helicity (respectively), consistent with the 
hypothesis that the irradiated cis- azobenzene linker better suits the i → i+4 and i → i+7 gap 
of an α-helix than the larger trans- azobenzene (see Figure 1.5A). Conversely, a similar 
peptide conjugate with an azobenzene cross-linker in a larger i → i+11 positioning, displays 
the opposite behaviour. Irradiation at 370 nm leads to a 40 % decrease of the helical content 
(see Figure 1.5B).[63] 
 
Figure 1.5 – Representation of the impact of cis-trans- isomerisation of the azobenzene cross-
linker on the peptide secondary structure when introduced at either position i → i+4 (A), or i 
→ i+11 (B)., adapted with permission from reference 63. Copyright Elsevier 2002. 
 
As an extension, Allemann and co-workers introduced the azobenzene cross-linker (i → 
i+4, i → i+7 and i → i+11) within synthetic helical peptides based on Bak72-87 and Bid91-111 
recognition domains, which are both able to inhibit the anti-apoptotic activity of Bcl-xL upon 
binding to its hydrophobic groove. Bcl-xL binding constant measurements for the azobenzene 
modified peptides, indicate that irradiation has a higher impact on Bcl-xL binding in cases 
where the dark-adapted trans- conformation are associated with the less helical peptide (ca i 
→ i+4 and i → i+7).[65] 
α-Helix stabilisation can also be achieved using other strategies, notably those involving 
extra linkages,[66,67] templating,[68-70] or modifications of the peptide backbone.[71] 
However, this introduction is limited to those strategies which have also found applications in 
controlling biomolecular recognition events. 
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1.2.2 – Other secondary structures 
Despite their simplicity, the low structural constraint, and the poor residual analogies 
within the motif, turns are nonetheless considered a secondary structure element where the 
peptide chain is folding back on itself due to an inter-residue hydrogen bond between a 
carboxyl oxygen and amine nitrogen.[72] They are classified based on the number of 
residues; i → i ± 1 hydrogen bond forms a δ-turn, i → i ± 2 a γ-turn, i → i ± 3 a β-turn, i → i 
± 4 a α-turn, and i → i ± 5 a π-turn. In contrast, an unstructured 6-16 residue peptide segment 
is defined as a loop.[73] Both loops and turns (especially β-turns) have been extensively 
mimicked, or stabilised,[74,75] but only the work involving polypyridine peptide conjugates 
will be herein presented. It is worth mentioning that careful introduction of turn mimics are 
often the decisive factor in stabilisation of supersecondary or tertiary structures.[76,77]  
Imperiali and co-workers prepared a series of 2,2’-bipyridine (bipy) bearing protected 
amine and carboxylic acid substituents, suitable for SPPS (solid-phase peptide synthesis [78]) 
and subsequent insertion into the backbone of artificial peptides.[79-82] They subsequently 
prepared a undecapeptide incorporating two bipy units, separated by four glycine residues 
bearing a cyanoanthracene fluorophore and a quencher on the N- and C-terminus, 
respectively. Upon addition of Zn(II), the fluorescence of the peptide conjugate decreased, 
consistent with the turn-like structure hypothesised, in which the quencher and the 
fluorophore are positioned in close enough proximity for efficient electron transfer (see 
Figure 1.6A).[82] McCafferty and co-workers isolated enantiomers from an octahedral 
Ru
II
(bipy)3 peptide conjugate derivative, composed of a peptide turn incorporating two bipy 
units within its backbone which are involved in Ru(II) coordination together with an 
additional unsubstituted bipy.[83] López and co-workers prepared a similar conjugate in 
which the two bipy units are separated by a 5-amino-3-oxapentanoic acid-glycine-proline-
glycine motif. Interestingly, upon changing the chirality of one residue, that is L-proline for D-
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proline, the chirality of the metal center was also altered.[84]  Constable and co-workers 
linked 4’-(4-carboxyphenyl)-2,2’,6’,2’’-terpyridine units at both the N- and C-terminus of a 
undecapeptide, bearing a glycine-proline β-turn inducer motif. Following reaction with a 
Fe(II) salt, the isolated conjugate was assigned to the expected cyclometallopeptide 
2,2’,6’,2’’-terpyridine (terpy) conjugate (see Figure 1.6B).[85]  
 
Figure 1.6 – Scheme illustrating the model peptides incorporating two bipy (A) or terpy 
units (B), stabilised in a turn conformation upon metal coordination and formation of ML2
2+
 
cyclometallopeptide complexes where L is a polypyridine unit, based on references 82, 85, 
86. 
 
 
Hairpins are long devices used to hold a person’s hair in place, whereas in biochemistry 
it describes a peptide supersecondary structure with a similar geometry, ca both ends of a turn 
are connected to flanking domains with defined secondary structures.[87] Certain artificial α-
hairpin (an α-helix-turn-α-helix motif), such as HN1, displayed interesting hydrolase 
activity,[88] which is dependent on the spatial proximity between the two helices.[89,90] 
Upon replacement of the turn motif by a stillbene linker, its activity can be regulated by light 
irradiation (see Figure 1.7).[91] 
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Figure 1.7 – Schemes illustrating (A) the trans-to-cis conformational transition of the 
stillbene linker upon light-irradiation, and (B) its impact on the supersecondary structure of 
the HN1 artificial hydrolase and especially the distance separating two imidazole side-chains, 
which are essential for the enzyme activity; adapted with permission from reference 91. 
Copyright 2009 Wiley-VCH. 
 
 
In the β-strand, the second most encountered secondary structure motif, the peptide 
backbone forms linear strands in which the side-chain is positioned alternatively up and 
down. It is stabilised by inter-strand hydrogen bonding between carboxy and amino groups 
either in an anti-parallel or parallel β-sheet arrangement.[92] Despite some β-branched 
(valine, isoleucine) and aromatic residues (threonine, tyrosine, tryptophan, phenylalanine) 
being encountered more frequently in β-sheets,[93] the role of the side-chains in stabilising 
the arrangement can only be explained with respect to the tertiary structure.[94] Mimicking 
large β-sheet assemblies usually leads to the formation of insoluble aggregates in water.[95] 
For this reason, more soluble and shorter assemblies such as β-hairpins [96] (β-strand-turn-β-
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strand motif [97]), are more attractive targets for chemist seeking to stabilise the β-sheet 
structural motif.[98] Herein, two strategies used to stabilise β-hairpins will be briefly 
introduced, with a focus on polypyridine(s) containing systems. 
Promoting inter-strand side-chain interactions is one strategy by which to stabilise β-
hairpins. This has been achieved through coordination bonds,[99] hydrophobic 
interactions,[100] or covalent bonding.[101] Imperiali and co-workers designed several 
artificial peptides with primary structures which have a different propensity to form β-
hairpins, but all of which incorporate two bipy bearing residues. The peptides with a high 
propensity to form β-hairpins, promoted formation of 1M:2bipy complexes (where M 
corresponds to either Zn(II) or Co(II)) consistent with the closer proximity of the two bipy 
groups. In contrast, their counterparts with non β-hairpins promoting sequences, formed 
mainly 1M:1bipy complexes (see Figure 1.8A).[81] A more common strategy for β-hairpin 
stabilisation, involves replacing the turn with an artificial mimic to ensure efficient and stable 
reversal of the peptide chain, whilst ensuring the strands remain hydrogen-bonded.[102] Kelly 
and co-workers designed metal-dependent β-hairpin switches taking advantage of the trans- 
to cis- conformational transition experienced by a bipy unit upon Cu(II) complexation.[103] 
Addition of Cu(II) was shown to promote β-strand formation for some of the peptide 
conjugates designed, likely due to strand realignment triggered by the conformation of the 
bipy turn (see Figure 1.8B). To the best of our knowledge, this constitutes the first and so far 
only application of conformational switches based on bipy within peptide scaffolds (other 
applications are introduced in Chapter 3). Alternative switches triggered by light were also 
studied in a similar context.[104-107] 
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Figure 1.8 – (A) Scheme illustrating the cooperativity between secondary structure formation 
and Co(II) coordination in the β-hairpin prepared by Imperiali et al. for which each strand 
contains one bipy side-chain.[81] (B) Scheme illustrating the stabilisation of β-hairpin motif 
by Cu(II) complexation resulting in the conformational transition of a bipy unit inserted in the 
peptide backbone as a metal-dependent turn mimic.[103] 
 
 
 
1.2.3 – Examples of higher order structure 
In nature, certain α-helical peptides such as keratin are able to associate resulting in the 
formation of a left-handed supercoil of helices.[108] These structures, termed coiled coils, are 
stabilised by multiple inter- and intramolecular interactions (including i → i+4).[109] The 
motif for the simplest example (a homodimeric parallel coiled coil) consists of two helical 
peptides based on the heptad repeat approach (peptide fragment of seven residues with 
positions denoted a-b-c-d-e-f-g and a’-b’-c’-d’-e’-f’-g’). In a polar environment such as water, 
helix association is favoured if all residues with hydrophobic side-chains are located on the 
same face of the helix (e.g. a, a’, d and d sites) thus triggering aggregation and formation of a 
hydrophobic core (see Figure 1.9A). Moreover, the formation of salt bridges in (e.g. in e, g 
and e’, g’) provides electrostatic interactions and further stabilisation. For sufficient stability a 
coiled coil requires several repeats of the heptad motif (3-4),[110] and a slight left-handed 
distortion to allow for correct side-chain alignment (due to the non-integer numbers of 
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residues per α-helical turn: 3.6). Such peptides bearing hydrophobic and hydrophilic faces are 
termed amphipathic and when most of the hydrophobic residues are leucines, the dimer is 
called a leucine zipper.[109] Natural coiled coils assembled into either parallel or antiparallel 
orientations, are important di- or trimerisation domains (see section 1.3.1). However, de novo 
(from “first principles”) design allows for the preparation of coiled coils with a right handed 
coiling,[111] assembling directly seven helices,[112] or more if involved in coiled coil 
packages.[113] 
 
Figure 1.9 – (A) Schematic top-down view of a helical wheel diagram depicting a dimeric 
parallel coiled coil motif where the hydrophobic side-chains of the residues in positions a, a’, 
d and d’ form the hydrophobic core (red), and the salt bridges formed between positions e, g 
and e’, g’ (orange). (B) Model of a three stranded coiled coil stabilised by formation of a 
Ru(bipy)3
2+
 complex, where each bipy unit is covalently bound to a helix N-termini. 
Reproduced with permission from reference 114. Copyright 1998 American Chemical 
Society. 
 
 
As for α-helices, designed coiled coils may undergo structural transitions as a function 
of pH,[115,116] temperature,[3] or upon metal addition.[117-119] Interestingly, Liberman 
and co-workers prepared a 15-mer amphipatic peptide with a bipy coupled to the N-terminus 
which displayed poor helicity (35%). However, addition of 0.33 equivalents of an Fe(II) salt 
resulted in an important increase in the helicity (85%), associated with formation of a 
[Fe
II
(bipy)3] complex and a three-α-helix coiled coil.[120] Case, McLendon and co-workers 
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prepared similar coiled coils based on peptide-bipy conjugates (see Figure 1.9B) and studied 
their stability upon changing the metal ion,[121] or the primary structure.[114] They also 
designed Ru(II) analogues, which they used to measure either electron transfer towards an 
additional coordination sites located on the exterior of the coiled coil,[122] or the binding of 
host molecules to an internal cavity.[123] 
Conversely, when introduced into a hydrophobic environment, such as a lipid bilayer, 
amphipathic helices can self-assemble and form hydrophilic pores across membranes, thus 
promoting the permeation and migration of molecules, hence their cytotoxic and antimicrobial 
activities.[124,125] It is possible to take advantage of pores created by artificial pH-dependent 
peptides such as GALA, that form amphipathic helices at pH lower than 6, to facilitate 
membrane crossing of drugs, in a virus-like fashion (see Figure 1.10A).[126,127] Based on 
these features, Futaki and co-workers prepared a metal-gated ion channel by introducing a 64 
residue peptide into a liposome (artificial membrane).[128] The peptide was composed of 
three domains: (1) a domain derived from alamethicin (a channel forming peptide [129]), (2) a 
flexible and unstructured tetraglycine linker, and (3) an extramembrane segment mimicking 
the leucine zipper domain of Fos,[130] but bearing two non-conserved Ida residues in position 
i → i+2. Fe(III) coordination at Ida destabilises α-helices in the extramembrane segments 
thus forming random coils, resulting in a significant increase in the pore size and the ion flux 
(see Figure 1.10B). A variant in which the extramembrane fragments resemble the C-terminal 
domain of calmodulin, was also prepared, and displayed increased ion-flux upon addition of 
Ca(II) associated with an increase of the hydrophic surface of the calmodulin segments.[131] 
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Figure 1.10 – Schemes illustrating (A) the pore formation by GALA peptides within a lipid 
bilayer membrane at acidic pH, for which two plausible mechanisms are displayed and (B) the 
metal-gated ion-channel, for which Fe(III) complexation results in destabilisation of the 
extramembrane helical segments (red) favoring ion flux through the pore (yellow); 
reproduced with permissions from references 126 and 128, respectively. Copyright 2004 
Elsevier and 2006 American Chemical Society. 
 
 
Finally, peptide conjugates have been assembled through coordination bonds to form 
even larger artificial peptide constructs. Tezcan and co-workers have prepared a variety of 
peptide building blocks based on cytochrome b562 peptides by functionalisation of side-chains 
with unnatural metal chelation motifs, such as 1,10-phenanthroline (phen), or terpy.[132] 
Following coordination studies, the building blocks were assembled by addition of metal ions 
leading to a large variety of periodic protein nanoarrays (see Figure 1.11).[133-135]  
 
 
Figure 1.11 – (A) Schemes representing the peptide self-assembly in triangles upon Ni(II) 
coordination to the phen side-chain, (B) the crystal structure of the resulting assymetric unit 
and cartoon side-on and top-down view, and (C) the lattice packing in top-down and side-on 
views; reproduced with permission from reference 134. Copyright 2009 American Chemical 
Society. 
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Similarly, Chmielewski and co-workers prepared artificial peptides based on collagen 
which incorporate multiple bipy moieties, and which can self-assemble upon metal ion 
coordination, promoting the formation of fibrous materials (see Figure 1.12).[136,137] 
 
Figure 1.12 – (A) Cryo-TEM image of self-assembled collagen inspired peptides 
functionalised with bipy-Fe(II) prior to, or (B) after addition of EDTA; reproduced with 
permission from reference 137. Copyright 2013 American Chemical Society. 
 
 
 
1.3 – DNA binding peptides and artificial derivatives  
1.3.1 – Common structural motifs of DNA bound proteins 
Deoxyribonucleic acid (DNA) is a polymeric chain of nucleotide motifs, which each 
include a phosphate, a sugar and one out of four possible aromatic nucleobases. In the most 
common structure adopted, B-DNA, the phosphosugar backbone forms an antiparallel right-
handed double helix. This is stabilised by inter-strand interactions between complementary 
nucleobases (see Figure 1.13A) which occupy a plane perpendicular to the double helix 
orientation while pointing towards its interior.[138] The exterior of the DNA presents gaps 
with alternated 12 and 22 Å width, termed the major and minor grooves, respectively, which 
are separated by the negatively charged backbone (see Figure 1.13B). 
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Figure 1.13 – (A) Scheme illustrating the chemical structure of the four different nucleotides, 
held together by specific hydrogen bonds (A-T: adenine-thymine, C-G: cytosine-guanine). (B) 
Structure of the B-DNA right-handed double helix with the major and minor grooves 
identified; adapted from reference 139. 
 
Within the group of DNA binding proteins, the most encountered structural motif is the 
helix-turn-helix (HTH),[14] which forms a triangular-like bundle including at least three α-
helices. The amphipathic recognition helix (α3) sits in the major groove of DNA and its side-
chains are involved either in specific hydrogen bonds or electrostatic interactions with 
nucleobases and phosphates, or in hydrophobic interactions with the other helices (α1 and α2), 
which contribute to pack and position α3, orthogonal to them, within the major groove (see 
Figure 1.14A). The sharp turn connecting α2 and α3 consists of a highly conserved primary 
structure within HTH proteins, hence the name of this superclass of proteins.[140-142] 
Among the simplest example, the homeodomain fold consists of one tri-helical HTH domain 
plus a N-terminal arm which binds to the DNA minor groove and makes specific hydrogen 
bonds with bases.[143] Homeodomain proteins all bear asparagine residues at position 51, 
thus enhancing recognition of AT-rich sequences, however there exist a large variety of 
mutants which bind different recognition sites (see Figure 1.14B).[14,144] For example, most 
homeodomain proteins bear a glutamine residue at position 50 and recognise 5’-TAATTG-3’ 
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and 5’-TAATTA-3’consensus sequences, whereas a variant including a lysine at this position 
(Q50K) will bind DNA with a higher affinity at the 5’-TAATCC-3’ site.[145] 
 
Figure 1.14 – (A) Cartoon of the engrailed homeodomain of Drosophyla complexed with 
DNA bearing the recognition site 5’-TAATTA-3’: secondary structure element contacting 
DNA is displayed in red, supporting helices in purple, and the sharp turn domain in light blue; 
based on pdb code 1HDD [143]. (B) Sequence logo representation of the average DNA 
recognition site and key peptide residues of 82 homeodomain proteins classified in specificity 
groups; reproduced with permission from reference 144. Copyright 2008 Elsevier. 
 
In the basic domain (bd) superclass, transcription factor proteins bind DNA as dimers 
(either as homodimers or heterodimers). Each monomer includes an unfolded bd containing 
basic residues, which folds into an α-helix in the presence of the DNA recognition site, thus 
fitting in its major groove and forming direct and specific contacts with the backbone and 
exposed nucleobases.[146-150] This is attached to a dimerisation domain located towards the 
C-terminus, which may consist, depending on the subclass, of a leucine zipper (basic leucine 
zipper = bZIP),[109] a four helix bundle (basic helix-loop-helix = bHLH),[151] or a 
combination of the two (basic helix-loop-helix zipper = bHLHZ).[152] Therefore, the overall 
structure of a DNA bound bZIP transcription factor, such as the general control non repressed 
4 (GCN4) basic zipper (bz) homodimer, is a helical fork made of uninterrupted α-helices (see 
Figure 1.15A), whereas these are interrupted by loops of variable length and sequence in 
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bHLH transcription factors, such as MyoD (see Figure 1.15B). In all cases, the selection of 
the dimerisation partner triggered by the dimerisation domains, is essential for DNA binding 
and bioactivity. For example, Fos proteins are unable to form homodimers, whereas Jun 
homodimers bind the 5’-TGAGTCAT-3’ DNA recognition site (AP1), although the affinity is 
low compared to that of the Fos/Jun heterodimer.[153] All heterodimers composed of proteins 
from the Jun, Fos, ATF and JDP families, are termed AP-1 transcription factors. In a given 
cell, a large number of combinations are possible, each characterised by distinct DNA affinity 
and transactivation, thus allowing for the regulation of a large variety of processes such as 
proliferation, differentiation, apoptosis and transformation.[154]  
 
Figure 1.15 – Cartoon of (A) the GCN4bz homodimer from Saccharomyces cerevisiae 
complexed with the 5’-TGACTCAT-3’ DNA recognition site, and (B) the MyoD homodimer 
from Mus Musculus complexed with the 5’-CAGCTG-3’ DNA site; bd are displayed in red, 
dimerisation domain in blue; based on pdb code 1YSA [155] and 1MDY [156]. 
 
 
The zinc finger is another important structural motif, in which Zn(II) co-factors are 
required to form the folded structure allowing for DNA binding, which can include β-
strands.[157-160] Transcription factors of this family often function as multidomain proteins 
and regulate various functions such as DNA recognition, RNA packaging and apoptosis.[160] 
A distinction can be made with metal transcription sensors (e.g. NikR or MerR), for which 
DNA binding is also regulated by metal ions, however these regulate the transcription of 
proteins involved in the recruitment, transport, sequestration and regulation of the metal-ion 
sensed.[10,161,162] It is worth mentioning that more families of DNA binding proteins have 
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been identified, and that some transcription factors contact DNA through β-strands rather than 
helical motifs.[13] 
 
1.3.2 – Artificial dimerisation and stitchery of basic domains  
 The DNA binding of basic transcription factors rely on the short bd sequence to form 
direct contact with the DNA target site, whereas slightly longer domains which allow for 
dimerisation and thus tight DNA binding, were assumed non-essential for the specificity. 
McKnight and co-workers interchanged the bd and zipper domains between transcription 
factors of the same sub-family, namely GCN4 and C\EPB, and tested their DNA selectivity. 
A mutant peptide bearing a GCN4bd and a C\EPB zipper domain was shown to selectively 
bind the GCN4 recognition site, whereas the reverse peptide (ca C\EPBbd and GCN4 zipper 
domain) selectively binds to C\EPB recognition site.[163] They concluded that DNA 
selectivity was not affected by the nature of the dimerisation domain and that the two distinct 
functions (dimerisation and selective DNA binding) are carried out independently by the 
zipper and bd. 
Based on these results, Kim and co-workers prepared a short peptide dimer, consisting 
of a fully conserved bd and a glycine-glycine-cysteine C-terminal sequence, which forms a 
disulfide bond upon oxidation, thus allowing for covalent dimerisation with a flexible turn-
like motif. The 2×34 residue synthetic dimer binds specifically to GCN4 recognition sites at 
low temperature with an affinity similar to that of the wild type protein and related bz 
peptides (see Figure 1.16).[164] This strategy was further exploited to estimate the minimum 
number of residues from GCN4bd required for sequence specific DNA binding, using a 
variety of disulfide bridged artificial dimers of varying length.[165] 
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Figure 1.16 – Sequence alignment for (A) b-ZIP C-terminal domain of wild type GCN4 
(residue 222-284), and (B) artificial peptide prepared by Kim et al. with 31 residues 
conserved from GCN4 wild type, including the whole bd (green), two glycines residues 
(underlined) for flexibility, and a cysteine residue (blue) for dimerisation; top lane indicates 
the relative heptad assignment based on the leucine zipper repeat; adapted from reference 164. 
 
 
Related studies have shown that GCN4bd dimerisation with other types of covalent 
bonds,[166] coordination bonds,[167-169] or electrostatic dipole-dipole (host-guest) 
interactions,[170,171] also result in DNA binding properties similar to that of wild-type 
GCN4. Schepartz and co-workers prepared a series of polypyridine GCN4bd conjugates, 
which self-assemble upon Fe(II) binding thus increasing their specific DNA affinity, and 
found that bulky dimerisation domains promoted binding to a DNA sequence where the two 
half-sites of the native target DNA sequence are separated by an additional central base-pair 
(bp) (see Chapter 5).[167-169] Morii and co-workers investigated the impact of 
conformational restriction in the dimerisation domain on DNA binding. For this, they 
prepared two artificial dimers, where GCN4bd moieties are linked through either a (9R, 10R)-
trans-9,10-dihydrophenanthrene-9,10-diol linker, or its (9S, 10S) enantiomer. Both conjugates 
display similar DNA affinity regardless of the linker orientation.[172] In contrast, a peptide 
mimicking the MyoDbd and dimerised through the (9R, 10R)-trans-9,10-
dihydrophenanthrene-9,10-diol linker displayed higher specificity toward the MyoD 
recognition site (E-box) than the analogue bearing the (9S, 10S) enantiomer (Figure 
1.17).[173] This is consistent with the crystal structure of the DNA-bound MyoD published 
the following year, displaying a right-handed orientation of the two bd with respect to the 
DNA helix.[156] 
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Figure 1.17 – (A) Cartoon illustrating the distance and orientation between two β-atoms of 
residue 123 of MyoD (equivalent to sulfur from cysteine and linker insertion position for the 
peptide prepared by Morii et al.) in the MyoD homodimer complexed with E-box; single 
letters indicate the DNA sequence of the recognition site; based on pdb code 1MDY [156] (B) 
Chemical structure of trans-9,10-dihydrophenanthrene-9,10-diol-based enantiomers used to 
dimerise the peptide based on the bd of MyoD; based on reference 173. 
 
 
Mascareñas and co-workers inserted an azobenzene dimerisation motif which mimics a 
turn between GCN4bd peptides. Binding of the resulting conjugate to the DNA recognition 
site was significantly enhanced upon light-irradiation, associated with conversion to the cis- 
azobenzene motif which pre-organises the peptide moieties for DNA binding (see Chapter 
4).[174] Chimeric fusion proteins incorporating artificial GCN4bd dimers and either 
cytochrome b562,[175,176] or photoactive yellow protein from Halorhodospira halophila 
[177] were shown to display redox and light-dependent DNA binding, respectively. As 
previously mentioned, metal transcription sensor proteins are involved in metal level 
regulation or detoxification, where the metal ions of interest are the trigger for sensing and 
DNA binding. Recent efforts have been directed towards the redesign of such proteins, ca 
design of a MerR (Hg sensor) analogue with a single chain coiled coil,[178] or redesign of the 
NikR tetramerisation allosteric site to favour [UO2]
2+
 rather than Ni(II) sensing.[179] 
Goddart III and co-workers came up with the concept of bd stitchery, which involves 
studying the consequence of displacing the artificial linker towards the N-terminus of the bd. 
A peptide based on Junbd and dimerised with a disulfide at the N-terminus specifically 
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recognised a palindromic sequence, similar to the wild-type Jun DNA recognition site (5’-
ATGACTCAT-3’), but with inverted half-sites and an additional central bp (5’-
TCATCGATGA-3’).[180] Moreover, an artificial Jun homodimer with a C- to N- terminus 
disulphide linker was shown to bind selectively to the non-palindromic sequence 5’-
ATGACGATGA-3’.[181] It was concluded that upon artificial dimerisation, each bd peptide 
recognises one DNA half-site (4 bp), the relative positionning of which are altered when 
peptides are dimerised through the N- rather than the C-terminus. The two central bp were 
required for high peptide-DNA affinity, and probably account for geometrical constraints. By 
analogy, a GCN4bz dimer with reversed sequences (C→N) recognise a DNA sequence, 
which half-site are inverted compared to the natural protein binding site (see Figure 
1.18).[182] The concept of protein stitchery was further extended to the design of artificial 
peptides composed of three bd able to recognise longer DNA sequences.[183]  
 
Figure 1.18 – Application of bd stitchery to GCN4bz peptides. Cartoon representation of (A) 
wild type GCN4bz binding to the CRE recognition sequence (red), or (B) GCN4bz with 
inverted sequence (N→C) binding with wild type affinity to a DNA palindromic site with 
reverted half-sites compared to CRE; bd are displayed in yellow, leucine zipper in green; 
reproduced with permission from reference 182. Copyright 2001 American Chemical Society. 
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Recently, Mascareñas and co-workers combined protein stitchery principles with the 
strategies previously developed for GCN4bd dimerisation, to design the first artificial dimer 
for which sequence preference is stimuli-responsive. For this, a GCN4bd peptide bearing a 
thiol group at the N-terminus and a side-chain functionalised with terpy towards the C-
terminus was prepared. The monomer was unable to bind any of the DNA duplexes tested. 
However, the dimer prepared by formation of a disulfide N-terminal linkage, binds 
preferentially to the inverted GCN4 recognition site rather than the wild-type site, whereas, 
under reducing conditions, addition of Ni(II) resulted in preferential binding to the wild-type 
GCN4 DNA recognition site.[184]  
 
1.3.3 – Stabilisation and destabilisation of helices to enhance or regulate DNA binding 
As discussed in section 1.3.1, the bd is a short unfolded peptide fragment which folds 
into a α-helix conformation in the presence of its DNA target site. Therefore, it was proposed 
that stabilising a bd in a helical conformation would increase its affinity for the DNA target 
site. The residue grafting strategy developed by Schepartz and co-workers (see section 1.2.1) 
was applied to the design of short DNA binding peptides. In the first example, 13 residues 
which were identified as essential for the sequence selective DNA binding of GCN4, were 
grafted onto the exterior of the well-folded aPP scaffold while retaining their functional 
spacing, affording a 39 residue sequence (different combinations were attempted as three 
positions generated conflict with aPP key residues) (see Figure 1.19). One of these (PPBR2
SR
) 
displayed affinity for the GCN4bd monomer recognition motif (5’-ATGAC-3’) similar to the 
GCN4 dimers affinity for the full recognition sites (either 5’-ATGACGTCAT-3’ or 
5’ATGACTCAT-3’).[185] The DNA affinity was further increased 3-fold upon substitution 
of the three C-terminal residues of the peptide for alanine, as in PPBR4
SR
. Moreover, peptide 
design was further refined using combinatorial mutations (screening and amplification of 
peptides or proteins based on a selection criteria, in this case binding to the GCN4 half-
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recognition sequence) on four residues of PPBR2
SR
 located in the polyproline II domain. The 
most potent candidate, named p007, displays affinity for 5’-ATGAC-3’ sites, 100 and 20,000 
times higher than PPBR4
SR
 and the GCN4bd monomer, respectively.[186] 
 
Figure 1.19 – Scheme illustrating the grafting of residues from GCN4bd, essential for DNA 
binding (purple), onto the well-folded aPP scaffold (key residues from the helix and 
polyproline domains are highlighted in blue and yellow respectively) affording PPBR 
peptides; reproduced from reference 185. Copyright 1999 American Chemical Society. 
 
 
 
Schepartz and co-workers further applied the residue grafting strategy to the design of 
short DNA binding peptides based on the engrailed homeodomain. Thirteen residues from 
helix 3 of Q50K engrailed mutant were grafted onto the aPP scaffold, affording the 34 residue 
peptide PPeng4, which displayed an affinity for the QRE recognition site (5’-TAATCC-3’) 
100 times higher than a peptide retaining the whole sequence of the helix 3. Despite not 
retaining the three residues from the N-terminal domain of Q50K responsible for 
discrimination of the 2 bp within the QRE site (underlined residues), PPeng4 binds with 32 
times greater affinity to the QRE rather than the MRE site (5’-CCATCC-3’).[187] Other 
noteworthy studies based on homodimer scaffolds used alanine,[188,189] or α-methylalanine 
enriched peptides [190] to increase α-helix stability and DNA binding. 
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The regulation of α-helical content using azobenzene photoswitches by Woolley and co-
workers (see section 1.2.1) was equally applied to the design of peptides with light-responsive 
DNA binding or transcription activity. The helicity of a peptide mimicking the GCN4 zipper 
domain cross-linked at positions f (i → i+7) was first shown to increase upon light-irradiation 
at 370 nm, which promotes conversion of azobenzene linkers towards the cis- 
conformation.[191] Dimerisation and sequence specific DNA binding of this peptide coupled 
to the GCN4bd, were subsequently shown to increase slightly upon light-irradiation at 370 
nm.[192] Further development involved the preparation of azobenzene cross-linked peptides 
mimicking the Fos zipper domain, which were shown to inhibit DNA binding of the Junbz 
homodimer and, more importantly, of the bioactive Fosbz/Junbz heterodimer (AP-1) upon 
light-irradiation at 365 nm (associated with conversion to the cis-azobenzene cross-linker and 
an increased helical content). This strategy relies on formation of heterodimers that lack one 
bd, hence their reduced DNA affinity (see Figure 1.20), and has been shown to efficiently 
reduce AP-1 transcription activity in vivo.[193] 
 
Figure 1.20 – Cartoon illustrating the indirect photoregulation of the Fosbz/Junbz 
heterodimer DNA binding by the repressor XAFosW which incorporates an azobenzene 
cross-linker (i → i+7) within a peptide mimicking the Fos leucine zipper but lacking a bd. 
Upon irradiation at 365 nm, the azobenzene converts to the cis- conformation associated with 
an α-helical conformation of XAFosW, which subsequently competes with Fosbz for 
dimerisation, thus inhibiting DNA binding; reproduced with permission from reference 193. 
Copyright 2010 Wiley-VCH. 
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The azobenzene cross-linker also allowed for sequence specific DNA binding 
photoregulation, when inserted in the bd of the MyoD homodimers,[194] or the Q50K 
engrailed homeodomain mutant.[195] Inouye and co-workers also investigated the 
photoregulated interactions between DNA and peptides mimicking different homeodomain 
proteins and bearing diarylethene linkers.[196] Futaki and co-workers equally applied the 
metal-induced helix destabilisation strategy (see section 1.2.1 and 1.2.3) to GCN4bz mimics, 
by introducing pairs of Ida residues at positions c, e or/and g, b (i → i+2) of the GCN4 
leucine zipper. They found that two Ida pairs were required to significantly alter the DNA 
binding ability of the GCN4bz peptides, and that Co(II) was a more potent effector than either 
Ni(II) or Mn(II).[46,197] Efforts have also been directed towards the design of short DNA 
binding peptides incorporating engineered β-hairpin motifs targeting single-stranded rather 
than double-stranded DNA.[198] 
1.4 – The coordination chemistry of polypyridines  
1.4.1 – Bipy metal complexes 
In the crystal structure of the [Fe(bipy)3]
2+
 complex, a low spin d
6
 (spin siglet) Fe(II) 
occupies a distorted octahedral coordination site made of six bipy nitrogens,[199] and the six 
electrons on its d-orbitals are in a low spin arrangement (spin singlet).[200,201] The racemic 
mixtures of ∆ and Λ enantiomers (see Figure 1.21) can be resolved by use of a chiral 
counteranion, thus modifying the optical rotation of the mixture (Pfeiffer effect [202]),[203] 
or alternatively enriched using an adsorbing clay.[204] Upon degradation of [Fe(bipy)3]
2+ 
(either pyrolysis or light-induced), few [Fe(bipy)2L2]
2+
 complexes have been obtained, and 
the Fe(II) environments were best described as distorted octahedrons where bipy units are 
positioned cis- to each other.[201] Even though [Fe(bipy)2L2]
2+
 complexes usually adopt high 
spin-states (quintet state), the heteroleptic complex [Fe(bipy)2(NCS)2]
2+ 
was shown to 
undergo a spin crossover upon raising the temperature.[201,205,206] I was unable to find a 
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crystal structure of [Fe(bipy)2(NCS)2]
2+
 (except for a retracted paper [207]) or any other 
mixed-ligand Fe(II)-bipy complexes, however, it must be noted that the crystal structure of 
the analogous 1,10-phenanthroline (phen) containing complex, [Fe(phen)2(NCS)2]
2+
, has 
been reported.[208] Fe(II) and bipy form almost exclusively the [Fe(bipy)3]
2+
 complex in 
aqueous solution, except when a huge excess of Fe(II) is present, consistent with the high 
logβ3 value and K3 > K1, K2 (see Table 1.1).[209] In the absence of a chiral counteranion, the 
two enantiomers, ∆ and Λ, have been shown to interconvert in solution.[210] 
 
 
Table 1.1 – Summary of the formation stability constant for M(II):nbipy metal complexes 
with M = Fe, Co, Ni, Cu, Zn (measurements performed at 298 K and ionic strength μ = 0.1 
M) and involving either a partition procedure,[209] potentiometric measurements (either 
pH,[211-215] or pAg-metric [213,214]), or redox measurements.[216] 
Metal ion log K1 log K2 log K3 Ref. 
Fe(II) 4.3 3.7 9.5 [209] 
Co(II) 
5.7 5.6 4.8 [209] 
6.1 5.4 4.6 [211] 
Ni(II) 
7.1 6.8 6.2 [209] 
7.1 6.9 6.5 [211] 
Cu(II) 
8.1 5.5 3.4 [209] 
8.0 5.6 3.5 [211] 
9.1
c
 5.9
c
 3.3
c
 [212] 
8.5
a
 5.6
 a
 3.5
 a
 [213] 
8.2
b
 5.5
b
 3.3
b
 [216] 
Zn(II) 
5.2 4.4 3.8 [209] 
5.3 4.5 3.8 [211] 
5.1 4.8 3.2 [213] 
5.2 4.5 3.7 [214] 
5.3
c,d
 4.6
 c,d
 4.0
 c,d
 [215] 
Ionic strength was set to either 0
a
, 0.3
b
, 1.0
c
 M; 
d
 measurement performed at 303.3 K. 
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Figure 1.21 – Representation of the (A) Λ-, and (B) ∆ enantiomers for the homoleptic 
[M(bipy)3]
2+
 complex. 
 
Similar to [Fe(bipy)3]
2+
, the Co(II) cation adopts a distorted octahedral coordination 
geometry in [Co(bipy)3]
2+
, but is d
7
 high spin (spin quartet),[217] and thus [Co(bipy)3]
2+
 
readily oxidises to [Co(bipy)3]
3+
.[218,219] As for the Fe(II) analogue, the two [Co(bipy)3]
2+ 
enantiomers can be separated based on the Pfeiffer effect.[203] Heteroleptic Co(II)-bipy 
complexes have been prepared either in solution,[220,221] or by decomposition of 
[Co(bipy)3]
2+
 which requires less energy than for their Fe(II) analogues.[222,223] Structural 
investigation of [Co(bipy)2]
2+
 indicates that Co(II) also adopts a distorted octahedral site and 
a high spin arrangement.[221,224-226] In solution, [Co(bipy)3]
2+
 dissociation occurs faster 
than its Fe(II) analogue (see Table 1.2),[227] and complexes with different stoichiometry are 
more likely to be formed.[209] 
Table 1.2 – Summary of the kinetic formation (kn) and dissociation constant (k-n) for 
1M(II):nbipy metal complexes with M = Fe, Co, Ni, Cu, Zn (calculated at 298 K). Species 
were quantified using spectroscopic measurement.[210,227-229] ML2 complexes could not be 
isolated. 
Metal ion log k1 log k3 log k-1 log k-3 Ref. 
Fe(II) 
5.2 / / / [228] 
5.2 5.1 / / [229] 
/ / / -3.1
a
 [210] 
Co(II) 
4.8 / / / [228] 
/ / / 1.55
b
 [227] 
Ni(II) 3.2 3.3 -4.3 -2.5 [228] 
Cu(II) > 7.0 / -0.7 / [228] 
Zn(II) 6.0 / 1.2 / [228] 
Ionic strength was set to 1.5
a
, or 2
b
 M. 
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As for the Co(II) and Fe(II) analogues, the Ni(II) cation adopts a distorded octahedral 
environment in [Ni(bipy)3]
2+
, which is associated with the high spin d
8
 (triplet state).[230] 
The [Ni(bipy)3]
2+
 cation can be resolved as salts which rapidly racemise in aqueous 
solution.[203,231] The structure of the complexes [Ni(bipy)2Cl2], [Ni(bipy)2(NCO)2] and 
[Ni(bipy)2(H2O)2]
2+
 have been solved, displaying Ni(II) in a distorted octahedral environment 
with bipy units in a cis- positions.[232-234] Despite being more thermodynamically stable 
than [Fe(bipy)3]
2+
, the complex [Ni(bipy)3]
2+
 is more labile in solution, probably due to the 
fact that K3 < K1, K2 (see Table 1.1).[209] Thus, complexes with Ni(II)-bipy stoichiometry of 
1:1 or 1:2 can also be formed in solution, even though there exist few solid-state structural 
studies.[231] The kinetics of bipy association and dissociation of the Ni(II)-bipy complexes 
are much slower compared to other metals of interest, making it a suitable choice for studying 
substitution mechanism (see Table 1.2).[228] 
The homoleptic complex [Cu(bipy)3]
2+
 can be prepared from the specific Cu(II) salts 
and excess bipy, affording a mixture of ∆ and Λ enantiomers in dynamic exchange and could 
not be isolated.[231] Structural study of the complex [Cu(bipy)3]
2+
 indicates that Cu(II) 
occupies a distorded octahedral environment, due to Jahn-Teller distortions.[235] Upon 
reduction, [Cu(bipy)3]
2+
 loses a coordinated bipy affording the [Cu(bipy)2]
+
 cation, which 
readily oxidises in the presence of dioxygen, forming [Cu(bipy)2]
2+
.[231] In [Cu(bipy)2]
+
 
complexes, Cu(I) occupies a tetrahedral environment,[231,236] however, there exists different 
geometry for the [Cu(bipy)2]
2+
 cation.[237] 
 
The Cu(II) coordination sphere in the structures of the [Cu(bipy)2(BF4)][BF4] and 
[Cu(bipy)2(ClO4)][ClO4] complexes are best described as elongated octahedron in which the 
two bipy units occupy trans- positions (the base of the xy plane of an octahedron elongated in 
z) and the bridging counteranions occupy the elongated axial (z) positions (see Figure 
1.22A).[238] In contrast, both counteranions are weakly associated in [Cu(bipy)2][PF6]2, 
resulting in a tetracoordinated Cu(II) cation (see Figure 1.22B).[239] The tetragonal 
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arrangement is favoured due to the steric strain associated with the presence of two bipy units 
in the same plane (H6 and H6’ protons, see Figure 2).[240] In the crystal structure of the 
cations [Cu(bipy)2Cl]
+
 and [Cu(bipy)2(H2O)]
2+
, Cu(II) adopt trigonal bipyramid coordination 
geometries (more or less distorted depending on the counter-anion), in which the two bipy are 
in a cis- arrangement (see Figure 1.22C).[241-244] Finally, the crystal structure of the 
complex [Cu(bipy)2(ONO2)]
+
, where (NO3)
-
 acts as a weakly coordinating dichelate, displays 
Cu(II) in a distorted octahedral environment (either 4+2 or 4+1+1 depending on the 
counteranion), where bipy units are in cis- arrangements (see Figure 1.22D).[245] To the best 
of my knowledge, no crystal structure of cis-[Cu(bipy)2L2]
2+
 complexes, where Cu(II) 
occupies a distorted octahedron and L represents a monodentate ligand, has been reported.  
Cu(II) complexes bearing a single bipy unit have been isolated in the solid state. 
Examples are complexes of the type [Cu(bipy)Cl2]n involving one and two μ-bridging chloro- 
ligand(s), in which Cu(II) adopt either a distorted square based pyramid,[246,247] or an 
octahedral geometry, respectively.[248] 
 
Figure 1.22 – Representation of the four main Cu(II) coordination geometries in the 
[Cu
II
(bipy)2]
2+
 cation where the bipy ligands occupy either trans- (A,B) or cis- positions 
(C,D): (A) octahedron [Cu(bipy)2(ClO4)][ClO4]; (B) tetragonal [Cu(bipy)2][PF6]2; (C) 
trigonal bipyramid [Cu(bipy)2Cl)]
+
; (D) distorted octahedron [Cu(bipy)2(NO3)]
+
 (4+2).[237] 
 
It is important to note that complexes from the Cu(II)-bipy systems are labile and 
undergo disproportion in solution, especially if alternative ligands are present.[249] As an 
example, some catalytic properties of [Cu(bipy)3]
2+
 complexes might partly arise from the 
presence of [Cu(bipy)2]
2+
, in which it disproportionates in anaerobic solutions.[231] The 
kinetics of association for the Cu(II)-bipy systems are too fast to be accurately measured, 
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however the complex dissociation is slow (see Table 1.2). Cu(II)-bipy complexes hydrolyse 
in aqueous solution, and the distribution of mono-, bis- and/or tris- chelated species is highly 
pH-dependent.[250-253] Based on absorbance measurements and continuous variation plots, 
Pfaulm et al. hypothesised that complexes with stoichiometry 2bipy:1Cu(II) predominate at 
pH 4, whereas 1bipy:1Cu(II) complexes are present at pH 12, following complex 
hydrolysis.[250] Cu(II)-bipy binding constants estimated in aqueous solution indicate that K1 
> K2 > K3 (see Table 1.1), thus favouring the formation of complexes with 1:1 and 1:2 
stoichiometry. Studies conducted in EtOH/water mixtures resulted in slightly lower binding 
constants,[213] associated with different EPR parameters.[252,254] Species distribution 
diagrams of the bipy-Cu(II) system as a function of pH have been reported (see Figure 
1.23).[212,252] When bipy and Cu(II) are present in equimolar amounts, complexes with the 
general formula [Cu(bipy)(OH)]n
n+
 predominate at physiological pH (see Figure 
1.23A).[212,252] The complex [Cu(bipy)(OH)]2
2+
, which prevails at concentrations close to 
or greater than 50 mM, can be differentiated from its analogue [Cu(bipy)(OH)]
+
, which 
constitutes the main species at lower concentrations, based on EPR or electronic absorption 
measurements (additional symmetry centre is present in the n = 2 species).[252] Recently, the 
complex [Cu(bipy)(OH)2], which predominates at slightly higher pH, was shown to be an 
efficient water-oxidation catalyst.[255] 
 
Figure 1.23 – Representation of Cu(II) species distribution diagram as a function of pH for 
the Cu(II)-bipy system (either (A) 1:1 or (B) 1:2 ratio) and [Cu] = 5 mmol. Reproduced with 
permission from reference 252. Copyright 2000 Elsevier. 
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In contrast, when bipy is present in excess, complexes of the type [Cu(bipy)2]
2+
 and 
[Cu(bipy)3]
2+
 represent the main species at physiological pH (see Figure 1.23B). 
[Cu(bipy)2]
2+
 species were successively proposed to adopt trans- (square planar Cu(II) 
coordination with tetragonal distortion) or cis- arrangement of bipy ligands (associated with 
square-based pyramid or trigonal bipyramid coordination).[256,257] EPR measurements and 
spectra simulation indicate that the trans- species is present in aqueous conditions, whereas 
the addition of ethanol (40 %) promotes formation of the cis- species (square pyramid).[252] 
Cu(II) can alternatively form ternary complexes with bipy and other ligands in solution, 
the most relevant to this thesis are amino-acids and derivatives thereof.[258,259] In the solid 
state, the crystal structure of various Cu(II)-bipy-glycine and Cu(II)-bipy-glycolic acid 
complexes have been solved, in which Cu(II) adopts either distorted octahedrons,[260,261] or 
distorded square based pyramids (both mono- [262-264] or dinuclear complexes [265]). 
Solution studies of various Cu(II)-bipy-dipeptide ternary systems by Sigel and co-workers, 
indicates that the presence of bipy tends to promote the coordination of the deprotonated 
amide groups over side-chain substituents. [266-268] In all cases, the species distribution 
diagram indicates the presence of multiple species at physiological pH, where complexes with 
stoichiometry 1:1:1 (Cu(II)-bipy-dipeptide) generally prevail for equimolar solutions.[267] 
 
Similarly to the Cu(II)-bipy system, complexes with 1Zn(II):1bipy, 1Zn(II):2bipy, or 
1Zn(II):3bipy stoichiometry have been studied.[269,270] The Zn(II) cation adopts an 
octahedral environment in the crystal structure of the homoleptic complex 
[Zn(bipy)3]
2+
.[231,270]. In the crystal structures of complexes [Zn(bipy)2(ONO)]
+
 and 
[Zn(bipy)2(OCO(Me))]
+
, the Zn(II) cation adopts a distorted hexa-coordinated environment 
(pseudo-octahedral) where the two bipy are in a cis-arrangement (see Figure 1.22D).[271-
273] However, no crystal structure of [Zn(bipy)2]
2+
 cation where bipy are in trans- 
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arrangement have to the best of my knowledge been reported. In the complexes 
[Zn(bipy)Cl2]
2+
 and [Zn(bipy)Br2]
2+
, the Zn(II) cations adopt slightly distorted tetrahedral 
environments.[270] 
Analysis of bipy-Zn(II) complexes formed in solution are complicated by the lack of 
spectroscopic feature for the Zn(II) cation, which is EPR silent and does not display any d-d 
transitions in the UV absorbance spectra. Based on the measured stability constant which 
indicates K1 > K2 > K3 (see Table 1.1), it is reasonable to assume that all mono-, bis, and tris- 
chelates are potentially present in aqueous solution depending on the pH, the bipy:Zn(II) ratio 
and the concentration.[209] The association of the 1bipy:1Zn(II) complex is fast and its 
dissociation slow, even if this is less pronounced compared to the Cu(II) analogue (see Table 
1.2). 
Ishiguro and co-workers reported the species distribution diagram for the binary system 
bipy-Zn(II) in DMF indicating that a complex with 1bipy:1Zn(II) stoichiometry is the main 
species in the sub millimolar range, whereas 2bipy:1Zn(II) and 3bipy:1Zn(II) complexes 
predominate at higher concentrations.[274] However, none were reported (to the best of my 
knowledge) in water, where bipy-Zn(II) stability constants are higher (ca one log unit) 
compared to DMF. 
No crystal structure have been reported for ternary systems bipy-Zn(II)-glycine or bipy-
Zn(II)-glycolic acid (to the best of my knowledge). However, the ternary system bipy-Zn(II)-
Aha (where Aha stands for hydroxamic acid) was studied in aqueous solution. The species 
distribution diagram for bipy-Zn(II)-Aha, when present in a ratio 2:1:2,  indicates that the 
sum of the molar fraction of four different  [Zn(bipy)p(Aha)q] complexes (with p = 0-1 and q 
= 1-2) represents 90 % of the species present under these conditions.[275] 
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1.4.2 – Terpy metal complexes 
Complexes with 1M(II):2terpy and 1M(II):1terpy stoichiometry (with M = Fe, Co, Ni, 
Cu) have been isolated in the solid-state (see Figure 1.24). Fe(II) adopts a distorted octahedral 
coordination geometry in [Fe(terpy)2]
2+
.[276,277] However, structural studies of 
[Fe(terpy)]
2+
 are consistent with a pentacoordinated Fe(II), which adopts a trigonal bipyramid 
coordination environment.[278,279] The Fe(II) d-electrons in [Fe(terpy)]
2+
 have been shown 
to adopt high-spin states (quintet),[278,279] contrasting with the low-spin state (singlet) 
associated with [Fe(terpy)2]
2+
.[278,280] Even though protonation of terpy and [Fe(terpy)2]
2+
 
hydrolysis can occur in aqueous solution, the [Fe(terpy)2]
2+
 complex is highly stable, 
consistent with K2 > K1 (see Table 1.3),[281,282] and hence represents the main species in 
solution (when Fe(II) is not present in large excess). Remarkably, kinetic measurements 
indicate that binding of the second terpy occurs more than 100 times faster than the first 
terpy (see Table 1.4).[229] 
 
Table 1.3 – Summary of the formation stability constants for M(II):nterpy complexes with M 
= Fe, Co, Ni, Cu, Zn (calculated at 298 K and and ionic strength μ = 0.1 M), involving either 
potentiometric,[283] spectroscopic,[229,284] or redox measurements.[216] 
Metal ion log K1 log K2 Ref. 
Fe(II) 7.1 13.6 [283] 
Co(II) 9.5 9.1 [283] 
Ni(II) 10.7 11.1 [283] 
Cu(II) 
~13
a,b
 / [216] 
12.3 6.8 [283] 
Zn(II) 
6.0 / [229,283] 
7.6
c
 / [284] 
a 
based on spectroscopic measurement performed in dioxane/water (1/1); Ionic strength were 
set to 
b
0.3 or 
c
0 M . 
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Figure 1.24 – Representation of the three main complexes formed between M(II) and terpy: 
(A) the [M(terpy)2]
2+
 complex in an approximate D2d geometry, and the [M(terpy)X2] either 
in (B) a trigonal bipyramid for M = Fe, Co, Ni, Zn, or (C) in a square-based pyramid for M = 
Cu. X corresponds to halogenates. 
 
Table 1.4 – Summary of the kinetic formation (kn) and dissociation rate constant (k-n) for 
M(II):nterpy metal complexes with M = Fe, Co, Ni, Cu, Zn (calculated at 298 K). For the 
first set of data, species were quantified using spectroscopic measurement,[229] whereas the 
second set involved [H
3
]-terpyridine and radioassays.[285] 
Metal ion log k1 log k2 log k-1 log k-2 Ref. 
Fe(II) 
4.9 ~7
 a
 -2.2 -6.8 [229] 
/ / 3.8 -0.77 [285] 
Co(II) 
4.4 6.7
a
 -4.0 -3.2 [229] 
/ / 2.0 2.8 [285] 
Ni(II) 
3.1 5.3 -7.6 -5.8 [229] 
/ / -1.6 0.22 [285] 
Cu(II) 
~7.3
b
 / / / [229] 
/ / > 5.1
c
 / [285] 
Zn(II) 6.1 / 0.1 / [229] 
Rate constant calculated at 
a
278, 
b
279.5, and 
c
273.1 K. 
 
In the solid state, [Co(terpy)2]
2+
 exists as a mixture of two species, where the electronic 
configuration of the Co(II) d-orbitals adopt either a high (quartet) or a low-spin state 
(doublet). The nature of the counter-anions and the hydration have been shown to impact the 
spin-state distribution,[286,287] however, no crystal with an exclusive spin-state has been 
isolated. In all cases, Co(II) adopts a distorted octahedral geometry in [Co(terpy)2]
2+
, due to 
Jahn-Teller effects. In contrast, the crystal structures of 1Co(II):1terpy complexes, such as 
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[Co(terpy)Br2]
2+
, display Co(II) cations in trigonal bipyramidal coordination geometries 
(mostly high spin in this case).[288,289] In solution, terpy derivatives have been shown to 
form both 1Co(II):1terpy and 1Co(II):2terpy complexes, consistent with K2 ~ K1 (see Table 
1.3), and the exact composition depends on the ratio of species present,[285,290] but also 
from the solvent.[291] As for Fe(II) complexes, kinetic measurements indicate that the 
binding of the second terpy motif is more than 100 times faster than the first terpy (see Table 
1.4).[229] 
As for Co(II), structural studies of complexes with 1Ni(II):2terpy and 1Ni(II):1terpy 
indicate that the Ni(II) cation adopts an octahedral,[292-294] or trigonal bipyramid 
coordination geometry (both distorted),[279,295] respectively. The stability constant 
calculated are again consistent with both, 1Ni(II):2terpy and 1Ni(II):1terpy species, being 
present in solution (consistent with K2 ~ K1, see Table 1.3), and again kinetic data indicate 
that coordination of the second terpy is more than 100 time faster than the first one (see Table 
1.4).[229] 
The homoleptic complex [Cu(terpy)2]
2+
 is readily prepared when reacting excess terpy 
with Cu(II). In the crystal structure, the Cu(II) cation adopts an octahedral site with an 
orthorhombic Jahn-Teller distortion.[296] In contrast, Cu(II) adopts a distorted square-based 
pyramid in the crystal structure of the complex [Cu(terpy)2Cl2] (see Figure 1.24C).[297] In 
aqueous solution and at room temperature, spectroscopic evidence supports the formation of 
complexes with 1terpy:1Cu(II) stoichiometry,[216,298-300] even at acidic and basic 
pH.[250] This is consistent with the binding constants for which K2 < K1 (see Table 1.3). 
Kinetic measurements indicate that both association and dissociation of the 1terpy:1Cu(II) 
complex are fast (see Table 1.4). When excess terpy is present, the complex [Cu(terpy)2]
2+
 
was reported to precipitate from solution,[285] however, spectroscopic evidence and binding 
constants suggest it might be present in solution as a minor species (see Table 1.3).[216,299] 
As for bipy, crystal structures of ternary complexes terpy-Cu(II)-glycine have been reported, 
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where glycine acts as an axial monodentate ligand in the square-based pyramid coordination 
environment of Cu(II).[301] 
Even though the literature seems to lack data for complexes of the type [Zn(terpy)2]
2+
, 
the structure of analogous complexes involving substituted terpy have been reported, in 
which the Zn(II) cation adopts a distorted octahedral site.[302] The structure of the complex 
[Zn(terpy)Cl2], where Zn(II) adopts a trigonal bipyramid, is also known.[303,304] In aqueous 
solution and at room temperature, potentiometric and spectroscopic studies both indicate 
formation of a complex with 1terpy:1Zn(II) stoichiometry.[229,283,284] Despite a fast 
association process, the decomposition of the complex [Zn(terpy)]
2+
 was very slow at room 
temperature (see Table 1.4). 
 
1.4.3 – Impact of polypyridine substituents on coordination 
The introduction of substituents on the polypyridine rings have been shown to impact 
the ability to bind protons or metal ions, depending on their nature and position. For example, 
Fe(II) coordination to bipy is prevented upon symmetrical dimethyl substitution at the 3,3’-
positions, due to sterically disfavouring the cis- conformation.[305,306] Most reports deal 
with the coordination ability of bipy substituted on 6- and 3- positions which are governed by 
steric effects (see Figure 1.25). However, coordination studies on phen indicate that 
electronic effects might also play a minor role. For instance, substitution of phen at either the 
4,7- or 3,8 positions slightly increases or decreases the metal ion affinity (respectively), 
consistent with π-delocalisation promoting metal-ion binding in the former case 
only.[306,307] Despite substitution at position 2- and/or 9- of phen (equivalent to 6,6’-for 
bipy) equally being able to favour coordination through electronic effects, the metal-ion 
affinity is in fact much lower than for phen.[308]  
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Figure 1.25 – Representation of the numbering scheme for (A) bipy and (B) phen substituent 
positions. 
 
Similarly, the bipy metal ion affinity significantly decreases upon introduction of 6,6’ 
as opposed to 4,4’ or 5,5’- substituents.[216] Interestingly, this allows for the preparation of 
polypyridine metal complexes with alternative coordination geometries,[309-311] or 
metal:ligand stoichiometries.[312] On a side-note, 5,5’-dimethyl substituents were reported to 
sterically hinder the formation of dinuclear bipy:M(II) complexes, thus promoting the 
formation of mononuclear analogues.[313] 
1.5 – Summary 
This Chapter briefly introduces the main secondary structure of peptides and the design 
of peptide mimics with stimuli- responsive and stabilised conformations. Protein interactions 
often rely on α-helices, and chemists have prepared a large variety of short peptide fragments 
stabilised in this conformation, using different strategies, able to recognise their specific target 
site. Moreover, incorporation of stimuli-responsive elements may allow for the control of 
biomolecular activity by artificial conformational regulation. Examples are emerging of 
biomolecular recognition involving β-strands, artificial mimics of which can be stabilised by 
promoting interactions between two or more strands. This can be achieved by introduction of 
side chains which promote such interactions, or incorporation of turn mimics which stabilise 
the chain reversal (U-shaped). So far, most polypyridine peptide conjugates prepared are 
cyclometallopeptides, which may serve as large turn mimics with specific chiral orientation or 
photoactive properties. Taken together, these studies might allow for the control of peptide 
tertiary or quaternary structures thus allowing for the development of functional peptides 
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capable of, for example introducing pores within membranes, or for the preparation of new 
peptide-based materials.   
Chromosomal DNA, which is packed in nucleosomes, is a biomolecular target for 
peptides involved in initiation and regulation of protein transcription. Unlike some of the 
proteins involved in DNA maintenance (copy, repair, or insertion), they often bind as 
multimers to symmetric recognition sites. These represent an important source of inspiration 
for the design of small molecules able to influence the transfer of genetic information. 
Miniature, highly specific and stimuli responsive transcription factors have been designed 
either using artificial dimerisation methods or artificial stabilisation of helices. They may 
ultimately allow for in vivo partial sequencing. Importantly, the access to alternative binding 
sites can be achieved through symmetry operations (stitchery), thus enlarging the scope of 
applications. Moreover, the identification of some natural proteins acting both as sensors and 
transcription regulators (in contrast to the trans- or cis- activation processes) is challenging 
and modulation of their activity with artificial inhibiters might help to identify their role. 
The stability constants for complexes 1M(II):1bipy and 1M(II):1terpy follow the order 
predicted by the Irving-Williams series.[314] However this is no longer the case for 
complexes containing more than one polypyridine ligand.[209] Cu(II) and Zn(II) have been 
shown to preferentially form 1:1 complexes with equimolar amounts of bipy and terpy under 
physiological conditions, and are therefore of particular interest for this work. 
 
 
1.6 – Project aims 
The aim of this work is to prepare and study some peptide dimer conjugates, the 
dimerisation domains of which consist of disubstituted polypyridine linkers. As previously 
seen, the cis-to-trans- conformational transition experienced by polypyridines upon metal 
complexation, could trigger reorientation of its substituents, and might allow for switching on 
and off the biomolecular recognition of peptide dimers. 
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Chapter 2 reports the synthesis and study of low molecular weight peptide dimer 
polypyridine conjugates, for which conformational and coordination studies were attempted. 
Part of this chapter was published as: Oheix E., Spencer N., Gethings L. A., Peacock A. F. A., 
Z. Anorg. Allg. Chem., 2013, 639, 1370-1383, as an invited contribution. 
Chapter 3 describes the preparation of larger peptides based on the bd of the GCN4 
transcription factor, their dimerisation with the bipy and terpy linkers, and studies of the 
Cu(II) and Zn(II) coordination of the resulting conjugates. Part of this chapter was published 
as: Oheix E., Peacock A. F. A., Chem. Eur. J, 2014, doi: 10.1002/chem.201303747. 
Chapter 4 describes the DNA binding studies of the GCN4bd polypyridine conjugates 
and the impact of metal addition on peptide-DNA interactions. Part of this chapter was 
published as: Oheix E., Peacock A. F. A., Chem. Eur. J, 2014, doi: 10.1002/chem.201303747. 
Chapter 5 presents initial work towards application of GCN4bd polypyridine conjugates 
as DNA sensors or nuclease agents. 
Chapter 6 concludes on the work done and develops new perspectives. 
The appendices describe the experimental techniques involved in this work. 
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2.1 – Introduction 
2.1.1 – Artificial regulation sites based on polypyridine 
Bipy is one of the most widely used metal-chelating units.[1] The lone pair on the 
nitrogen atoms are basic and allow for metal ion coordination. Moreover, binding of a single 
metal to both nitrogen atoms results in the formation of a 5-membered chelate ring, with high-
stability. Therefore, most divalent metal ions bind bipy through both nitrogen atoms, thus 
stabilising a cis- arrangement of the two pyridine rings, with respect to the axial bond. In the 
absence of a metal ion, the inter-ring conjugation of π orbitals is believed to be less important 
and non-planar conformations are allowed.[2,3] Repulsion between hydrogens in position 3- 
strongly destabilise the cis- arrangement, however, the trans- arrangement represents the 
energetic minima in the absence of metal ion coordination.[4] Experimental evidence such as 
dipolar momentum,[2] and X-ray analysis[5] are consistent with bipy adopting the trans- 
conformation in aprotic solvents and in the solid-state. As a result, metal-complexation of 
bipy results in a conformational transition involving the rotation of one of the pyridine units 
by up to 180°, with respect to the second pyridine. 
Rebek et al. first took advantage of this metal-induced conformational transition as a 
regulation site, by incorporating the bipy unit into a crown ether.[6] In the resulting bipy-
crown ether, metal ion binding at the bipy regulation site impacts the geometry and the size of 
the polyether ring, thus altering its affinity for alkali metal ions (see Figure 2.1). This concept 
was subsequently applied to regulate the binding of a large variety of substrates, including 
metal ions, nucleotides, amino-acids, and fullerenes.[7] Bipy conformational transitions have 
also been exploited in the construction of molecular machines.[8] 
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Figure 2.1 – Scheme illustrating the regulation of alkali metal ion binding through allosteric 
mechanism developed by Rebek. Transition metal coordination at the bipy (allosteric site) 
regulates the size of the ether crown (active site), and therefore its affinity for alkali metal 
ions.  (A) the metal ion regulation process, (B) a side view of the device (bipy is metal-
unbound), and (C) 2D projection of the device (metal-bound to bipy); adapted from reference 
6. 
 
 
Even though terpy was first isolated in the 1930’s,[9] it only became increasingly used 
in the 1980’s. In a similar fashion to bipy, it preferentially adopts a trans- arrangement of the 
pyridine rings in the absence of metal ions, and is able to form very stable metal-chelate 
complexes. Terpy is able to coordinate to metal ions with different coordination modes, 
involving two or three pyridines, and resulting in either a cis-cis- or a cis-trans- 
conformation.[10, 11] Based on this, molecular tweezers (acyclic molecules bearing a cavity 
where a host molecule can fit) containing terpy units, were designed by Lehn and co-workers. 
These exploit the conformational transition on metal ion coordination to regulate binding of 
an aromatic substrate, such as 7,7’,8,8’-tetracyanoquinodimethane (TCNQ) (see Figure 
2.2).[12] 
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Figure 2.2 – Scheme illustrating Lehn’s tweezer. Zinc binding at the terpy (allosteric site) 
allows for pre-organisation of anthracene moieties for π stacking interaction with an aromatic 
guest molecule such as TCNQ (active site). (A) Schematic representation and (B) ChemDraw 
scheme of the terpyridine conformational change, and repositioning of anthracene units, on 
metal ion coordination; adapted with permission from reference 12. Copyright 2004 American 
Chemical Society. 
 
The polypyridine regulation ability is linked to the rotation of pyridines around their 
axial bond, and is often described by the value of the dihedral angle N-C-C-N or φ (see Figure 
2.1B). In order for metal ion coordination to result in a significant structural change, essential 
for a regulation trigger, the two constituents which make up the active site need to be attached 
to the polypyridine through different pyridine rings. There are various locations at which 
these constituents can be attached to the pyridine ring. Successful regulation processes 
involving repositioning of the active sites substituents at position 6,6’-,[13] 4,4’-,[14] and 
3,3’-,[6,15] of bipy, have been reported. In contrast, 5,5’- positioning constitutes an 
exception, because the metal ion induced cis-trans conformational transition does not result in 
modification of the relative position of the two active site constituents, however the relative 
orientation of the substituents is altered by as much as the dihedral angle φ. In contrast, the 
5,5’-disubstituted bipy unit has been exploited as a regulation site, by taking advantage of the 
different π conjugation between the metal bound- and free- species. This allows for electron 
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transfer between two active sites, thus altering the global electronic transition within the 
supramolecular building blocks (see Figure 2.3).[16,17] 
 
Figure 2.3 – Scheme depicting the supramolecular building block developed by Drain et al.: 
Metal binding at bipy results in the alignment of the porphyrin ring in the same plane, thus 
facilitating π molecular orbital overlap and electronic transfer; adapted from reference 16. 
 
Alternatively, building blocks attached to bipy or terpy can be self-assembled upon 
metal coordination and formation of 2:1 polypyridine metal complexes. This property was 
exploited for the preparation of material displaying metal-dependent sol-gel transitions.[18] or 
for crosslinking of nanoparticles.[19] 
The conformational transition resulting from bipy complexation has also been exploited 
to regulate the secondary structure of biomolecules. Sugimoto and co-workers inserted a 4,4’-
disubstituted bipy within the DNA backbone of an oligonucleotide containing guanine 
tetrameric repeats. In the absence of divalent metal ion, the artificial construct adopted an 
antiparallel G-quadruplex in aqueous solution at pH 6. However, addition of divalent cations 
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such as Ni(II), Co(II), or Zn(II), results in a transition to a parallel G-quadruplex, and in 
formation of G-wires of various lengths.[14]. 
Kelly and co-workers prepared several short peptides with a bipy unit introduced 
directly into the peptide backbone.[20] The peptide sequence and the pH were found to 
influence the conformational state of the bipy, as a result the free ligand was only able to 
adopt the trans- conformation under alkaline conditions. At pH 9.5 they demonstrated that 
Cu(II) coordination led to a structural reorganisation of the bipy linker to the cis- 
conformation, resulting in a secondary structure transition from random coil to -sheet (see 
Figure 2.4). However, the bipy linker could not be used as a switch at a physiologically 
relevant pH. This highlights the importance for a better understanding of the factors (c.a. 
protonation of polypyridine, substituent nature and positioning) which govern the 
conformational state of bipy and related polypyridine units, if they are to be exploited as 
potential artificial allosteric regulation sites. 
 
Figure 2.4 – Scheme showing the peptide with incorporated bipy prepared by Kelly et al.  
Cu(II) addition results in a trans-to-cis conformational transition of the bipy linker, thus 
inducing a random coil to β-sheet transition; adapted from reference 20. 
 
As for inorganic materials, the ability of bipy and terpy to form assemblies following 
complexation and formation of 2:1 or 3:1 polypyridine metal ion complexes, were exploited 
for the formation of a large variety of peptide,[21,22,23] or DNA scaffolds.[24,25,26] Among 
the dication of first-row metal transitions (second half only), Fe(II) has been shown to form 
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the most stable 3bipy:1M(II) and 2terpy:1M(II) complexes in aqueous solution (though 
Ni(II) has the highest overall stability, it was shown to disproportionate in solution). In 
contrast, Zn(II) and Cu(II) represent the most suitable candidates for the predominant 
formation of 1:1 complexes with equimolar amounts of bipy and terpy at physiological pH 
(see Chapter 1).  
Several strategies allow one to efficiently incorporate non-natural molecules within 
proteins (for reviews see [27-30]). An attractive approach for incorporation of non-natural 
molecules such as bipy within synthetic peptides is the preparation of synthetic amino-acids, 
with suitable protection schemes for incorporation within solid-phase peptide 
synthetis.[20,31] Alternatively, bipy, terpy or phen derivatives were often incorporated into 
peptides or proteins through coupling to amino-acid side chains. [32-34] Cysteine is a 
particularly attractive residue for coupling with, because (1) its nucleophilic thiol side-chain is 
unique among natural amino-acids, (2) cysteine has a low natural abundance, making it a 
suitable candidate for selective mutation,[35] and (3) cysteine can easily be introduced  into 
peptides by site-directed mutagenesis. [27] Similarly, there exists a plethora of methods for 
the chemical attachment to cysteine.[35] 
2.1.2 – Aims of the chapter 
The aim is to prepare peptide polypyridine conjugates, for which metal binding at the 
polypyridine (allosteric site) would result in the spatial realignment of peptide fragments, 
which could be used to regulate a biomolecular recognition process. For this, an investigation 
of the polypyridine metal-coordination ability, as well as the conformational transition 
resulting from metal-binding, was envisioned. One can reason that small peptide dimer 
conjugates would allow to more readily study and interpret the chemistry at the metal 
polypyridine site. This chapter therefore reports the design, preparation, and characterisation 
of model compounds, where cysteine and glutathione (GSH) are both dimerised through 
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Me2pyr, Me2bipy, and Me2terpy linkers (see Figure 2.5). Cu(II) and Zn(II) binding studies 
of the resulting conjugates were subsequently monitored by UV-visible, CD, or NMR 
spectroscopy. 
 
Figure 2.5 – Scheme representing linkers relative to this work: (A) 2,6-dimethylpyridine 
(Me2pyr), (B) 5,5’-dimethyl-2,2’-bipyridine (Me2bipy), and (C) 6,6’’-dimethyl-2,2’:6’,2’’-
terpyridine (Me2terpy). 
 
Cysteine and GSH were first dimerised through a commercially available pyridine 
linker, affording highly water-soluble conjugates with low Cu(II) and Zn(II) affinity. 
Polypyridine linkers, bearing bipy or terpy chelation motif were then prepared, and their 
interactions with Zn(II) in the organic solvent DMSO-d6 were investigated by NMR. These 
linkers were further used to dimerise cysteine and GSH, affording conjugates with contrasted 
solubility under physiological conditions. Cu(II) and Zn(II) interactions with GSH conjugates 
were studied in more details. 
2.2 – Results and discussion 
2.2.1 – Cysteine and glutathione dimerised through a pyridine linker 
2.2.1.1 – Design, preparation and stability 
Initial studies involved testing the proposed amino-acid/peptide dimerisation through a 
single pyridinyl linker with limited metal ion coordination ability, then studying the stability 
of the resulting conjugates in solution, and finally their interactions with metal ions. For the 
coupling, alkylation of cysteine was used, as it involves simple and well described preparation 
steps.[36,37] At pH 8, the thiol group of cysteine can act as a nucleophile (pKa = 8.35), and 
react with electrophilic alkyl- derivatives, to form thioethers. These conditions are also 
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favourable to thiol oxidation, which is the kinetic determinant step for disulphide formation. 
Therefore, formation of peptide dimers, as side-products, is expected. 
Coupling of two equivalents of cysteine with commercially available water soluble 2,6-
bis(bromomethyl)pyridine (pyr-Br2), was first attempted following the procedure reported by 
Prakash et al. to dimerise cysteine-glycine dipeptides through a 4,4’-dimethylazobenzene 
linker.[38] Phosphate buffer, used to regulate the pH of the reaction mixture, was changed for 
Tris.HCl, thus facilitating monitoring by ES-TOF and MALDI-TOF spectrometry.[39] The 
amount of dimethylformamide (DMF) was also reduced (2% instead of 50%) in order to 
facilitate both purification by analytical HPLC, and on-plate crystallisation prior to MALDI-
TOF characterisation. This amount was previously reported to be low enough to ensure 
homogeneity of the medium.[40]  
Cysteine was reacted with pyr-Br2, affording the desired cys2pyr conjugate (Figure 
2.6), which was purified by preparative HPLC, using a water/acetonitrile gradient for elution 
(without additional acid). After lyophilisation of isolated fractions, the resulting white solid 
was characterised by 
1
H and 
13
C NMR, ES-TOF, MALDI-TOF, UV-visible spectroscopy, 
elemental analysis, and the purity confirmed by analytical HPLC. 
 
Figure 2.6 – Synthetic scheme for preparation of cys2pyr. 
 
The 
1
H NMR spectrum recorded of a solution of cys2pyr in D2O (pD~6) displays 5 
signals attributed to cys2pyr (see Figure 2.7A). Following acquisition, the sample was stored 
at room temperature for 15 days, and a new 
1
H NMR spectrum recorded (see Figure 2.7B). 
Similarities with the previous spectrum suggest that cys2pyr is stable under these conditions. 
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Figure 2.7 – 1H NMR spectra of cys2pyr in D2O at pD ~ 6 recorded at 300 MHz, directly (A) 
and 15 days (B) after preparation, dioxane was added as an internal reference. 
 
In order to test our dimerisation procedure with peptides, pyr-Br2 was reacted with the 
tripeptide GSH following a similar procedure, affording pyr-GS2. During the reaction, the 
concentration of reduced GSH was monitored by the Ellman’s assay (see appendix). After 14 
hours, the pH had reduced significantly, and NaOH was added to restart the reaction. The plot 
of absorbance at 412 nm corresponding to Ellman’s test recorded at different reaction times, 
indicates a decrease in the reduced GSH concentration, which plateaus at ca 30 hours (see 
Figure 2.8). 
 
Figure 2.8 – Graph monitoring the available thiol concentration during pyr-GS2 synthesis. 
This was estimated by Ellman’s test at different reaction times (0 hours corresponds to GSH 
addition). The absorbance at 412 nm relative to Ellman’s test was plotted as the primary y-
axis (left), and can be normalised to the percentage remaining thiol (secondary y-axis, right). 
The pH was adjusted with NaOH after 14 hours, after which it remained constant (ca 7.5). 
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Pyr-GS2 was also purified by preparative HPLC. In contrast to cys2pyr, no efficient 
separation could be obtained using water/acetonitrile mixtures as eluents, and required 
addition of 0.05% trifluoroacetic acid (TFA) to the water/acetonitrile eluents. The resulting 
colorless gel was successfully characterised by 
1
H and 
13
C NMR, ES-TOF, MALDI-TOF, UV 
spectroscopy, and analytical HPLC. However, elemental analysis did not indicate the 
expected composition, suggesting that the compound was recovered as a mixture of salts. The 
best match of analytical data was found for pyr-GS2,3TFA,3.5H2O (see section 2.4.2), which 
is consistent with the HPLC conditions employed. 
1
H NMR spectra recorded of a pyr-GS2 solution in D2O (pD ~ 1 due to TFA salts 
present) displays 9 signals attributed to pyr-GS2 (see Figure 2.9A). The sample containing 
pyr-GS2 solution was stored at room temperature for 14 days, and a new 
1
H NMR spectrum 
recorded. Again, the second acquisition was found to be very similar to the original (see 
Figure 2.9B). 
 
Figure 2.9 – 1H NMR of pyr-GS2 recorded in D2O at 300 MHz, directly (A) and 14 days 
after preparation (B), dioxane was added as a reference. 
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The stability of pyr-GS2 in aqueous solution was also monitored by analytical HPLC, 
and the same single absorption peak was detected after samples were stored in solution for 31 
days (see Figure 2.10). 
 
 
Figure 2.10 – Analytical C18-HPLC of pyr-GS2 aqueous solution recorded directly (A) and 
31 days (B) after preparation. Solutions were eluted (monitoring at 220 nm) using a linear 
gradient from 0 to 100 % acetonitrile in water (+0.05 % TFA) over 40 min (flow 1 mL/min). 
 
2.2.1.2 – UV studies of pyr-Br2, cys2pyr and pyr-GS2 
UV spectra of pyr-Br2 solutions buffered at pH 8.0 display one band centred at 275 nm 
attributed to the π→π* transition of the pyridine ring (see Figure 2.11A). Another peak can be 
observed at higher energies but the maximum is in the far-UV domain. UV spectra of cys2pyr 
solutions buffered at pH 8.0, display a similar profile, with the maximum of the π→π* 
transition centred at 272 nm (see Figure 2.11B). 
Extinction coefficients relative to pyr-Br2 and cys2pyr maxima were determined based 
on triplicate absorbance measurements (independent solutions), in 20 mM phosphate buffer 
pH 8. Absorbance measurements relative to different stock solutions were averaged, and 
plotted versus concentration (either pyr-Br2 or cys2pyr) (see Figure 2.11A and B). Linear 
regression was performed, affording values of extinction coefficients for the absorbance 
maxima of ε275 nm 5,190 ± 390 M
-1
 cm
-1
 (pyr-Br2) and ε272 nm 5,530 ± 170 M
-1
 cm
-1
 (cys2pyr) 
(see Figure 2.11C and D). Within error, the absorbance maxima of cys2pyr and pyr-Br2 have 
similar extinction coefficients. 
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Figure 2.11 – Determination of extinction coefficient for cys2pyr and pyr-Br2. Top: UV 
spectra for pyr-Br2 (A) and cys2pyr (B) independent solutions (---) and average spectra (▬) 
recorded in phosphate buffer pH 8 at 20, 40, 60 and 80 µM. Bottom: plot of average 
absorbance at 275 (C) or 272 nm (D) as a function of  the concentration of pyr-Br2 (C) and 
cys2pyr (D), error bars correspond to the standard deviation. 
 
UV spectra of pyr-GS2 solutions buffered at pH 8.0, display a similar profile, with the 
maximum of the π→π* transition centred at 274 nm, however, the extinction coefficient 
seems significantly lower, ca ε274 nm 3,190 ± 70 M
-1
 cm
-1
 (average of two independent 
experiments). Despite analytical HPLC showing a single peak, the elemental analysis was not 
consistent with pure pyr-GS2, rather a hydrated TFA salt. Therefore, one can conclude that 
mass is not a reliable way to estimate the amount of pyr-GS2 in solution, and by extension, of 
other peptide conjugates purified using TFA containing eluents. 
2.2.1.3 – Cu(II) titration of cys2pyr and pyr-GS2 monitored by UV spectroscopy 
Cys2pyr and pyr-GS2 might possess similar metal ion affinities due to their similar 2,6-
bis(thiomethyl)pyridine motif. If that is the case, it might be possible to correlate 
spectroscopic changes during a metal titration, with the starting concentration. For this, Cu(II) 
titrations were performed on solutions containing 40 μM of cys2pyr or pyr-GS2 for which 
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concentration were based on mass, and monitored the pyridinyl π→π* absorbance. Blank 
solutions containing 80 μM L-glycine were used as controls, in order to account for Cu(II) 
coordination occurring through the 2,6-bis(thiomethyl)pyridine motif, only. 
 CuCl2 addition to solutions containing 40 μM of cys2pyr or pyr-GS2 buffered at pH 
8.0, results in the steady increase of the absorbance at 240 nm (see Figure 2.12A and B). 
Similarly, an increase in the absorbance centred at 240 nm was observed upon addition of 
CuCl2 to solution containing buffer only (see Figure 2.12C). In contrast, Cu(II) addition to a 
solution containing 80 μM L-glycine buffered at pH 8.0, resulted in the appearance of a new 
peak initially centred at 235 nm, but which shifted to lower wavelength at higher Cu(II) 
concentration (see Figure 2.12D). However, ZnCl2 addition to solutions containing cys2pyr or 
pyr-GS2 buffered at pH 8.0, did not result in any changes to the UV spectra recorded (data 
not shown). 
 
Figure 2.12 – UV spectra recorded upon CuCl2 addition to either blank solution (A), 80 µM 
L-glycine (B), 40 µM cys2pyr (C), or 40 µM pyr-GS2 (D) (based on mass). All solutions were 
buffered at pH 8.0 with 20 mM phosphate. (▬) 0 eq., (▬) 1 eq., (▪▪▪) between 0 and 1 eq., 
and (─▪─) more than 1 eq. CuCl2 added. 
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The absorbance at 240 nm was plotted as a function of the Cu(II) concentration (see 
Figure 2.13). Plots are consistent with either a two stage increase (cys2pyr, pyr-GS2 and L-
glycine), or a one stage increase (blank) of the absorbance. A titration curve for the blank was 
fitted by linear regression using a one stage model indicating a linear coefficient of 2.2 mM
-1
 
(see Figure 2.13A). The remaining three curves were fit by linear regression to two stage 
models, and equivalent points were calculated by extrapolation. For the conjugates, the 
increase of the absorbance at 240 nm was estimated to reach transition points at C = 38.4 μM 
(cys2pyr) and 24.4 μM (pyr-GS2) of Cu(II) added (see Figure 2.13C and D). The first stage of 
absorbance growth are characterised by different linear coefficient for solutions containing 
cys2pyr (0 - 38.4 μM, 3.8 mM
-1
) and pyr-GS2 (0 - 24.4 μM, 5.4 mM
-1
). In contrast, linear 
coefficients relative to the second stage of absorbance growth are identical to that recorded for 
the blank solution, ca cys2pyr (38.4 – 60 μM, 2.2 mM
-1
) and pyr-GS2 (24.4 – 60 μM, 2.2 
mM
-1
). This contrasts with the fitting of the A240nm plot for the L-glycine solution, where the 
equivalence point is at 27.4 μM Cu(II) and linear coefficients of 0.003 μM-1 (0 - 27.4 μM), 
and 0.0014 μM-1 (27.4 - 60 μM) were measured. 
Figure 2.13 – Plot of the evolution of absorbance at 240 nm as a function of CuCl2 
concentration. (A) buffer blank, (B) 80 µM L-glycine, (C) 40 µM cys2pyr, (D) 40 µM pyr-
GS2. Slopes are fitted to one or two linear functions (▬). 
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These titrations indicate that both cys2pyr and pyr-GS2 seems to interact weakly with 
Cu(II), however they behave very differently than L-glycine and 2,6-methylpyridine (data not 
shown), suggesting that they coordinate Cu(II) through the pyridinyl nitrogen and/or sulphurs 
from the thioether linkages. For both cys2pyr and pyr-GS2, Cu(II) addition past the 
equivalence point is consistent with Cu(II) addition to buffer. For the cysteine conjugate, the 
equivalence point determined is consistent with the expected 1:1 cys2pyr:Cu(II) ratio. 
However, this is not the case for the GSH conjugate, consistent with the previous conclusion 
concerning the presence of a hydrated TFA salt, and therefore unreliable concentration based 
on mass. Indeed, if one assume that both cys2pyr and pyr-GS2 bind Cu(II) in a 1:1 ratio, the 
equivalence value measured upon Cu(II) addition would correspond to the actual 
concentration of cys2pyr and pyr-GS2. If the UV spectra of cys2pyr and pyr-GS2 are 
corrected to account for this, two spectra which are superimposable in the π→π* band region 
are obtained. In summary, polypyridine conjugates containing peptide substituents are likely 
to be isolated as hydrated TFA salts, and the molecular weight cannot be reliably used. 
Rather, the absorbance of π→π* transition should be used to determine their concentration in 
solution. 
 
2.2.2 – Polypyridine linkers Me2bipy and Me2terpy 
2.2.2.1 – Design and preparation of the polypyridine linkers 
Our aim was to study a polypyridine linker that can act as a regulation site capable of 
controlling the relative orientation of the peptide moieties. In the case of bipy and terpy, 
protonation of pyridinyl nitrogen(s) are known to result in conformational transitions (bipy: 
trans -> cis, terpy: trans-trans -> trans-cis -> cis-cis),[11,41] therefore the cation H
+
 alone 
might be able to regulate the peptide moieties’ orientation. Bipy and terpy have different 
Brønsted basicity (bipy 4.44, terpy 2.59 - 4.16).[41] Both basicity and conformation of the 
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protonated state might change upon substitution of bipy and terpy, especially upon 
attachment of bulky peptide arms. The stability constant for the 1:1 complexes  that Cu(II) 
and Zn(II) form with terpy are greater by roughly 4 and 1.6 log unit, respectively, compare to 
those formed with bipy (see Chapter 1). This is particularly important when undertaking work 
under biologically relevant conditions, where high concentration of species able to effectively 
compete for metal ion coordination are present. Working with both bipy and terpy linkers, 
for which the substituent position would be different, would give a broader perspective, and 
would increase the odds to observe a trans-to-cis conformational rearrangement upon binding 
to a transition metal ion, at physiological pH (unlike Kelly and co-workers [20]). 
Two linker units form the focus of this work: 5,5’-dimethyl-2,2’-bipyridine (Me2bipy) 
and 6,6’’-dimethyl-2,2’,6’,2’’-terpyridine (Me2terpy). Me2bipy has previously been used to 
dimerise peptides through cysteine alkylation.[42][43] A trans-to-cis conformational 
transition within the Me2bipy linker is expected to result in realignment of peptide 
substituents, while the distance separating them should remain unchanged (see Figure 2.14A). 
The reorientation could be compensated for by the free- rotation of the dimethylsulfide group 
connecting the bipy unit to the peptide backbone (see Figure 2.14C), and therefore this linker 
can be thought of as allosteric-ineffective.[4] In contrast, trans-to-cis conformational 
transitions of the Me2terpy linker are expected to modify the distance separating the two 
peptide substituents (see Figure 2.14B). Distances separating the two methyl carbon 
substituents, in the cis- or trans- conformation, were estimated from reported crystal 
structures of analogous compounds: 5,5’-dimethyl-2,2’-bipyridine,[44] 6,6’’-
bis(trimethylsilylethynyl)-2,2’:6’,2’’-terpyridine,[45] catena-poly[[(5,5’-dimethyl-2,2’-
bipyridine-κ2N,N’)cadmium(II)]-di-μ-iodido][46] and [[6,6’’-dicarboxylic acid bisanthracen-
9-ylamide-(2,2’:6’,2’’-terpyridine-κ3N,N’,N’’)]zinc(II)]-di-trifluoroacetic acid.[12]  
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Figure 2.14 – Schematic illustrating the impact of conformational transition in (A) Me2bipy 
and (B) Me2terpy on the inter-substituent distance and relative orientation. (C) Illustration of 
the flexibility of the thioether linkage of (2-polypyridine) substituted at position 5-. Distances 
displayed are estimated based on reported structures for analogous compounds.[12,44-46] 
 
The dimethyl- compounds were either purchased (Me2bipy) or prepared following 
previously reported procedures (Me2terpy).[47,48]  NMR was used to estimate their 
interaction with Zn(II), and the resulting conformational transitions (see section 2.2.2.2). 
However, the synthetic strategy chosen for peptide dimerisation required the preparation of 
the di-bromomethyl polypyridine derivatives. Therefore, 5,5’-bis(bromomethyl)-2,2’-
bipyridine (bipy-Br2), and 6,6’’-bis(bromomethyl)-2,2’:6’,2’’-terpyridine (terpy-Br2) were 
prepared following previously reported procedures,[48,49] and were characterised by 
1
H and 
13
C NMR, UV, as well as HRES-TOF spectroscopy. Interestingly, the UV profile recorded for 
these species display π→π* transitions at slightly higher wavelength (5-15 nm) compared to 
previously reported values for bipy and terpy.[41] However, the substitution pattern of the 
polypyridine ring can be confirmed through the coupling pattern observed in the 
1
H NMR 
spectra. 
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2.2.2.2 – Zn(II) binding studies for Me2bipy and Me2terpy monitored by 
1
H NMR 
spectroscopy. 
1
H NMR was used to study the interaction of Zn(II) with the Me2bipy and Me2terpy 
polypyridine linkers. The 
1
H NMR spectrum of 25 mM Me2bipy recorded in DMSO-d6 
displays 3 signals in the aromatic region, which are centred at 8.49 (d), 8.24 (d) and 7.73 ppm 
(dd). These peaks were attributed to H
6
, H
3
, and H
4
 respectively, as determined by 2D COSY 
NMR. Addition of aliquots of ZnCl2 solution in DMSO-d6, resulted in a shift of all three 
peaks toward higher frequencies, 8.60, 8.50, and 8.10 ppm (see Figure 2.15A). Though the H
6
 
proton does not shift significantly a plot of H
3
 and H
4
 chemical shift as a function of Zn(II) 
equivalence, is consistent with a 1:1 binding ratio (see Figure 2.15B). The stoichiometry of 
the main complex formed between ZnCl2 and Me2bipy was confirmed to be 1:1 by 
performing a jobplot analysis (see Figure 2.15C). 
 
 
Figure 2.15 – Stack of NMR spectra (A) and plot of the chemical shift evolution of Me2bipy 
aromatic resonances as a function of Zn(II) equivalence (B), relative to the Zn(II) titration 
experiment monitored by 
1
H NMR at 300 MHz in DMSO-d6. (C) Jobplot based on 
1
H NMR 
spectra at 300 MHz in DMSO-d6 recorded for mixtures of Me2bipy and Zn(II) (Ctotal constant 
and equal to 25 mM). The molar fraction of Me2bipy complexed with Zn(II) ((Zn:Me2bipy), 
calculated from the variation of chemical shift for the different resonances) is plotted versus 
the molar fraction represented by Me2bipy (bound and free) among the different species 
present in solution ((Me2bipy)T). (●) H
4
 ; (X) H
3
. 
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The 
1
H NMR spectrum of a solution of Me2terpy in DMSO-d6 (23.2 mM, 0.75 mL) 
displays four signals in the aromatic region, which are centred at 8.42 (H
3
+H
3a
), 8.07 (H
4
), 
7.88 (H
4a
) and 7.35 ppm (H
5a
). Aliquots of a concentrated ZnCl2 stock solution in DMSO-d6 
(232 mM) were added, resulting in a gradual decrease in intensity of these four resonances, 
and the gradual appearance of four new peaks, 8.81 (H
3
), 8.54 (H
4
), 8.52 (H
3a
), 8.14 (H
4a
) and 
7.64 ppm (H
5a
), consistent with slow exchange on the NMR-timescale (see Figure 2.16).[12] 
All the original four resonances have fully disappeared on addition of one equivalent of 
ZnCl2, indicating a binding ratio of 1:1 Me2terpy:ZnCl2. 
 
Figure 2.16 –1H NMR Zn titration of a 23.2 mM Me2terpy solution in DMSO-d6, recorded at 
300 MHz. 
 
NOESY spectra of Me2terpy can provide information on the conformation of the 
terpyridine unit through inter-ring coupling, in particular the H
3
 <-> H
3a
 cross-peak. However, 
data acquisition is complicated by overlapping of H
3
 and H
3a
 resonances in polar solvents 
(CD3CN and DMSO-d6). Unfortunately, complexes formed between Me2terpy and ZnCl2 
have poor solubility in solvents of low or intermediate polarity (e.g. CD3CN and CDCl3). The 
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1
H NMR spectrum of Me2terpy in CDCl3, displays two distinct doublets attributed to H
3
 and 
H
3a
, at 8.46 and 8.41 ppm (assigned based on COSY NMR), respectively. In the NOESY 
spectra, no cross-peaks were observed between resonances at 8.46 and 8.41 ppm (see Figure 
2.17A). In contrast, the NOESY spectrum recorded of Me2terpy in the presence of one 
equivalent of ZnCl2 in DMSO-d6, displays a cross-peak between signals at 8.81 (H
3
*) and 
8.52 ppm (H
3a
*) (attribution based on COSY spectrum) (see Figure 2.17B). 
 
Figure 2.17 – NOESY spectra of Me2terpy recorded in (A) the absence (CDCl3) and (B) 
presence of 1 eq. ZnCl2 (DMSO-d6), at 400 MHz (T = 298 K). Positive levels (▬), negative 
levels (▬). 
 
1
H NMR can also provide an indication on the conformation of polypyridine in the 
absence and presence of metal ions. Previous NMR studies conducted on bipy and derivatives 
thereof, concluded that H
4
 and H
5
 resonances shift towards higher frequency, upon trans-to-
cis transition, whereas H
6
 and H
3
 can display contrasting shifts, depending on the bipy 
substitution, the nature of the cation bound (monovalent/divalent), and the solvent.[3,50-52] 
This is in line with our NMR measurement on Me2bipy recorded in the absence and presence 
of ZnCl2. Similarly, broadening of the peak upon Zn(II) addition is consistent with the rapid 
kinetics previously reported for bipy-Zn(II) complexation (see Chapter 1).[53] 
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Concerning Me2terpy, our results suggest that all aromatic signals also move to higher 
chemical shifts upon ZnCl2 addition, and proton signals relative to the central pyridine (H
3
 
and H
4
) experience higher shift than their counterpart (H
3a
, H
4a
 and H
5a
). This is in stark 
contrast to two recent reports, which indicate that H
3a
 resonances move to lower chemical 
shift upon trans-to-cis conformational transition.[11,12] However, the 
1
H NMR spectra of 
Me2terpy recorded in the absence and presence of ZnCl2 are similar to the NMR spectra of 
terpy and its Pt(II) complex, reported by Cini et al.[54] Moreover, NOESY spectra would be 
consistent with Me2terpy adopting a trans-trans- conformation in the absence of metal ions, 
where protons H
3
 and H
3a
 point in opposite directions and are separated by distances of ~4.5 
Å,[45] associated with weak coupling in the NOESY. In contrast, the NOESY spectra of 
Me2terpy in the presence of 1 equivalent of ZnCl2 in DMSO-d6 displays cross-peaks between 
protons H
3
 and H
3a
, consistent with the expected cis- conformation of the Me2terpy:ZnCl2 
complex, where H
3
 and H
3a
 would be separated by approximately ~2.3 Å.[12] Our two 
NOESY experiments cannot be directly compared as they were recorded in different solvents 
(as a consequence of resonance overlapping and solubility issues previously described), and 
overlapping of resonances H
3a
* and H
4a
*. On a side-note, the 
1
H NMR spectra of Me2terpy 
recorded in the presence of ZnCl2 display sharper peaks compared to those recorded for 
Me2bipy, which is consistent with the tenfold greater kinetics of dissociation for bipy-Zn(II) 
compared to terpy-Zn(II) complexes (see Chapter 1).[55] 
2.2.3 – Cysteine dimerisation with polypyridine linkers 
2.2.3.1 – Preparation of polypyridine-cysteine conjugates 
Our synthetic strategy is to dimerise peptides through the cysteine side-chain: initial 
studies included dimerising two equivalents of cysteine in order to establish optimal 
conditions, and to evaluate if the metal binding properties of the linker unit is retained. The 
preparation of cys2bipy and cys2terpy were first attempted following the procedure used to 
prepare cys2pyr and pyr-GS2 (section 2.2.1.1), however little cysteine-polypyridine 
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conjugates, if any, could be obtained, most likely due to the low solubility of bipy-Br2 and 
terpy-Br2 in polar solvents such as DMF and water. 
Bipy-Br2 and terpy-Br2 were reacted with cysteine at room temperature in different 
solvent mixtures such as buffer/acetonitrile, buffer/acetone, buffer/THF (where buffer 
corresponds to 100 mM Tris.HCl pH 8.0), again few conjugates were formed. However, 
cys2bipy and cys2terpy were efficiently prepared in buffer/acetonitrile mixtures when heated 
at 338 K in a microwave reactor for 3 hours. Analytical HPLC run on the crude mixtures 
indicate the presence of either a few (cys2bipy), or numerous side-products (cys2terpy) (see 
Figure 2.18). Cysteine alkylation reactions were reported to better proceed in the presence of 
the reducing agent tris(2-carboxyethyl)phosphine (TCEP).[56] However, under our 
experimental conditions (338 K), TCEP forms an adducts with Me2terpy as identified by 
MALDI-TOF. 
 
Figure 2.18 – Analytical C18 HPLC traces of the crude mixture for the synthesis of cys2bipy 
(A) and cys2terpy (B). (A) Mixture was eluted with 0 to 20 % gradient of acetonitrile in water 
over 40 min ( = 280 nm) ; (B) mixture was eluted with 0 to 100 % gradient of acetonitrile in 
water over 40 min ( = 290 nm). (*) marks the top of the peak attributed to the expected 
compound (assigned based on mass spectrometry). 
 
Cys2bipy and cys2terpy were purified by preparative HPLC eluted with 
water/acetonitrile gradients (no TFA), and dried in vacuo. However, addition of acid (HCl) 
was required to re-solubilise the resulting solids and subsequently characterise them. The 
1
H 
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NMR spectrum of cys2bipy and cys2terpy solutions were recorded at acidic pD only. Raising 
the pD of the NMR solution (millimolar range) to 7, resulted in precipitation of cys2bipy and 
cys2terpy conjugates from the solution. After drying in vacuo, conjugates were recovered as 
hydrated salts, for which elemental analysis was not reproducible, in part due to sample 
hydration. The solubility was sufficient at physiological pH to allow for UV studies 
(micromolar range). 
 
2.2.3.2 – Cu(II)/Zn(II) titration of cys2bipy and cys2terpy monitored by UV spectroscopy 
Previous reports indicate that the π→π* transition of bipy and terpy shifts to lower 
energy upon metal coordination. This was proposed to result from π* orbital 
stabilisation,[57,58] and subsequent reduction of the energetic separation between the π and 
π* level. In the absorbance spectra of terpy, the lower energy π→π* band separates into two 
sub-bands, upon metal binding. This is explained by the fact that the three pyridine rings are 
not equivalent. The resulting lower energy band with weaker absorbance is attributed to the 
central pyridinyl ring.[41] The shift of π→π* band was previously used to estimate the metal-
ligand affinity.[59] 
Despite having established that the theoretical molecular weight differs from the 
experimental molecular weight due to recovery as a salt, it remained to determine the 
relationship between these taking advantage of the UV chromophore for the π→π*1 transition. 
For this, the impact of Cu(II) and Zn(II) addition on the UV spectra of cys2bipy and 
cys2terpy for which concentrations were based on mass was first studied. The UV spectrum 
of cys2bipy contains two bands with maxima at 296 nm (ε296 nm  14,397 M
-1
 cm
-1
) and 245 nm 
(ε245 nm 10,240 M
-1
 cm
-1) assigned as π→π*1 and π→π*2, respectively. The UV spectrum 
recorded for cys2terpy also displays a band at 298 nm (ε298 nm 16,857 M
-1
 cm
-1
) assigned as 
π→π*1, however the π→π*2 around 225 nm overlaps with a more intense band towards the 
far-UV domain. ZnCl2 addition to solutions containing 50 μM cys2bipy or 70 μM cys2terpy 
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(concentration based on mass) at pH 8, results in a redshifts of the π→π* band centred at 296 
nm (cys2bipy) to 313 and 320 nm, and 298 nm (cys2terpy) to 328 and 340 nm (see Figure 
2.19). Isosbestic points at 304 (cys2bipy) and 315 nm (cys2terpy) are consistent with two-
state transitions. 
 
Figure 2.19 – UV spectra for the Zn(II) titration of model switches. ZnCl2 was added to 
solutions containing either 50 µM of cys2bipy (A) or 70 µM of cys2terpy (B) in 20 mM 
phosphate buffer pH 8. (▬) 0 eq., (▬) 1 eq., (■■■) between 0 and 1 eq., (▬●▬) more than 1 
equivalent ZnCl2 added. 
 
The absorbance at 320 (cys2bipy) and 340 nm (cys2terpy), was plotted as a function of 
the Zn(II) concentration, and fitted by linear regression (two stage): equivalent points of 35.5 
(cys2bipy) and 52.3 μM (cys2terpy) were estimated (see Figure 2.20).  
 
Figure 2.20 – Plot of absorbance for ZnCl2 titration of (A) cys2bipy (50 μM) monitored at 
320 nm or (B) cys2terpy (70 μM) monitored at 340 nm. Line (▬) represents linear regression 
fit. 
 
Cys2bipy and cys2terpy titrations with CuCl2 were similarly monitored by absorption 
spectroscopy. CuCl2 addition to solutions containing 50 μM cys2bipy and 70 μM cys2terpy 
(concentration based on mass) at pH 8, result in a redshift of the π→π* band centred at 296 
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nm (cys2bipy) to 318 and 328 nm, and at 298 nm (cys2terpy) to 324 and 335 nm (see Figure 
2.21A and B). Isosbestic points at 308 nm (cys2bipy) and 311 nm (cys2terpy) are consistent 
with a two-state transition.  
 
Figure 2.21 – UV spectra for the metal titration of model switches. CuCl2 was added to 
solutions containing either 50 µM of cys2bipy (A) or 70 µM of cys2terpy (B) in 20 mM 
phosphate buffer pH 8. (▬) 0 eq., (■■■) between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 eq. 
CuCl2 added. 
 
The absorbance at 328 (cys2bipy) and 335 nm (cys2terpy), was plotted as a function 
of the Cu(II) concentration (see Figure 2.22C and D), and an equivalent points of 57.4 μM 
was estimated for cys2terpy. In contrast, an equivalent point for Cu(II) titration of cys2bipy 
could not be estimated, due to the absence of a plateau. 
 
Figure 2.22 – Plot of absorbance for CuCl2 titration of (A) cys2bipy (50 μM) monitored at 
328 nm, or (B) cys2terpy (70 μM) monitored at 335 nm. Line (▬) represents linear regression 
fit. 
 
The conjugates cys2bipy and cys2terpy were previously prepared as salts. Therefore, 
solution preparation based on mass most likely results in concentration overestimation. 
Absorbance properties of metal-free bipy and terpy derivatives were previously reported, and 
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Table 2.1 contains a summary of the π→π* characteristics for some bipy derivatives reported 
in the literature. 
 
Table 2.1 – Range of λmax (ε λmax) values for π→π* bands of some bipy derivatives. 
 
compound π→π*1 π→π*2 solvent Ref. 
 
283 
(10,200) 
244 
(6,600) 
EtOH [41] 
 
281 
(13,580) 
235 
(10,448) 
MeOH [60] 
 
282 
(13,300) 
238 
(10,600) 
MeOH [61] 
 
286 
(17,000) 
240 
(12,600) 
MeOH [61] 
 
289 
(26,700) 
244 
(18,600) 
MeOH [61] 
 
298 
(13,000) 
256 
(6,900) 
EtOH 
this 
work 
 
289 
(19,196) 
237 
(11162) 
MeOH [60] 
 
281 
(13,800) 
233 
(10,600) 
Water  
(pH 12) 
[41] 
 
284 
(13,420) 
238 
(8,950) 
Water 
(free 
zwitterion) 
[62] 
 
Absorbance profiles of cys2bipy and cys2terpy display π→π* maxima at higher 
wavelengths than previously reported profiles for bipy and terpy derivatives (see Table 2.1 
and [63] respectively). However, they are in line with bipy-Br2 and terpy-Br2 profiles 
recorded in EtOH (see section 2.4.2 and Table 2.1), and consistent with trans- rather than 
non-planar cis- arrangement of pyridine rings for the metal-free conjugates.[60] Determined 
extinction coefficients are primarily influenced by the purity of the compounds, but also differ 
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slightly, depending on the substituents (nature, number and position), and the solvent used. 
Therefore, it was not possible to define cys2bipy and cys2terpy π→π* extinction coefficient 
based on previously reported values, despite previous reports of bipy or terpy insertion 
within macromolecules used such methods.[31,64] 
Redshift of cys2bipy and cys2terpy π→π* bands upon Cu(II) and Zn(II) addition are 
consistent with both species binding to both metal ions. As for pyr-GS2, the π→π* extinction 
coefficient of cys2bipy and cys2terpy can be estimated based on their coordination properties, 
and assuming a 1:1 binding ratio. Previous studies of the Cu(II) and Zn(II) coordination of 
terpy are consistent with a 1:1 ratio.[59,63] However, small fractions of 2:1 complexes are 
expected for bipy-Cu(II) and bipy-Zn(II) at high concentration and when the ligand is present 
in large excess, despite 1:1 complexes being largely predominant.[22,65] The assumed 1:1 
ratio is supported by the Zn(II) titration of Me2bipy and Me2terpy (see section 2.2.2.2). 
The total concentration of cys2bipy and cys2terpy for the titration was corrected such as 
it is equal to the concentration of metal at equivalence, ca 35.5 μM (cys2bipy), and 55.3 μM 
(cys2terpy). The concentration of cys2bipy and cys2terpy were then used to recalculate 
extinction coefficient resulting in ε296 nm 20,000 M
-1
 cm
-1
 (bipy conjugate) and ε298 nm 21,000 
M
-1
 cm
-1
 (terpy conjugate). These were subsequently used for quantification of all analogous 
bipy and terpy peptide dimer conjugates used in this work. 
The plot of absorbance at 320 nm relative to Zn(II) equivalents added of cys2bipy was 
fitted to a 1:1 binding ratio using a non-linear regression (see Figure 2.23), based on a 
previously reported method.[31,59]. A log KM of 6.05 ± 0.06 was calculated for 
Zn(II):cys2bipy, taking into account the competitive metal ion binding of the phosphate buffer 
employed in these experiments, for which the Zn(II) binding constant is known (see section 
2.4.3.4).[66] In contrast, analogous plots for the Cu(II) and Zn(II) titrations of cys2terpy, do 
not display sufficient dissociation of the metal complexes and are therefore, not suitable for 
binding constant determination (see Figures 2.20B and 2.22B). To overcome this problem, 
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these titrations needed to be carried out either at a lower concentration, or in the presence of a 
species able to compete for metal-binding, for which the KM is known.[33] Finally, the plot of 
absorbance at 328 nm relative to Cu(II) titration of cys2bipy suggests that more than two 
species are in equilibrium, and therefore cannot be fit to a 1:1 model (see Figure 2.22A). 
 
Figure 2.23 – Zn(II) titration of cys2bipy, plot of absorbance at 320 nm as a function of 
Zn(II) added (■), and its best fit calculated by non-linear regression to a 1:1 model (▬). 
 
2.2.4 – Glutathione model compounds 
2.2.4.1 – Design and preparation 
The prime objective of this chapter is the study of small polypyridine peptide conjugates 
coordination to Cu(II) and Zn(II), how this impacts on the polypyridine linker, and the 
resulting impact on peptide orientation. Therefore, the preparation of conjugates bearing 
slightly larger peptide moieties, but containing the same bipy and terpy linkers, and their 
comparison to cys2bipy and cys2terpy, was envisioned. Larger peptide units might compete 
for metal binding and increase the solubility of conjugates under physiological conditions, 
thus allowing for a conformational study by NMR. 
Following the procedure used to prepare cys2bipy and cys2terpy (less heating is 
required as products are more soluble in the reaction mixture), analogous bipy-GS2 and 
terpy-GS2 conjugates were obtained in high yields, purified by HPLC, and recovered as TFA 
salts. The following sections report the study of Cu(II) and Zn(II) interaction with bipy-GS2 
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and terpy-GS2, for which concentrations are based on their UV profile and the extinction 
coefficients calculated for their dicysteine analogues. 
2.2.4.2 –pH, Cu(II), and Zn(II) titrations of bipy-GS2 and terpy-GS2 monitored by UV-
visible spectroscopy 
Nakamoto first studied the pH dependence of bipy and terpy in water, and 
demonstrated that at low pH, free bipy and terpy display similar absorption profiles to those 
of the metal complexes, consistent with the cis- and cis-cis- conformation. However, the 
* bands shift to higher energy on increasing the pH, and resemble those recorded in 
organic solvents, consistent with the trans- and trans-trans- conformations.[41,59] It was 
hypothesised that deprotonation of the pyridinyl ring on increasing the pH, resulted in cis-to-
trans conformational transitions of the bipy and terpy, and has been supported more recently 
by theoretical studies.[67-69] Protonation of the pyridinyl nitrogen is believed to induce 
delocalisation of π electrons over two rings instead of only one for unprotonated 
analogues.[3,67] 
Similar to the UV spectra of unsubstituted bipy and terpy, the absorbance of bipy-GS2 
and terpy-GS2 in aqueous solution is sensitive to pH variation. The UV spectra of a 5 μM 
solution (quantification based on UV profile) of bipy-GS2 recorded between pH 6 and 10, 
display two transitions with λmax at 295 (ɛ295 nm 19,600 M
-1
 cm
-1
) and 245 nm (ɛ245 nm 15,200 
M
-1
 cm
-1
), assigned as π→π*1 and  π→π*2 transitions (see Figure 2.24A).[70] The analogous 
terpy-GS2 spectrum displays a peak with λmax 297 nm (ɛ297 nm 20,300 M
-1
 cm
-1
) attributed to 
π→π*1, however, the π→π*2 transition which occurs around 221 nm, overlaps with that for 
the peptide bond (Figures 2.24B). Upon acidification by addition of concentrated HCl, these 
bands decrease in intensity whilst new bands appear at lower energy. A plot of absorbance as 
a function of pH allows for an approximation of the associated pKa values (see Figure 2.24C 
and D). 
Chapter 2 – Model peptide switches as allosteric regulators 
 
97 
 
 
Figure 2.24 – pH Titration of model compounds monitored by UV spectroscopy. UV spectra 
of 5 µM bipy-GS2 (A) and terpy-GS2 (B) recorded at pH values between 1.5 and 10, (▬) 
acidic, (■■■) intermediary, (▬) basic. Plot of the absorbance maxima as a function of pH for 
(C) bipy-GS2 (295 nm, ; and 319 nm,□) and (D) terpy-GS2 (295 nm, ; 340 nm,□; and 367 
nm, ∆); dotted line represents approximation of pKa values. 
 
The UV spectra recorded for bipy-GS2 and terpy-GS2 at pH 8 are very similar to those 
recorded for cys2bipy and cys2terpy, under similar conditions (see section 2.2.3.2). Plots of 
absorbance at 295, 319 nm (bipy-GS2) and 295, 340, 367 nm (terpy-GS2) as a function of 
pH, are consistent with pKa values within 0.5 log unit from the pKa values reported for bipy 
(4.44) and terpy (2.59, 4.16).[41] More importantly, absorbance of the maxima does not 
change between 6-9. Therefore, slight variation of the pH solution in this range would not 
have important consequences on the UV spectra and the conformation of the linker unit, and 
that at physiological pH our linkers adopt the trans- conformation. 
The shift of the π→π* band was used to estimate the Cu(II) and Zn(II) binding 
constants to bipy-GS2 and terpy-GS2, similarly to Zn(II) titration for cys2bipy (see Figure 
2.23). Titrations were performed at physiological pH (7.4), low micromolar concentrations, 
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and where necessary a competitor was introduced. Aliquots of a stock solution of ZnCl2 were 
titrated into a 5 μM solution of either bipy-GS2 or terpy-GS2 in 20 mM phosphate buffer pH 
7.4. This resulted in the steady decrease in the absorbance at 295 (bipy-GS2) and 297 nm 
(terpy-GS2), and an increase in the absorbance at 308 and 320 nm (bipy-GS2), and 330 and 
340 nm (terpy-GS2), respectively (see Figures 2.25A and B). Between 0 and 1 equivalent of 
Zn(II) added, the observation of isosbestic points at 303 (bipy-GS2) and 313 nm (terpy-GS2) 
are consistent with the clean formation of the Zn(II) complex.  
 
Figure 2.25 – UV spectra for the Zn(II) titration of model switches. ZnCl2 was added to 
solutions containing 5 µM of either bipy-GS2 (A) or terpy-GS2 (B) in 20 mM phosphate 
buffer pH 7.4. (▬) 0 eq., (▬) 1 eq., (■■■) between 0 and 1 eq., (▬●▬) more than 1 eq. ZnCl2 
added. 
 
A plot of the absorbance as a function of Zn(II) concentration indicates the formation of 
a 1:1 complex between Zn(II) and both the model ligands (see Figure 2.26). Upon non-linear 
fitting to a 1:1 binding model, extinction coefficients at 320 nm for bipy-GS2 and 
Zn(II):bipy-GS2 were determined to be 1,180 M
-1
 cm
-1
 and 22,700 M
-1
 cm
-1
, respectively. 
The extinction coefficients at 340 nm for terpy-GS2 and Zn(II):terpy-GS2 were estimated to 
be 800 M
-1
 cm
-1
 and 19,850 M
-1
 cm
-1
, respectively. Formation constants, log KM, were 
calculated to be 6.86 ± 0.05 for Zn(II):bipy-GS2 and 6.22 ± 0.04 for Zn(II):terpy-GS2, see 
Table 2.2. 
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Figure 2.26 – Plot of absorbance for the Zn(II) titration of (A) bipy-GS2 monitored at 320 nm 
(■), or (B) terpy-GS2 monitored at 340 nm (●) versus the equivalence of Zn(II). Line 
represents best fit for a 1:1 Zn(II):model switch binding ratio.  
 
Table 2.2 – Summary of data obtained for Zn(II) coordination to model switches.  
 λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
Bipy-GS2 320 2.27 ± 0.02  Е +04 1.21 ± 0.75  Е +06 7.30 ± 0.89  Е +06 0.9965 
Terpy-GS2 340 1.99 ± 0.03  Е +04 2.77 ± 0.29  Е +05 1.67 ± 0.17  Е +06 0.9983 
 
The analogous titration performed with CuCl2, resulted in a decrease in the absorbance 
at 295 nm (bipy-GS2) and 297 nm (terpy-GS2), accompanied by an increase in the 
absorbance at 317 and 328 nm (bipy-GS2) and at 335 and 347 nm (terpy-GS2), assigned to 
the formation of Cu(II):bipy-GS2 and Cu(II):terpy-GS2, respectively. Between 0 and 1 
equivalent of Cu(II) added, the isosbestic points at 305 (bipy-GS2) and 315 nm (terpy-GS2) 
are again consistent with a single equilibrium (see Figure 2.27A and B). 
 
Figure 2.27 – UV spectra for the Cu(II) titration of model switches. CuCl2 was added to 
solutions containing 5 µM of either bipy-GS2 (A) or terpy-GS2 (B) in 20 mM phosphate 
buffer pH 7.4. (▬) 0 eq., (▬) 1 eq., (■■■) between 0 and 1 eq., (▬●▬) more than 1 eq. CuCl2 
added. For (A) buffer concentration was 100 mM and 20 mM L-glycine was added as 
competitor. 
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Monitoring the absorbance at 328 nm (bipy-GS2) and 335 nm (terpy-GS2) and plotting 
these as a function of CuCl2 equivalence, is also consistent with the formation of 1:1 
complexes (see Figure 2.28). Non-linear fitting results in extinction coefficient estimations of 
ε317 nm 19,500 M
-1
 cm
-1 
(Cu(II):bipy-GS2), and ε335 nm 13,400 M
-1
 cm
-1, ε347 nm 15,300 M
-1
 cm
-1 
(Cu(II):terpy-GS2). Formation constants, log KM, were estimated to be 12.53 ± 0.04 for 
Cu(II):bipy-GS2 and two slightly different values of 8.04 ± 0.04 (A335) and 7.14 ± 0.04 (A347) 
were obtained for Cu(II):terpy-GS2, depending on the wavelength monitored, see Table 2.3. 
 
Figure 2.28 – Plot of absorbance for the Cu(II) titration of (A) bipy-GS2 monitored at 328 
nm (□), or (B) terpy-GS2 monitored at 335 (○) and 347 nm (◊), versus the equivalence of 
Cu(II). Line represents best fit for a 1:1 Cu(II):model switch binding ratio. 
 
Table 2.3 – Summary of data obtained for Cu(II) coordination to model switches.  
 λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
Bipy-GS2 328 1.95 ± 0.01  Е +04 6.73 ± 0.66  Е +05 3.39 ± 0.34 Е +12
a
 0.9987 
Terpy-GS2 
335 1.34 ± 0.00  Е +04 3.33 ± 0.31  Е +06 1.09 ± 0.10 Е +08 0.9997 
347 1.53 ± 0.02  Е +04 4.21 ± 0.42  Е +05 1.38 ± 0.14 Е +07 0.9988 
a
 Titration performed with L-glycine (20 mM) as competitor in addition to phosphate buffer. 
 
Cu(II) and Zn(II) titrations of bipy-GS2 and terpy-GS2 solutions, for which 
concentrations were based on UV profiles and using extinction coefficients determined for 
cys2bipy and cys2terpy respectively, all indicate 1:1 (conjugate:metal ion) binding ratio. 
These results demonstrate that the π→π* transition is not sensitive to replacing the cysteine 
amino-acid with GSH, and that 1:1 complexes are formed under these experimental 
conditions. 
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The binding constants reported in Tables 2.2 and 2.3 are in good agreement with those 
reported previously for related ligands.[31,33,54,59,63,71] However, the affinity of bipy-GS2 
for Zn(II) (measured at C = 5 μM and pH 7.4) seems slightly higher than that for the 
analogous cys2bipy (measured at C= 35.5 μM and pH 8), but experimental conditions were 
different. Our model compounds, bipy-GS2 and terpy-GS2, display higher affinity for Cu(II) 
than for Zn(II), consistent with the Irving-Williams series and previous reports,[59] and bipy-
GS2 displays a higher affinity for both Cu(II) and Zn(II) than terpy-GS2. The latter 
observation is consistent with lowering of the binding constant for terpy-GS2 resulting from 
the strain introduced by substitutions at position 6- and 6’’-, as previously reported for 
polypyridine.[31,72] In the case of terpy-GS2, fitting the data for the two π→π* transitions as 
a function of Cu(II) concentration lead to different affinities, related by a factor of 10 (see 
Table 2.3). One can postulate that these could be due to different Cu(II) coordination 
environments (possibly arising from partial deprotonation of water bound to Cu(II)[73]), 
where two different Cu(II):terpy-GS2 complexes contribute differently to the absorbance at 
335 and 347 nm. 
The addition of CuCl2 to solutions of bipy-GS2 and terpy-GS2 buffered at pH 7.4 was 
also accompanied by weaker transitions between 400-900 nm. Aliquots of a stock solution of 
CuCl2 titrated into a more concentrated 350 μM solution of bipy-GS2, resulted in an increase 
in the absorbance at 622 nm up to 1.5 equivalents of Cu(II). Further addition of CuCl2 led to 
only a small increase in the absorbance at 622 nm and an increase at 440 nm, consistent with 
addition of CuCl2 to the blank buffered solution (see Figure 2.29A and C).  An analogous 
titration of CuCl2 into a 100 μM solution of terpy-GS2 buffered at pH 7.4, resulted in an 
increase in the absorbance at 675 nm up to 2.0 equivalents of Cu(II), which blue-shifted 
slightly to 670 nm on addition of between 1.0 and 1.5 equivalents of Cu(II). No further 
changes were observed upon addition of between 2.0 and 3.0 equivalents of CuCl2 (see Figure 
2.29B and D). 
Chapter 2 – Model peptide switches as allosteric regulators 
 
102 
 
 
Figure 2.29 – UV spectra for the Cu(II) titration of model switches. CuCl2 was added to 
solutions containing either 350 μM bipy-GS2 (A) or 100 μM terpy-GS2 (B) buffered at pH 
7.4. Plot of absorbance monitored at 622 (■) and 440 nm (◊) for bipy-GS2 (C) and 670 (■) 
and 500 nm (◊) for terpy-GS2 (D), versus the equivalence of Cu(II). 
 
Monitoring of the d-d band by visible spectroscopy (400-900 nm range), which appears 
upon coordination of Cu(II), indicates the final formation of a 1.5Cu(II):1bipy-GS2 and 
2Cu(II):1terpy-GS2  complex (see Figures 2.29C and D). The d-d band for Cu(II) 
coordination to bipy-GS2 in a 1Cu(II):1bipy-GS2  ratio, (bipy-GS2: λmax = 620 nm, ε620 = 51 
M
-1
 cm
-1
) is consistent with previous reports for the formation of  [Cu
II
(bipy)(OH)2] (λmax = 
620 nm, ε620 = 49 M
-1
 cm
-1
).[65] In contrast, the d-d band for the Cu(II) coordination to 
terpy-GS2 in a 1:1 ratio (terpy-GS2: λmax = 675 nm, ε675 = 131 M
-1
 cm
-1
) has an absorption 
coefficient higher than the values reported for the [Cu
II
(terpy)]
2+
 cation at pH 4 (λmax = 680 
nm, ε680 = 75 M
-1
 cm
-1
[74,75]), but much lower compared to the πS→Cu(II) charge transfer 
bands characteristic of blue copper proteins (λmax = 625 nm, ε625 = 5,000 M
-1
 cm
-1
 [76]). 
However, calorimetric and EPR studies on [Cu
II
(terpy)]
2+
 are consistent with a partial 
deprotonation of Cu(II)-bound water at physiological pH (pKa = 8.11), resulting in a 
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tetrahedral distortion in the plane of [Cu
II
(terpy)]
2+
.[73] This distortion could be consistent 
with a larger absorptivity of the ligand field.[77] 
Small d-d band shifts are observed upon addition of between 1-1.5 eq. Cu(II) (bipy-
GS2) or 1-2 eq. Cu(II) (terpy-GS2), consistent with only minor changes to the Cu ion 
coordination environment. Similarly the lack of contribution from the π→π* on formation of 
the 1.5Cu(II):1bipy-GS2 and 2Cu(II):1terpy-GS2 complexes, is consistent with no significant 
change to the polypyridine coordination chemistry with respect to the analogous 1:1 
complexes.  
It is possible that the Cu(II) coordinates to the bipy or terpy ligand, and groups from 
the GSH units ca N- or C-termini, amino acid side chains or amide bonds, on formation of the 
initial 1:1 complexes.[78-82] The formation of the 1.5Cu:1bipy-GS2 complex could involve 
the formation of a new intermolecular Cu(II) coordination site between two [Cu
II
(bipy-GS2)] 
complexes (see Figure 2.30A). Whereas on formation of the 2Cu:1terpy-GS2 complex, the 
second Cu(II) could be coordinated exclusively by the GSH units (see Figure 2.30B). 
 
Figure 2.30 – Scheme depicting the hypothesised successive formation of complexes upon 
Cu(II) addition to either bipy-GS2 (A) or terpy-GS2 (B). X represents exogenous water, 
hydroxide, or chloride ligands. 
 
One can expect that the formation of complexes where Cu(II) is surrounded by a 
glycine-like chelating motif would have a d-d transition in the region 600-650 nm 
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([Cu
II
(glyglyNH2-H)2]: λmax = 650 nm, ε650 = 69 M
-1
 cm
-1
 [83], where glyglyNH2 stands for 
amidated diglycine), and would therefore be undistinguishable from the d-d for Cu-
polypyridine and mixed Cu-glycil-polypyridine complexes ([Cu
II
(bipy)(glyNH2)]: λmax = 618 
nm, ε618 = 60 M
-1
 cm
-1
),[84] where glyNH2 stands for amidated glycine). 
 
2.2.4.3 – Cu(II)/Zn(II) titration of bipy-GS2 and terpy-GS2 monitored by CD 
The CD spectra of 350 µM solutions of bipy-GS2 and terpy-GS2, recorded from 400 to 
200 nm, did not display any notable signal. However, the addition of increasing 
concentrations of ZnCl2 to the solution of bipy-GS2 at pH 7.4 led to the appearance of new 
positive transitions centred at 220, 241, 310 and 320 nm, as well as a negative transition at 
266 nm, with isosbestic points at 251 and 285 nm (Figure 2.31A). In contrast, addition of 
ZnCl2 to terpy-GS2 resulted in negative transitions at 228, 329, and 340 nm and positive 
transitions at 283 and 290 nm, with isosbestic points at 270 and 298 nm (Figure 2.31B). In 
both cases, addition of excess ethylenediamine tetraacetic acid (EDTA), 20 equivalence with 
respect to metal, resulted in CD spectra which were in good agreement with those of bipy-
GS2 and terpy-GS2 recorded in the absence of Zn(II). 
 
Figure 2.31 – CD spectra for Zn(II) titration of model switches. ZnCl2 titration into 350 µM 
of either (A) bipy-GS2 or (B) terpy-GS2 in 10 mM phosphate buffer pH 7.4. (▬) 0 
equivalent, (■■■) between 0 and 1 eq., (▬) 1 eq., (▬ ▬) more than 1 eq. ZnCl2. 
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Plots of molar ellipticity for the maximum as a function of ZnCl2 equivalence reaches a 
plateau at ca. 0.9 (bipy-GS2) and 1.0 equivalents (terpy-GS2) of Zn(II) per model switch 
(Figure 2.32). 
 
 
Figure 2.32 – Plot of the molar ellipticity as a function of the equivalence of Zn(II) for model 
switches titration: (A) bipy-GS2 monitored at 241 (♦), 266 (■), 310 () and 320 nm (Χ); (B) 
terpy-GS2 monitored at 228 (◊), 283 (□), 290 (■), 329 (Χ) and 340 nm (∆). 
 
 
Similarly, the addition of CuCl2 to bipy-GS2 (see Figure 2.33A) resulted in the 
appearance of positive transitions at 247 and 320 nm, and a negative transition centred at 278 
nm. The peak intensities increase up to 1.0 equivalent of Cu(II), with clear isosbestic points at 
265 and 292 nm. Further addition of CuCl2 resulted in a gradual shift of the positive 
transitions toward 251 and 310 nm, and the negative transition toward 282 nm. All signals 
decreased in intensity, reaching a minimum on addition of 1.5 equivalents of CuCl2. No 
further spectral changes occur on addition of up to 3.0 equivalents CuCl2 (see Figure 2.33A). 
The titration of increasing concentrations of CuCl2 into a 350 µM solution of terpy-GS2 at pH 
7.4 resulted in the appearance of a negative transition centred at 215 nm. Two overlapping 
negative transitions at 335 and 347 nm appear on addition of between 1.0 and 2.0 equivalent 
of CuCl2. No further spectral changes occur on addition of up to 3.0 equivalents CuCl2 (see 
Figure 2.33B). In both cases, addition of excess EDTA (20 eq. with respect to metal) resulted 
in CD spectra which were in good agreement with those of bipy-GS2 and terpy-GS2 recorded 
in the absence of Cu(II). 
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Figure 2.33 – CD spectra for Cu(II) titration of model switches. CuCl2 titration into 350 µM 
of either A) bipy-GS2 or B) terpy-GS2 in 10 mM phosphate buffer pH 7.4. (▬) 0 eq, (■■■) 
between 0 and 1 eq., (▬) 1 eq., (▬ ▬) between 1 and 2 eq. CuCl2 added. 
 
Plots of molar ellipticity as a function of CuCl2 concentration reach plateaus at ca 1.5 
equivalents (bipy-GS2), or 2.0 equivalents (terpy-GS2) of Cu(II) per model switch (see 
Figure 2.34). 
 
Figure 2.34 – Plot of the molar ellipticity as a function of the equivalence of Cu(II) for model 
switches titration: A) bipy-GS2 monitored at 247 (♦), 278 (■) and 320 nm (▲); B) terpy-GS2 
monitored at 215 (♦) and 334 nm (■). 
 
The relatively featureless CD spectra of the model switches are altered dramatically 
upon metal coordination. Titrations of bipy-GS2 and terpy-GS2, display chiral induced CD 
signals relative to the bipy and terpy π→π* bands (250-400 nm range). In contrast, similar 
Cu(II)/Zn(II) titration of 350 μM solution of pyr-GS2 did not result in intensity increase of 
π→π* band. The cotton effect induced upon Zn(II) addition is opposite for terpy-GS2 and 
bipy-GS2 (see Figure 2.31). This indicates that the lower energy transition for [Zn(terpy-
GS2)Xn]
m+
 might arise from π→π* electronic absorptions involving molecular orbitals 
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composed mainly from atomic orbitals from atoms composing the central pyridine ring, as 
previously suggested.[41] In contrast, the second lower energy transition (centred at 287 nm) 
for [Zn
II
(terpy-GS2)Xn]
m+
 could involve orbitals comprising contributions mainly from the 
external pyridines, and is therefore more similar to the lower energetic absorption band for 
[Zn
II
(bipy-GS2)Xn]
m+
. These observations are consistent with UV studies and formation of a 
1:1 complex with the Zn(II) coordinated to the intended polypyridine chelate of both bipy-
GS2 and terpy-GS2.  
Metal complexation of bipy or terpy results in polarisation of the π→π* transitions, and 
the appearance of induced CD signals.[85] Octahedral complexes bearing a single bidentate 
π-conjugated ligand, such as Co(phen)(en)2 (en = ethylenediamine and phen = 1,10-
phenanthroline), usually display weak π→π* signals in the CD, compared to M*(phen)2 or 
M*(phen)3 complexes,[86,87] for which the metal ions are chiral centres (see Figure 2.35A). 
As a significant exception, a previously reported Me2bipy bearing acidic peptide substituents 
displays more intense CD signal for the 1:1 compared to the 1:3 Fe(II):Me2bipy complex.[88] 
In this work, slow addition of FeCl2, which is expected to form octahedral Fe(bipy)3 
complexes with bipy at physiological pH,[88-90] to a 350 μM solution of bipy-GS2 resulted 
in precipitation of the conjugate, and no chiral induced π→π* were observed. Hence, the 
3bipy-GS2:1M complexes might have low solubility under these experimental conditions. 
The intensity of CD π→π* induced signals for bipy-GS2 and terpy-GS2 metal complexes 
could be explained by additional coordination through uncapped terminal amines, and sensing 
of the chirality at Cα from peptide units. To the best of our knowledge, no CD study was 
reported for complexes of the type Co(phen)(en)2, where en-like units are covalently attached 
to phen or bipy through one or several chiral center(s), similarly to bipy-GS2. If one envision 
CD spectra of metal complexes including one bipy and two en ligands, differing by presence 
of chiral centers or covalent bonding between the different ligands (compare Figures 2.35B, 
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C, and F), it is reasonable to assume that the intensity of the CD induced π→π* signals, could 
follow the order M*(bipy)(en)2 < M*(bipy)(en*)2 < M*[κ
6
-(bipy-en2)**].  
 
Figure 2.35 – Scheme depicting octahedral mixed complexes with bipy and en mixed ligand. 
X represents exogenous water or hydroxide, * indicate chiral centres, and (---) depict covalent 
bonding. (A) M*(bipy)3, (B) M*(bipy)(en)2, (C) M*(bipy)(en*)2 , (D) M(en*)2X2, (E) M[κ
4
-
(bipy-en)*]X2, and (F) M*[κ
6
-(bipy-en2)**]. For (C), (D) and (F), additional isomers arise 
from the relative positions of the en substituents.  
 
The shift in the bipy-GS2 and terpy-GS2 π → π* band (200-400 nm range) in the UV 
spectra upon addition of Cu(II), is also consistent with a ca. 1:1 ratio in all cases (see Figure 
2.28). However, CD spectra suggest that the complexation of Cu(II) is more complicated, and 
involves the formation of two different Cu(II) complexes with differing contributions to the 
metal-bound π → π* bands. This is not obvious in the UV spectra, but is observed for Cu(II) 
complexation to both bipy-GS2 and terpy-GS2 by CD, due to exciton effects.[91-94] The CD 
titration of Cu(II) into bipy-GS2, results in chiral induced signals relative to the bipy π→π* 
band (250-400 nm range) up to one equivalent consistent with the formation of a 1:1 complex 
involving coordination through the pyridine units.  However, the CD titration indicates that 
this is followed by the formation of a 1.5Cu(II):1bipy-GS2 complex, as a result of a reduction 
in these induced CD signals. In contrast, the analogous CD titration with terpy-GS2 did not 
result in the formation of induced CD signals relative to the bipy π→π* band up to one 
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equivalent of Cu(II). However, it is consistent with the initial formation of a 1:1 complex, 
followed by a 2Cu(II):1terpy-GS2 complex (see Figure 2.34). 
The successive events observed by CD upon Cu(II) addition to bipy-GS2 or terpy-GS2, 
are consistent with the growing of d-d bands monitored by UV-vis (see Figure 2.29), and can 
be explained by the successive formation of different Cu(II) complexes hypothesised (see 
Figure 2.30). Following the proposed order of Cu(II) complexation events, addition of Cu(II) 
would first result in the formation of a complex type Cu
II
[κ6-(bipy-en2)**], followed by 
reorganisation into Cu
II
[κ4-(bipy-en)*X2] and Cu
II
(en*)2X2, hence the decrease in signal 
intensities observed (see Figures 2.35D, E, and F). The weak exciton coupling for Cu
II
[κ6-
(bipy-en2)**] compared to Zn
II
[κ6-(bipy-en2)**] might result from the Jahn-Teller 
distortion.[95-97] It is more difficult to interpret observations for terpy-GS2, as the different 
π→π* contribution and chiral induced signals of terpy have been less extensively studied and 
reported in the literature. 
 
2.2.4.3 – Zn(II) titration of bipy-GS2 and terpy-GS2 monitored by NMR 
The 
1
H NMR spectrum of a 5 mM solution of bipy-GS2 in D2O at pD 1, displays two 
singlets at 8.83 and 8.42 ppm in the aromatic region, integrating to two and four protons, 
respectively. In contrast, one singlet at 8.59 ppm and two overlapping doublets at 8.04 and 
8.00 (AB pattern), each integrating to 2 protons, are observed on raising the pD to 7.4 (see 
Figure 2.36A). A titration of ZnCl2 into a 5 mM solution of bipy-GS2 in D2O buffered at pD 
7.4, results in the broadening and decrease in intensity of the peaks at 8.59, 8.04 and 8.00 
ppm, and the appearance of new peaks at 8.66 (broadened, H
6
), 8.42 (doublet, H
3
) and 8.20 
(doublet, H
4
) ppm on addition of 1.0 equivalent of ZnCl2 (see Figure 2.36B). A plot of peak 
integration of the overlapping doublets (8.04 and 8.00 ppm) as a function of equivalence of 
ZnCl2 indicates a 1:2 Zn:bipy-GS2 ratio. Similarly a plot of peak integration for the resulting 
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doublet for the Zn-bipy-GS2 adduct at 8.20 ppm, also plateaus at 0.5 equivalence ZnCl2 
consistent with a 1:2 Zn:bipy-GS2 ratio (see Figure 2.36C). After 0.5 equivalents of ZnCl2 
have been added the peaks at 8.59, 8.04 and 8.00 ppm appear to have been replaced with 
broad new peaks at 8.42 and 8.20 ppm. Upon addition of between 0.5 and 1.0 eq. ZnCl2 these 
peaks sharpen into doublets and a broad peak attributed to H
6
 appears at higher frequency 
(8.66 ppm). Only very small changes are observed on addition of between 1.0 and 2.0 
equivalents of ZnCl2 (see Figure 2.36B). Addition of excess EDTA (20 eq. with respect to 
ZnCl2) resulted in a 
1
H NMR spectrum which is in good agreement with that of bipy-GS2 
recorded in the absence of ZnCl2 (see Figure 2.36B). 
 
Figure 2.36 – (A) 1H NMR spectra of 5 mM bipy-GS2 recorded at pD ~ 1, (B) 
1
H NMR 
Zn(II) titration of 5 mM bipy-GS2 in solution buffered at pD 7.4. (C) Plot of change in 
percentage peak integration as a function of equivalence of ZnCl2 for 8.04-8.00 ppm 
resonances for H
3
 and H
4
 of the free model switch, bipy-GS2 (●), as well as for the new peak 
at 8.20 ppm for H
4
 of the Zn-bipy-GS2 adduct (Χ). All spectra were recorded at 300 MHz and 
293 K. 
 
At acidic pD (ca. 1) the 
1
H NMR spectrum of terpy-GS2 recorded in D2O displays 5 
aromatic signals (all doublets of doublets) at 8.68 (2H
3a,b
), 8.67 (2H
4a,b
), 8.59 (2H
3
), 8.47 
(1H
4
) and 8.17 ppm (2H
5a,b
), which were assigned using COSY and NOESY NMR (see 
Chapter 2 – Model peptide switches as allosteric regulators 
 
111 
 
Figure 2.37). The COSY spectrum displays cross-peaks between H
3
 <-> H
4
 and H
4a
 <-> H
5a
 
(n.b. H
3a
 and H
4a
 are too close, so the cross-coupling overlaps with the diagonal peaks). In 
contrast, NOESY NMR recorded under similar conditions, displays an additional H
3a
 <-> H
3
 
inter-ring coupling (see Figure 2.37B). 
 
 
Figure 2.37 – 2D NMR of terpy-GS2 9 mM solution in D2O (pD ~1, 300 K). (A) COSY 
spectrum recorded at 400 MHz; (B) NOESY spectrum recorded at 500 MHz, 450 ms mixing 
time. 
 
On raising the pD to 7.4, three aromatic resonances are observed at 8.08 (1H
4
, 2H
3
, 2H
3a
), 
7.96 (2H
4a
) and 7.55 ppm (2H
5a
). A titration of ZnCl2 into a 5 mM solution of terpy-GS2 in 
D2O buffered at pD 7.4, resulted in the decrease in intensity of the peaks at 8.08, 7.96 and 
7.55 ppm, and the appearance of new broad peaks at 8.31, 8.13 and 7.65 ppm. This is 
accompanied by a decrease in the intensity of the singlet at 3.99 ppm assigned to the CH2-
pyridinyl group. A plot of the peak integration for the singlet at 3.99 ppm, as a function of 
ZnCl2 concentration (Figure 2.38C), is consistent with formation of a 1:1 complex between 
Zn(II) and terpy-GS2. Addition of excess EDTA (20 eq. with respect to ZnCl2) resulted in a 
1
H NMR spectrum which is in good agreement with that of terpy-GS2 recorded in the 
absence of ZnCl2 (see Figure 2.38B). 
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Figure 2.38 – (A) 1H NMR spectra of 9 mM terpy-GS2 recorded at pD ~ 1 (500 MHz, 298 
K), (B) 
1
H NMR Zn(II) titration of 5 mM terpy-GS2 in solution buffered at pD 7.4 (300 
MHz, 293 K). (C) Plot of change in percentage peak integration as a function of equivalence 
of ZnCl2 for terpy-GS2 methyl singlet (♦) at 3.99 ppm. The peak at 3.96 ppm labelled with †, 
was attributed to the 
13
C satellite relative to the -N-CH2-COOH signal of EDTA centred at 
3.72 ppm. 
 
The 
1
H NMR spectrum of bipy-GS2, recorded under acidic conditions is very different 
from that recorded at neutral pD. A single resonance, attributed to H
3
 and H
4
 of bipy-GS2, is 
observed at pD 1, however, an AB pattern where the two overlapping doublets are located at a 
lower chemical shift, is observed at pD 7.4. Both spectra are different from those of Me2bipy 
recorded in DMSO-d6 (see Figure 2.15A), probably due to the strong second order coupling. 
Addition of ZnCl2 to a 5 mM solution of bipy-GS2 at pD 7.4 results in new broad peaks 
which indicates that bipy-GS2 and the complex(es) it forms with ZnCl2 are in 
slow/intermediary exchange(s) on the NMR time-scale. A plot of peak integration as a 
function of Zn(II) equivalence is consistent with either the formation of a 2bipy-GS2:1Zn 
complex, or an equilibrium involving 3bipy-GS2:1Zn, 2bipy-GS2:1Zn, and 1bipy-GS2:1Zn 
complexes. The spectrum at 0.5 equivalents Zn(II) does not display any signal assigned to H
6
, 
most likely due to signal broadening as a result of H
6
 proximity with the chloride ligands. 
However a broad resonance assigned to H
6
 reappears on addition of more ZnCl2 (between 0.5 
Chapter 2 – Model peptide switches as allosteric regulators 
 
113 
 
and 1 equivalent) and sharpens in the presence of excess Zn(II) (5 and 10 equivalents), which 
may be consistent with conversion of the 2bipy-GS2:1Zn(II) complex into a 1bipy-
GS2:1Zn(II) complex.[51,98]  
Theoretical studies suggest that even though monoprotonated bipy and bidentate metal 
complexes of bipy have energy minima with similar conformations (cis), flexibility around 
the axial bond of bipy is much higher in the monoprotonated bipy compared to the metal 
complexes.[99] In fact, the difference in potential energy separating cis- and trans- 
conformations has been reported to be comparable for the monoprotonated and free 
bipy.[67,68,99] This could account for the similarity of resonances assigned as H
3
 and H
4 
in 
spectra of bipy-GS2 recorded at acidic and neutral pD, which in turn differ from those 
recorded for the Zn(II) complex (see Figure 2.39). 
 
 
Figure 2.39 – Illustration of the relationship between energy profiles and 1H NMR spectra for 
bipy-GS2. 
1
H NMR spectra of bipy-GS2 are more greatly influenced by conformational 
flexibility rather than the conformation of the lowest energy structure. Representation of 
energy profiles regulating the population of the different conformers of the (A) 
monoprotonated bipy-GS2, (B) bipy-GS2 and (C) when complexed to Zn(II), alongside 
1
H 
NMR spectra (D2O, 300 MHz, 293 K). Energy profiles and activation barriers are based on ab 
initio reports for the cis-trans interconversion of bipy.[67,69,99] The impact of substitutions 
at position 5 and 5’ on the rotation of the bipy can be ignored.[4] 
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NMR spectra of bipy or derivatives where H
3
 and H
4
 resonances overlap have 
previously been recorded in aqueous solution at both acidic[3,51] and physiological 
pH,[51,52] however, this is not exclusively the case.[3] Interpretation of bipy conformation 
based on NMR chemical shift can therefore lead to contradictory results. For example, 
theoretical studies suggest that H
3
 are deshielded in the trans- (cation free) bipy due to the 
close proximity with the nitrogen on the second ring.[4] Cation binding to bipy is expected to 
result in deshielding of aromatic resonances. In contrast, H
3
 can display only a moderate 
deshielding,[3] or shielding[100] upon trans-to-cis conformational transition, as deshielding 
effects on H
3
 from the proximal nitrogen are lost.[50,51] Therefore an attractive method by 
which to assign the bipy-GS2 conformation is by monitoring intra-ring coupling by NOESY 
NMR,[22] however, this is only possible for an asymmetric bipy for which H
3
 peaks are 
inequivalent, and so cannot be applied to bipy-GS2. 
In contrast, NOESY can be applied to terpy-GS2. At pD 1, the cross-peak observed 
between H
3
 and H
3a
 in the NOESY spectrum is consistent with at least half of the terpyridine 
adopting a cis- conformation (see Figure 2.37). The 
1
H NMR profile of terpy-GS2 at pD 1 is 
different for those recorded for Me2terpy in DMSO-d6, both in the absence or presence of 
Zn(II). The 
1
H NMR spectrum of terpy-GS2 recorded at pD 7.4 is different from that 
recorded at acidic pD, and is not suitable for determination of intra-ring coupling as the 
resonances for H
3
 and H
3a
 overlap. Upon raising the pD from 1 to 7.4, all aromatic signals 
move to lower frequency, and proton signals relative to external pyridine (H
3a
, H
4a
 and H
5a
) 
experience higher shielding than their counterpart (H
3
 and H
4
), consistent with a transition 
from mixed cis-trans- conformation to a trans-trans- conformation.[11] The 
1
H NMR profile 
of terpy-GS2 at pD 7.4 resembles that recorded for Me2terpy in DMSO-d6, with additional 
strong coupling (compare Figure 2.16 and 2.38). Addition of ZnCl2 lead to formation of broad 
resonances for a 1terpy-GS2:1Zn complex in slow/intermediary exchange on the NMR 
timescale. Signals are generally broad and difficult to assign, but integration of the three 
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signals indicates that the spectrum is different from that recorded for terpy-GS2 both at acidic 
and neutral pD, and could be consistent with the cis-cis conformation of a terpyridine metal 
complex.[63,54] 
Titration of Zn(II) into a 5 mM solution of terpy-GS2 monitored by 
1
H NMR, is 
consistent with a 1:1 binding ratio (see Figure 2.38C). In contrast, the titration of Zn(II) into a 
5 mM solution of bipy-GS2 indicates the formation of a 2bipy-GS2:1Zn(II) complex (see 
Figure 2.36C).[51,98] This is in stark contrast to the analogous titrations (CD, UV) recorded 
under more dilute (14 times and 1000 times respectively) and biologically relevant conditions, 
suggesting that the formation of a 2:1 complex with bipy-GS2 only occurs at high 
concentrations, and that the 1:1 [Zn
II
(bipy-GS2)Xn]
m+
 species dominates under more dilute 
conditions. 
2.3 – Summary 
This chapter reports the dimerisation of the single cysteine amino acid as well as a short 
cysteine containing tripeptide through (poly)pyridine linkers, and the study of the resulting 
species in terms of conformation, and Cu(II)/Zn(II) affinity. Both cysteine and GSH were 
dimerised through a 2,6-pyridinyl linker, affording cys2pyr and pyr-GS2 conjugates, 
respectively. After purification, cys2pyr could be obtained as a pure solid; however, pyr-GS2 
was recovered as a salt. Both conjugates only interact weakly with Cu(II) and not at all with 
Zn(II). Cu(II) titrations indicate a binding ratio of 1:1 cys2pyr:Cu(II), and 1:0.6 pyr-
GS2:Cu(II). The latter ratio was in fact demonstrated to correspond to 1:1 pyr-GS2:Cu(II), 
when the mass of salt was taken into consideration and the experimental molecular weight 
corrected accordingly. 
Following the pyridine work, Me2bipy (allosteric ineffective) and Me2terpy (allosteric 
effective) linkers were prepared. Zn(II) titrations monitored by 
1
H NMR, indicate formation 
of complexes with 1:1 Zn(II):linker stoichiometry. Additionally, 2D NMR studies indicate 
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that the Me2terpy linker undergoes trans-to-cis conformational transitions upon Zn(II) 
coordination.  
As this was the proposed strategy by which to dimerise larger peptides or protein 
fragments, cysteine was dimerised through Me2bipy and Me2terpy linkers, affording 
cys2bipy and cys2terpy. These conjugates both displayed limited solubility at physiological 
pH, incompatible with NMR studies, but could be solubilised upon addition of acid.  
Following this, analogous conjugates based on GSH, bipy-GS2 and terpy-GS2, were 
prepared and displayed higher solubility at physiological pH than their cysteine analogues. 
Extinction coefficients estimated for cys2bipy and cys2terpy π→π* bands, were used for 
quantification of bipy-GS2 and terpy-GS2, respectively. Their Cu(II) and Zn(II) coordination 
ability were evaluated in different concentration ranges and monitored by UV-visible, CD and 
NMR (Zn(II) only) spectroscopy. Titrations indicated that terpy-GS2 binds Cu(II) and Zn(II) 
in a 1:1 ratio. In contrast, Zn(II) titration of 5 mM bipy-GS2 monitored by 
1
H NMR indicate 
either the formation of a 2bipy-GS2:1Zn(II) complex or an equilibrium between different 
species, whereas Cu(II)/Zn(II) titration of solution containing 350 μM  and 5 μM bipy-GS2 
are in good agreement with formation of 1bipy-GS2:1Zn(II) complex under dilute conditions. 
Unlike for Zn(II), Cu(II) titrations monitored by CD indicate formation of 1:1 complexes 
followed by 1.5Cu:1bipy-GS2 and 2:1terpy-GS2 complexes. Moreover, monitoring of the 
Cu(II) d-d transitions also agrees with the formation of 1.5Cu:1bipy-GS2 and 2Cu:1terpy-
GS2 complexes. The different ratio are interpreted as a result of the reorganisation of Cu(II) 
coordination spheres.  
Cu(II) and Zn(II) titration at physiological pH were performed at low concentration and 
monitored by UV spectroscopy, indicating high affinity of the conjugates for both metal ions 
(log KM > 6). Cu(II) binding constants were found to be higher than those obtained for Zn(II), 
and the sterically less strained conjugates (5,5’-substitutions) form more stable complexes 
with both metal ions. The following chapter will focus on the preparation of conjugates where 
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these polypyridine regulation sites are used to dimerise larger peptide moieties, for which 
their spatial alignment is important for biomolecular recognition. 
2.4 – Experimental section 
2.4.1 – Reagents and equipment 
NaHCO3, Na2SO4, NaNO2, NaOH, KOH, mono- and dihydrogen potassium salts, tris 
base, ethylene diamine tetra acetic acid (EDTA), chloroform (CHCl3), methanol (CH3OH), 
ethanol, tetrahydrofuran (THF), toluene, dichloromethane (CH2Cl2), acetonitrile, dioxane, 
water (HPLC grade), hydrobromic acid 48 %w, HCl 32 %w, ammonia 35 %w,  bromine, 
were all obtained from Fisher Scientific. 2,6-Bis(bromomethyl)pyridine, 5,5’-dimethyl-2,2’-
bipyridine, N-butyllithium 1.6 M in hexane, diethylether, copper chloride (CuCl2), L-glycine, 
and cysteine were obtained from Sigma-Aldrich. 2-Bromopicoline, 2,6-dibromopyridine, 
tetrakis-(triphenylphosphine) palladium, trifluoroacetic acid (TFA), tributyltin chloride, zinc 
chloride (ZnCl2) were obtained from BOC. N-Bromosuccinimide was obtained from Alfa-
Aesar. 5,5’-Dithiobis-(2-nitrobenzoic acid) and glutathione (> 97 % pure by HPLC, as a sum 
of enantiomers) were obtained from Fluka. TCEP.HCl was obtained from Thermo Scientific. 
Deuterated solvents (CDCl3, DMSO-d6 and D2O) were obtained from Cambridge Isotope 
Laboratory Inc. Dimethylformamide (DMF) was obtained from AGTC Bioproducts. 
HRES and ES-TOF MS were recorded on a Microwaters LCT TOF spectrometer 
equipped with a 3000 V capillary voltage, and a cone voltage of 35 V. GC-MS were recorded 
on a Waters GCT Premier Micromass equipped with an EI probe. Analytical RP-HPLC traces 
were recorded on C18 column using a 0 to 100 % gradient acetonitrile in water over 40 
minutes (either containing 0.05% TFA or not) and the absorption was monitored at 220 nm. 
The compound purity is reported as a percentage of its peak integral over the total integration 
for all peaks present between 0 and 40 minutes. UV-visible spectra were recorded in a 1 cm 
pathlength quartz cuvette at 298 K on either a CARY50 (spectrometer(a)) or Shimadzu 1800 
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(spectrometer(b)). Wavelengths (λ) are given in nm, and extinction coefficient (ε) in M-1 cm-1. 
CD spectra were recorded in 1 mm pathlength quartz cuvettes at 298 K on a Jasco J-715 
spectropolarimeter. The observed ellipticities in millidegrees were converted into molar 
ellipticity, [Ф], and are reported in units of deg dmol-1 cm2. All 1H and 13C NMR spectra were 
collected on either a Bruker DRX500 (500 MHz 
1
H and 125 MHz 
13
C, Gradient NOESY, and 
Phase cycle ROESY, T = 300 K), AVIII400 (400 MHz 
1
H, 100 MHz 
13
C, DQF-COSY, and 
Gradient NOESY, T = 298 K) or AVIII300 (300 MHz 
1
H, T = 293 K) spectrometer equipped 
with a 5 mm probe. Solvent residual signal, DMSO quintet (δ = 2.50 ppm), CHCl3 singlet (δ = 
7.26 ppm), were used as an internal reference. As an exception, dioxane was added to the tube 
and used as the internal standard (δ = 3.75 ppm), for all experiments recorded in D2O. For pD 
measurement, either pH paper (when sign ~ is used), or a Jenway 3510 pH meter were used. 
Chemical shifts (δ) are given in parts per million (ppm) to higher frequency compared to the 
methyl signal of either trimethylsilane (organic solvent), or the sodium salt of 3-
(trimethylsilyl)propanesulfonicacid (D2O) at 0 ppm.[101] Data were processed using Bruker 
Topspin version 2.1 (300 and 400 MHz) or 1.3 (500 MHz) and Mestrenova Lite version 5.2.5. 
 
2.4.2 – Synthetic procedure and characterisation 
Synthesis of cys2pyr: 2,6-bis(methyl-S-cysteinyl)pyridine 
 
To a degassed solution of cysteine (20.4 mM , 245 mL, 5 mmol) in 50 mM aqueous 
Tris.HCl buffer pH 8.0, was added 2,6-bis(bromomethyl)pyridine in DMF (0.4 M, 2.5 mL, 1 
mmol) dropwise. A white solid initially precipitated and was redissolved on addition of DMF 
(2.5 mL) and stirring for 4 hours under N2 bubbling at room temperature. The solvent was 
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evaporated in vacuo at 322 K to yield a white solid. The crude product was purified by 
preparative RP-HPLC (C18 Phenomenex, using water/acetonitrile methods, monitoring 
absorbance at 210 and 256 nm) twice: (1) between 2 and 3 % acetonitrile in water (isocratic 
sequence, but composition of the eluent was slightly varied depending on the quantity 
injected), and (2) 0 to 6 % gradient acetonitrile in water over 10 min, followed by 6 % 
isocratic acetonitrile in water for an additional 15 minutes. The solvent was evaporated in 
vacuo to yield pure 2,6-bis(methyl-S-cysteinyl)pyridine, as a white solid (112 mg, 32 %). 
1
H 
NMR (300 MHz, D2O, dioxane reference, pD ~ 6): 7.83 (t, 
3
JH4-H3 = 7.8 Hz, 1H, H
4
), 7.39 (d, 
3
JH3-H4 = 7.8 Hz, 2 H, H
3
), 3.92 (s, 4 H, H
7
), 3.88 (dd, 
3
JH9-H8b = 7.6 Hz, 
3
JH9-H8a = 4.3 Hz, 2 H, 
H
9
), 3.07 (dd, 
2
JH8a-H8b = 14.9 Hz,  
3
JH8a-H9 = 4.3 Hz, 2 H, H
8a
), 2.96 (dd, 
2
JH8b-H8a = 14.9 Hz,  
3
JH8b-H9 = 7.6 Hz, 2 H, H
8b
). 
13
C NMR 
1
H decoupled (100 MHz ; D2O ; dioxane reference, pD 
~ 6): 157.9 (C
2
), 139.8 (C
4
), 123.4 (C
3
), 54.3 (C
9
), 37.1 (C
7
), 32.5 (C
8
). HRES-TOF (water), 
calculated exact mass for C13H19N3O4NaS2: 368.0715; measured: 368.0721. ES-TOF: m/z = 
368.2 [M+Na]
+
 (50 %), m/z = 346.2 [M+H]
+
 (100 %). MALDI-TOF: m/z = 378.8 
[M+CH3OH+H]
+
 (23 %), m/z = 367.8 [M+Na]
+
 (30 %), m/z = 345.8 [M+H]
+
 (100 %). RP-
HPLC (no TFA): 100%. Elemental analysis: % calculated for C13H19N3O4S2: C 45.20, H 5.54, 
N 12.16; % measured: C 45.10, H 5.38, N 12.14. UV (water): 272 (5,530). 
 
Synthesis of pyr-GS2: 2,6-bis(methyl-S-glutathionyl)pyridine 
 
2,6-Bis(bromomethyl)pyridine (75.8 mg, 0.286 mmol) was added to 40.4 mL of 60 mM 
aqueous Tris.HCl buffer pH 8.0 solution. The suspension was degassed by N2 bubbling 
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directly into the solution, glutathione (58.8 mM, 0.573 mmol, 9.75 mL) aqueous solution was 
added, and the suspension was stirred at room temperature. The concentration of glutathione 
was monitored by Ellman’s test during the reaction. After 14 hours, the pH dropped down to 
3.7 and was increased to 7.4 by adding NaOH solution (1 M, 0.5 mmol, 500 µL). The reaction 
was stopped after 48 hours and the crude mixture was dried under vacuum, affording a 
colorless gel. The crude product was purified by preparative RP-HPLC (C18 Phenomenex, 
monitoring absorbance at 210 and 260 nm) in twice : (1) 0 to 25 % gradient of acetonitrile in 
water over 40 min (both containing 0.05 % TFA), and (2) 0 to 5 % gradient of acetonitrile in 
water over 20 min, followed by 5 % of acetonitrile in water isocratic for an additional 20 min 
(all eluents contained 0.05 % TFA). The solvent was evaporated in vacuo to yield 2,6-
bis(methyl-S-glutathionyl)pyridine as a salt, and as a colorless gel (160 mg, 78 %). 
1
H NMR 
(300 MHz, D2O, dioxane reference, pD ~ 1): 8.47 (t, 
3
JH4-H3 = 8.0 Hz, 1 H, H
4
), 7.93 (d, 
3
JH3-
H4 = 8.0 Hz, 2 H, H
3
), 4.54 (dd, 
3
JH9-H8a = 5.4 Hz, 
3
JH9-H8b = 8.3 Hz, 2 H, H
9
) ; 4.16 (s, 4 H, 
H
7
), 4.07 (t, 
3
JH16-H15 = 6.6 Hz, 4 H, H
16
), 3.99 (s, 4 H, H
11
), 3.04 (dd, 
2
JH8a-H8b = 14.2 Hz,  
3
JH8a-H9 = 5.4 Hz, 2 H, H
8a
), 2.88 (dd, 
2
JH8b-H8a = 14.2 Hz,  
3
JH8b-H9 = 8.3 Hz, 2 H, H
8b
), 2.57 
(m, 4 H, H
14
), 2.22 (m, 4 H, H
15
). 
13
C NMR 
1
H decoupled (100 MHz ; D2O ; dioxane 
reference, pD ~ 1): 174.9 (C
13
), 173.4 (C
12
), 172.8 (C
10
), 172.2 (C
17
), 154.5 (C
2
), 148.0 (C
4
), 
126.6 (C
3
), 53.3 (C
9
), 52.9 (C
16
), 41.7 (C
11
), 33.4 (C
8
), 33.1 (C
7
), 31.5 (C
14
), 26.1 (C
15
). 
HRES-TOF (water, negative mode) calculated exact mass for C27H40N7O12S2: 718.2176; 
measured: 718.2184. ES-TOF: m/z = 716.1 [M-H]
-
 (100 %). MALDI-TOF: m/z = 740.3 
[M+Na]
+
 (87 %), m/z = 718.2 [M+H]
+
 (100 %), m/z = 565.3 (11 %), m/z = 413.6 [M-
C10H16N3O6S+H]
+
 (33 %), m/z = 309.0 [C10H17N3O6S +H]
+
 (13 %). RP-HPLC (no TFA): 
100%. Elemental analysis : % calculated for C27H39N7O12S2 (pyr-GS2): C 45.18, H 5.48, N 
13.66; % measured: C 38.82, H 4.55, N 8.83; best match found: C33H49N7O43/2S2F9 (pyr-
GS2,3TFA,3.5H2O): C 35.30, H 4.40, N 8.73. UV: 274 (based on pyr-GS2: 3,190; based on 
pyr-GS2,3TFA,3.5H2O: 4,976). 
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Synthesis of bipy-Br2: 5,5'-dibromomethyl-2,2'-bipyridine [48,49] 
 
5,5’-dimethyl-2,2’-bipyridine (0.389 g, 2.11 mmol), N-bromosuccinimide (0.756 g, 4.23 
mmol) and azobisisobutyronitrile (10 mg, 0.06 mmol) were dissolved in 20 mL 
dichloromethane, refluxed using a 500 W halogen lamp, and the reaction progress monitored 
by TLC (SiO2, eluent: CH2Cl2/CH3OH (9/1)). After 4 hours, more N-bromosuccinimide 
(0.375 g, 2.10 mmol) was added and the reaction was refluxed for a further 2 hours. The 
mixture was allowed to cool to room temperature and the solution extracted with 0.1M 
aqueous NaHCO3 (5x 20 mL). The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. The solid was re-dissolved in 15 mL of a 50/50 mix CHCl3/CH3OH, 
and the resulting solution stored in the freezer overnight (253 K). A white solid precipitate 
was collected by filtration, air-dried, and recrystallized from CHCl3, to afford white crystals 
(0.219 g, 30 %). 
1
H NMR (300 MHz, CDCl3): 8.69 (d, 
3
JH6-H4 = 2.1 Hz, 2H, H
6
), 8.41 (d, 
3
JH3-
H4 = 8.2 Hz, 2H, H
3
), 7.86 (dd, 
3
JH4-H6 = 2.3 Hz,
 3
JH4-H3 = 8.2 Hz, 2H, H
4
), 4.54 (s, 4H, H
7
); 
13
C NMR 
1
H decoupled (100 MHz, CDCl3): 155.4 (C
2
), 149.4 (C
6
), 137.9 (C
4
), 134.1 (C
5
), 
121.4 (C
3
), 29.6 (C
7
); HRES-TOF (CH2Cl2) calculated mass for C12H10N2
79
Br2Na: 362.9108; 
measured: 362.9126. ES-TOF : m/z = 362.9 ([M+Na]
+
, 100 %). UV (ethanol): 256 (6,900), 
298 (13,000). 
  
Synthesis of 2-bromo-6-methyl pyridine[47] 
 
2-bromopicoline (10.8 g, 115 mmol) in 40 mL of hydrobromic acid (48 %) was cooled 
to 253 K in an ethanol bath. Bromine (14.4 mL, 280 mmol) was added dropwise, and the 
suspension was stirred for 90 min at 253 K. 30 mL of an aqueous solution of NaNO2 (8.9 M, 
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268 mmol) was added dropwise, and the solution was allowed to warm to room temperature 
over 2 hours with stirring. The mixture was re-cooled to 253 K, and 110 mL of a cool NaOH 
aqueous solution (16.5 M, 1.81 mol) added slowly, while maintaining the temperature below 
283 K. The mixture was allowed to warm to room temperature over the course of one more 
hour with continuous stirring. The mixture was then extracted with ethyl acetate and the 
organic layer dried over Na2SO4, filtered and concentrated in vacuo. The dark oil was then 
purified by Kugelrohr distillation to yield a colourless oil (9.906 g, 50 %). 
1
H NMR (300 
MHz, CDCl3): 7.43 (t, 
3
JH4-H5 = 
3
JH4-H3 = 7.7 Hz, 1H, H
4
), 7.29 (d, 
3
JH5-H4 = 7.9 Hz, 1H, H
5
), 
7.10 (d, 
3
JH3-H4 = 7.4, 1H, H
3
), 2.54 (s, 3H, H
7
); 
13
C NMR 
1
H decoupled (100 MHz, CDCl3): 
160.2 (C
6
), 141.5 (C
2
), 138.7 (C
4
), 125.2 (C
5
), 122.2 (C
3
), 24.3 (C
7
); HRES-TOF (CH2Cl2) 
calculated exact mass for C6H6
79
BrN: 170.9684; measured: 170.9686. EI-TOF: m/z = 171.0 
([M
.+
], 50 %), 92.0 ([M-Br]
+
, 100 %), 65.0 ([M-C2H3Br]
+
, 75 %). 
 
Synthesis of 2-tributylstannyl-6-methyl pyridine[47] 
 
A solution of 2-bromo-6-methylpyridine (4.63 g, 27 mmol) in dry THF (20 mL) was 
cooled to 213 K, 27 mL of n-butyllithium in hexane (1.1 M, 30.1 mmol) added dropwise, and 
the solution stirred for 2 hours at 213 K. Tributyltin chloride (8.9 mL, 32.8 mmol) was slowly 
added and the solution allowed to return to room temperature over 20 minutes with 
continuous stirring. Water (30 mL) was added to the reaction mixture, and phases were 
separated. The organic phase was washed with water (3x 30 mL), and the combined aqueous 
layers washed with diethylether (4x 30 mL). The combined organic phases were dried over 
Na2SO4, filtered and concentrated in vacuo to afford a black oil (9.534 g, 92 %). The crude 
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product was determined to be ca. 95% pure by GC analysis and so used directly in the 
following synthesis. 
1
H NMR (300 MHz, CDCl3): 7.36 (t, 
3
JH4-H5 = 
3
JH4-H3 = 7.5 Hz, 1 H
4
), 
7.17 (d, 
3
JH4-H5 = 7.3 Hz, 1H, H
5
), 6.96 (d, 
3
JH4-H3 = 7.9, 1H, H
3
), 2.54 (s, 3 H
7
), 1.56 (m, 6H, 
H
9
), 1.33 (m, 6H, H
10
), 1.09 (m, 6H, H
8
), 0.88 (t, 
3
JH11-H10 = 7.2, 9H, H
11
); 
13
C NMR 
1
H 
decoupled (100 MHz, CDCl3): 173.2 (C
6
), 158.7 (C
2
), 133.3 (C
4
), 129.5 (C
5
), 121.6 (C
3
), 29.2 
(C
9
), 27.5 (C
10
), 25.1 (C
7
), 13.8 (C
11
), 10.0 (C
8
); HRES-TOF (CH2Cl2): calculated exact mass 
for C18H33N
120
Sn: 384.1713; measured: 384.1715. EI-TOF: m/z = 326.0 ([M-C4H9]
+
, 52 %), 
268.0 ([M-C8H19]
+
, 54 %), 211.9 ([M-C12H26]
+
, 100 %), 177.0 ([M-C14H24]
+
, 14 %), 120.9 
([M-C18H32]
+
, 37 %), 93.1 ([M-C12H26Sn]
+
, 25 %). 
 
Synthesis of Me2terpy: 6,6’’-dimethyl-2,2’:6’,2’’-terpyridine[48] 
 
A solution of 2,6-dibromopyridine (1.39 g, 5.9 mmol), 2-tributylstannyl-6-methyl-
pyridine (5.02 g, 13.1 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.38 g, 0.33 
mmol) was refluxed in 40 mL degassed toluene for 5 days under a nitrogen atmosphere. Extra 
tetrakis(triphenylphosphine)palladium(0) (0.38 mg, 0.33 mmol) was added and the reaction 
refluxed for a further day under a nitrogen atmosphere. The crude mixture was then 
concentrated in vacuo, and dichloromethane (50 mL) and 6M hydrochloric acid (10 mL) 
added to form a dark brown slurry. The aqueous layer was washed with dichloromethane (2x 
50 mL) and the combined organic layers were washed with 6M hydrochloric acid (3x 10 mL). 
The combined aqueous layers were filtered and cooled in ice. Ammonia was slowly added 
until a light brown solid precipitated out. The resulting solid was filtered, air dried, 
redissolved in dichloromethane, dried over Na2SO4, and concentrated in vacuo. The crude 
product was purified on a chromatography column (Al2O3, hexane/DCM gradient) to afford 
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the pure 6,6’’-dimethyl-2,2’:6’,2’’-terpyridine as a white solid (0.63 g, 41 %). 1H NMR (300 
MHz, CDCl3): 8.46 (d, 
3
JH3-H4 = 7.8 Hz, 2H, H
3
), 8.41 (d, 
3
JH3a-H4a = 7.8 Hz, 2H, H
3a
), 7.93 (t, 
3
JH4-H3 = 7.8 Hz, 1H, H
4
), 7.73 (t, 
3
JH4a-H3a ~ 
3
JH4a-H5a = 7.7 Hz, 2H, H
4a
), 7.19 (d, 
3
JH5a-H4a = 
7.6 Hz, 2H, H
5a
), 2.65 (s, 6H, H
7
); 
13
C NMR 
1
H decoupled (100 MHz, CDCl3): 158.0 (C
6a
), 
155.9 (C
2/2a
), 155.8 (C
2/2a
), 137.8 (C
4
), 137.1 (C
4a
), 123.3 (C
5a
), 121.0 (C
3
), 118.3 (C
3a
), 24.8 
(C
7
); HRES-TOF (CH2Cl2): calculated mass for C17H15N3Na: 284.1164; measured: 284.1152. 
ES-TOF: m/z = 284.0 [M+Na]
+
 (100 %). 
 
Synthesis of terpy-Br2: 6,6’’-dibromomethyl-2,2’:6’,2’’-terpyridine[48,49] 
 
A solution of 6,6’-dimethyl-2,2’:6’,2’’-terpyridine (0.44 g, 1.7mmol), N-
bromosuccinimide (0.77 g, 4.3mmol) and azobisisobutyronitrile (10 mg, 0.06 mmol) in 
dichloromethane (30 mL) was refluxed using a 500 W halogen lamp. Progress of the reaction 
was monitored by TLC (SiO2, eluent: CH2Cl2/CH3OH (9/1)). After 15 hours, further N-
bromosuccinimide (0.3 g, 1.7mmol) was added and the reaction refluxed for a further 17 
hours. The mixture was extracted with 0.1 M NaHCO3 (5x 50 mL), the organic layers dried 
over Na2SO4 and concentrated in vacuo. Addition of a 50/50 mixture of CHCl3/CH3OH (15 
mL) and storage at 253 K overnight resulted in the formation of a white precipitate. This was 
collected by filtration, air-dried, and recrystallized from CHCl3 to afford white crystals (0.41 
g, 58 %). 
1
H NMR (300 MHz, CDCl3): 8.53 (d, 
3
JH3-H4 = 7.8 Hz, 2H, H
3
), 8.52 (d, 
3
JH3a-H4a = 
7.8 Hz, 2H, H
3a
), 7.96 (t, 
3
JH4-H3 = 7.8 Hz, 1H, H
4
), 7.86 (t, 
3
JH4a-H3a ~ 
3
JH4a-H5a = 7.8 Hz, 2H, 
H
4a
), 7.50 (d, 
3
JH5a-H4a = 7.7 Hz, 2H, H
5a
), 4.66 (s, 4H, H
7
). 
13
C NMR 
1
H decoupled (100 
MHz, CDCl3): 156.4 (C
2/2a
), 156.1 (C
2/2a
), 155.1 (C
6a
), 138.0 (C
4
), 137.0 (C
4a
), 123.6 (C
5a
), 
121.6 (C
3a
), 120.4 (C
3
), 34.3 (C
7
); HRES-TOF (CH2Cl2): calculated exact mass for 
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C17H13N3
79
Br
81
BrNa: 441.9353; measured: 441.9355 ([M+Na]
+
). ES-TOF: m/z = 440.0 
([M+Na]
+
 (100 %). UV (EtOH): 212 (28,900), 248 (12,800), 290 (15,900). 
 
Synthesis of cys2bipy: 5,5’-bis(methyl-S-cysteinyl)-2,2’-bipyridine 
 
In a microwave-vessel containing a suspension of 5,5’-bis(bromomethyl)-2,2’-
bipyridine (23 mg, 67.3 µmol) in 3 mL of acetonitrile, was added 100 mM aqueous tris.HCl 
buffer pH 8.0 (2 mL), and a solution of cysteine (135 mM, 1 mL, 0.135 mmol) in the same 
buffer. The suspension was bubbled with N2 for 10 minutes and was then stirred for 3 hours at 
338 K and 100 W in a microwave reactor. The solvent was evaporated in vacuo at 323 K to 
yield a pink gel. Concentrated acid was added in order to solubilise the product, and pH was 
neutralised using a solution of NaOH. The crude product was purified by preparative RP-
HPLC (C18 Phenomenex, monitoring absorbance at 210 and 290 nm) using 0 to 20 % 
gradient acetonitrile in water over 30 min. The solvent was evaporated in vacuo to yield pure 
5,5’-bis(methyl-S-cysteinyl)-2,2’-bipyridine, as a pink solid (19 mg, 67 %). 1H NMR (300 
MHz ; D2O ; dioxane reference ; pD~ 1) : 8.86 (br. s, 2 H, H
6
), 8.44 (br. s, 4 H, H
3/4
), 4.17 (br. 
m, 2 H, H
9
), 4.06 (br. s, 4 H, H
7
), 3.08 (br. m, 2 H, H
8
). 
13
C NMR 
1
H decoupled (100 MHz ; 
D2O ; dioxane reference, pD~1) : 171.9 (C
10
), 146.7 (C
6
), 144.0 (C
4
), 138.8 (C
5
), 124.4 (C
3
), 
53.3 (C
9
), 32.6 (C
7
), 31.6 (C
8
). HRES-TOF (water): calculated exact mass for C18H23N4O4S2: 
423.1161; measured: 423.1172. ES-TOF: m/z = 423.3 [M+H]
+
 (100 %), m/z = 192.2 (42 %). 
MALDI-TOF: m/z = 444.5 [M+Na]
+
 (100 %), m/z = 422.5 [M+H]
+
 (29 %). RP-HPLC (no 
TFA): 100%. UV: 245 (10,240), 296 (14,397). 
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Synthesis of cys2terpy: 6,6’’-bis(methyl-S-cysteinyl)-2,2’:6’,2’’-terpyridine 
 
In a microwave-vessel containing a suspension of 6,6’’-bis(bromomethyl)-2,2’:6’,2’’-
terpyridine (25.5 mg, 60.8 µmol) in 3 mL of acetonitrile, was added 100 mM aqueous 
Tris.HCl buffer pH 8.0 (2 mL), and a solution of cysteine (122 mM, 1 mL, 0.122 mmol) in the 
same buffer. The suspension was bubbled with N2 for 10 minutes and was then stirred for 3.5 
hours at 338 K and 100 W in a microwave reactor. The solvent was evaporated in vacuo at 
323 K to yield a colorless gel. Concentrated acid was added in order to solubilise the product, 
and pH was neutralised using a solution of NaOH. The crude product was purified by 
preparative RP-HPLC (C18 Phenomenex, monitoring absorbance at 210 and 290 nm) using 0 
to 60 % gradient acetonitrile in water over 25 min. The solvent was evaporated in vacuo to 
yield pure 6,6’’-bis(methyl-S-cysteinyl)-2,2’:6’,2’’-terpyridine, as a white solid (7 mg, 23 %). 
1
H NMR (300 MHz ; D2O ; dioxane reference ; pD~1): 8.76 (dd, 
3
JH4a-H3a = 8.2 Hz ; 
 3
JH4a-H5a 
= 7.0 Hz, 2 H, H
4a
), 8.72 (dd, 
3
JH3a-H4a = 8.3 Hz ; 
 4
JH3a-H5a = 2.0 Hz, 2 H, H
3a
), 8.62 (d, 
3
JH3-H4 
= 7.9 Hz, 1 H, H
3
), 8.46 (dd, 
3
JH4-H3 = 7.4 Hz ; 
3
JH4-H3 = 8.6 Hz, 1 H, H
4
), 8.24 (dd, 
3
JH5a-H4a = 
7.0 Hz ; 
4
JH5a-H3a = 1.9 Hz, 2 H, H
5a
), 4.53 (s, 4 H, H
7
), 4.43 (dd, 
3
JH9-H8b = 6.8 Hz, 
3
JH9-H8a = 
4.6 Hz, 2 H, H
9
), 3.31 (dd, 
2
JH8a-H8b = 15.0 Hz,  
3
JH8a-H9 = 4.6 Hz, 2 H, H
8a
), 3.21 (dd, 
2
JH8b-H8a 
= 15.0 Hz,  
3
JH8b-H9 = 6.9 Hz, 2 H, H
8b
). 
13
C NMR 
1
H decoupled (125 MHz ; D2O ; dioxane 
reference, pD~1): 171.9 (C
10
), 155.0 (C
6a
), 148.4 (C
2/2a
), 148.0 (C
4a
), 148.0 (C
2/2a
), 142.2 (C
4
), 
128.83 (C
5a
), 126.4 (C
3
), 124.6 (C
3a
), 53.3 (C
9
), 33.2 (C
7
), 31.7 (C
8
). HRES
-
-TOF (water, 
negative mode): calculated exact mass for C23H24N5O4S2: 498.1270; measured: 498.1263. ES-
TOF: m/z = 498.2 [M-H]
-
 (100 %) ; m/z = 411.2 (5 %). MALDI-TOF:  m/z = 520.0 [M+Na]
+
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(22 %), m/z = 498.2 [M+H]
+
 (100 %), m/z = 379.8 [M-C3H6NO2S+H]
+
 (65 %). RP-HPLC (no 
TFA): 84%. UV: 298 (16,857). 
 
Synthesis of bipy-GS2: 5,5’-bis(methyl-S-glutathionyl)-2,2’-bipyridine 
 
A solution of glutathione (30.3 mM, 5 mL, 0.152 mmol) in 100 mM Tris.HCl buffer pH 
8.0 was added to a solution of 5,5’-bis(bromomethyl)-2,2’-bipyridine (15.3 mM, 76.6 µmol, 5 
mL) in acetonitrile. The resulting suspension was degassed with N2(g) for 10 minutes and then 
stirred for 11 hours at room temperature. The solvent was evaporated in vacuo at 323 K to 
yield a pink gel. Deionised water (ca. 5 mL) and few drops of HCl (35 % w) were added to 
the gel resulting in complete solubilisation. The pH was neutralised on addition of NaOH (1 
M) solution. The product was purified by preparative RP-HPLC (C18 Phenomenex, 
monitoring absorbance at 210 and 290 nm) using 0 to 15% gradient acetonitrile in water 
(containing 0.05% TFA) over 30 min. The solvent was evaporated in vacuo to yield pure 5,5’-
bis(methyl-S-glutathionyl)-2,2’-bipyridine as a pink solid (42 mg, 68 %). 1H NMR (300 MHz, 
D2O, pD ~ 1): 8.83 (s, 2H, H
6
), 8.42 (s, 4H, H
3 
and H
4
), 4.53 (dd, 
3
JH9-H8a = 5.3 Hz, 
3
JH9-H8b = 
8.4 Hz, 2H, H
9
), 4.02 (s, 4H, H
7
), 4.00 (m, 2H, H
16
), 3.99 (s, 4H, H
11
), 3.04 (dd, 
2
JH8a-H8b = 
14.2 Hz,  
3
JH8a-H9 = 5.4 Hz, 2H, H
8a
), 2.86 (dd, 
2
JH8b-H8a = 14.2 Hz, 
3
JH8b-H9 = 8.5 Hz, 2H, H
8b
), 
2.56 (m, 4H, H
14
), 2.19 (m, 4H, H
15
); 
13
C NMR 
1
H decoupled (100 MHz, D2O,  pD ~ 1): 
175.0 (C
13
), 173.5 (C
12
), 173.1 (C
10
), 172.7 (C
17
), 146.6 (C
6
),  144.0 (C
4
), 139.4 (C
5
), 124.3 
(C
3
), 53.4 (C
9
), 53.2 (C
16
), 41.7 (C
11
), 33.1 (C
8
), 32.8 (C
7
), 31.6 (C
14
), 26.2 (C
15
); HRES-TOF 
Chapter 2 – Model peptide switches as allosteric regulators 
 
128 
 
(water): calculated exact mass for C32H43N8O12S2: 795.2442; measured: 795.2476. ES-TOF: 
m/z = 817.2 [M+Na]
+
 (45 %), m/z = 795.5 [M+H]
+
 (100 %). RP-HPLC (0.05% TFA): 100%. 
 
Synthesis of terpy-GS2: 6,6’’-bis(methyl-S-glutathionyl)-2,2’:6’,2’’-terpyridine 
 
To a suspension of 6,6’’-bis(bromomethyl)-2,2’:6’,2’’-terpyridine (2.52 mM, 25.2 
µmol, 10 mL) in acetonitrile, was added 100 mM aqueous Tris.HCl buffer pH 8.0 (5 mL) and 
a solution of glutathione (20.1 mM, 5 mL, 0.100 mmol) in the same buffer. The suspension 
was degassed with N2(g) for 10 min, heated to 318 K and stirred at this temperature for 8 
hours. The solvent was evaporated in vacuo at 323 K to yield a colourless gel. Deionised 
water (ca. 5 mL) and few drops of HCl (35 % w) were added to the gel resulting in complete 
solubilisation. The pH was neutralised on addition of few drops of NaOH (1 M) solution. The 
product was purified by preparative RP-HPLC (C18 Phenomenex, monitoring absorbance at 
210 nm) using 0 to 30% gradient acetonitrile in water (containing 0.05 % TFA) over 25 min. 
The solvent was evaporated in vacuo to yield pure 6,6’’-bis(methyl-S-glutathionyl)-
2,2’:6’,2’’-terpyridine as a white solid (17 mg, 76 %). 1H NMR (300 MHz, D2O, pD ~ 1): 
8.68 (dd, 
3
JH4a-H3a = 8.1 Hz, 
 3
JH4a-H5a = 6.2 Hz, 2H, H
4a
), 8.67 (dd, 
3
JH3a-H4a = 8.1 Hz, 
 4
JH3a-H5a 
= 2.7 Hz, 2H, H
3a
), 8.59 (d, 
3
JH3-H4 = 7.5 Hz, 1H, H
3
), 8.47 (dd, 
3
JH4-H3 = 7.1 Hz, 
3
JH4-H3 = 8.8 
Hz, 1H, H
4
), 8.17 (dd, 
3
JH5a-H4a = 6.2 Hz, 
4
JH5a-H3a = 2.5 Hz, 2H, H
5a
), 4.56 (dd, 
3
JH9-H8b = 8.2 
Hz, 
3
JH9-H8a = 5.5 Hz, 2H, H
9
), 4.38 (s, 4H, H
7
), 4.01 (t, 
3
JH16-H15 = 6.6 Hz, 2H, H
16
), 3.89 (s, 
4H, H
13
), 3.15 (dd, 
2
JH8a-H8b = 14.2 Hz,  
3
JH8a-H9 = 5.6 Hz, 2H, H
8a
), 2.94 (dd, 
2
JH8b-H8a = 14.2 
Hz,  
3
JH8b-H9 = 8.3 Hz, 2H, H
8b
), 2.51 (dd, 
3
JH14-H15a = 7.0 Hz, 
3
JH14-H15b = 7.9 Hz, 4H, H
14
), 
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2.14 (m, 4H, H
15
). 
13
C NMR 
1
H decoupled (125 MHz, D2O, pD ~ 1): 174.8 (C
13
), 173.3 (C
12
), 
172.7 (C
10
), 172.1 (C
17
), 155.8 (C
6a
), 148.4 (C
2/2a
), 148.1 (C
2/2a
), 147.7 (C
4a
), 142.5 (C
4
), 
128.6 (C
5a
), 126.2 (C
3
), 124.3 (C
3a
), 53.3 (C
9
), 52.8 (C
16
), 41.6 (C
11
), 33.9 (C
8
), 33.6 (C
7
), 
31.5 (C
14
), 26.0 (C
15
); HRES
-
-TOF (water): calculated exact mass for C37H45N9O12S2Na: 
894.2527; measured: 894.2498. ES-TOF: m/z = 894.7 [M+Na]
+
 (100%), 872.7 [M+H]
+
 (40%), 
589.5 [M-C10H16N3O6S+Na]
+
 (17%), 567.5 [M-C10H16N3O6S+H]
+
 (19%). RP-HPLC (no 
TFA): 100%. 
 
2.4.3 – Analytical procedures 
2.4.3.1 – Pyridine conjugates of cysteines and glutathione (related to section 2.2.1) 
For monitoring of pyr-GS2 formation by Ellman’s test, 20 μL of 50 mM 5,5’-dithiobis-
(2-nitrobenzoic acid) in 100 mM phosphate buffer pH 8 was mixed with 600 μL of 100 mM 
phosphate buffer pH 8 in a 1 mL cuvette, and a blank spectrum was recorded on 
spectrometer(a). To the cuvette, 2 μL of either 11.8 mM glutathione stock solution or reaction 
mixture were then added, and a new spectrum recorded after 10 min equilibration. All 
measurements were run in triplicate. The absorbance at 412 nm was converted to thiol 
concentration knowing the extinction coefficient of the 5-thiolato-2-nitrobenzoate anion (ε412 
nm 14,150 M
-1
 cm
-1
).[102] 
For the determination of extinction coefficient, 3 distinct solutions of cys2pyr and pyr-
Br2 were prepared based on mass. 2 mM stock solutions were prepared in deionised water 
based on mass. Sonification and gentle heating were required to ensure substrates were fully 
dissolved. Prior to each measurement, spectrometer(a) was blanked with 2.6 mL of 23 mM 
phosphate buffer pH 8.0 solution in a 3 mL cuvette. Then, 30, 60, 90, or 120 μL of stock 
solution were added, as well as V = 400 – X μL of water to adjust the total volume to 3 mL (X 
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equal volume of stock solution), and a spectrum recorded. Linear regression on the 
absorbance versus concentration plot was performed in excel 2007. 
For the Cu(II) titration of pyridine linkers monitored by UV, aliquots of an aqueous 6 
mM stock solution of CuCl2 were titrated into 3 mL of solutions that all contained 20 mM 
potassium phosphate buffer pH 8, and either: nothing else (blank), 40 μM cys2pyr or pyr-
GS2, or 80 μM L-glycine. Spectra were recorded on spectrometer(a), after 30 seconds 
equilibration. Linear fitting were performed with excel 2007. 
2.4.3.2 – Polypyridine linkers (related to section 2.2.2) 
Titrations were performed by addition of aliquots of a 250 (Me2bipy) or 232 mM 
(Me2terpy) stock solution of ZnCl2 in DMSO-d6 to 0.75 mL of the dimethyl-polypyridine 
linker solution, 25 mM (Me2bipy) or 23.2 mM (Me2terpy), in the same solvent. NMR spectra 
were recorded on an AVIII 300 MHz spectrometer. All solution concentrations were based on 
mass. 2D NMR of Me2terpy in either CDCl3 or DMSO-d6, were recorded on AVIII400: 
DQF-COSY and Gradient NOESY spectra (400 ms mixing time). 
For the continuous variation method, a 25 mM stock solution of ZnCl2 (SZn) and 
Me2bipy (Sbipy) in DMSO-d6 were prepared. From these stocks, 10 NMR tubes containing 1 
mL of solution were prepared. Each tube contained a different volume of the SZn stock (from 
0 to 0.9 mL, with a 0.1 mL step), and a volume of Sbipy equal to 1-V(SZn) mL. For each 
solution, the fraction of complex present in solution, χ (Zn:Me2bipy), can be calculated from 
the ratio of chemical shift variation over the total variation, using equation (2.1).[103] 
  (          )    (       )   
        
      
 (2.1) 
 
χ (Me2bipy)T represents the molar fraction of Me2bipy (complexed and free) over the 
total concentration of species present (total Me2bipy and ZnCl2). δobs corresponds to the 
observed chemical shift, δ0 the chemical shift of the free ligand (Me2bipy), and δ∞ that for the 
Chapter 2 – Model peptide switches as allosteric regulators 
 
131 
 
solution with the highest ZnCl2:Me2bipy ratio (chemical shift at χ (Me2bipy)T = 0.1 was used 
here). 
2.4.3.3 – Bipy and terpy conjugates of cysteine (related to section 2.2.3) 
For the metal titration of cysteine conjugates monitored by UV spectroscopy, aliquots of 
aqueous 15 (cys2bipy) or 21 mM (cys2terpy) stock solution of either CuCl2 or ZnCl2, were 
titrated into 3 mL of solutions either 50 (cys2bipy) or 70 μM (cys2terpy) cysteine 
polypyridine conjugates in 20 mM potassium phosphate buffer pH 8, and the spectra recorded 
on spectrometer(a), after 30 seconds equilibration. Linear fitting were performed with excel 
2007. Additionally, Kapp and KM values for Zn(II) titration of cys2bipy were calculated by 
non-linear fitting, using the same method than for glutathione conjugates, as described in the 
following section. 
2.4.3.4 – Bipy and terpy conjugates of glutathione (related to section 2.2.4) 
The concentrations of all bipy-GS2 or terpy-GS2 stock solutions were calculated after 
recording the UV profile in phosphate buffer (pH was either 7.4 or 8), and assuming 
extinction coefficients of 20,000 (± 200) M
-1
 cm
-1
 (bipy-GS2), or 21,000 (± 210) M
-1
 cm
-1
 
(terpy-GS2). For the pH titration of model switches monitored by UV spectroscopy, aliquots 
of HCl, NaOH (terpy-GS2) or KOH (bipy-GS2) solutions of various concentrations (0.01, 
0.1, 1M) were added to cuvettes containing 3 mL of a 5 μM solution of the model switch. The 
solution was allowed to equilibrate for 10 min prior to recording the pH on a Jenway 3510 pH 
meter, and recording a UV spectrum on spectrometer(b). 
For the metal titrations of model switches monitored by UV (range 200-400 nm), 
aliquots of an aqueous 750 (± 32) μM stock solution of either CuCl2 or ZnCl2, were titrated 
into 3.00 (± 0.03) mL of a 5.00 (± 0.05) μM solution of model switches in 20.0 (± 0.3) mM 
potassium phosphate buffer pH 7.4, and the spectra recorded after 3 min equilibration on 
spectrometer(b). Non-linear fitting was performed with Kaleidagraph software version 4.0. 
Chapter 2 – Model peptide switches as allosteric regulators 
 
132 
 
Kapp values were calculated by fitting data for the absorbance maximum of the metal 
complexes as a function of Cu(II)/Zn(II) concentration, to equations (2.2) and (2.3): 
  [ ]     [ ](      )   (2.2) 
[ ]  
       ([ ]  [ ])  √(       ([ ]  [ ]))
 
   (    ) [ ][ ]
      
 
(2.3) 
 
b corresponds to the cuvette pathlength, [C] corresponds to the concentration of the 1:1 
complex, [L] the total bipy-GS2 or terpy-GS2 and [M] the total CuCl2/ZnCl2 concentration at 
each point, εL and εC are the extinction coefficient of the ligand and complex at the 
wavelength of interest, respectively.  
In order to ensure an accurate estimation, measurements were performed at 
concentrations close to the apparent dissociation constants, such that: 
[ ]
  
 
 
    
 [ ] 
 
The KM values were corrected by accounting for the contribution from phosphate metal 
ion binding, based on values reported in the literature,[66] see equation (2.4): 
         (    
   [ ]
  (   [ ]
) (2.4) 
 
This is based on the assumption that the concentration of free phosphate, [P], is equal to 
the total amount of phosphate in solution. KM and KPM corresponds to the estimated binding 
constant of the metal ion to the ligand of interest and the phosphate anion, respectively. When 
L-glycine was added as a competitor, KM was estimated using equation (2.5), based on the 
reported Cu(II) binding constant for L-glycine.[104] The contribution from the phosphate 
anion was regarded as negligible, when 20.0 (± 0.4) mM L-glycine was present. 
         (    
     [   ]
 
  (    [   ] )
) (2.5) 
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The absolute errors (∆a) indicated for solution concentrations arise from the highest 
values obtained upon calculation of the error accumulations which account for each solution 
preparation (error on mass and volume) and dilution step (error on concentration and 
volumes), following the general equation (2.6). The absolute errors on volume measurements 
cumulate the errors for each pipetting step, based on the general equation (2.7). The errors for 
the ligand concentrations ([∆L]) and extinction coefficients arise from the errors on the related 
equivalences (volumes and concentrations) calculated using the same method, and 
considering the cumulated errors after each aliquot addition. For the non-linear fittings, the 
errors on Kapp cumulate the errors on calculation (given by the software) with the 
experimental errors introduced in the non-linear fitting. In the latter case, the relative error, 
∆Kapp(exp)/Kapp, were maximised upon replacement of the parameter [L] by [L-∆L] in the 
fitting equations (2.2) and (2.3), and the list of [M] values by [M+∆M] (with ∆M, the 
cumulated errors for each addition step) affording a value of 0.088. The relative error ∆KM/KM 
arises either from the errors calculated for Kapp, [P] and reported for KPM (0.089 for titrations 
performed in the absence of L-glycine), or from the errors calculated for Kapp, [Gly] and 
reported for KGly (0.092 for titrations performed in the presence of L-glycine). On a side-note, 
the errors reported in the tables for the metal complexes extinction coefficients are absolute 
calculation errors (associated with the fitting only). The errors were calculated by uncertainty 
analysis on sum/difference (2.6) and product/quotient (2.7),[105] where b and c are random 
independent variables from which a is calculated: 
For        or           
 
 √(
  
 
)
 
  (
  
 
)
 
  (2.6) 
For        or           √(  )   (  )   (2.7) 
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For the metal titrations of model switches monitored by visible spectroscopy (range 
400-900 nm), aliquots of aqueous stock solution either 21 (bipy-GS2) or 3 mM (terpy-GS2) 
of CuCl2, were titrated into 600 μL of either 350 (bipy-GS2) or 100 μM (terpy-GS2) solution 
of model switches in 20 mM potassium phosphate buffer pH 7.4, and the spectra recorded 
after 3 min equilibration on spectrometer(b). 
Metal-titrations of model compounds monitored by circular dichroism were performed 
by addition of aliquots of a 21 mM stock solution of CuCl2 or ZnCl2, into a 350 μM solution 
of bipy-GS2/terpy-GS2 in 10 mM phosphate buffer pH 7.4. Spectra did not change over two 
minutes, and therefore samples were allowed to equilibrate for two minutes prior to 
measurement. Reported spectra are an average of 5 scans recorded between 200 and 400 nm 
at 200 nm min
-1
 (0.5 nm pitch) and the buffer blank subsequently subtracted (except for Cu 
titration of terpy-GS2). After two (Zn) or three (Cu) equivalents of metal ion were added, 21 
or 31.5 µL respectively of a 0.2 M EDTA stock solution was added to assess reversibility (20 
equivalents of EDTA per metal ion). 
For the preparation of NMR samples, stock solutions of bipy-GS2/terpy-GS2 and 
phosphate buffer pD 7.4 in D2O were premixed, and the pD adjusted with a 0.1 M solution of 
NaOH in D2O, using the Jenway 3510 pH meter. D2O was added to adjust the concentrations 
of bipy-GS2/terpy-GS2 and phosphates to 5 and 50 mM, respectively, and the pD was 
checked, prior to transfer to the NMR tube. Titrations were performed by addition of aliquots 
of a 0.1 M stock solution of ZnCl2 in D2O to a 5 mM solution of polypyridyl-conjugate in 50 
mM phosphate buffer pD 7.4 in D2O, and either 4 mM dioxane (δ = 3.75 ppm) or 1 mM 
acetone (δ = 2.22 ppm) was used as an internal reference. Addition of two equivalents ZnCl2 
resulted in no more than a 10% increase to the total volume. 0.8 mL of a 0.25 M solution of 
EDTA in D2O (pH adjusted to 8), and 100 µL D2O, were then added (20 equivalents EDTA 
vs. Zn) to the NMR sample, resulting in a dilution of the sample by two. Changes in peak 
integrations (see Figure 2.38) are reported relative to the internal dioxane reference. 
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2D NMR of terpy-GS2 in D2O at acidic pD (dioxane internal reference), were first 
recorded on AVIII400: DQF-COSY and Gradient NOESY spectra (400 ms mixing time). 
Additionally, Gradient NOESY (States-TPPI, 450 ms mixing time) and Phase cycle ROESY 
(States-TPPI, 450 ms mixing time, 10 kHz spin lock field and an offset of 10 kHz in spin lock 
period to minimise HOHAHA effects) experiments were recorded on DRX500 with partial 
presaturation of water signal, both displaying the previously mentioned inter-ring coupling. 
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3.1 – Introduction 
3.1.1 – Artificial dimerisation of transcription factors 
Transcription factors are proteins whose functions are to regulate genes accessibility for 
RNA polymerase (see Figure 3.1). Transcription factor activity, achieved by binding to 
specific sequences of DNA, is regulated by allosteric mechanisms and binding of effector 
molecules.[1] Cell events resulting in binding of the effector molecule to a specific domain of 
the transcription factor protein, can result in structural preorganisation of a different domain 
for binding to the DNA recognition site, which can, in turn, activate or deactivate genes thus 
regulating transcription. Sensing cell events and signalling to the genomic machine is part of a 
wider signalling process, called mechanotransduction.[2]  
 
 
Figure 3.1 – Illustration showing the RNA polymerase II (yellow) during synthesis of the 
RNA (silver gray) templated on DNA (red). Several transcription factors (blue) are also 
represented along the DNA. Illustration was obtained from Stroma Studio.[3] 
 
Transcription factors are usually classified, based on the DNA site they target and the 
binding mode (see Chapter 1).[4] GCN4 is a bacterial transcription factor involved in the 
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regulation of amino-acid synthesis. It contains 281 amino-acids and binds DNA recognition 
sites bearing the consensus sequence 5’-TGACTCA-3’ or 5’-TGACGTCA-3’ (AP1 and CRE, 
respectively [4,5]), as a homodimer. However, the minimum sequence required for sequence 
selective binding to DNA involves 60 amino-acids located towards the C-terminus of GCN4. 
This consists of 2 subdomains, the first is responsible for protein dimerisation (zipper 
domain),[6,7] whereas the second involves interaction with the DNA recognition site through 
specific contact (bd).[8,9] Both functions are indispensable to ensure strong DNA binding, 
however recent studies have shown that the zipper domain could be conveniently replaced by 
a simple covalent bond.[10] 
 
Kim and co-workers prepared two synthetic peptides based on GCN4, and compared 
their specific DNA binding activity in vitro. The first one, GCN4–bZIP1, contains a fully 
conserved wild-type DNA binding domain (bd and zipper subdomain), and the second, 
GCN4-br1, contains a conserved bd and a glycine-glycine-cysteine motif toward its C-
terminus. In the latter, dimerisation is achieved by formation of an intermolecular disulphide 
bond between unique cysteine residues, whereas glycine residues were added to increase the 
flexibility of the linkage (see Figure 3.2).[10] GCN4–bZIP1 and dimerised GCN4-br1 were 
both shown to bind DNA tightly. However, DNA binding of GCN4br1, but not GCN4–
bZIP1, was reversed upon addition of the reducing agent dithiotreithiol (DTT).[10] This work 
demonstrated how carefully designed chemical linkers, much less cumbersome than the 30 
amino-acid zipper domain, could perform dimerisation, while retaining sequence-specific 
DNA binding in vitro. Following this pioneering work, different linkers have been used to 
artificially dimerise peptides derived from GCN4,[11-14] or related transcription 
factors.[15,16] 
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Figure 3.2  – Scheme illustrating the replacement of the zipper domain (blue) of GCN4, by a 
simple  sulphur-sulphur bond between cysteines, introduced at the C-terminus of GCN4br1 
(red).  Kim and co-workers have shown that the resulting peptide dimer displays sequence-
specificity similar to peptides with conserved zipper and bd domains; based on reference 10, 
and prepared using pdb file 1YSA.[9] 
 
Schepartz and co-workers prepared a large variety of terpy-GCN4bd conjugates, where 
terpy units bearing a single thiol group are attached to the sulphur side-chains of cysteine 
bearing GCN4bd peptides with dithiol linkages. The conjugates displayed poor DNA affinity 
in the absence of metals or in the presence of Cu(II), which was expected to form only 1:1 
complexes (terpy-GCN4bd)Cu(II). However addition of Fe(II), which forms 2:1 complexes 
(terpy-GCN4bd)2Fe(II), led to dimerisation of two terpy units, each coupled to a single 
GCN4bd, and resulted in a significant increase in DNA binding.[13] 
In a different approach, Mascareñas and co-workers successfully dimerised a synthetic 
analogue of GCN4bd, with an azobenzene linker by cysteine alkylation. The resulting 
GCN4bd-azobenzene-GCN4bd conjugate adopts the relaxed trans- conformation, associated 
with a 12-13 Ǻ separation between the two peptide moieties, and poorly binds CRE DNA. 
Upon irradiation at 365 nm, the azobenzene linker switches to the cis-conformation, 
associated with a shorter 8-9 Ǻ gap between peptide moieties and a higher affinity for CRE 
DNA (see Figure 3.3).[14] However, the process is not reversible. This constitutes the first 
report of DNA binding regulation of a GCN4bd derivative, by a conformational transition of 
the linker. 
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Figure 3.3 – Scheme illustrating DNA binding of GCN4bd dimerised with an azobenzene 
linker. Mascareňas and co-workers have shown that the sequence-specific DNA binding 
ability of this conjugate was significantly increased upon irradiation at 365 nm, as a result of 
trans-to-cis conformational transition of the azobenzene linker; based on reference 14, 
adapted from pdb file 1YSA.[9] 
 
The design of artificial peptides which mimic the DNA binding of transcription factors, 
but which are regulated by alternative mechanisms, represent a developing area for 
biochemists.[17,18] The main interest is to artificially regulate the synthesis of proteins, and 
therefore, to take control of a cell’s activity. Artificial transcription could allow for control of 
the cell defence, in the case of a deficient natural immune response, associated with protein 
mis-regulation (proteostasis deficiency), such as Alzheimer disease.[19] 
 
3.1.2 – Aims of the chapter 
As previously shown, metal coordination to polypyridine linkers results in a 
conformational transition that can alter the relative positioning of substituents. The aim is to 
take advantage of this repositioning in the context of sequence-selective DNA binding by 
artificial analogues of transcription factors (for review of the field see reference 20,21). For 
this, artificial peptides bearing the primary sequence of a transcription factor which binds 
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DNA as a homodimer (e.g. GCN4), could be artificially dimerised with the previously studied 
polypyridine linkers. The aim of this chapter is to design and prepare such peptide dimer 
conjugates, and to study their affinity for Cu(II) and Zn(II). DNA binding studies will be 
reported in the following Chapter 4. 
Our interest was driven towards GCN4 due to the large volume of reports on its DNA 
binding characteristics as well as various mutagenesis studies. Based on these reports, a first 
peptide GCN4bd1 was designed, which contains a high number of conserved residues from 
GCN4bd, in order to ensure strong DNA binding. A more minimalist peptide, GCN4bd2, 
was also designed. The polypyridine conjugates were prepared, purified, and their interaction 
with Cu(II) and Zn(II) analysed by UV and CD spectroscopy. 
 
3.2 – Results and discussion 
3.2.1 – Polypyridine-GCN4bd1 peptide conjugates 
3.2.1.1 – Design of GCN4bd1 peptide 
Aside from terpy-GCN4bd conjugates, Schepartz and co-workers prepared a G28-
bipy-G28 conjugate, in which two GCN4bd peptides are dimerised with a 5,5’-dimethyl-2,2’-
bipyridine linker (Me2bipy), by cysteine alkylation.[22] DNA binding properties of G28-
bipy-G28 were studied by band shift assays, however, the impact of metal coordination at the 
bipy linker on DNA binding was not investigated. The preparation and study of a similar bipy 
GCN4bd peptide dimer conjugate of similar size would be a good starting point. Therefore, a 
29 amino-acid peptide based on GCN4bd, and named GCN4bd1, was designed (see Figure 
3.4).  
 
Chapter 3 – Peptide switches based on GCN4 as potential metal-dependent DNA binders 
 
147 
 
 
 
Figure 3.4 – Sequence alignment for wild type GCN4 (residue 224-263), G28 peptide [22] 
and GCN4bd1 (this work). Letter coding (top) represents residues positioning in α-helical 
heptad repeat. Domain highlighted in green is considered essential for binding to the CRE 
site, as it contains all residues believed to make contact with DNA. The nature of DNA 
contacts for each residues is indicated with the following terminology: b, direct to base ; w, 
via water to base ; p, direct to phosphate ; x, via water to phosphate.[23] Underlined residues 
are believed to be important for the thermal stability of the GCN4:DNA complex.[24] 
Cysteine residues highlighted in dark blue in G28 and GCN4bd1 are essential for 
dimerisation. 
 
The GCN4bd1 primary structure includes all residues from GCN4 which are believed 
to make contact with the DNA target site, in order to achieve strong DNA binding.[23] A 
cysteine residue, which is essential for dimerisation, was introduced either at position 253 
(G28), or position 256 (GCN4bd1) relative to wild-type GCN4. In contrast to G28, a glycine-
glycine motif separates cysteine from the GCN4 conserved residues in GCN4bd1, in order to 
bring sufficient flexibility in the dimerisation region,[14,22] and an additional glycine residue 
was added at the C-terminus to prevent epimerisation upon attachment of the first residue to 
the solid support during peptide synthesis.[25] Moreover, the leucine at position 253 was 
conserved in GCN4bd1 in order to better position the cysteine residue (vide infra) and to 
promote hydrophobic interactions between peptides. The N- and C-terminus of the peptide 
were both capped to avoid potential interactions resulting from carboxylic- and amino- 
groups. Remarkably, GCN4bd1 does not contain any aromatic residues, or other natural 
chromophore. Therefore, polypyridine-GCN4bd1 conjugates require quantification based on 
the π→π* transition of the polypyridine linkers. 
Structural [9,23] and spectroscopic evidence [26] suggests that, in the presence of the 
DNA target site, GCN4 basic zipper peptides (GCN4bz) form uninterrupted α-helices. The C-
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terminal region of DNA-bound GCN4bd1 dimer can be interpreted as a dimeric parallel 
coiled coil motif, where the introduced cysteine (residue 256) would occupy a g position in 
the α-helix heptad terminology (see Figure 3.5).  
 
Figure 3.5 – Helical wheel diagram representing a dimeric coiled coil and relative positioning 
of residues (a-g) describing the α-helices heptad motifs. Positions of residues 243 to 263 
(inside to outside starting from a) from wild type GCN4 are indicated. Positions occupied by 
cysteines in the GCN4bd analogues designed (this work) were underlined and marked as 
follow: GCN4bd1 (
1
), GCN4bd2 (
2
); based on reference 4. 
 
The C-terminal region of GCN4bd1 contains three glycine residues which are known to 
disfavour helix formation. Therefore, it is more likely that this short section constitutes a 
highly flexible domain, incompatible with the coiled coil representation. 
 
3.2.1.2 – Synthesis of GCN4bd1 peptide and polypyridine conjugates 
GCN4bd1 peptide was prepared by Fmoc solid-phase peptide synthesis on rink amide 
MBHA resin using a CEM Liberty 1 synthesiser, as described in the experimental section (see 
section 3.3). After cleavage from the solid support, the peptide was purified by HPLC and 
characterised by ESI, MALDI-TOF mass spectrometry (MS) and analytical HPLC. 
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As for the model compounds, the dimerisation of GCN4bd1 with Me2pyr by alkylation 
of cysteine, was first attempted. The reaction progress was monitored by the Ellman’s assay 
(see Appendices). A plot of absorbance at 412 nm as a function of reaction time, indicates that 
after 20 hours 75 % of the thiol groups have been consumed, and that the reaction is near-
completion (see Figure 3.6). However, this does not indicate whether thiol groups were 
converted to thioether or disulphide linkages. 
 
 
Figure 3.6 – Plot monitoring the available thiol concentration during pyr(GCN4bd1)2 
synthesis, based on the Ellman’s assay. Absorbance at 412 nm (primary Y axis, left), and 
remaining thiol percentage (secondary Y axis, right) were estimated at different reaction 
times. 
 
 
GCN4bd1 peptide dimerised with the Me2pyr linker has a very similar retention time 
to the oxidised dimer (GCN4bd1)2, under our HPLC elution conditions (C18 column, 
water/acetonitrile/TFA gradients) (see Figure 3.7B). Therefore, DTT was added to the 
reaction mixture, in order to reduce the disulphide bond from (GCN4bd1)2, thus reforming 
GCN4bd1 starting material (see Figure 3.7A and C). HPLC of the reaction mixture recorded 
after reduction displays enhanced peak resolution (see Figure 3.7D), thus allowing for 
purification and qualitative estimation of GCN4bd1 conversion to pyr(GCN4bd1)2. 
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Figure 3.7 – Analytical C18 RP-HPLC profile for a solution containing: (left) GCN4bd1 
partly oxidised before (A) or after DTT addition (C); (right) crude reaction mixture for 
pyr(GCN4bd1)2 preparation before (B) or after DTT addition (D). All solutions were eluted 
with gradients of 0 to 30 % acetonitrile in water (+0.05 % TFA constant) over 60 min and 
were monitored at 210 nm (▬) and 256 nm (---). Peaks observed were assigned to: (1) 
GCN4bd1 monomer, (2) (GCN4bd1)2 oxidised dimer and (3) the product pyr(GCN4bd1)2 
(based on electrospray spectra recorded for collected fractions). 
 
Bipy(GCN4bd1)2 and terpy(GCN4bd1)2 were similarly prepared by reaction of excess 
GCN4bd1 with bipy-Br2 or terpy-Br2. However, the preparation of the conjugate 
terpy(GCN4bd1)2 required heating of the reaction mixture, the HPLC analysis of which 
indicated the formation of numerous side-products (the retention times were not 
reproducible). The purification of the conjugate was attempted using HPLC and various 
elution sequences (involving both gradients and isocratic mixtures of water/acetonitrile/TFA), 
but the conjugate could not be efficiently purified. Electrospray and analytical HPLC recorded 
are both consistent with a mixture of the expected compound terpy(GCN4bd1)2 and the 
analogous monomer, terpy(GCN4bd1), in a ~70:30 ratio (see Figure 3.8). Despite this, the 
mixture was used in the subsequent analysis described in Chapter 3 and 4. 
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Figure 3.8 – Analytical C18 RP-HPLC profile for terpy(GCN4bd1)2 after rounds of HPLC 
purification. Solution was eluted with 0 to 50 % gradient of acetonitrile in water (+0.05 % 
TFA constant) over 40 min (absorbance monitored at 210 nm). Main peaks were assigned as 
(1) terpy(GCN4bd1) monomer and (2) terpy(GCN4bd1)2 dimer by ESI-MS. 
 
Conjugates (pyr(GCN4bd1)2, bipy(GCN4bd1)2) and mixture relative to 
(terpy(GCN4bd1)2), were characterised by ESI-MS, even though the isotopic distribution of 
the high charge peaks (+7 - +14) could not be resolved, and analytical HPLC. Attempts to 
characterise the conjugates by MALDI-TOF led to either no or a weak signal at the expected 
masses. 
 
3.2.1.3 – Cu(II) addition to GCN4bd1-polypyridine conjugates monitored by UV 
spectroscopy 
Here, the UV spectra of pyr(GCN4bd1)2, bipy(GCN4bd1)2 and terpy(GCN4bd1)2 are 
reported both in the absence and presence of Cu(II). The UV spectrum of a 10 μM solution of 
pyr(GCN4bd1)2 at pH 8 displays one transition with λmax at 276 nm (ε276 nm 5,500 M
-1
 cm
-1
), 
assigned as a π → π* transition. Addition of 1 equivalent of Cu(II), resulted in a slight 
increase of the absorbance at 276 nm (ε276 nm 6,200 M
-1
 cm
-1) and 255 nm (ε255 nm: 3,600 → 
5,600 M
-1
 cm
-1
) (see Figure 3.9). 
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Figure 3.9 – UV spectra of a 10 μM solution of pyr(GCN4bd1)2 in 20 mM phosphate buffer 
pH 8, before (▬) and after (▬) addition of 1 eq. CuCl2. 
 
The UV spectrum of a 4.5 μM solution of bipy(GCN4bd1)2 recorded in solution 
buffered at pH 8, displays two transitions with λmax at 257 (ε257 nm 13,500 M
-1
 cm
-1
) and 310 
nm (ε310 nm 20,100 M
-1
 cm
-1
), assigned as π → π*1 and  π → π*2 transitions. Gradual addition 
of Cu(II) resulted in the steady decrease of the absorbance at 310 nm (N.B. the absorbance at 
310 nm is similar in the presence of 0 and 1 equivalent of CuCl2, but lower between these two 
values), and an increase in the absorbance at 313 and 328 nm (ε313 nm: 19,700 → 21,100; ε328 
nm: 12,200 → 17,100 M
-1
 cm
-1
) (see Figure 3.10A). The transition is characterised by the 
absence of a clear isosbestic point. The UV spectrum of a 2.1 μM solution of 
bipy(GCN4bd1)2 recorded in the presence of 0.3 mM EDTA, displays a profile similar to 
that recorded in buffer pH 8, but both π→π* maxima are slightly shifted towards lower 
wavelength (243 and 304 nm) (see Figure 3.10B). 
 
Figure 3.10 – (A) Cu(II) titration of a 4.5 μM solution of bipy(GCN4bd1)2 in 20 mM 
phosphate buffer pH 8, monitored by UV spectroscopy (0.3 eq. step): (▬) 0 eq., (▪▪▪) between 
0 and 1 eq., (▬●▬) more than 1 eq. CuCl2 added. (B) UV profile of 2.1 μM bipy(GCN4bd1)2 
recorded in either 20 mM phosphate pH 8 (▬), or 0.3 mM EDTA solution (▬). 
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The UV spectrum of a 1.1 μM solution of terpy(GCN4bd1)2 recorded in solution 
buffered at pH 8, displays one transition with λmax at 299 nm (ε299 nm 21,000 M
-1
 cm
-1
), 
assigned as π → π*1 transition. Addition of 1 equivalent Cu(II) resulted in the steady decrease 
of the absorbance at 299 nm (ε299 nm 16,000 M
-1
 cm
-1
), and an increase of the absorbance at 
348 nm (ε348 nm: 4,500 → 6,700 M
-1
 cm
-1
) (see Figure 3.11). 
 
Figure 3.11 – UV spectrum of a 1.1 μM terpy(GCN4bd1)2 solution in 20 mM phosphate 
buffer pH 8, before (▬) and after (▬) addition of 1 eq. Cu(II). 
 
The absorbance profile of pyr(GCN4bd1)2 is very similar to that recorded for cys2pyr 
and pyr-GS2 under similar conditions, both in the absence and presence of CuCl2 (compare 
Figures 3.12C, D and 3.9). In contrast, the UV spectrum recorded for bipy(GCN4bd1)2, 
contains bands shifted 12-15 nm towards higher wavelength compared to cys2bipy and bipy-
GS2. However, the UV spectrum of bipy(GCN4bd1)2 recorded in the presence of EDTA, 
displays maxima at slightly lower wavelength, suggesting that our bipy(GCN4bd1)2 stock 
solution may be contaminated with low concentrations of metal ions. The addition of one 
equivalent of Cu(II) results in only a minor shift, but the resulting spectrum is similar to that 
recorded for cys2bipy and bipy-GS2 in the presence of Cu(II), suggesting formation of a 
similar bipy-Cu species (see Figure 3.25A, 3.32A and 3.10). The spectra of 
terpy(GCN4bd1)2 recorded in the absence of CuCl2 is similar to that recorded for cys2terpy 
and terpy-GS2 (compare Figure 3.25B, 3.32B and 3.11). Upon addition of CuCl2, the UV 
spectrum displays a new band at 348 nm, consistent with the spectra recorded for cys2terpy-
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Cu and terpy-GS2-Cu, but less intense, suggesting terpy(GCN4bd1)2 binds Cu(II) less 
tightly than terpy-GS2 and cys2terpy. 
UV analysis of impure bipy(GCN4bd1)2 and terpy(GCN4bd1)2 are not conclusive, 
due to the small shift of the π→π* band upon Cu(II) addition (for which high binding would 
be expected based on model compounds studies). It remains unclear if these conjugate linkers 
are undergoing a significant conformational rearrangement upon metal-addition.  
 
3.2.2 – Polypyridine GCN4bd2 short peptide dimer 
3.2.2.1 – Design of GCN4bd2 peptide 
Experiments described in Chapter 4, indicate that DNA binding of GCN4bd1 
polypyridine conjugates is not influenced by metal ion coordination. In order to understand 
this result, one needs to consider the global flexibility within the conjugates, which might 
buffer conformational change occurring at the linker, preventing peptide reorientation. 
Another explanation would be that peptide moiety reorientation would occur, but would not 
significantly influence DNA binding. Therefore, a second shorter peptide, GCN4bd2, was 
designed in order to try to address these issues. Analogous polypyridine conjugates bear DNA 
binding domains proximal to the linker and highly sensitive to its conformation (unlike 
GCN4bd1). Glycine introduced between cysteine and the conserved GCN4bd (as for 
GCN4bd1) brings unnecessary flexibility and so have been removed in our second design. 
Structures of GCN4bz homodimers bound to AP1 [9] and CRE [23] DNA target sites 
have been reported (pdb code 1YSA and 2DGC, respectively), and allow for a qualitative 
estimation of inter-strand distances. As can be seen in Figure 3.12, distances separating the γ-
atoms increase on approaching the DNA, but remain minimal between residues located within 
the core of the homodimer, which correspond to position a and d of the homodimer coiled 
coil (see Figure 3.5). The ideal substitution position corresponds to a residue for which this 
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distance would match that previously estimated for bipy and terpy linkers (see Chapter 2), 
allowing us to identify the most suitable site cysteine introduction. 
 
 
Figure 3.12 – Illustration of peptide separation in a GCN4bz homodimer (residue 229 to 257, 
shown in red (bd), zipper domain shown in blue) complexed with AP1 (A), and CRE (B) 
DNA (double helix was replaced by brown circles for clarity). Distances correspond to the 
separation between γ-atoms from residues located in positions a and d from α-helical heptad 
repeats; adapted from pdb files 1YSA [9] and 2DGC,[23] respectively. 
 
In order to retain sequence-specific DNA binding, the majority of residues believed to 
make direct contact with DNA need to be conserved. Additional studies by Kim and co-
workers estimate the impact of residue truncation within the GCN4bd on DNA binding 
properties of relative artificial dimers.[24] Even though crystal structure studies of 
GCN4bz:CRE complex indicate that Lysine246 makes water mediated contact with base G-3 
of the palindromic CRE site,[23] Kim et al. report that it is not essential for sequence-specific 
binding. Indeed, artificially dimerised GCN4br6
SS
, which lacks residue Lysine246, was 
shown to bind selectively to the CRE target site.[24] Moreover it has been suggested that the 
uncharged side-chain of leucine247, can clash with the DNA backbone in the GCN4:CRE 
complex crystal structure, thus destabilising the complex.[23] Residues 248 to 252, which 
precede the zipper domain (QRMKQ), are not believed to make contact with DNA, but were 
suggested to be important for the thermal stability of the GCN4:DNA complex [24]. In order 
to give the keys of the GCN4bd orientation to polypyridine linkers, residues relative to the 
hinge area needs to be suppressed. Based on these requirements, the peptide GCN4bd2 was 
designed (see Figure 3.13). 
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Figure 3.13 – Sequence alignment for wild type GCN4 (residue 224-263), GCN4br6SS 
(shortest artificial GCN4bd dimer reported to selectively bind CRE sites[24]), and GCN4bd2 
(this work). Domains highlighted in green contain all residues believed to make contact with 
DNA.[23] Underlined residue are believed to be important for thermal stability of the 
GCN4:DNA complexes [24]. Cysteine residues (dark blue) are essential for dimerisation.  
 
GCN4bd2 contains 17 conserved residues from GCN4 (corresponding to the domain 
located between residue 229 and 245) including the GCN4bd, but lacks the flexible GCN4 
linker domain. The location of cysteine (equivalent to lysine246 of native GCN4) is such that 
the two thiols from the side chains should be positioned ca. 5.7 Å apart, a more suitable 
distance for the cis- form of the Me2terpy linker unit, in the folded GCN4:AP1 complex 
(measurements based on crystal structure pdb code 1YSA [9]), or 7.1 Å apart, in the 
GCN4:CRE complex, suitable for either a Me2bipy (cis- or trans-) or for the cis- form of 
Me2terpy (measurements based on crystal structure pdb code 2DGC).[23] Different distances 
in the two peptide dimer DNA complexes may indicate that peptide moieties retain the same 
specific contacts to DNA in both complexes, but the presence of an extra central base pair in 
the CRE site, results in a slightly larger distance separating the two peptides (see Figure 3.14). 
 
Figure 3.14 – Cartoon illustrating distances separating two sulphur atoms from a theoretical 
cysteine, introduced as the best aligned rotamer, in place of residue lysine246 of the GCN4 
homodimer complexed with AP1 (A) or CRE duplex (B).  DNA base from the semi-
palindromic (A) and palindromic sites (B) are marked with one-letter symbol on one strand; 
adapted from pdb files 1YSA [9] and 2DGC,[23] respectively. 
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3.2.2.2 – Preparation and characterisation of GCN4bd2 and conjugates 
GCN4bd2 was prepared by Fmoc solid-phase peptide synthesis on rink amide MBHA 
resin using a CEM Liberty 1 synthesiser. After cleavage from the solid support, the peptide 
was purified by HPLC and characterised by ESI, MALDI-TOF mass spectrometry and 
analytical HPLC. 
In order to estimate the propensity of peptide oxidation under the coupling conditions, a 
solution containing GCN4bd2 was incubated at pH 8.0 and room temperature for 16 hours, 
and analytical HPLC was recorded indicating only partial oxidation (see Figure 3.15A). In 
contrast, similar incubation performed in the presence of 0.5 equivalent of bipy-Br2 lead to 
near total conversion to bipy(GCN4bd2)2, as indicated by HPLC and ESI-MS (see Figure 
3.15B and C). 
 
Figure 3.15 – Analytical C18 RP-HPLC profile for a 0.48 mM solution of GCN4bd2 in 
acetonitrile and 85 mM Tris.HCl buffer pH 8.0 (1:1) incubated at room temperature in the 
absence (A), or presence of 0.5 eq. of bipy-Br2 (B and C). Incubation times were either 16 
hours (A), two minutes (B), or 13.5 hours (C). 100 μL of solution was injected and eluted 
with a 0 to 30 % gradient of acetonitrile in water (+0.05 % TFA constant) over 40 min 
(absorbance monitored at 210 nm). Peaks observed were assigned to: (1) GCN4bd2, (2) 
(GCN4bd2)2 oxidised dimer, (3) bipy(GCN4bd2)2 (based on ESI-MS data recorded on 
collected fractions). No fraction relative to peak (4) was collected, and it might corresponds to 
an intermediary species, such as the monomer bipy(GCN4bd2). 
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Peptide conjugates bipy(GCN4bd2)2 and terpy(GCN4bd2)2 were prepared, following 
procedures similar to those previously described for the preparation of GCN4bd1 dimer 
conjugates. Dimerisation due to disulphide bond formation at pH 8.0 was slower for 
GCN4bd2, than previously observed for GCN4bd1. In contrast, alkylation of cysteine by 
reaction with dibromo- linker was faster and cleaner (see Figure 3.15 and section 3.2.1.2). 
Unlike GCN4bd1, the GCN4bd2 peptide dimer conjugates and oxidised dimer have 
sufficiently different retention times under these HPLC conditions, such that they could be 
readily be separated, without need for additional reducing agents (see Figure 3.15C). They 
were obtained in high purity, as indicated by analytical HPLC. 
For comparison purposes and for use as a control dimer, the oxidised dimer 
(GCN4bd2)2, where the two peptides are linked with a disulphide bond, was also prepared by 
incubation of GCN4bd2 at pH 8.0 and 313 K overnight. Conversion was monitored by 
analytical HPLC and was found to be greater than 97 %. ESI-MS of the same mixture gave 
the expected mass, and the stock solution was used directly, without further purification. ESI-
MS spectra recorded for (GCN4bd2)2, bipy(GCN4bd2)2 and terpy(GCN4bd2)2, all display 
the expected charge envelopes, with appropriate isotopic distributions. 
 
3.2.2.3 – Cu(II) and Zn(II) addition to bipy(GCN4bd2)2 and terpy(GCN4bd2)2 
monitored by UV spectroscopy 
The UV spectrum of a 5 ± 0.6 μM solution of bipy(GCN4bd2)2 in 20 mM phosphate 
buffer pH 7.4 displays two transitions with λmax at 299 (ε299 nm 20,000 M
-1
 cm
-1
) and 246 nm 
(ε246 nm 16,900 M
-1
 cm
-1
), assigned as π → π*1 and  π → π*2 transitions.[27] The analogous 
spectrum of terpy(GCN4bd2)2 shows a peak with λmax 298 nm (ε298 nm 21,000 M
-1
 cm
-1
) 
attributed to π → π*1, however, the π → π*2 transition overlaps with that for the peptide bond. 
These bands shift to lower energy upon Zn(II) and Cu(II) complexation, allowing estimation 
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of an apparent binding constant.[28] Aliquots of a stock solution of ZnCl2 were titrated into a 
5 μM solution of bipy(GCN4bd2)2 or terpy(GCN4bd2)2 in 20 mM phosphate buffer pH 7.4, 
up to 3 equivalent of ZnCl2. This resulted in the steady decrease in the absorbance at 299 
(bipy(GCN4bd2)2) and 298 nm (terpy(GCN4bd2)2), and an increase in the absorbance at 
313 and 320 nm (bipy(GCN4bd2)2), or at 328 and 341 nm (terpy(GCN4bd2)2), respectively 
(see Figure 3.16). The isosbestic point at 308 (bipy(GCN4bd2)2) and 318 nm 
(terpy(GCN4bd2)2) are consistent with the clean conversion to a metal bound complex. 
 
Figure 3.16 – UV spectra for the Zn(II) titration of peptide conjugates. ZnCl2 was added to 
solutions containing 5 µM of either bipy(GCN4bd2)2 (A) or terpy(GCN4bd2)2 (B) in 20 
mM phosphate buffer pH 7.4. (▬) 0 eq., (▬) 1 eq., (■■■) between 0 and 1 eq., or (▬●▬) more 
than 1 eq. ZnCl2 added.  
 
A plot of the absorbance of the new transitions versus Zn(II) concentration was fitted to 
a 1:1 binding model (see Figure 3.17), and the extinction coefficients of the peptide dimers 
and the resulting Zn(II) complexes determined and reported in Table 3.1. Taking into account 
the competitive metal ion binding of the phosphate buffer employed in these experiments,[29]  
binding constants, log KM, were calculated to be 6.92 ± 0.05 for formation of the Zn-
bipy(GCN4bd2)2 complex, and 5.67 ± 0.05 for the analogous complex with 
terpy(GCN4bd2)2. 
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Figure 3.17 – Plot of absorbance monitored at 320 nm (■) for bipy(GCN4bd2)2 (A) and 341 
nm (●) for terpy(GCN4bd2)2 (B) versus the equivalence of ZnCl2. (▬) Represents best fit 
for formation of a 1:1 metal:peptide dimer conjugate complex.  
 
Table 3.1 – Summary of the UV data obtained for Zn(II) coordination to polypyridyl peptide 
conjugates, bipy(GCN4bd2)2 and terpy(GCN4bd2)2 
Pep. conjugate λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
bipy(GCN4bd2)2 320 1.95 ± 0.01  Е +04 1.38 ± 0.16  Е +06 8.29 ± 0.95  Е +06 0.9986 
terpy(GCN4bd2)2 341 1.89 ± 0.06  Е +04 7.74 ± 0.86  Е +04 4.66 ± 0.52  Е +05 0.9989 
 
The addition of increasing aliquots of CuCl2 into a 5 ± 0.6 µM solution of 
bipy(GCN4bd2)2 or terpy(GCN4bd2)2 in 20 mM phosphate buffer pH 7.4, resulted in a 
decrease in the absorbance at 299 nm (bipy(GCN4bd2)2) and 298 nm (terpy(GCN4bd2)2), 
and an increase in the absorbance at 317 and 328 nm (bipy(GCN4bd2)2) and at 335 and 348 
nm (terpy(GCN4bd2)2). Again the isosbestic points at 309 (bipy(GCN4bd2)2) and 320 nm 
(terpy(GCN4bd2)2) are consistent with clean formation of the complex (see Figure 3.18). 
 
Figure 3.18 – UV spectra for the Cu(II) titration of peptide conjugates. Cu(II) was added to 
solutions containing 5 µM of either bipy(GCN4bd2)2 (A) or terpy(GCN4bd2)2 (B) in 20 
mM phosphate buffer pH 7.4. (▬) 0 eq., (▬) 1 eq., (■■■) between 0 and 1 eq., (▬●▬) more 
than 1 eq. CuCl2 added. For (A) buffer concentration was 100 mM and 20 mM L-glycine was 
added as competitor.  
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The plot of absorbance as a function of increasing Cu(II) concentration was fitted to a 
1:1 binding equation, from which extinction coefficients were determined (see Figure 3.19 
and Table 3.2). Titration of bipy(GCN4bd2)2 with Cu(II) had to be performed in the presence 
of a competitor (20 mM L-glycine), in order to accurately estimate the Cu(II) affinity, see 
Table 3.2. Formation constants, log KM, were determined to be 13.17 ± 0.07 for the Cu-
bipy(GCN4bd2)2 complex, and 7.87 ± 0.05 (A335), 7.94 ± 0.06 (A348) for the Cu-
terpy(GCN4bd2)2 complex. 
 
Figure 3.19 – Plot of absorbance monitored at 328 nm (□) for bipy(GCN4bd2)2 (A), 335  nm 
(○) and 348 nm (♦) for terpy(GCN4bd2)2 (B) versus the equivalence of CuCl2. (▬) 
Represents best fit for formation of a 1:1 metal:peptide dimer conjugate binding ratio.  
 
Table 3.2 – Summary of the UV data obtained for Cu(II) coordination to polypyridyl peptide 
conjugates, bipy(GCN4bd2)2 and terpy(GCN4bd2)2. 
Pep. conjugate λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
bipy(GCN4bd2)2 328 1.55 ± 0.01  Е +04 2.94 ± 0.47  Е +06 1.48 ± 0.24 Е +13
a
 0.9966 
terpy(GCN4bd2)2 
335 1.21 ± 0.01  Е +04 2.25 ± 0.30  Е +06 7.37 ± 0.97  Е +07 0.9973 
348 1.14 ± 0.01  Е +04 2.67 ± 0.36  Е +06 8.72 ± 1.18  Е +07 0.9972 
a 
Titration performed in the presence of 20 mM L-glycine as competitor. 
 
The continuous variation method was used in order to confirm the formation of 1:1 
complexes.[30] The total concentration of peptide conjugate plus metal ion was kept constant 
and equal to 10 μM, and absorbance spectra were recorded for mixtures with different peptide 
conjugate/metal ratios. Absorbance maxima for metal complexes, before and after subtraction 
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of the free ligand contribution,[30] was plotted versus the total fraction of peptide conjugate 
in solution χ (PJ)T. Corrected jobplots indicate that in all four cases the main complex is 
formed in a 1:1 peptide conjugate:metal ion ratio (see Figure 3.20). 
 
Figure 3.20 – Jobplot based on UV spectra for mixtures of metal and peptide conjugates 
(Ctotal constant and equal to 10 μM), recorded in 20 mM phosphate buffer pH 7.4: (A) ZnCl2 
with bipy(GCN4bd2)2, (B) ZnCl2 with terpy(GCN4bd2)2, (C) CuCl2 with bipy(GCN4bd2)2 
and (D) CuCl2 with terpy(GCN4bd2)2. Empty symbols represent plot of absorbance 
(monitored at 320 (□), 328 nm (□) for bipy(GCN4bd2)2 and 341 (○), 348 nm (○) for 
terpy(GCN4bd2)2 versus the molar fraction of peptide conjugate. Filled symbol represent the 
absorbance corrected for contribution from the metal-free peptide conjugate, represented by 
the dotted line (---). 
 
In contrast to the UV spectra recorded for bipy(GCN4bd1)2 and terpy(GCN4bd1)2, 
significant π→π* redshift are observed for bipy(GCN4bd2)2 and terpy(GCN4bd2)2 upon 
addition of CuCl2 or ZnCl2 consistent with previously described trans-to-cis conformational 
transitions (see Chapter 2). For the latter only, UV spectra in the absence or presence of metal 
ion are similar to those recorded for bipy-GS2 and terpy-GS2, respectively (see Chapter 2). 
Similarly, a plot of absorbance maxima relative to the new π→π* transition were used to 
estimate the affinity of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 for Cu(II) and Zn(II), by 
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fitting to 1:1 binding models (supported by the jobplot, see Figure 3.20). Affinity constants 
calculated for bipy(GCN4bd2)2:Zn(II) and terpy(GCN4bd2)2:Cu(II) polypyridine 
conjugates, are very similar to those previously reported for analogous glutathione conjugates 
(see table 3.3 and 3.4 and Figure 3.21). However, unlike for terpy-GS2, fitting of absorbance 
data upon addition of CuCl2 to terpy(GCN4bd2)2 for both the 335 and 348 π→π* transition, 
results in similar binding constants (within error), suggesting formation of a single 
Cu(II):terpy(GCN4bd2)2 species. 
 
Figure 3.21 – Histogram representing the log KM values calculated for GCN4bd2 and GS 
polypyridine conjugates for Cu(II) (left, ■, horizontal stripes) and Zn(II) (right, ■, vertical 
stripes). (A) Comparison of Cu(II) and Zn(II) affinities for bipy(GCN4bd2)2 and bipy-GS2 
(based on absorbance at 328) (B) comparison of Cu(II) and Zn(II) affinities for 
terpy(GCN4bd2)2 and terpy-GS2 (based on absorbance at 335 nm). Error bars represent the 
absolute error relative to calculation.  
 
In contrast, the Cu(II) affinity of bipy(GCN4bd2)2 is ten times greater that for the 
analogous bipy-GS2, and the Zn(II) affinity of terpy(GCN4bd2)2 is three time lower than 
that for terpy-GS2. These differences illustrate the influence of extra-ligands from the peptide 
backbone that can complement the polypyridyl-M(II) coordination sphere, thus increasing the 
stability of bipy(GCN4bd2)2:Cu(II) compared with bipy-GS2:Cu(II). Alternatively, these 
extra ligands may compete with the terpy linker, in order to form separate and independent 
Zn(II) binding sites, thus decreasing the Zn(II) affinity of the terpy moiety in 
terpy(GCN4bd2)2:Zn(II) compared to terpy-GS2:Zn(II). 
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3.2.2.4 – Cu(II) and Zn(II) addition to bipy(GCN4bd2)2 and terpy(GCN4bd2)2 
monitored by circular dichroism 
The CD spectrum of a 5 μM solution of (GCN4bd2)2 in 10 mM phosphate buffer pH 
7.4, displays one transition with an intense minima around 200 nm, and a shoulder at 220 nm. 
The CD spectra recorded for bipy(GCN4bd2)2 and terpy(GCN4bd2)2 under similar 
conditions display similar transitions (see Figure 3.22). Upon addition of either CuCl2 or 
ZnCl2, to (GCN4bd2)2, bipy(GCN4bd2)2, or terpy(GCN4bd2)2 solutions, no significant 
changes are observed in the recorded CD spectra (see Figure 3.22). Similarly no changes were 
observed upon addition of EDTA to solutions containing peptide conjugates and metals. 
 
Figure 3.22 – CD spectra of 5 µM peptide dimer, (GCN4bd)2 (A), peptide dimer conjugates 
bipy(GCN4bd)2 (B) and terpy(GCN4bd)2 (C) before (▬) or after addition of two eq. of 
metal ion, either CuCl2 (▬) or ZnCl2 (▬), recorded in 10 mM phosphate buffer pH 7.4. 
Reversibility was monitored by addition of excess EDTA (10 eq. to metal ion (▬)).  [Ф]MRE 
represents the molar residual ellipticity in ×10
3
 deg cm
2
 dmol
-1
 res
-1
.  
 
The addition of ZnCl2 to bipy(GCN4bd2)2 was repeated at higher concentration of 100 
μM. Similarly, addition of two equivalents of ZnCl2 does result in significant changes to the 
CD profile of bipy(GCN4bd2)2. A closer look at the region from 220-380 nm, in which 
π→π* contribution could be expected (see Chapter 2), shows weak transitions (range: -5,000 
to 5,000 deg cm
2
 dmol
-1
) with minima at 277 and 322 nm, and negative maxima at 277 and 
322 nm. Upon addition of ZnCl2, minima at 277 nm decreases in intensity, whilst minima at 
322 nm increases in negative ellipticity (see Figure 3.23). 
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Figure 3.23 – Zn(II) titration of 100 µM bipy(GCN4bd)2 solution containing 10 mM 
phosphate buffer pH 7.4, monitored by CD. (▬) 0 eq., (■■■) 0.2, 0.4, 0.6 eq., or (▬) 2 eq. 
ZnCl2. [Ф] represents the molar ellipticity in ×10
3
 deg cm
2
 dmol
-1
. Insert on the right 
represent a zoom on the region indicated with a dotted square on the full spectra. 
 
CD spectra recorded for (GCN4bd2)2, bipy(GCN4bd2)2 and terpy(GCN4bd2)2, in the 
absence or presence of two equivalent of either CuCl2 or ZnCl2, are consistent with peptide 
moieties that do not adopt a defined secondary structure (random coil), as indicated by the 
negative transition at 200 nm attributed to the n→π* transition of the peptide bond. For CD 
spectra of bipy(GCN4bd2)2 recorded at a higher concentration (100 μM), weak CD signals (-
5,000 deg cm
2
 dmol
-1
 res
-1) could be distinguished in the polypyridine π→π* transition region 
(250-350 nm). Upon addition of ZnCl2 there is a slight shift of the signal, but no significant 
change in ellipticity is observed. This contrasts with addition of ZnCl2 to bipy-GS2, which 
resulted in a significant increase in both negative and positive ellipticity (-30,000 to 70,000 
deg cm
2
 dmol
-1
 res
-1
). N-terminus capped bipy(GCN4bd2)2 and terpy(GCN4bd2)2 do not 
retain metal-induced chirality of polypyridine π→π* transition, even though the number of 
chiral center in the conjugate has significantly increased (from 4 chiral center in the 
glutathione dimer conjugates, to 38 for GCN4bd2 dimer conjugates). This supports the 
hypothesis that the uncapped N-terminus of glutathione participates in the formation of hybrid 
complexes with bipy/terpy:Zn and bipy/terpy:Cu complexes in the glutathione based model 
compounds, as suggested in Chapter 2. 
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3.3 – Summary 
Two new peptides based on GCN4bd were designed GCN4bd1 and GCN4bd2, 
differing in the number of conserved residues and the flexibility of the sequence directly 
preceding the linker attachment. Polypyridine conjugates pyr(GCN4bd1)2, 
bipy(GCN4bd1)2, and terpy(GCN4bd1)2 of the longer GCN4bd1 peptide were prepared. 
Only small quantities of the latter two could be obtained, and they proved challenging to 
purify. UV spectra recorded for pyr(GCN4bd1)2, in the absence and presence of CuCl2 
resemble those recorded for the smaller glutathione analogue. In contrast, similar experiments 
performed with bipy(GCN4bd1)2, and terpy(GCN4bd1)2 indicate reduced CuCl2 binding 
and partial trans-to-cis conformational transition. 
Peptide conjugates bipy(GCN4bd2)2, and terpy(GCN4bd2)2, based on the shorter 
peptide GCN4bd2, were prepared in larger quantities, and in higher purity. UV analysis of 
bipy(GCN4bd2)2, and terpy(GCN4bd2)2 recorded in the absence and presence of both 
CuCl2 and ZnCl2, respectively, are consistent with the conformational transition and metal 
binding observed for bipy-GS2 and terpy-GS2, respectively. Small differences were observed 
between glutathione and GCN4bd2 conjugates, as illustrated by slightly different binding 
constant estimated for bipy:Cu and terpy:Zn systems. Moreover, metal ion addition (CuCl2 or 
ZnCl2) to bipy(GCN4bd2)2, and terpy(GCN4bd2)2 did not result in significant induced CD 
signals for polypyridine π→π* transitions, as was previously observed for bipy-GS2 and 
terpy-GS2, even though GCN4bd2 contains 9 times more chiral center than glutathione. It is 
possible that capping of N- and C-termini of GCN4bd2 reduce their metal-ions affinity, thus 
preventing the formation of the chiral complexes of the type [M*(к6-bipy-gly2)**] and 
[M*(к4-terpy-gly)**] (see Chapter 2). Despite respective GCN4bd2 and glutathione 
polypyridine conjugates bind Cu(II) and Zn(II) in similar ratio and with similar affinity, the 
resulting complexes are different. 
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This chapter successfully illustrates that polypyridine can be used to dimerise large 
peptides (19 or 29 amino acids) and in the case of the former was shown to retain similar 
Cu(II)/Zn(II) binding affinity to the linker domain. 
3.4 – Experimental 
3.4.1 – Equipment and reagents 
Sodium hydroxide, mono- and dihydrogen potassium salts, Tris base, ethylene diamine 
tetraacetic acid (EDTA), acetonitrile, water (HPLC grade), HCl 32 %w, acetic anhydride were 
all obtained from Fisher Scientific. Copper chloride (CuCl2), and L-glycine were obtained 
from Sigma-Aldrich. Trifluoroacetic acid (TFA), zinc chloride (ZnCl2) were obtained from 
BOC. All peptide synthesis reagents, dithiotreithiol, and diisopropylethylamine (DIEA) were 
obtained from AGTC bioproducts. 5,5’-Dithiobis-(2-nitrobenzoic acid) was obtained from 
Fluka. Pyr-Br2, bipy-Br2 and terpy-Br2 were prepared as described in Chapter 2. 
ES-TOF MS were recorded on a Microwaters LCT TOF spectrometer equipped with a 
3000 V capillary voltage, and a cone voltage of 35 V. Analytical RP-HPLC spectra were 
recorded on C18 column using a 0 to 100 % gradient acetonitrile in water over 40 minutes 
(with 0.05% TFA constant) and the absorption was monitored at 220 nm. The compound 
purity is reported as a percentage of its peak integral over the total integration for all peaks 
present between 0 and 40 minutes, at the exception of the signal attributed to buffer salts 
which was neglected. UV measurements were recorded in a 1 cm pathlength quartz cuvette at 
298 K, either on a CARY50 (spectrometer(a)), or Shimadzu 1800 spectrometer 
(spectrometer(b)). CD spectra were recorded in 1 mm pathlength quartz cuvettes at 298 K on 
a Jasco J-715 spectropolarimeter. Cartoon figures based on GCN4 were all prepared using 
pymol version 1.1eval from files deposited in the protein data bank (pdb). Non-linear fitting 
were performed using Kaleidagraph software version 4.0 and was similar to that described in 
Chapter 2.  
 
Chapter 3 – Peptide switches based on GCN4 as potential metal-dependent DNA binders 
 
168 
 
3.4.2 – Synthetic procedure and characterisation 
This section describes the synthesis and characterisation of peptides and peptide 
conjugates relevant to this chapter. Peptide conjugate preparation was adapted from previous 
work on polypyridine peptide conjugates.[22] Peptides formula and molecular weight were 
calculated using an online calculator.[31] 
 
Synthesis of GCN4bd1 : 
GCN4bd1 (Ac-ALKRARN TEAARRS RARKLQR MKQLGGC G-NH2) was prepared 
by Fmoc solid-phase peptide synthesis[25] on a CEM Liberty 1 automated synthesiser. DMF 
was the main solvent, and all steps were carried out under a N2 atmosphere. The scale selected 
was 0.25 mmol. Rink amide MBHA resin (0.65 mmol/g, 0.385 g) was used as the solid 
support, and a protected peptide chain was prepared by successive steps consisting of Fmoc 
deprotection (20% piperidine in DMF), and amino-acid coupling (25 W, 348 K, 330 sec, 5 
equivalent of Fmoc protected amino-acids, DIEA and HBTU were used as activators). Resin 
was washed with DMF in between each step. Fmoc-L-Arg(Pbf)-OH and Fmoc-L-Cys(Trt)-OH 
were double coupled to ensure high yield. After all coupling and N-terminal deprotection 
cycles were carried out (including deprotection of the last residue), the resin was transferred 
from the synthesiser reaction vessel to a round bottom flask. The peptide was then capped 
(acetylated), by stirring the resin in a mixture containing DIEA/acetic anhydride/DMF 
(20/20/60) for 20 min. The resin was successively washed with 5x10 mL of DMF, 5x10 mL 
CH2Cl2, and 2x10 mL of diethylether. After drying of the resin in a dessicator overnight, the 
peptide was simultaneously cleaved from the support and the amino acid side-chains 
deprotected, by stirring the resin in a 10 mL cleavage mixture containing TFA / thioanisole / 
ethanedithiol / anisole (90 / 5 / 3 / 2), for 2 hours. The resin was removed by filtration and 
washed with TFA. The filtrate volume was reduced to ~5-7 mL by blowing air over the top of 
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the solution, and the peptide was precipitated by addition of cold diethylether (~10 times the 
volume of filtrate). After storing in the freezer overnight, the supernatant was removed, and 
diethylether added. The solution was allowed to stand in the freezer for 1 hour, after which 
the supernatant was removed once more. The remaining diethylether was removed in vacuo, 
affording a white solid/gel, a small fraction of which was analysed by MALDI-TOF and 
analytical HPLC indicating incomplete deprotection. Therefore, the whole deprotection step 
was repeated. The peptide was then purified by preparative RP-HPLC (C18 Phenomenex, all 
eluents contained 0.05 % TFA, absorbance monitored at 210 and 220 nm) using a 5 to 18 % 
gradient of acetonitrile in water over 30 min, directly followed by isocratic elution with 18 % 
acetonitrile in water for a further 15 minutes (Rt = 38.4 min). Solvents were removed in 
vacuo, and the peptide freeze-dried, affording GCN4bd1 as salts (167 mg, 20 %). ES-TOF 
(water) calculated for C135H247N57O37S2: 3324; found: 3323; m/z = 1,108.7 [M+3H]
3+
 (18 %), 
m/z = 831.7 [M+4H]
4+
 (59 %), m/z = 665.6 [M+5H]
5+
 (100 %), m/z = 554.8 [M+6H]
6+
 (41 
%). MALDI-TOF: m/z = 3324.9 [M+H]
+
 (100 %). RP-HPLC: 100%. 
 
Synthesis of pyr(GCN4bd1)2: 2,6-bis(methyl-S-GCN4bd1)pyridine 
Di(bromomethyl)pyridine (0.4 mg, 1.51 µmol) was added to 4.026 mL of 62 mM 
aqueous Tris.HCl buffer pH 8.0 solution, degassed by N2 bubbling directly into the 
suspension, and an aqueous solution of GCN4bd1 (6.20 mM, 6.04 µmol, 974 µL) added 
(water was degassed prior to peptide dissolution and the concentration was then determined 
by the Ellman’s test). The suspension was stirred at room temperature and the concentration 
of free thiol in solution monitored by the Ellman’s test. After 21 hours, fresh dithiotreithiol 
solution (0.32 M, 0.32 mmol, 1 mL) was added to the reaction mixture, stirred for 1 hour, and 
then purified by preparative RP-HPLC (C18 Phenomenex, monitoring at 210 and 260 nm, all 
eluents contained 0.05 % TFA) using a 0 to 19 % gradient of acetonitrile in water over 30 
minutes, directly followed by isocratic elution with 19 % acetonitrile in water for a further 15 
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minutes. Peptide (Rt = 35.8 min) and product (Rt = 37.6 min) were isolated. Solvents were 
removed in vacuo, and the peptide conjugate freeze-dried, affording pyr(GCN4bd1)2 as a salt 
(7 mg, 69%). ES-TOF (water) calculated for C277H499N115O64S4: 6753; found: 6753; m/z = 
965.8 [M+7H]
7+
 (12 %), m/z = 845.2 [M+8H]
8+
 (28 %), m/z = 751.5 [M+9H]
9+
 (55 %), m/z = 
676.5 [M+10H]
10+
 (83 %), m/z = 615.0 [M+11H]
11+
 (100 %), m/z = 563.9 [M+12H]
12+
 (79 
%), m/z = 520.6 [M+13H]
13+
 (43 %), m/z = 483.5 [M+14H]
14+
 (12 %). RP-HPLC: 100%. 
 
Synthesis of bipy(GCN4bd1)2: 5,5’-bis-(methyl-S-GCN4bd1)-2,2’-bipyridine 
Acetonitrile (80 µL) and water (180 µL) were added to a 5,5’-bis-(bromomethyl)-2,2’-
bipyridine solution in acetonitrile (0.64 µmol, 0.64 mM, 1.00 mL). The suspension was 
degassed with N2 bubbling, and GCN4bd1 solution (2.6 µmol, 2.89 mM, 900 µL) in 100 mM 
Tris.HCl buffer pH 8 was added (buffer was degassed prior to peptide dissolution and 
concentration was then checked by Ellman’s test), and the suspension stirred at room 
temperature. After 15 hours, fresh dithiotreithiol solution (0.13 mmol, 0.32 M, 0.4 mL) was 
added to the reaction mixture, stirred for 1 hour, and then purified by preparative RP-HPLC 
(C18 Phenomenex, absorbance monitored at 210 and 260 nm, all eluents contained 0.05 % 
TFA) using a 0 to 19 % gradient of acetonitrile in water over 30 minutes, directly followed by 
isocratic elution with 19 % acetonitrile in water for a further 15 minutes. Peptide (Rt = 35.8 
min) and product (Rt = 38.0 min) were isolated. Solvents were removed in vacuo, and the 
peptide conjugates freeze-dried, affording bipy(GCN4bd1)2 as a salt (3 mg, 14%). ES-TOF 
(water) calculated for C282H502N116O74S4: 6830; found: 6831; m/z = 976.7 [M+7H]
7+
 (22 %), 
m/z = 854.9 [M+8H]
8+
 (53 %), m/z = 760.0 [M+9H]
9+
 (75 %), m/z = 684.1 [M+10H]
10+
 (76 
%), m/z = 622.0 [M+11H]
11+
 (90 %), m/z = 570.2 [M+12H]
12+
 (100 %), m/z = 526.4 
[M+13H]
13+
 (63 %), m/z = 488.9 [M+14H]
14+
 (20 %). RP-HPLC: 100%. 
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Synthesis of terpy(GCN4bd1)2: 6,6’’-bis(methyl-S-GCN4bd1)-2,2’:6’,2’’-terpyridine 
6,6’’-bis-(bromomethyl)-2,2’:6’,2’’-terpyridine (0.34 mg, 0.63 µmol) was added to a 
flask containing 5 mL of degassed acetonitrile. 100 mM aqueous Tris.HCl buffer pH 8.0 
solution (2.5 mL), and water (2.104 mL) were then added. The suspension was degassed for 
20 min, by N2 bubbling directly into the stirring suspension. Then, GCN4bd1 (6.31 mM, 2.5 
µmol, 396 µL) aqueous solution was added (water was degassed prior to peptide dissolution 
and concentration was then checked by Ellman’s test). The flask equipped with a condenser 
was heated at ~323 K under N2 for 2 days. Analytical HPLC of an aliquot did not show any 
sign of coupling. More 6,6’’-bis-(bromomethyl)-2,2’:6’,2’’-terpyridine (0.08 mg, 0.20 µmol) 
was added, and the reaction was heated at 343 K under N2 for a further 5 days. Again an 
aliquot was analysed by analytical HPLC and ES-TOF, indicating partial formation of the 
expected product. The crude product was purified by RP-HPLC (C18 Phenomenex, 
absorbance monitored at 210 nm, all eluents contained TFA) in twice: (1) 0 to 30 % gradient 
of acetonitrile in water over 40 minutes on preparative column (Rt = 37.9 min), (2) 0 to 35 % 
gradient of acetonitrile in water over 40 minutes on semi-preparative column (Rt = 29.7 min). 
A mixture of ~70:30 expected compound terpy(GCN4bd1)2 and related monomer 
terpy(GCN4bd1) was obtained. Solvents were removed in vacuo, and the mixture freeze-
dried, affording terpy(GCN4bd1)2:terpy(GCN4bd1) in a 70:30 mixture, as a red gel (0.18 
mg, 3 %). ES-TOF (water) calculated for C287H505N117O74S4: 6907; found: 6907; m/z = 
1152.1 [M+6H]
6+
 (20 %), m/z = 987.7 [M+7H]
7+
 (31 %), m/z = 864.3 [M+8H]
8+
 (60 %), m/z 
= 768.4 [M+9H]
9+
 (73 %), m/z = 691.7 [M+10H]
10+
 (74 %), m/z = 628.9 [M+11H]
11+
 (100 
%), m/z = 576.6 [M+12H]
12+
 (98 %), m/z = 532.2 [M+13H]
13+
 (63 %), m/z = 494.4 
[M+14H]
14+
 (16 %). RP-HPLC: 87%. 
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Synthesis of GCN4bd2 
GCN4bd2 (Ac-ALKRARN TEAARRS RARCG-NH2) was prepared by Fmoc solid-
phase peptide synthesis [25] on a CEM Liberty 1 automated synthesiser, as previously 
reported for GCN4bd1. Peptide was purified by preparative RP-HPLC (C18 Phenomenex, 
monitoring at 210 and 220 nm, all eluents solution contained 0.05 % TFA) using a 0 to 30 % 
gradient of acetonitrile in water over 30 minutes, directly followed by isocratic elution with 
30 % acetonitrile in water over 7 more minutes (Rt = 34.0 min). The collected fraction was 
analysed by MALDI-TOF and analytical HPLC indicating incomplete deprotection. The 
whole deprotection and purification steps were repeated, but the composition of the cleavage 
mixture was changed for: TFA / triethylsilane / ethanedithiol (90 / 5 / 5),[32] and the HPLC 
purification involved a 0 to 15 % gradient of acetonitrile in water over 20 minutes, directly 
followed by isocratic elution with 15 % acetonitrile in water (Rt = 27.0 min). Solvents were 
removed in vacuo, and the peptide freeze-dried, affording GCN4bd2 as a salt (63 mg, 12 %). 
ES-TOF (water), calculated for C86H158N40O25S: 2184; found: 2184; m/z = 1,092.7 [M+2H]
2+
 
(35 %), m/z = 728.7 [M+3H]
3+
 (90 %), m/z = 546.8 [M+4H]
4+
 (100 %). MALDI-TOF: m/z = 
2185.4 [M+H]
+
 (100 %), m/z = 2501.3 (52 %), m/z = 2818.2 (25 %). RP-HPLC: 99%. 
 
Synthesis of (GCN4bd2)2 
To an aqueous solution of GCN4bd2 (2.70 mM, 0.080 µmol, 29.6 µL), were added:  
100 mM phosphate buffer pH 7.4 (20 µL) and water (150.4 µL) and the mixed solution was 
incubated at 310 K for 12 hours. The oxidation was monitored by analytical HPLC. The 
solution was used without the need for further purification. ES-TOF (water) calculated for 
C172H314N80O50S2: 4367; found: 4367; m/z = 874.3 [M+5H]
5+
 (9 %), m/z = 728.7 [M+6H]
6+
 
(30 %), m/z = 624.8 [M+7H]
7+
 (63 %), m/z = 546.8 [M+8H]
8+
 (100 %), m/z = 486.1 
[M+9H]
9+
 (69 %), m/z = 437.6 [M+10H]
10+
 (55 %). RP-HPLC: 97%. 
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Synthesis of bipy(GCN4bd2)2: 5,5’-bis-(methyl-S-GCN4bd2)-2,2’-bipyridine 
To a 25 mL round-bottom flask containing 100 mM Tris.HCl buffer pH 8 (4 mL), and 
acetonitrile (2.98 mL) degassed mixture, were successively added: GCN4bd2 aqueous 
solution (5.92 mM, 4.44 µmol, 0.750 mL), and 5,5’-bis(bromomethyl)-2,2’-bipyridine (1.46 
mM, 2.22 µmol, 1.52 mL) dissolved in acetonitrile. The suspension was degassed by N2 
bubbling directly into the solution, and the suspension was stirred at room temperature. 
Progress of the reaction were monitored by analytical HPLC, indicating the reaction was 
quasi complete after 14 hours. The reaction mixture was dried on rotavapor, redissolved in 
water and purified by preparative RP-HPLC (C18 Phenomenex column, absorbance 
monitored at 210 nm, all eluents contained 0.05 % TFA) using a 0 to 21 % gradient of 
acetonitrile in water over 50 minutes (Rt = 45.7 min). Solvents were removed in vacuo, 
affording bipy(GCN4bd2)2 together with salts (5.6 mg, 56 %). ES-TOF (water), calculated 
for C184H324N82O50S2: 4549; found: 4550; m/z = 910.8 [M+5H]
5+
 (41 %), m/z = 759.2 
[M+6H]
6+
 (52 %), m/z = 650.9 [M+7H]
7+
 (79 %), m/z = 569.6 [M+8H]
8+
 (100 %), m/z = 
504.4 [M+9H]
9+
 (96 %), m/z = 455.9 [M+10H]
10+
 (25 %). RP-HPLC: 100%. 
 
Synthesis of terpy(GCN4bd2)2: 6,6’’-bis(methyl-S-GCN4bd2)-2,2’:6’,2’’-terpyridine 
In a 25 mL round bottom flask, were successively added: 100 mM Tris.HCl pH 8 (0.9 
mL), GCN4bd2 aqueous solution (5.92 mM, 0.592 µmol, 100 µL), acetonitrile (876 µL), 
6,6’’-bis(bromomethyl)-2,2’,6’,2’’-terpyridine (1.19 mM, 0.148 µmol, 124 µL) solubilised in 
acetonitrile. The suspension was degassed by N2 bubbling directly into the solution, and then 
stirred at room temperature. Progress of the reaction was monitored by analytical HPLC, 
indicating that after 16 hours, the reaction was not proceeding further. The reaction mixture 
was dried on rotavapor, redissolved in water and purified by semi-preparative RP-HPLC (C18 
Phenomenex column, absorbance monitored at 210 and 290 nm, all eluents contained 0.05 % 
TFA) using a 0 to 23 % gradient of acetonitrile in water over 50 min (Rt = 45.1 min). 
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Solvents were removed in vacuo, affording a colorless gel (0.15 mg, Y = 22 %). ES-TOF 
(water), calculated for C189H327N83O50S2: 4626; found: 4626; m/z = 926.1 [M+5H]
5+
 (16 %), 
m/z = 771.7 [M+6H]
6+
 (30 %), m/z = 661.8 [M+7H]
7+
 (62 %), m/z = 579.2 [M+8H]
8+
 (100 
%), m/z = 514.9 [M+9H]
9+
 (71 %), m/z = 463.6 [M+10H]
10+
 (26 %). RP-HPLC: 100%. 
 
3.4.3 – Analytical procedures 
3.4.3.1 – Pyr, bipy and terpy conjugates of GCN4bd1 (related to section 3.2.1) 
For monitoring of pyr(GCN4bd1)2 formation by the Ellman’s test,[33,34] 20 μL of a 
50 mM 5,5’-dithiobis-(2-nitrobenzoic acid) in 100 mM phosphate buffer pH 8.0 solution, was 
premixed with 600 μL of 100 mM phosphate buffer pH 8.0 in a 1,000 μL cuvette, and a blank 
spectrum recorded on spectrometer(a). To the cuvette, 2 μL of either GCN4bd1 stock 
solution, or reaction mixture was added, and a new spectrum was recorded after 15 min 
equilibration. All measurements were performed in triplicate and averaged. Spectra recorded 
for GCN4bd1 stock solution was corrected to account for dilution upon reaction mixture 
preparation. 
UV spectra of pyr(GCN4bd1)2, bipy(GCN4bd1)2 and terpy(GCN4bd1)2 were 
obtained by respective addition of 30 μL of 210 μM, 10 μL of 280 μM and 8 μL of 85 μM of 
conjugate aqueous stock solutions to cuvettes containing 600 μL of 20 mM phosphate buffer 
pH 8.0, on spectrometer(a). For pyr(GCN4bd1)2 and terpy(GCN4bd1)2, 1 equivalent of 
CuCl2 was added directly using either 1.5 μL of 4.2 mM (for pyr(GCN4bd1)2 spectrum), or 
1.4 μL of 0.5 mM (for terpy(GCN4bd1)2 spectrum) CuCl2 stock solution. Solutions were 
allowed to equilibrate for 15 min prior to recording spectra. For the bipy(GCN4bd1)2 Cu(II) 
titration, aliquots of a 0.28 mM CuCl2 solution were added to the 600 μL solution containing 
4.5 μM bipy(GCN4bd1)2 (0.1 equivalent per step). Equilibration time between CuCl2 
addition and recording spectra was three hours after the first addition; it was reduced to 10 
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min for the following 4 additions, and 2 minutes for the remainder of the titration. A plot of 
absorbance at 313 nm versus equivalence of CuCl2 could not be fitted using non-linear 
regression due to the strong contribution of free bipy(GCN4bd1)2 at this wavelength.  
In order to check for contamination of bipy(GCN4bd1)2 stock solution with metal ions, 
blank spectra were recorded for two cuvettes containing 600 μL of either 20 mM phosphate 
pH 8.0 solution, or 0.3 mM EDTA solution (pH was not recorded). It is important to note that 
the spectrum recorded for the EDTA solution was saturated below 220 nm. To each cuvette, 2 
μL of stock solution containing 620 μM bipy(GCN4bd1)2, was added and new spectra (blank 
subtracted) were recorded. 
 
3.4.3.2 – Bipy and terpy conjugates of GCN4bd2, and (GCN4bd2)2 (relative to section 
3.2.2) 
For metal ion titrations of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 monitored by UV 
spectroscopy, aliquots of aqueous 300 (± 13) μM stock solutions of CuCl2 or ZnCl2, were 
titrated into 600 µL of between 4.40 and 5.60 (± 0.05) μM solution of polypyridyl-peptide 
dimer conjugate in 20.0 (± 0.3) mM potassium phosphate buffer pH 7.4. Spectra were 
recorded on spectrometer(b) after 3 min equilibration. When the apparent Cu(II) binding 
constant was too high to be accurately estimated, L-glycine was added as a competitor ligand. 
20.0 (± 0.4) mM L-glycine was present for the reported titration of bipy(GCN4bd2)2. Kapp 
values were calculated by fitting data for the absorbance maximum of the metal complexes as 
a function of Cu(II)/Zn(II) concentration, following the method described in Chapter 2. 
For the continuous variation methods monitored by UV spectroscopy, solutions of 
varying ratio of bipy(GCN4bd2)2/terpy(GCN4bd2)2 were prepared from 120 μM stock 
solutions, so that the total concentration of substrate CPJ+CM was equal to 10 μM (where CPJ 
and CM represent the concentration of peptide dimer conjugate and metal ion, respectively). 
UV-visible spectra were recorded and the absorbance at λmax, for the metal complexes π→π* 
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transition, plotted vs. the fraction of ligand. Due to a contribution at this wavelength from the 
free-ligand (bipy(GCN4bd)2 and terpy(GCN4bd)2), the absorbance values were corrected to 
account for this.[30] The fraction of peptide conjugates, χ bipy(GCN4bd)2 and χ 
terpy(GCN4bd)2, are defined as the ratio Cp/(Cp+CM). 
For CD spectra of 5 μM (GCN4bd2)2, bipy(GCN4bd2)2, or terpy(GCN4bd2)2, a 300 
µL blank solution containing 10 mM phosphate buffer pH 7.4 was first recorded. 7.5 µL of a 
200 µM peptide dimer or peptide dimer conjugate solution was added, and the data collected 
after 15 minute equilibration. Two equivalents of CuCl2 or ZnCl2 (1.5 mM, 3 nmol, 2 µL) was 
added and the solution allowed to equilibrate for 15 min prior to recording spectrum. Ten 
equivalents of EDTA per metal ion (10 mM, 30 nmol, 3 µL, pH 6-8) were added and the CD 
spectra recorded, in order to investigate reversibility. Spectra are an average of 20 scans 
recorded between 185 and 400 nm at 500 nm min
-1
 (0.5 nm pitch). Difference spectra were 
obtained by subtracting CD spectra of buffer alone (blank), from that of mixtures containing 
both peptide and buffer, in order to observe the CD contribution from the peptide component 
only. The observed ellipticities in millidegrees were converted into residual molar ellipticity, 
ФRME, reported in units of deg cm
2
 dmol
-1
 res
-1
, thus allowing estimation of secondary 
structure. Finally, spectra were blanked a second time by subtracting from each data point, the 
average ФRME measured between 400 and 300 nm for the same spectra (a region were no 
intense peak are expected).  
The CD spectrum of a 100 μM bipy(GCN4bd2)2 solution was recorded directly in 100 
μM bipy(GCN4bd2)2 and 10 mM phosphate pH 7.4. Aliquots of a 3 mM solution of ZnCl2 
were added to the solution, and spectra recorded after 15 minute equilibration. The measured 
ellipticity was converted into molar ellipticity, Ф, reported in units of deg cm2 dmol-1, thus 
allowing intensity comparison of the polypyridine π→π* chiral induced signal, with bipy-GS2 
model compounds (see Chapter 2). 
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4.1 – Introduction 
4.1.1 – Sequence specific DNA binding by b-ZIP peptides and derivatives 
In the mid 1980’s, the GCN4 protein (previously AAS3 [1]) was shown to bind 5’-
TGACTC-3’ promoter sites (similar to the AP1 binding sites: 5’-TGAG/CTCA-3’ [2,3]) from 
genes such as HIS4, thus participating in regulation of the amino-acids biosynthesis in 
cerevisae.[4-6] It was later shown that, in vitro, GCN4 also binds the consensus sequence 5’-
TGACGTC-3’ [7] (similar to the CRE site [2]), differing from AP1 by addition of a central 
bp. Various N-terminal truncations of wild-type GCN4, and subsequent affinity studies by 
bandshift assay (see Appendices) indicated that a C-terminal domain, consisting of 60 
residues, is essential for binding to AP1 sites (see Figure 4.1).[8] 
 
Figure 4.1 – Radiogram for bandshift assay performed on GCN4 derivatives with varying N-
terminal deletion (the number of conserved GCN4wt residues are indicated at the top of the 
lane) by Struhl and co-workers. Peptides are products from cloned pSP64 gene expression 
bearing 
35
S-methionine label, and were incubates with either: (N) no DNA, (H) excess 
specific DNA (TaqI digested pUC8-His3), or (V) excess non-specific DNA (pUC9), prior to 
resolution on denaturing gel. Fast-migrating free protein is out of frame except for GCN4-
C210 lane. The intense bands in the H lanes were attributed to specific GCN4-DNA 
complexes, and others to non-specific binding; adapted with permission from reference 8. 
Copyright 1986 Elsevier. 
 
Chapter 4 – DNA binding of peptide dimer conjugates based on GCN4 
 
181 
 
The 60 residue C-terminal domain was later shown to consist of 2 subdomains with 
distinct functions: (A) the bd, which makes specific contact to DNA,[9] and (B) the zipper 
domain responsible for dimerisation.[10,11] CD studies of a synthetic peptide containing the 
fully conserved basic and zipper domains of GCN4 (GCN4bz) demonstrated that peptide α-
helicity increases in the presence of the AP1 and CRE DNA target sites (Figure 4.2A).[12] 
Considering precedent CD studies on leucine zipper peptides,[7] it was suggested that the bd 
undergoes a coil-to-helix structural transition in the presence of the DNA binding site. More 
recently, bandshift assays and CD studies performed on GCN4bz peptides, indicated similar 
affinity for and induced peptide folding in the presence of DNA containing the half-CRE site 
(containing half the palindromic CRE site) than for CRE and the natural AP1 binding site 
(Figures 4.2B and C).[13] 
 
 
Figure 4.2 – (A) CD spectra for GCN4bz peptide recorded in the absence (------) or presence (-
- - ) of CRE DNA (0.5 eq.). (B) Radiogram of bandshift assay displaying sequence specificity 
of GCN4bz: lower band corresponds to free DNA, and the upper to the peptide/DNA 
complex; Increasing concentrations of peptide were incubated with  different DNA sites 
labelled at the 5’-end with 32P (poly[dI.dC] was present in all mixtures as a competitor). (C) 
CD spectra for GCN4bz peptide in the absence (●), or presence of 0.5 equivalent DNA, 
containing the NON (◊), Half-CRE (○), or AP1 target site (▲); [Ф]MRE represents the molar 
residual ellipticity in ×10
3
 deg cm
2
 dmol
-1
 res
-1
; adapted with permissions from references 12 
and 13, respectively. Copyright 1990 Nature Publishing Group and 2000 American Chemical 
Society. 
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As previously mentioned, Kim et al. prepared an artificial GCN4bd dimer, lacking a 
zipper domain, but dimerised through oxidation of an introduced cysteine (GCN4brI
SS
). 
DNase footprint studies conducted at 277 K indicate that both GCN4brI
SS
 and GCN4bz 
peptides selectively protect AP1 consensus sites from enzymatic cleavage (see Figure 4.3A). 
However, DNase footprinting conducted at higher temperatures indicated that, unlike 
GCN4bz, sequence-specific DNA binding of GCN4brI
SS
 is lost at 297 K.[14] CD studies 
conducted at 298 K are consistent with GCN4brI
SS
 alone adopting a random coil secondary 
structure, which folds into an α-helix in the presence of the AP1 DNA target site (see Figure 
4.3B). 
 
 
Figure 4.3 – DNA binding studies of (GCN4brISS) performed at 277 K. Left (A): Relevant 
section of radiogram relative to DNaseI footprinting experiment run for each single strand (1-
4 and 5-8) of 251bp DNA duplex containing AP1 site (
32P labelled on each 5’-end). 
Enzymatic cleavage were performed on solutions containing DNA only (lanes 1,4,5,8), or in 
presence of either GCN4brI
SS 
(lanes 2,6), or GCN4bz peptide (3,7). Right: CD spectra of 
GCN4brI
SS
 alone, (B) or in the presence of 1 eq. AP1 (C); [Ф]MRE represents the molar 
residual ellipticity in x10
3
 deg cm
2
 dmol
-1
 res
-1
; adapted with permission from reference 14. 
Copyright 1990 AAAS. 
 
It was later shown that double-stranded DNA can serve as a template to induce the 
folding of short peptides containing alanine and lysine residues into amphipatic α-helices 
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(positive residues located on the same side of the helix), without specific peptide-DNA 
contacts.[15] Therefore, it is necessary to compare the folding of GCN4bd derivatives in the 
presence of different oligonucleotides containing specific or non-specific sites, in order to 
assess sequence specificity. Sequence-specific DNA binding properties of artificially 
dimerised peptides based on GCN4bd (see section 4.1) are normally studied by 
electrophoresis and/or CD, and involve oligonucleotides containing specific (AP1, CRE) as 
well as non-specific sequences (NON and half-CRE).[16,17] Notably, [G28TS]2Fe conjugates 
prepared by Schepartz and co-workers were shown by CD and bandshift assays to 
discriminate between CRE and AP1. It was proposed that artificial dimerisation with a bulky 
linker reduces the conjugate’s affinity for AP1, without affecting its affinity for the larger 
CRE site (see Figure 4.4).[18] Even though GCN4 peptides have been shown to bind AP1 and 
CRE with similar affinity, CRE has been shown to better accommodate the bulk resulting 
from the large polypyridine linker used to artificially dimerised GCN4.[18] These structural 
features are likely the reason why CRE target sites are generally used in previous DNA 
binding studies of artificially dimerised GCN4bd.[17,19,20] 
 
Figure 4.4 – Bandshift assays display a strong preference of conjugate [G28TS]2Fe for CRE 
rather than AP1 sites (A), as opposed to G28
SS 
 able to bind both sequences with similar 
affinity (B). Gel radiograms correspond to electro-elution of solutions containing increasing 
amounts of [G28TS]2Fe or G28
SS , together with constant amounts of DNA, 5’-end labelled 
with 
32
P and containing either the CRE or AP1 site; adapted with permission from reference 
21. Copyright 1995 American Chemical Society. 
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4.1.2 – Aims of the chapter 
In the preceding chapter, the preparation of peptide analogues of GCN4bd, and their 
dimerisation with several polypyridine linkers was reported. Metal coordination and the 
influence on linker conformation was also investigated and compared to shorter analogues. 
The work described in this chapter was aimed to evaluate the ability of conjugates bearing 
GCN4bd moieties to bind target and non-target DNA, and how it is influenced by the addition 
of metal ions, using CD measurement and bandshift assay. The metal affinity of the 
conjugates in the presence of DNA bearing either a specific or non-specific site was also 
studied, so as to evaluate the cooperativity between metal ion and sequence specific DNA 
binding. 
 
4.2 – Results and discussion 
4.2.1 – DNA binding of GCN4bd1 and related conjugates 
4.2.1.1 – CD studies of GCN4bd1 and conjugates in the presence or absence of the DNA 
target site 
The CD profiles of solutions containing 10 μM GCN4bd1 were recorded in the 
presence of excess tris(2-carboxyethyl)phosphine (TCEP), a suitable reagent for disulphide 
bonds reduction,[22] in order to prevent formation of the dimer. In the absence of DNA, 
GCN4bd1 alone displays weak ellipticity at 222 nm (Ф222 -7,514 deg dmol
-1
 cm
2
 res
-1
), 
which is consistent with a random coil structure. In the presence of non-specific DNA, the CD 
signal relative to that of GCN4bd1 displays a slightly higher negative ellipticity value at 222 
nm (Ф222 -13,366 deg dmol
-1
 cm
2
 res
-1
). However, in the presence of the target CRE DNA 
site, the CD profile displays an important increase of ellipticity at 222 nm (Ф222 -26,140 deg 
dmol
-1
 cm
2
 res
-1
), and the spectrum is consistent with that of an α-helix (see Figure 4.5A). 
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Figure 4.5 – (A) CD profile of 10 μM GCN4bd1 alone (▬), in the presence of 0.5 eq. DNA 
bearing either NON (▬), or the CRE sites (▬) (1 mM TCEP present, contribution from DNA 
was subtracted). (B) Impact of oxidation on the CD spectra of 10 μM GCN4bd1 in the 
presence of 0.5 eq. of CRE DNA; solutions contained either 1 mM TCEP (ii, ▬), or 100 μM 
DTT (iii, ▬) as reducing agent (solution iii was incubated for 12 hours at 298 K). (C) 
Analytical C18 RP-HPLC for solutions containing GCN4bd1 partially oxidised (i), or relative 
to CD measurements in B (ii, iii). Peaks observed in (i) were assigned to: (1) GCN4bd1 
monomer, and (2) (GCN4bd1)2 oxidised dimer (based on electrospray mass spectra recorded 
for collected fractions). [Ф]MRE represents the molar residual ellipticity in ×10
3
 deg cm
2
 dmol
-
1
 res
-1
.  
 
Unlike TCEP, DTT rapidly oxidises in air losing its ability to reduce peptide bonds.[23] 
As a result, the CD spectrum recorded of a solution containing 10 μM GCN4bd1, 5 μM CRE, 
and 100 μM DTT changes over time. After incubation at 298 K for 12 hours, the ellipticity at 
222 nm has significantly increased (Ф222 -26,492 → -36,316 deg dmol
-1
 cm
2
 res
-1
), and HPLC 
indicates total oxidation and formation of (GCN4bd1)2 (see Figures 4.5B and C). 
CD spectra of solutions containing 5 μM peptide conjugates pyr(GCN4bd1)2, 
bipy(GCN4bd1)2, and terpy(GCN4bd1)2 were also recorded. As mentioned in Chapter 3, 
terpy(GCN4bd1)2 but also to some extent the bipy(GCN4bd1)2 used for these experiments 
are not pure (despite using HPLC), and related results are to be treated qualitatively rather 
than quantitatively. The 3 conjugates display low negative ellipticity at 222 nm in the absence 
of DNA (pyr(GCN4bd1)2 Ф222 -5,219; bipy(GCN4bd1)2 Ф222 -3,560; terpy(GCN4bd1)2 
Ф222 -5,598 deg dmol
-1
 cm
2
 res
-1
), and in the presence of NON DNA (pyr(GCN4bd1)2 Ф222 -
8,295; bipy(GCN4bd1)2 Ф222 -5,393; terpy(GCN4bd1)2 Ф222 -6,058 deg dmol
-1
 cm
2
 res
-1
). 
In contrast, the ellipticity at 208 and 222 nm of the 3 conjugates increased significantly in the 
presence of DNA containing the CRE site (pyr(GCN4bd1)2 Ф222 -17,009; bipy(GCN4bd1)2 
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Ф222 -11,329; terpy(GCN4bd1)2 Ф222 -11,987 deg dmol
-1
 cm
2
 res
-1
), suggesting partial 
formation of α-helices (see Figure 4.6). 
 
Figure 4.6 – CD spectra of 5 µM GCN4bd1 dimer conjugates in 10 mM phosphate buffer pH 
7.4, recorded in the absence (▬) or presence of 5 µM DNA containing either NON (▬), or 
CRE sites (▬) (contribution from DNA was subtracted). [Ф]MRE represents the molar residual 
ellipticity in ×10
3
 deg cm
2
 dmol
-1
 res
-1
. (A) pyr(GCN4bd1)2, (B) bipy(GCN4bd1)2 and (C) 
terpy(GCN4bd1)2. 
 
The folding of the GCN4bd1 peptide and related conjugates in the presence of DNA 
containing the CRE target site, is consistent with the sequence-selective folding previously 
described for GCN4bd derivatives.[14,18] Notably, peptide oxidation and subsequent 
dimerisation with a disulphide linker results in a further increase of the helicity in the 
presence of CRE DNA. Dimerisation through larger linkers, such as Me2pyr, Me2bipy, and 
Me2terpy results in similar sequence selectivity, however the conjugates are notably less α-
helical than either GCN4bd1 or the oxidised dimer. 
4.2.1.2 – Bandshift assay to estimate GCN4bd1 and conjugates affinity for CRE sites 
Further investigations on the DNA binding of GCN4bd1 conjugates were envisioned, 
including the calculation of their affinity for CRE DNA using bandshift assays, by analogy 
with previous reports on GCN4bd synthetic dimers. The affinity can be calculated from 
relative quantities of bound versus free peptide or DNA, and therefore requires partial 
dissociation of the peptide/DNA complex, which is achieved by working at concentrations 
close to or below the dissociation constant. GCN4bz homodimers and artificial GCN4bd 
dimers were previously estimated to bind CRE sites with nanomolar affinities by bandshift 
assay.[7,13] Therefore, related dissociation constant estimation involves use of a sensitive 
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detection method, such as radioactive labelling. Consequently, oligonucleotides containing 
CRE sites were labelled at the 5’-end with 32P-ATP, affording DNA strands with activity of 
~20 Ci/mmol (based on the assumption that the labelling reaction reached completion and 
calculated using the activity indicated by the manufacturer at day 0). DNA solutions 
containing as low as 10 nM 
32
P-DNA (~4 nCi) were eluted on polyacrylamide gels and 
detected on a phosphorimaging screen, visualised with a phosphorimager. 
Similarly, solutions containing 10 nM 
32
P-labelled CRE DNA in binding buffer and 
increasing amount of pyr(GCN4bd1)2 were loaded on a polyacrylamide gel and subsequently 
electrophoresed. Upon visualisation, the radiogram indicates that the five solutions containing 
0-4 nM pyr(GCN4bd1)2 all eluted as single bands with similar retention times, which was 
attributed to the free DNA (see Figure 4.7). However, electro-elution of the sixth and seventh 
solution, containing 6.5 and 10 nM pyr(GCN4bd1)2, resulted in formation of an additional 
slower-migrating band, attributed to the pyr-(GCN4bd1)2-DNA complex. The intensity of 
the fast-migrating band decreases as the concentration of pyr(GCN4bd1)2 increases, whereas 
the slow-migrating band increases in intensity. As a result, electro-elution profiles of solutions 
containing 15-100 nM pyr(GCN4bd1)2 all display an intense slow-migrating band and only a 
faint fast-migrating band. Solutions containing more than 100 nM display bands at the wells 
latitude, indicating precipitation of DNA under these conditions of high excess of peptide. 
 
Figure 4.7 – Radiogram recorded after electro-elution of solutions containing ~10 nM of 5’-
end labelled CRE oligonucleotides (
32
P, 4 nCi), and increasing amounts of pyr(GCN4bd1)2 
(concentrations are indicated in nM below the radiogram) in binding buffer. When the 
pyr(GCN4bd1)2 concentration was higher than 100 nM, 
32
P DNA precipitated in the loading 
well (out of frame). 
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As expected, addition of pyr(GCN4bd1)2 to solutions containing DNA bearing the 
CRE site, resulted in band retardation, characteristic of complex formation and consistent 
with peptide folding observed in CD. Relative intensity indicates that 50% DNA present is 
peptide bound, when the pyr(GCN4bd1)2 concentration is between 6.5 and 10 nM. This 
concentration correspond to near equimolar amounts of pyr(GCN4bd1)2 and DNA, and 
might indicate formation of a 1:1 complex. One can conclude that the dissociation constant 
for pyr(GCN4bd1)2/CRE would be close to or lower than 10 nM, even though it cannot be 
accurately estimated from this experiment (see section 4.4.3.1). 
Solutions of bipy(GCN4bd1)2 and terpy(GCN4bd1)2 were not available of sufficient 
purity for such quantitative estimation and analogous experiments were not performed or are 
not described. 
 
4.2.1.3 - Influence of Cu(II) and Zn(II) on bipy(GCN4bd1)2 and terpy(GCN4bd1)2 
folding in the presence of target DNA 
 
It remained to evaluate if sequence selective folding of GCN4bd1 polypyridine 
conjugates was sensitive to the presence of Cu(II) and Zn(II) ions, and specifically whether 
these could regulate the conformation of the polypyridine linker domain in such a way that 
could be exploited to control DNA binding. For this, the CD spectra of solutions containing 
CRE DNA and peptide conjugates (either bipy(GCN4bd1)2, or terpy(GCN4bd1)2 both 5 
μM), before and after addition of Cu(II) or Zn(II) were compared. In both case, Cu(II) and 
Zn(II) addition does not result in significant changes in the CD profile of the polypyridine-
peptide dimer conjugates (see Figure 4.8). It must be noted that bipy(GCN4bd1)2 stock 
solution used in this experiment was not pure, and resulting spectra poorly compare with that 
displayed in Figure 4.6. 
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Figure 4.8 – CD spectra of (A) bipy(GCN4bd1)2, or (B) terpy(GCN4bd1)2 in the presence 
of 1 eq. CRE DNA in 10 mM phosphate buffer pH 7.4, in the absence (▬) or presence of 
either CuCl2 (▬) or ZnCl2 (▬). Reversibility was monitored by addition of excess EDTA (10 
equivalents to metal ion (▬)). [Ф]MRE represents the molar residual ellipticity in ×10
3
 deg cm
2
 
dmol
-1
 res
-1
. 
 
Previous UV measurements recorded at micromolar concentrations were consistent with 
conjugates bipy(GCN4bd1)2 and terpy(GCN4bd1)2 binding Cu(II) at the polypyridine linker 
sites (see Chapter 3). In contrast, it seems that addition of Cu(II) or Zn(II) are unable to alter 
folding of the peptide moieties, and by extension, the DNA binding ability of either 
bipy(GCN4bd1)2 or terpy(GCN4bd1)2 under these experimental conditions. 
 
4.2.2 – DNA binding of GCN4bd2 and related conjugates 
4.2.2.1 – CD study of GCN4bd and conjugates 
Cu(II) and Zn(II) addition were previously shown to not affect the CD spectra of 
solutions containing (GCN4bd2)2, bipy(GCN4bd2)2, and terpy(GCN4bd2)2 (see Chapter 
3). In this section, the CD profile of these conjugates recorded in the presence of equimolar 
amounts of DNA containing various sites (NON, CRE, Half-CRE, or AP1), and for which the 
contribution of the DNA has been subtracted, are reported and discussed. Ellipticity values at 
222 nm, which are directly indicative of the peptide helicity,[24] are summarised in Table 4.1. 
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Table 4.1 – Summary of residual molar ellipticities values at 222 nm (displayed as ×103 deg 
cm
2
 dmol
-1
 res
-1
) for peptide conjugates in the absence and presence of 1 equivalent of DNA 
bearing different consensus sequences. Two equivalents of metal ion (CuCl2 or ZnCl2) were 
then added to each solution, followed by addition of 10 equivalents EDTA.  
Pep. conjugate metals no DNA NON CRE Half-CRE AP1 
(GCN4bd2)2 
no -3.39 -5.58 -14.58 -9.69 -11.31 
CuCl2 -2.77 -4.86 -14.20 -10.41 -9.89 
ZnCl2 -3.60 -4.21 -13.42 -10.18 -9.79 
EDTA -3.13 -5.35 -13.71 -9.37 -8.94 
bipy(GCN4bd2)2 
no -4.40 -4.52 -13.14 -8.05 -9.44 
Cu -2.90 -4.77 -17.00 -9.47 -8.86 
Zn -4.08 -4.41 -22.30 -11.58 -10.86 
EDTA -3.98 -3.92 -10.97 -8.46 -8.11 
terpy(GCN4bd2)2 
no -4.23 -4.05 -9.92 -6.07 -4.89 
Cu -3.43 -6.67 -19.97 -16.90 -22.57 
Zn -3.75 -4.93 -15.37 -11.04 -11.26 
EDTA -4.05 -4.08 -9.54 -5.40 -3.38 
 
The CD spectra of solutions containing 5 μM of NON and either (GCN4bd2)2, 
bipy(GCN4bd2)2, or terpy(GCN4bd2)2 all display two negative minima of different 
intensity located around 200 and 222 nm, which are not characteristic of any particular 
peptide secondary structure. These are similar to CD spectra recorded in the absence of DNA, 
and ellipticity recorded at 222 nm have low values ((GCN4bd2)2 Ф222 -5,583; 
bipy(GCN4bd2)2 Ф222 -4,523; terpy(GCN4bd2)2 Ф222 -4,046 deg dmol
-1
 cm
2
 res
-1
), and 
spectra are largely unaffected by addition of two equivalents of CuCl2 or ZnCl2, and followed 
by 10 equivalents EDTA (see Figure 4.9). An exception being addition of two equivalents of 
CuCl2 to a solution containing 5 μM of NON and terpy(GCN4bd2)2, which resulted in a 
small increase of the negative ellipticity at 222 nm (Ф222 -4,046 → -6,670 deg dmol
-1
 cm
2
 res
-
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1
), which is fully reversed upon addition of 10 equivalent EDTA (Ф222 -6,670 → -4,075 deg 
dmol
-1
 cm
2
 res
-1
) (see Figure 4.9C). 
 
 
Figure 4.9 – CD spectra of 5 µM GCN4bd2 dimer and conjugates in the presence of 5 µM 
NON DNA in 10 mM phosphate buffer pH 7.4. [Ф]MRE represents the molar residual 
ellipticity in x10
3
 deg cm
2
 dmol
-1
 res
-1
. A) (GCN4bd2)2 oxidised dimer, B) bipy(GCN4bd2)2 
and C) terpy(GCN4bd2)2 DNA, recorded in the absence (▬) and presence of 2 equivalents 
of either CuCl2 (▬) or ZnCl2 (▬). Reversibility was monitored by addition of excess EDTA 
(10 equivalents to metal ion (▬)). 
 
In contrast, more can be said about CD spectra of conjugates recorded in the presence of 
DNA containing the CRE site. The spectra of 5 μM (GCN4bd2)2 and bipy(GCN4bd2)2 
recorded in the presence of CRE DNA displays two negative bands centred at 208 and 220 
nm of similar intensities, suggesting partial folding into α-helices (see Figures 4.10A and B). 
In contrast, the spectrum of 5 μM terpy(GCN4bd2)2 recorded in the presence of CRE DNA 
displays a more intense band around 204 nm, and a weaker band centred at 220 nm, which are 
consistent with terpy(GCN4bd2)2 being more folded in the presence of CRE DNA than in 
the presence of NON, but less helical compared to either the disulphide or bipy analogues 
(see Figure 4.10C). Upon addition of two equivalents of CuCl2 or ZnCl2, the CD profile of 
(GCN4bd2)2 remains largely unaffected (see Figure 4.10A). In contrast, the helicity of 
bipy(GCN4bd2)2 in the presence of CRE DNA, increases by 29% upon addition of two 
equivalents of CuCl2 (Ф222 -13,139 → -16,997 deg dmol
-1
 cm
2
 res
-1
) and 70%  upon addition 
of two equivalents of ZnCl2 (Ф222 -13,139 → -22,301 deg dmol
-1
 cm
2
 res
-1
) (see Figure 
4.10B). Moreover, the peptide helicity of terpy(GCN4bd2)2 in the presence of CRE DNA 
doubles upon addition of two equivalents of CuCl2 (Ф222 -9,925 → -19,974 deg dmol
-1
 cm
2
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res
-1
), but only increases by a modest 55% upon addition of two equivalents of ZnCl2 (Ф222 -
9,925 → -15,370 deg dmol-1 cm2 res-1) (see Figure 4.10C). 
 
Figure 4.10 – CD spectra of 5 µM GCN4bd2 dimer and conjugates in the presence of 5 µM 
CRE DNA in 10 mM phosphate buffer pH 7.4. A) (GCN4bd2)2 oxidised dimer, B) 
bipy(GCN4bd2)2 and C) terpy(GCN4bd2)2 DNA. Spectra recorded in the absence (▬) or 
presence of 2 eq. either CuCl2 (▬) or ZnCl2 (▬). Reversibility was monitored by addition of 
excess EDTA (10 eq. to metal ion (▬)). [Ф]MRE represents the molar residual ellipticity in 
×10
3
 deg cm
2
 dmol
-1
 res
-1
. 
 
 
In order to assess reversibility, excess EDTA (10 equivalents per metal ion) was added 
to solutions of the metal-peptide conjugates in the presence of CRE DNA, resulting in a 
decrease in the negative ellipticity at 222 nm for both bipy(GCN4bd2)2 (Cu Ф222 -16,997 → 
-10,965; Zn Ф222 -22,302 → -10,967 deg dmol
-1
 cm
2
 res
-1
) and terpy(GCN4bd2)2 (Cu Ф222 -
19,974 → -9,538; Zn Ф222 -15,370 → -7,998 deg dmol
-1
 cm
2
 res
-1
), whereas the spectra of 
(GCN4bd2)2 were largely unaffected (see Figure 4.10). 
At this stage, it was neccessary to evaluate whether an increase of α-helicity upon metal 
addition was consistent with metal-binding at the polypyridine linkers, and if peptide helicity 
was optimum when two equivalents of metal ion were present. For this, solutions containing 
10 μM CRE and 10 μM of either bipy(GCN4bd2)2 or terpy(GCN4bd2)2 were titrated with 
Cu(II) and Zn(II), and CD spectra were recorded for each 0.2 equivalence step (see Figure 
4.11). 
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Figure 4.11 – CD spectra for metal ion titration of 10 µM peptide dimer conjugates and CRE 
DNA in 10 mM phosphate buffer pH 7.4. (A) Zn(II) titration of bipy(GCN4bd2)2, (B) Zn(II) 
titration of terpy(GCN4bd2)2, (C) Cu(II) titration of bipy(GCN4bd2)2, and (D) Cu(II) 
titration of terpy(GCN4bd2)2; (▬) 0 eq. metal ion, (■■■) between 0 and 1 eq., (▬) 1 eq., 
(▬●▬) more than 1 eq. ZnCl2 added; (■■■) between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 
eq. CuCl2 added. [Ф]MRE represents the molar residual ellipticity in ×10
3
 deg cm
2
 dmol
-1
 res
-1
. 
 
 
Molar ellipticities at 222 nm were plotted as a function of metal ion equivalence. Out of 
the four plots, three are consistent with the formation of 1:1 complexes, and the ellipticity at 
222 nm reaching a maximum when 2 equivalents of metal ion (either CuCl2 or ZnCl2) have 
been added. The exception could be the Cu(II)-bipy(GCN4bd2)2-CRE system where the less 
intense change is less conclusive (Figure 4.12). Data were fitted to 1:1 models to determine 
equilibrium constant values relative to metal-induced folding (Kmf). Metal-induced folding 
constants, log Kmf, were determined to be 5.87 ± 0.21 for the Zn-bipy(GCN4bd2)2-CRE 
complex, 6.72 ± 0.21 for the Cu-terpy(GCN4bd2)2-CRE complex, and 5.88 ± 0.14  for the 
Zn-terpy(GCN4bd2)2-CRE complex. However, the data for the Cu(II)-bipy(GCN4bd2)2-
CRE could be fitted to neither 1:1, nor 1:2 binding model. 
Chapter 4 – DNA binding of peptide dimer conjugates based on GCN4 
 
194 
 
 
 
Figure 4.12 – Plot of residual molar ellipticities at 222 nm versus the metal ion equivalence, 
relative to CuCl2 (■ and ●) and ZnCl2 (■ and ●) titration of solution containing 10 μM CRE 
DNA and either (A) bipy(GCN4bd2)2, or (B) terpy(GCN4bd2)2. (▬) represents best fit for 
a 1:1 metal:peptide dimer conjugate binding ratio. Data for the Cu titration 
bipy(GCN4bd2)2/CRE could not be fitted. 
 
Table 4.2 – Summary of the CD data obtained for Zn(II)/Cu(II) titration of polypyridine 
peptide dimer conjugates, bipy(GCN4bd2)2 and terpy(GCN4bd2)2. 
Pep. conjugate Metal Ф222 (deg cm
2
 dmol
-1
 res
-1
) Kmf (M
-1
) R
2
 
bipy(GCN4bd2)2 
Zn -2.34 ± 0.07  Е +04 7.33 ± 4.64  Е +05 0.9738 
Cu
a
 - - - 
terpy(GCN4bd2)2 
Zn -1.92 ± 0.03  Е +04 7.55 ± 2.78  Е +05 0.9928 
Cu -2.24 ± 0.02  Е +04 5.20 ± 3.24  Е +06 0.9960 
a
 data could not be fitted to a 1:1 and 1:2 models. 
 
As an extension to this work, the impact of metal addition to conjugates complexed with 
oligonucleotides similar to CRE, namely AP1 and half-CRE, was investigated. In the absence 
of Cu(II) or Zn(II), the CD spectra recorded for the three conjugates in the presence of half-
CRE or AP1 are similar to that recorded in the presence of CRE:  (GCN4bd2)2 and 
bipy(GCN4bd2)2 display more helical profiles compared to terpy(GCN4bd2)2, which 
displayed lower ellipticity at 222 nm (see Figure 4.13). As for previous measurements, the 
addition of either CuCl2 or ZnCl2 does not alter the CD spectrum of (GCN4bd2)2. Moreover, 
the addition of metal ions does not significantly alter the CD spectra of bipy(GCN4bd2)2 in 
the presence of either AP1 or half-CRE DNA, despite being sensitive to the presence of these 
metal ions in the presence of CRE DNA. In contrast, the helicity of terpy(GCN4bd2)2 in the 
presence of half-CRE and AP1, is highly sensitive to the presence of metal ions. For both 
half-CRE and AP1 the addition of Zn(II) is consistent with a more α-helical peptide (half-
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CRE Ф222 -6,649 → -11,039; AP1 Ф222 -6,328→ -11,264 deg dmol
-1
 cm
2
 res
-1), of similar α-
helicity as the bipy(GCN4bd2)2 analogue. However the addition of Cu(II) is accompanied by 
a very significant increase in the α-helical  signal at 222 nm (half-CRE Ф222 -6,074→ -16,901; 
AP1 Ф222 -4,896→ -22,572 deg dmol
-1
 cm
2
 res
-1
) (Figure 4.13). As for spectra recorded in the 
presence of CRE, all changes observed upon addition of two equivalent CuCl2 or ZnCl2 were 
fully reversed when excess EDTA was added to the solution.  
 
Figure 4.13 – CD spectra of 5 µM GCN4bd2 dimer and conjugates in the presence of 5 µM 
DNA containing either half-CRE (A, B, C), or AP1 sites (D, E, F) in 10 mM phosphate buffer 
pH 7.4. (GCN4bd2)2 oxidised dimer (A, D), bipy(GCN4bd2)2 (B, E), terpy(GCN4bd2)2 (C, 
F). Spectra recorded in the absence (▬) and presence of 2 eq. of either CuCl2 (▬) or ZnCl2 
(▬). Reversibility was monitored by addition of excess EDTA (10 eq. to metal ion 
(▬)).[Ф]MRE represents the molar residual ellipticity in ×10
3
 deg cm
2
 dmol
-1
 res
-1
. 
 
CD spectra of (GCN4bd2)2 recorded in the presence or absence of specific or non-
specific DNA, are all unaffected by Cu(II) or Zn(II) addition. This is consistent with the 
design which lacks a metal ion chelating polypyridine linker unit. However, CD spectra 
indicate that both bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in the presence of the CRE site 
experience an increase in the negative ellipticity at 222 nm upon metal ion addition, which in 
turn is highly dependent on the nature of the metal ion, i.e. Cu(II) vs. Zn(II).  
Stepwise addition of metal ion to solutions containing CRE and equimolar amounts of 
bipy(GCN4bd2)2 or terpy(GCN4bd2)2, indicates that the increase of ellipticity at 222 nm 
plateaus after addition of between 1 and 2 equivalents of metal ion, and is consistent with 
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formation of 1:1:1 ternary complexes (metal ion:peptide conjugate/CRE), except for Cu(II) 
addition to bipy(GCN4bd2)2/CRE that might result from the successive formation of 
different complexes (see Figure 4.12). The intensity of the change in molar ellipticity at 222 
nm suggests a higher affinity for DNA containing the CRE target site for 
Cu(II):terpy(GCN4bd2)2 and Zn(II):bipy(GCN4bd2)2 complexes, and a lower affinity for 
the Zn(II):terpy(GCN4bd2)2 and Cu(II):bipy(GCN4bd2)2 complexes (see Figure 4.10 and 
5.11). The molar ellipticity at 222 nm in the presence of CRE DNA for 
Cu(II):terpy(GCN4bd2)2 and Zn(II):bipy(GCN4bd2)2 resembles those reported for CD 
studies of related GCN4bd artificial dimers bound to CRE DNA.[17,20] These changes are 
accompanied by the appearance of a positive band at 268 nm in the difference CD spectra, 
appearing upon addition of peptide conjugates to CRE DNA and growing in intensity upon 
metal addition. This can be assigned to the bending of the DNA which has previously been 
reported to occur upon binding of bz peptides (including some miniature GCN4 
peptides).[12,25,26] 
Upon addition of EDTA, all increase of helicity resulting from metal addition to 
bipy(GCN4bd2)2 and terpy(GCN4bd2)2 is lost, and spectra resemble those previously 
recorded, consistent with fully reversible processes. In some cases, EDTA addition resulted in 
an even greater decrease of the negative ellipticity at 222 nm, which could result from a low 
level of contamination from trace metal ions.  
Folding constants obtained from CD titrations display a larger margin of error compared 
to metal-binding constants previously estimated based on UV measurements. These constants 
cannot be described as metal-polypyridine, nor peptide-DNA binding constants since the 
shifts monitored account for peptide folding, which represent indirect consequences of the 
metal-binding at the polypyridine linker sites. However, trends observed (such as Cu binding 
tighter than Zn) and the order of magnitude (compare Kapp with Kmf) are consistent with those 
determined when monitoring by UV spectroscopy, vide infra (see section 4.2.2.3).  
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A different titration experiment was performed in order to estimate the peptide-DNA 
binding constants using CD spectroscopy. For this, peptide conjugates bipy(GCN4bd2)2 or 
terpy(GCN4bd2)2 were added stepwise to solutions containing CRE DNA, both in the 
absence or presence of excess metal ion. However, plots of ellipticity versus peptide 
conjugates equivalence, plateaued only when a high excess of peptide conjugates were 
present, and this coincided with precipitation (data not shown). The absence of plateau at one 
equivalent might arise from simultaneous specific and non-specific binding, the latter being 
important in the CD relevant concentration range, even though it does not result in significant 
peptide folding. 
The helicity of conjugate terpy(GCN4bd2)2 in the presence of half-CRE and AP1 was 
shown to increase upon addition of Cu(II) and Zn(II), in much the same fashion as was 
previously observed in the presence of CRE DNA. Helicity is greater in the presence of AP1 
DNA compared to CRE where both peptide strands are proposed to bind in an α-helical 
fashion and with a high affinity, in contrast to half-CRE in which only one binding site exists 
for one of the peptide strands to bind with high affinity. Unlike native GCN4, it appears that 
the Cu(II):terpy(GCN4bd2)2 complex is able to discriminate between AP1 and CRE sites, 
that differ by a single central bp. In contrast, metal regulated folding of bipy(GCN4bd2)2 is 
unable to discriminate between AP1 and half-CRE sites which respectively lacks one central 
bp, and half of the binding sites compared to CRE, respectively. These results are in perfect 
agreement with the original design which estimates that both 5,5’-disubstituted bipy, in both 
the cis- and trans- conformation, and the cis-cis- conformation of 6,6’-disubstituted terpy 
would result in the correct spatial alignment of the peptide substituents for binding to the CRE 
DNA target site. In contrast, only the cis-cis- conformation of 6,6’-disubstituted terpy was 
foreseen to satisfy the shorter distance between peptides when the dimers are bound to the 
AP1 DNA (see Chapter 3). 
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4.2.2.2 – Bandshift assay for GCN4bd2 conjugates 
The study of the metal-dependent behaviour of bipy(GCN4bd2)2 was further studied, 
using bandshift assays. For this, solutions containing 20 nM of 5’-end labelled CRE and 
increasing amounts of bipy(GCN4bd2)2, either in the absence or presence of unlabelled CRE 
(480 or 980 nM), were loaded on polyacrylamide gels (10 or 7%). Following electro-elution 
with different buffer (either 1× or 0.5× Tris-glycine or TG) and phosphorimaging, none of the 
radiograms obtained displayed a significant bandshift, even when DNA and peptide 
conjugates were present at micromolar concentrations (see Figure 4.14). 
 
 
Figure 4.14 – Radiogram obtained from electro-elution at 277 K of solutions containing CRE 
(labelled and unlabelled), and increasing amounts of bipy(GCN4bd2)2 (concentration are 
indicated in nM below radiogram): large excess of peptide conjugates over DNA results in 
precipitation in wells. (A) All solutions contained 20 nM of 5’-end labelled CRE (32P) and 
were loaded on 10% polyacrylamide gel in 1xTG buffer pH 8.7, eluted at 120 V. (B) 
Solutions containing 20 nM of 5’-end labelled CRE (32P), unlabelled CRE (5 left slot: 480 
nM; 5 right slot: 980 nM), and were loaded on 7% polyacrylamide gel in 0.5×TG buffer pH 
8.7, eluted at 100 V. 
 
Electrophoretic measurements were performed on bipy(GCN4bd2)2 and CRE DNA 
only, as conjugate terpy(GCN4bd2)2 and oligonucleotides containing the AP1 site were not 
available at the time of the experiment. No significative bandshift which could be assigned as 
the bipy(GCN4bd2)2/CRE complex were observed, even when DNA and dimer conjugates 
were present at high concentrations, similar to those used for CD measurements. One can 
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conclude that even though CD measurements indicate interactions between bipy(GCN4bd2)2 
and CRE DNA, the resulting complex is not stable under the electrophoretic conditions used, 
consistent with our peptide design that lacks the hinge area (KLQRMKQ), which is important 
for the complex stability.[16] By analogy, the peptide dimer GCN4br5
SS
 was shown, by Kim 
and co-workers, to bind sequence specifically to the CRE DNA site by comparative CD 
melting studies, even though footprinting studies indicated it does not protect this site from 
enzymatic cleavage.[16] For instance, the shortest artificial GCN4bd dimer reported 
displaying bandshift in the presence of specific DNA, has 23 residues conserved from wild 
type GCN4 (six more than this work).[27] As a potential alternative, a recent study used 
fluorescence anisotropy to estimate the peptide-DNA affinity of an artificial derivative of the 
homeodomain transcription factor  to oligonucleotides labelled with fluorescent dyes and 
bearing various target sites.[28] 
4.2.2.3 – Cu(II) and Zn(II) binding studies of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in 
the presence of DNA monitored by UV spectroscopy 
Conversely, an investigation of the impact of DNA on the metal affinity of linkers from 
GCN4bd2 conjugates was attempted in order to prove coordination was indeed still occurring 
at the polypyridine linker when in the presence of DNA (to rule out metal ion binding to DNA 
playing a role). Therefore, Cu/Zn addition to solutions containing bipy(GCN4bd2)2 or 
terpy(GCN4bd2)2 and one equivalent of DNA bearing either CRE or NON sites, were 
monitored by UV spectroscopy, and the metal-binding constants for the polypyridine peptide 
dimer conjugates in the presence of DNA were estimated, following methods analogous to 
those used in the absence of DNA (see Chapter 3). However, the band due to the π → π*2 
transition overlaps with a gap resulting from DNA signal subtraction (DNA nucleobases 
absorb light at 260 nm resulting in intense bands at 5 μM, which saturate the detector), thus 
preventing an accurate quantification of the conjugates. Therefore, the concentration of 
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peptide conjugates for these titrations were calculated based on the stock solution 
concentration. The UV spectra of solutions containing  5 μM of conjugate (either 
bipy(GCN4bd2)2 or terpy(GCN4bd2)2) and NON in 20 mM phosphate buffer pH 7.4 
display transitions with λmax at 298 (bipy(GCN4bd2)2) or 296 nm (terpy(GCN4bd2)2), 
assigned as π → π*1. Aliquots of a stock solution of ZnCl2 were titrated into a solution 
containing 5 μM bipy(GCN4bd2)2/NON or terpy(GCN4bd2)2/NON in 20 mM phosphate 
buffer pH 7.4, up to 3 equivalent of ZnCl2. This resulted in the steady decrease in the 
absorbance at 298 (bipy(GCN4bd2)2) and 296 nm (terpy(GCN4bd2)2), and an increase in 
the absorbance at 308 and 320 nm (bipy(GCN4bd2)2), or at 328 and 341 nm 
(terpy(GCN4bd2)2) (see Figures 4.15A and B). In contrast, absorbance for the new peaks 
were centred at 316 and 328 nm (bipy(GCN4bd2)2) or at 335 and 348 nm 
(terpy(GCN4bd2)2), upon addition of CuCl2 into similar solutions (see Figures 4.15C and 
D). Isosbestic points at 303 (Zn:bipy(GCN4bd2)2), 314 (Zn:terpy(GCN4bd2)2), 308 
(Cu:bipy(GCN4bd2)2), and 319 nm (Cu:terpy(GCN4bd2)2) are again consistent with clean 
formation of the complex. 
Figure 4.15 – UV spectra for the metal ion titration of solutions containing 5 µM peptide 
conjugates and NON DNA in 20 mM phosphate buffer pH 7.4 (DNA contribution has been 
subtracted). ZnCl2 titration of (A) bipy(GCN4bd2)2/NON, (B) terpy(GCN4bd2)2/NON. 
CuCl2 titration of (C) bipy(GCN4bd2)2/NON, (D) terpy(GCN4bd2)2/NON. (▬) 0 eq. metal 
added, (■■■) between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 eq. ZnCl2 added, (■■■) 
between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 eq. CuCl2 added. 
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Plots of absorbance of the new transitions versus Cu/Zn equivalence were fitted to 1:1 
binding equations (see Figure 4.16), and the extinction coefficients of the peptide dimers and 
the resulting Cu(II)/Zn(II) complexes determined and reported in Table 4.3. Taking into 
account the competitive metal ion binding of the phosphate buffer employed in these 
experiments,[29]  binding constants in the presence of NON, log KM, were calculated to be 
5.63 ± 0.09 for formation of the Zn-bipy(GCN4bd2)2 complex, and 6.16 ± 0.06 for the 
analogous complex with terpy(GCN4bd2)2. Titration of bipy(GCN4bd2)2 with Cu(II) had to 
be performed in the presence of a competitor (10 mM L-glycine), in order to accurately 
estimate the Cu(II) affinity. Formation constants in the presence of NON, log KM, were 
determined to be 11.97 ± 0.06 for the Cu-bipy(GCN4bd2)2 complex, and 8.04 ± 0.09 for the 
Cu-terpy(GCN4bd2)2 complex. 
 
Figure 4.16 – Plot of absorbance versus the equivalence of metal ion, either ZnCl2 (□ and ○) 
or CuCl2 (□ and ○). Absorbance was monitored at (A) 320 (□, values were subtracted with 
absorbance at 400 nm), 328 nm (□) for bipy(GCN4bd2)2/NON, and (B) 341 (○), 348 nm (○) 
for terpy(GCN4bd2)2/NON. Cu titration of bipy(GCN4bd2)2/NON was performed in the 
presence of 10 mM L-glycine. (▬) Represents best fit for a 1:1 metal:peptide dimer conjugate 
binding ratio. 
 
Table 4.3 – Summary of the UV data obtained for Cu/Zn coordination to polypyridyl peptide 
conjugates, bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in the presence of 1 eq. NON DNA. 
Pep. conjugate Metal λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
bipy(GCN4bd2)2 
Zn 320 1.74 ± 0.08  Е +04a 7.20 ± 1.58  Е +04 4.34 ± 0.95  Е +05 0.9939 
Cu 328 1.54 ± 0.01  Е +04 7.34 ± 1.10  Е +05 9.24 ± 1.41  Е +11b 0.9979 
terpy(GCN4bd2)2 
Zn 340 1.80 ± 0.03  Е +04 2.43 ± 0.35  Е +05 1.46 ± 0.21  Е +06 0.9987 
Cu 348 1.32 ± 0.01  Е +04 3.40 ± 0.74  Е +06 1.11 ± 0.25  Е +08 0.9941 
a
Absorbance value at 320 nm corrected by subtraction of absorbance recorded at 400 nm. 
b
Titration performed in the presence of 10 mM L-glycine as competitor. 
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The UV spectra of solutions containing  5 μM of conjugate (either bipy(GCN4bd2)2 or 
terpy(GCN4bd2)2) and CRE DNA in 20 mM phosphate buffer pH 7.4 display transitions 
with λmax at 299 (ε299 nm 17,624 M
-1
 cm
-1
) (bipy(GCN4bd2)2) or 296 nm (ε296 nm 19,134 M
-1
 
cm
-1
) (terpy(GCN4bd2)2), assigned as π → π*1. However, the π → π*2 transition overlaps 
with a gap resulting from DNA signal subtraction. Aliquots of a stock solution of ZnCl2 were 
titrated into solution containing 5 μM bipy(GCN4bd2)2/CRE or terpy(GCN4bd2)2/CRE in 
20 mM phosphate buffer pH 7.4. This resulted in the steady decrease in the absorbance at 299 
(bipy(GCN4bd2)2) and 296 nm (terpy(GCN4bd2)2), and an increase in the absorbance at 
311 and 320 nm (bipy(GCN4bd2)2), or at 328 and 341 nm (terpy(GCN4bd2)2), respectively 
(see Figures 4.17A and B). In contrast, absorbance for the new peaks were centred at 316 and 
328 nm (bipy(GCN4bd2)2) or at 335 and 348 nm (terpy(GCN4bd2)2), upon addition of 
CuCl2 into similar solutions (see Figures 4.17C and D). Isosbestic points at 304 
(Zn:bipy(GCN4bd2)2), 315 (Zn:terpy(GCN4bd2)2), 310 (Cu:bipy(GCN4bd2)2), and 319 
nm (Cu:terpy(GCN4bd2)2) are consistent with clean formation of the complex. 
Figure 4.17 – UV spectra for the metal ion titration of solutions containing 5 µM peptide 
conjugates and CRE duplex DNA in 20 mM phosphate buffer pH 7.4 (contribution of DNA 
was subtracted). ZnCl2 titration of (A) bipy(GCN4bd2)2/CRE, (B) terpy(GCN4bd2)2/CRE 
and CuCl2 titration of (C) bipy(GCN4bd2)2/CRE, (D) terpy(GCN4bd2)2/CRE. (▬) 0 eq. 
metal added, (■■■) between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 eq. ZnCl2 added, (■■■) 
between 0 and 1 eq., (▬) 1 eq., (▬●▬) more than 1 eq. CuCl2 added. 
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Plots of absorbance of the new transitions versus Cu/Zn equivalence were fitted to a 1:1 
binding equation (see Figure 4.18), and the extinction coefficients of the peptide dimers and 
the resulting Cu(II)/Zn(II) complexes determined and reported in Table 4.4. Taking into 
account the competitive metal ion binding of the phosphate buffer employed in these 
experiments,[29]  binding constants, log KM, were calculated to be 6.89 ± 0.11 for formation 
of the Zn-bipy(GCN4bd2)2/CRE complex, and 6.62 ± 0.06 for the analogous complex with 
terpy(GCN4bd2)2. Titration of bipy(GCN4bd2)2/CRE or terpy(GCN4bd2)2/CRE with 
Cu(II) had to be performed in the presence of 10 and 0.2 mM L-glycine, respectively, in order 
to accurately estimate the Cu(II) affinity. Formation constants, log KM, were determined to be 
12.26 ± 0.08 for the Cu-bipy(GCN4bd2)2/CRE complex, and 9.41 ± 0.09 for the Cu-
terpy(GCN4bd2)2/CRE complex. 
 
Figure 4.18 – Plot of absorbance versus the equivalence of metal ion, either ZnCl2 (□ and ○) 
or CuCl2 (□ and ○). Absorbance was monitored at 320 (□), 328 nm (□) for 
bipy(GCN4bd2)2/CRE (A) and 341 (○), 348 nm (○) for terpy(GCN4bd2)2/CRE (B). CuCl2 
titration of bipy(GCN4bd2)2/CRE and terpy(GCN4bd2)2/CRE were performed in the 
presence of 10 and 0.2 mM L-glycine, respectively. (▬) represents best fit for a 1:1 
metal:peptide dimer conjugate binding ratio. 
 
Table 4.4 – Summary of the UV data obtained for Cu/Zn coordination to polypyridyl peptide 
conjugates, bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in the presence of 1 eq. CRE DNA. 
Pep. conjugate Metal λ (nm) εML (M
-1
 cm
-1
) Kapp (M
-1
) KM (M
-1
) R
2
 
bipy(GCN4bd2)2 
Zn 320 1.90 ± 0.02 Е +04 1.29 ± 0.36 Е +06 7.77 ± 2.19 Е +06 0.9904 
Cu 328 1.47 ± 0.01 Е +04 1.45 ± 0.27 Е +06 1.82 ± 0.35 Е +12a 0.9945 
terpy(GCN4bd2)2 
Zn 340 1.62 ± 0.02 Е +04 6.94 ± 1.06 Е +05 4.18 ± 0.64 Е +06 0.9976 
Cu 348 1.35 ± 0.07 Е +04 4.80 ± 1.07 Е +06 2.57 ± 0.58 Е +09b 0.9950 
Titration performed in the presence of 10
a
 and 0.2
b
 mM L-glycine as competitor. 
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CuCl2 and ZnCl2 titrations monitored by UV were carried out in the presence of one 
equivalent of duplex DNA (5 μM) containing either the CRE or NON site, so as to investigate 
metal binding to the polypyridine linkers under these conditions and to evaluate if metal 
binding to these linkers and DNA binding of the peptide substituents is cooperative. If one 
considers a thermodynamic cycle linking the four main species (peptide, peptide/metal, 
peptide/DNA, and peptide/metal/DNA) in equilibrium, any change in the metal-binding 
affinity of the peptide dimer conjugates is due to the peptide dimer DNA affinity which could 
alter the polypyridyl linkers conformation.[30,31] The affinity of terpy(GCN4bd2)2 in the 
presence of NON DNA is slightly greater for Zn(II) and almost unchanged for Cu(II) 
compared to the affinity determined in the absence of DNA. However, the affinity for Cu(II) 
and Zn(II) is enhanced 20 and 10 times, respectively, in the presence of DNA containing the 
CRE target site (see Figure 4.19). Therefore, one can expect the affinity of the peptide 
conjugates for the CRE DNA site to be increased by the same amount upon respective 
addition of Cu(II) or Zn(II). Therefore, the DNA binding regulation by the terpy linker in the 
terpy(GCN4bd2)2 conjugate appears smaller compared to that reported for GCN4bd 
dimerised with azobenzene (see section 4.1.1).[17] This result is consistent with the reversible 
and irreversible control of DNA binding afforded by the terpy and azobenzene conjugates, 
respectively. 
 
Figure 4.19 – Histogram representing the log KM values calculated for GCN4bd2 
polypyridine conjugates in the absence or presence of DNA bearing either NON or CRE site. 
Comparison of calculated Cu(II) and Zn(II) affinities for (A) bipy(GCN4bd2)2, or (B) 
terpy(GCN4bd2)2. Cu(II) (horizontal stripes, ■) and Zn(II) (vertical stripes, ■); error bars 
displayed stand for absolute errors associated with calculation. 
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The Zn(II) affinity of bipy(GCN4b2)2 decreases very slightly in the presence of NON 
DNA, and remains largely unchanged in the presence of DNA containing the CRE target site. 
The Cu(II) affinity of bipy(GCN4bd2)2 decreases in the presence of DNA, regardless of the 
presence of the target site (see Figure 4.19). These results are consistent with DNA binding 
not promoting the more favourable cis- conformation for metal ion chelation on binding to 
DNA, consistent with a design in which both the cis- and trans- conformation are appropriate 
for DNA binding. Instead the DNA acts like a competitive ligand for the metal ions, either 
directly (metal binding to DNA), or indirectly (peptide donor atoms which contribute to the 
metal ion coordination sphere are no longer available when bound to DNA). The latter is less 
relevant to terpy which provides more of the donor atoms for metal ion coordination than 
bipy. Even though peptide binding to target DNA is enhanced in the presence of metal ions 
(due to a combination of electrostatics and conformational changes), binding to target DNA 
decreases the metal ion affinity (most significantly for Cu(II)). 
Both peptide dimers display a higher affinity for Cu(II), which is known to favour a 
square planar (bipy)[32] or square-pyramidal (terpy)[33] coordination geometry, over Zn(II), 
which commonly adopts a tetrahedral (bipy)[34,35] or trigonal bipyramid (terpy) [33] 
geometry. However, peptide folding in the presence of CRE DNA, an indication of DNA 
binding, is greatest for bipy(GCN4bd2)2 bound to Zn(II), for which it has a lower affinity. 
Whereas for terpy(GCN4bd2)2 this is the case when bound to Cu(II), for which it has a 
higher affinity than Zn(II). Based on the determined binding constants, one can predict that 
under conditions relevant to CD measurement (Figure 4.10) ca. 99 % of Cu(II) and 87 % of 
Zn(II) will be bound to terpy(GCN4bd2)2 in the presence of CRE DNA. The slightly higher 
occupancy of the metal binding site in the presence of two equivalents Cu(II), compared to 
two equivalents Zn(II), does not account for differences of peptide helicity observed in the 
CD spectra. 
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Metal ion affinity and the ability to regulate DNA binding are therefore not mutually 
inclusive. A parallel can be drawn with two natural transcription factors involved in metal ion 
regulation, through a repressive process. Nmtr and SmtB adopt a similar quaternary structure, 
but are capable of sensing different metal ions. This is achieved due to the metal ion 
coordination geometry offered by the allosteric site, but is not dependent on the metal ion 
affinity. Robinson and co-workers report that, within a cyanobacterial cytosol, the regulatory 
metalloproteins Synechococcus PCC7942 SmtB functions in response to Zn(II) coordination 
but not Co(II), even though in vitro studies have shown that Zn(II) and Co(II) binds to the 
same tetrahedral allosteric site.[36] In contrast, the Ni(II) and Co(II) responsive 
metalloprotein NmtR from Mycobacterium tuberculosis regulating the nmt operator, contains 
an allosteric metal-binding site on helix α5 of the winged helix-turn-helix motif, similarly to 
SmtB, but involving two additional ligands for potential metal ion coordination in an 
octahedral fashion (the two additional ligands require reorganisation to bind octahedral metal 
ions). NmtR binds Co(II) with lower affinity compared to SmtB, but this results in a structural 
transition which in turn inhibits DNA binding. Moreover, Zn(II) binds to NmtR with greater 
affinity than Co(II), but is unable to reduce DNA binding.[37,38]  These examples illustrate 
that metal ion allosteric regulation is largely dependent on preferred metal ion coordination 
geometry and how that might alter protein structure, rather than metal ion affinity. Therefore 
our examples above need to be considered not in terms of enhanced metal ion affinity and 
resulting DNA affinity, but rather in terms of preferred coordination geometry and resulting 
DNA affinity. 
4.3 –  Summary 
The DNA binding studies by CD and bandshift assays of polypyridine conjugates 
bearing GCN4bd mimics, prepared in Chapter 3, is reported. CD studies are consistent with 
all conjugates adopting random coil secondary structures, both in the absence and presence of 
non-specific DNA. However, some folding of the peptide conjugates into α-helices is 
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promoted in the presence of DNA containing the CRE target site. For the longer design, 
GCN4bd1 conjugates dimerised through metal chelation motif were shown by CD to interact 
in a similar fashion with the target CRE site, before and after Cu(II) or Zn(II) addition. 
Bandshift assays run on pyr(GCN4bd1)2 and CRE are consistent with the binding constant 
previously estimated for similar GCN4bd dimers. In contrast, the shorter GCNbd2 
conjugates/CRE complexes are not stable under our electrophoretic conditions, preventing 
binding constant estimation by this technique. Similar metal addition did increase the helical 
content of peptide moieties for the second generation conjugates bearing the shorter peptide 
GCN4bd2 and the very same linkers, in the presence of target DNA sites only.  
This is consistent with the hypothesis that reducing the flexibility of conjugates with 
careful design increases the influence of linker conformation on the DNA binding ability. 
These results are also consistent with our polypyridine linker design, for which metal ion 
coordination will promote the cis- or cis-cis- conformations, triggering the alignment of 
peptide moieties capable of sequence selectively binding to DNA. In comparison, Cu(II) or 
Zn(II) addition to solutions containing the disulphide bridged dimer (GCN4bd2)2 and the 
CRE site do not affect the CD spectrum. Aside from the control, two conjugates 
bipy(GCN4bd2)2 which contains an allosteric ineffective Me2bipy unit, and 
terpy(GCN4bd2)2 which contains the allosteric effective Me2terpy unit, are studied. In the 
presence of CRE DNA, the former displayed a greater increase of helicity upon Zn(II) rather 
than Cu(II) coordination, whereas the opposite trend is observed for the latter. 
The Cu(II) and Zn(II) affinity of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in the 
absence and presence of DNA containing the CRE site was estimated. Both peptide dimers 
display a higher affinity for Cu(II) rather than Zn(II), and for bipy(GCN4bd2)2 the binding 
constant either remains unchanged or decreases slightly in the presence of DNA. However, 
this is not the case for terpy(GCN4bd2)2, which binds more tightly to both Cu(II) and Zn(II) 
in presence of CRE DNA, consistent with the cis- conformation required for both DNA 
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binding and metal ion coordination. Intriguingly, a higher metal ion affinity does not correlate 
with enhanced binding to CRE DNA as determined by CD, probably due to the allosteric site 
and metal ion coordination geometry. 
Complementary CD studies performed in the presence of DNA containing the AP1 or 
half-CRE target site (both of which have previously been shown to interact with GCN4 in 
vitro, but with slightly different structural requirements compared to CRE), display the most 
significant CD change, consistent with DNA binding, for terpy(GCN4bd2)2 in the presence 
of Zn(II) and to an even greater extent with Cu(II). Significantly the enhanced AP1 binding of 
metallated terpy(GCN4bd2)2 is consistent with a cis-cis- terpyridine conformation which 
positions the two peptide moieties at an optimal distance for binding to the AP1 DNA target 
site. In contrast, similar metal addition did not result in significant changes in the CD profile 
of bipy(GCN4bd2)2 recorded in the presence of AP1, where the inter-peptide distance is too 
large for binding to the AP1 target site. Metal ion coordination and peptide realignment to 
promote DNA binding are fully reversible upon addition of excess EDTA.  
As an extension of this work, the potential of these polypyridine peptide conjugates as 
sequence-selective DNA sensors or nuclease agents, was partly investigated. The preliminary 
results will be presented in the following chapter. 
4.4 – Experimental 
4.4.1 – Equipment and reagents 
Mono- and dihydrogen potassium phosphate salts, sodium chloride, potassium chloride, 
Tris Base, DNA grade water, glycine (electrophoresis buffer only), polyacrylamide stock 
solution 40%, ammonium persulfate, tetramethylethylenediamine, ethylene diamine tetra 
acetic acid (EDTA) were all obtained from Fisher Scientific. Copper chloride (CuCl2), 
glycerol, IGEPAL CA-630, L-glycine and bovine serum albumin were obtained from Sigma-
Aldrich, trifluoroacetic acid (TFA) and zinc chloride (ZnCl2) from BOC. The QIAquick 
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Nucleotide removal kit and the loading dye, were obtained from QIAgen; polykinase T4 
enzyme and kinase 10x buffer were from promega. 
32
P-ATP was obtained from Perkin-Elmer. 
UV measurements were recorded in 1 cm pathlength quartz cuvette at 298 K, on 
Shimadzu 1800 spectrometer. CD spectra were recorded in 1 mm pathlength quartz cuvettes 
at 298 K on a Jasco J-715 spectropolarimeter. In all cases, difference spectra were obtained by 
subtracting the CD spectrum of buffer alone or in the presence of DNA (blank), from that of a 
mixture containing both peptide and DNA, in order to observe the CD contribution from the 
peptide component only. The observed ellipticities in millidegrees were converted into 
residual molar ellipticity, ФRME, reported in units of deg cm
2
 dmol
-1
 res
-1
, thus allowing 
estimation of secondary structure. Finally, spectra were baselined by subtracting from each 
data point, the average ФRME measured between 400 and 300 nm for the same spectra (a 
region were no intense peak are expected). Radioactivity is reported in Curie unit (Ci). 
Electrophoresis were run in a web scientific big runner tank, gels were visualised using a 
Biorad molecular imager FX, and processed with Quantity One software version 4.6.8, 
following exposure on a Kodak FX screen 20 x 25 cm.  Figures based on GCN4 were all 
obtained using pymol version 1.1eval and file deposited in the protein data bank (pdb). Non-
linear fitting were performed using Kaleidagraph software version 4.0, as described in 
Chapter 2. 
4.4.2 – Synthetic procedure and characterisation 
Preparation of peptide and peptide conjugates were reported in the preceding chapter 3. 
Oligonucleotides were provided by Professor James Tucker and co-workers following 
preparation on an Applied Biosystems 394 DNA/RNA synthesizer. These were subsequently 
purified using Phenomenex Clarity Oligo-RP semi-preparative HPLC column eluted with a 
gradient of 0.1 M triethylammonium-acetate aqueous solution pH 7 and acetonitrile, 
following the methodology established by the Tucker group.[39] Following purification, 
oligonucleotides (single strand) were characterised by electrospray and analytical HPLC. 
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Table 4.5 – Summary of electrospray data and theoretical extinction coefficients for the 
different single-strand oligonucleotides used in this study. 
Name Sequence (5’- to 3’-) ε260 (M
-1
 cm
-1
)
a
 MWtheor.
b
 MWexp. 
NON1 TGGAGTATGCGTCGATTCGT 1.924  Е +05 6,179.1 6,180.0 
NON2 ACGAATCGACGCATACTCCA 1.972  Е +05 6,055.0 6,056.0 
CRE1 ACGAGATGACGTCATCTCCA 1.976  Е +05 6,086.0 6,086.0 
CRE2 TGGAGATGACGTCATCTCGT 1.930  Е +05 6,148.1 6,149.0 
Half-CRE1 TGGAGATGACGTTGTCTCGT 1.912  Е +05 6,179.1 6,179.0 
Half-CRE2 ACGAGACAACGTCATCTCCA 1.970  Е +05 6,055.0 6,055.0 
AP1-A TGGAGATGACTCATCTCGTG 1.920  Е +05 6,148.1 6,148.0 
AP1-B CACGAGATGAGTCATCTCCA 1.966  Е +05 6,086.0 6,086.0 
a
Theoretical absorbance values were obtained using online calculator,[40] and were used for 
oligonucleotides quantification. 
b
Mass obtained using online calculator.[41] 
 
Oligonucleotide concentrations were estimated from the absorbance value at 260 nm, 
using theoretical molar absorptivity values (see Table 4.5). Duplex DNA were prepared by 
annealing two complementary oligonucleotide strands (50 µM in 10 mM Tris.HCl buffer pH 
7 and 0.1 M NaCl) at 75 °C, and subsequently allowing the annealed DNA to return to room 
temperature overnight. 
 
4.4.3 – Analytical procedures 
4.4.3.1 – Measurements on GCN4bd1 and related dimer conjugates (relative to section 
4.2.1) 
For CD spectra of solutions containing 10 μM GCN4bd1, or 5 μM pyr(GCN4bd1)2, 
bipy(GCN4bd1)2, terpy(GCN4bd2)2, recorded in the presence or absence of 5 μM DNA 
duplex bearing either NON, or CRE consensus sites, a 300 µL blank solution containing 10 
mM phosphate buffer pH 7.4, reducing agents (GCN4bd1 only), and 5 μM duplex DNA (if 
present) was first recorded. Equimolar amounts of peptide dimer or peptide dimer conjugate 
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solution was added, and the data collected after 15 minute equilibration (GCN4bd1: 600 μM, 
3 nmol, 5 µL; pyr(GCN4bd1)2: 200 μM, 1.5 nmol, 7.5 µL; bipy(GCN4bd1)2: 300 μM, 1.5 
nmol, 5 µL; terpy(GCN4bd1)2: 73.8 μM, 1.5 nmol, 20.3 µL). CD spectra are an average of 
10 scans recorded between 180 and 400 nm at 200 nm min
-1
 (0.2 nm pitch). For GCN4bd1, 1 
mM TCEP (Figure 4.5B, and B(ii)) or alternatively 100 μM DTT (Figure 4.5B(iii)) were 
present in the blank solution in order to prevent sulphur oxidation and dimer formation. For 
metal addition to terpy(GCN4bd1)2, one equivalents of CuCl2 or ZnCl2 (1 mM, 1.5 nmol, 1.5 
µL) was added and the solution allowed to equilibrate for 15 min prior to recording spectra. 
Ten equivalents of EDTA per metal ion (10 mM, 30 nmol, 3 µL, pH 6-8) was added and the 
CD spectra recorded, in order to investigate reversibility. However, analogous experiments of 
bipy(GCN4bd1)2 (Figure 4.7) followed a similar method, but using different stock solutions 
(bipy(GCN4bd1)2: 200 μM, 1.5 nmol, 7.5 µL; Cu/Zn: 3 mM, 1.5 nmol, 2 µL) and spectra 
were instead an average of 20 scans recorded between 185 and 400 nm at 500 nm min
-1
 (0.5 
nm pitch). 
!Caution the following steps need to be carried out in a designated area for handling of 
radioactive material! 
Oligonucleotide CRE1 was labelled at the 5’-end using 32P-ATP by preparing a mixture 
containing CRE1 stock solution (195 μM, 2.048 nmol, 10.5 μL), ultrapure water (1.5 μL), 10x 
solution of polynucleotide T4 kinase (10 unit μL-1, 20 unit, 2 μL), and 10× kinase buffer (2 
μL). To this solution was added 32P labelled ATP (10mCi mL-1, 3000 Ci mmol-1, 13.33 pmol, 
4 μL) behind a protective shield. Following mixing and centrifugation, the reaction mixture 
was incubated at 310 K for 1 hour.  In order to deactivate the enzyme the temperature was 
then raised to 363 K for 1 min, followed by cooling on ice. The labelled oligonucleotide was 
then purified using the QIAquick nucleotide removal kit from QIAgen (containing disposable 
columns and eluting solutions) following provider indications. Following purification, an 
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aqueous solution containing 
32P 5’-end labelled oligonucleotide CRE1 (59.1 μM, 2.068 nmol, 
35 μL, 40 μCi) was obtained. The CRE duplex was prepared by mixing 32P labelled CRE1 
(59.1 μM, 591 pmol, 10 μL, 11.4 μCi), with unlabelled CRE2 (195 μM, 585 pmol, 3 μL), 10x 
annealing buffer containing 100 mM Tris.HCl pH 7 and 1 M NaCl (1.5 μL), and ultrapure 
water (0.5 μL). Following mixing and centrifugation, the mixture was heated to 353 K for 1 
min, and allowed to cool down to room temperature over 4 hours. A 
32P 5’end labelled DNA 
duplex stock solution (39 μM, 585 pmol, 15 μL, 11.4 μCi) was obtained and further diluted 
with ultrapure water (nb: activity displayed are indicative only and are calculated based on 
manufacturer calibration for day 0: 3000 Ci mmol
-1
). 
For the bandshift assay experiment, aliquots for 15 reaction mixtures (20 μL each) were 
prepared, containing 
32P duplex CRE (0.1 μM, 0.2 pmol, 2 μL, 3.9 nCi), 2× binding buffer (10 
μL), and different amounts of pyr(GCN4bd1)2 (see Table 4.6). The 2× binding buffer was 
prepared following previous reports [21] and contained 20 mM phosphate buffer pH 7.4, 200 
mM NaCl, 5 mM KCl, 10% glycerol, 0.2% IGEPAL CA-630, and 80 μg mL-1 bovine serum 
albumin. Volumes of binding solutions were adjusted to 20 μL with ultrapure water and 
solutions were mixed and centrifuged, prior to incubation at 277 K for 1 hour. 
 
Table 4.6 – Summary of pyr(GCN4bd1)2 quantities present in each binding reaction, and the 
volumes of stock solutions used. 
Lane nº 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
conc
a
 (nM) 0 1 1.5 2.5 4 6.5 10 15 25 40 65 100 150 250 400 
V1
b
 (μL) - 1 1.5 2.5 4 6.5 - - - - - - - - - 
V2
c
 (μL) - - - - - - 1 1.5 2.5 4 6.5 - - - - 
V3
d
 (μL) - - - - - - - - - - - 1 1.5 2.5 4 
a 
Concentration of pyr(GCN4bd1)2 in each binding solution. 
b,c,d
 Volume of pyr(GCN4bd1)2 
stock solution either 20
b
, 200
c
, or 2000 nM
d
 added to each binding solution. 
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In a coldroom (277 K), binding solutions were loaded on a 10% polyacrylamide (19:1 
crosslinking) gel cast in running buffer. The gel was electro-eluted at 120 V for 3.5 hours in 
1× TG buffer (20 mM Tris, 153 mM glycine, pH 8.7) at 277 K, and subsequently exposed for 
18 hours on a Kodak-FX screen. It was then visualised using a molecular imager FX and 
processed. 
If one considers the simple case of a protein binding a particular DNA site as a 
monomer, the dissociation constant is calculated following equation 4.1-4.3: 
    
[ ]  [ ] 
[  ]
 (4.1) 
[ ]   [ ]  [  ] (4.2) 
[ ]   [ ]  [  ] (4.3) 
KD represents the protein-DNA dissociation constant, [P]F and [P]T the DNA unbound 
and total concentration of the protein, [D]F and [D]T the protein unbound and total 
concentration of the DNA respectively, and [PD] the concentration of the protein-DNA 
complex. When [D]F << KD, then [P]F >> [PD] and we can write [P]T = [P]F thus obtaining 
equation 4.4: 
    
[ ]  [ ] 
[  ]
 (4.4) 
Therefore, the protein-DNA dissociation constant can be calculated experimentally if 
the proportion of free DNA over protein-DNA complex, and the total protein concentration, 
are known. When the concentration of free DNA is equal to the concentration of protein-DNA 
complex, the total protein concentration is equal to the protein-DNA dissociation 
constant.[42] 
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4.4.3.2 – Measurements on GCN4bd2 dimer, and related conjugates (relative to section 
4.2.2) 
For CD spectra of solutions containing 5 μM (GCN4bd2)2, bipy(GCN4bd2)2, or 
terpy(GCN4bd2)2, and 5 μM NON, CRE, Half-CRE, or AP1 DNA, 300 µL blank solutions 
containing 10 mM phosphate buffer pH 7.4 and 5 μM DNA duplex were first recorded. 7.5 
µL of 200 µM peptide dimer or peptide dimer conjugate solutions were added, and the data 
collected after 15 minute equilibration. Two equivalents of CuCl2 or ZnCl2 (1.5 mM, 3 nmol, 
2 µL) was added and the solution allowed to equilibrate for 15 min prior to recording spectra. 
Ten equivalents of EDTA per metal ion (10 mM, 30 nmol, 3 µL, pH 6-8) were added and the 
CD spectra recorded, in order to investigate reversibility. Spectra are an average of 20 scans 
recorded between 185 and 400 nm at 500 nm min
-1
 (0.5 nm pitch).  
Metal titrations of peptide/CRE DNA complexes were performed at a higher 
concentration (10 µM bipy(GCN4bd2)2/terpy(GCN4bd2)2, 10 µM DNA). To a 1 mm 
pathlength cuvette, 60 (± 1) µL of a 50.0 µM solution of CRE DNA, 30 (± 1) µL of 100 mM 
phosphate buffer pH 7.4 and 195 (± 1) µL deionised water, were successively added. A blank 
spectrum was recorded, and 15.0 (± 0.2) µL of bipy(GCN4bd2)2 or terpy(GCN4bd2)2 
solution (200 ± 2 µM) was added. Samples were allowed 15 min equilibration prior to 
recording spectra. Aliquots of aqueous stock solutions of CuCl2 or ZnCl2 (300 ± 13 μM) were 
then titrated into the solution containing 10.0 (± 0.2) µM of the peptide/CRE DNA complex, 
and the CD recorded after 7 min equilibration. Spectra are an average of 8 scans recorded 
between 190 and 300 nm at 200 nm min
-1
 (0.5 nm pitch). The residual molar ellipticity values 
were corrected to account for dilution. Kmf values were calculated by fitting data for the 
ellipticity at 222 nm of the ternary complexes as a function of Cu(II)/Zn(II) concentration, 
following the method described for the Kapp in Chapter 2. 
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!Caution the following steps need to carried out in designated area for handling of 
radioactive material! 
Bandshift assays run on bipy(GCN4bd2)2 (Figure 4.14) involved steps similar to the 
one previously described with little adjustments (see section 4.4.3.1). The reaction mixture for 
labelling step contained CRE1 stock solution (60 μM, 300 pmol, 5 μL), 10× solution of 
polynucleotide T4 kinase (10 unit μL-1, 10 unit, 1 μL), 10× kinase buffer (1 μL), and 32P 
labelled ATP (10 mCi mL
-1
, 3000 Ci mmol
-1, 10 pmol, 3 μL). Following labelling, 
purification, and annealing as previously described, a 5’-end labelled DNA duplex (32P) stock 
solution (2 μM, 90 pmol, 45 μL, 9 μCi) was obtained. The 6 + 10 binding solutions (20 μL 
each) contained 
32P duplex CRE (0.2 μM, 0.4 pmol, 2 μL, 40 nCi), and 2× binding buffer (10 
μL) which contained 40 mM phosphate buffer pH 7.4, 100 mM NaCl, 5 mM KCl, 10% 
glycerol, 0.1% IGEPAL CA-630. Increasing amounts of bipy(GCN4bd2)2 and unlabelled 
CRE duplex (Figure 4.14B only) were also added to the mixture as in Table 4.7 or 5.8. 
Volumes of binding solutions were adjusted to 20 μL with ultrapure water and solutions were 
mixed and centrifuged, prior to incubation at 277 K for 30 minutes.  
Table 4.7 – Summary of bipy(GCN4bd2)2 quantities present in each binding reaction, and 
volumes of stock solutions used, relative to gel in Figure 4.14A. 
Lane nº 1 2 3 4 5 6 
CP 
a
 (nM) 0 10 20 30 40 50 
VP 
b
 (μL) - 1 2 3 4 5 
a
 Concentration of bipy(GCN4bd2)2 in each binding solution. 
b
 Volume of bipy(GCN4bd2)2 
200 nM stock solution added to each binding solution. 
 
Binding solutions relative to Figure 4.14A were loaded on a 10% polyacrylamide (19:1 
reticulation) gel cast in running buffer. The gel was electro-eluted at 120 V for 4.5 hours in 1× 
TG buffer (20 mM Tris, 153 mM glycine, pH 8.7) at 277 K, and subsequently exposed for 16 
hours on a Kodak-FX screen. 
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Table 4.8 – Summary of bipy(GCN4bd2)2 and unlabelled CRE quantities present in each 
binding reactions, and volumes of stock solutions used, relative to gel in Figure 4.14B. 
Lane nº 1 2 3 4 5 6 7 8 9 10 
CP
 a
 (μM) 0 0.5 1 2 5 0 0.5 1 2 5 
CD 
b
 (μM) 0.48 0.48 0.48 0.48 0.48 0.98 0.98 0.98 0.98 0.98 
VP1
c
 (μL) - 5 - - - - 5 - - - 
VP2
d
 (μL) - - 1 2 5 - - 1 2 5 
VD1
e
 (μL) 1 1 1 1 1 - - - - - 
VD2
f
 (μL) - - - - - 1 1 1 1 1 
Concentration of bipy(GCN4bd2)2
a
, or unlabelled CRE DNA
b
 in each binding solution. 
Volume of stock solution either 2
c, or 20 μMd bipy(GCN4bd2)2 and volume of stock solution 
either 9.6
e, or 19.6 μMf unlabelled CRE DNA added to each binding solution. 
 
In contrast, binding solutions relative to Figure 4.14B were loaded on a 7% 
polyacrylamide (37.5:1 cross-linking) gel cast in running buffer. The gel was electro-eluted at 
100 V for 5 hours in 0.5× TG buffer (10 mM Tris, 76 mM glycine, pH 8.7) at 277 K, and 
subsequently exposed for 14 hours on a Kodak-FX screen. Both gels were then visualised and 
processed. 
For metal ion titrations of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 in the presence of 
DNA monitored by UV spectroscopy, aliquots of aqueous 300 (± 13) μM stock solutions of 
CuCl2 or ZnCl2, were titrated into 600 µL of a solution containing 5.00 (± 0.19) μM of 
polypyridyl-peptide dimer conjugate and double stranded oligonucleotide in 20.0 (± 0.3) mM 
potassium phosphate buffer pH 7.4. Spectra were recorded after 3 min equilibration. When 
the apparent Cu(II) binding constant was too high to be accurately estimated, L-glycine was 
added as a competitor ligand. L-glycine was present for the reported titration of 
bipy(GCN4bd2)2 in the presence of both DNA sites (10.0 ± 0.2 mM), and of 
terpy(GCN4bd2)2 in the presence of CRE only (200 ± 4 μM). Kapp values were calculated by 
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fitting data for the absorbance maximum of the metal complexes as a function of Cu(II)/Zn(II) 
concentration, and KM were calculated following the method described in Chapter 2. 
 
4.5 – References 
                                                          
[1] Lucchini G., Hinnebusch A. G., Chen C., Fink G. R., Mol. Cell. Biol., 1984, 4, 1326-1333. 
[2] Hurst H. C., Protein Profiles Transcription Factors 1:bZIP Proteins, Academic Press, 
London, 1994, ISSN 1070-3667. 
[3] Angel P., Karin M., Biochim Biophys. Acta, 1991, 1072, 129-157.  
[4] Hope I. A., Struhl K., Cell, 1985, 43, 177-188. 
[5] Arndt, K.; Fink, G. R. Proc. Natl Acad. Sci. USA, 1986, 83, 8516-8520. 
[6] Hinnebusch A. G., Microbiol. Rev., 1988, 52, 248-273.  
[7] Sellers J. W., Vincent A. C., Struhl K., Mol. Cell. Biol., 1990, 10, 5077-5086.  
[8] Hope I. A., Struhl K., Cell, 1986, 46, 885-894.  
[9] Agre P., Johnson P., McKnight S., Science, 1989, 246, 922-926. 
[10] Landschulz W., Johnson P., McKnight S., Science, 1988, 240, 1759-1764. 
[11] O’ Shea E. K., Rutkowski R., Kim P. S., Science, 1989, 243, 538-542.   
[12] Weiss M. A., Ellenberger T., Wobbe C. R., Lee J. P., Harrison S. C., Struhl K., Nature, 
1990, 347, 575-578.   
[13] Hollenbeck J. J., Oakley M. G., Biochemistry, 2000, 39, 6380-6389.  
[14] Talanian R. V., McKnight C. J., Kim P. S., Science, 1990, 249, 769-771.  
[15] Johnson N. P., Lindstrom J., Baase W. A., von Hippel P. H., Proc Natl. Acad. Sci. USA, 
1994, 91, 4840-4844. 
[16] Talanian R. V., McKnight J., Rutkowski R., Kim P. S., Biochemistry, 1992, 31, 6871-
6875. 
[17] Cammaño A. M., Vásquez M. E., Martínez-Costas J., Castedo L., Mascareñas J. L., 
Angew. Chem. Int. Ed., 2000, 39, 3104-3107.   
Chapter 4 – DNA binding of peptide dimer conjugates based on GCN4 
 
218 
 
                                                                                                                                                                                     
[18] Cuenoud B., Schepartz A., Proc. Natl. Acad. Sci. USA, 1993, 90, 1154-1159. 
[19] Jiménez-Balsa A., Pazos E., Martínez-Albardonedo B., Mascareñas J. L., Vázquez M. E., 
Angew. Chem. Int. Ed., 2012, 51, 8825-8829.   
[20] Morii T., Saimei Y., Okagami M., Makino K., Sugiura Y., J. Am. Chem. Soc., 1997, 119, 
3649-3655.   
[21] Palmer C. R., Sloan L. S., Adrian Jr J. C., Cuenoud B., Paolella D. N., Schepartz A., J. 
Am. Chem. Soc., 1995, 117, 8899-8907. 
[22] Dmitrenko O., Thorpe C., Bach R. D., J. Org. Chem., 2007, 72, 8298-8307.  
[23] Burns J. A., Butler J. C., Moran J., Whitesides G. M., J. Org. Chem., 1991, 56, 2648-
2650.  
[24] Woody R. W., Koslowski A., Biophys. Chem., 2002, 101-102, 535-551.  
[25] Conte M. R., Lane A. N., Bloomberg G., Nucleic Acids Res., 1997, 25, 3808-3815. 
[26] Dragan A. I., Liu Y., Makeyeva E. N., Privalov P. L., Nucleic Acids Res., 2004, 32, 
5192-5197. 
[27] Ueno M., Murakami A., Makimo K., Morii T., J. Am. Chem. Soc., 1993, 115, 12575-
12576. 
[28] Guerrero L., Smart O. S., Woolley G. A., Allemann R. K., J. Am. Chem. Soc., 2005, 127, 
15624-15629.  
[29] Banerjea D., Kaden T. A., Sigel H., Inorg. Chem., 1981, 8, 2586-2590. 
[30] Grossoehme N. E., Giedroc D. P., Spectroscopic methods of analysis: Methods and 
protocols, Methods in molecular biology, Chapter 8: Illuminating allostery in metal sensing 
transcriptional regulators, 875, Springer science+business media, New York, 2012, p167. DOI 
10.1007/978-1-61779-806-1_8.  
[31] Hoersey I., Krishnan-Ghosh Y., Balasubramanian S., Chem. Commun., 2002, 1950-1951.  
[32] Garribba E., Micera G., Sanna D., Strinna-Erre L., Inorg. Chim. Acta, 2000, 299, 253-
261. 
Chapter 4 – DNA binding of peptide dimer conjugates based on GCN4 
 
219 
 
                                                                                                                                                                                     
[33] Bertrand H., Monchaud D., De Cian A., Guillot R., Mergny J.-L., Teulade-Fichou M.-P., 
Org. Biomol. Chem., 2007, 5, 2555-2559.  
[34] Rama G., Ardá A., Maréchal J., Gamba I., Ishida H., Jiménez-Barbèro J., Vázquez M. E., 
López M. E. V., Chem. Eur. J., 2012, 18, 7030-7035.  
[35] Khalighi A., Ahmadi R., Amani V., Khavasi H. R., Acta Crystallogr. E, 2008, E64, 
m1211-m1212. 
[36] VanZile M. L., Cosper N. J., Scott R. A., Giedroc D. P., Biochemistry, 2000, 39, 11818-
11829.   
[37] Tottey S., Harvie D. R., Robinson N. J., Acc. Chem. Res., 2005, 38, 775-783.  
[38] Cavet J. S., Meng W., Pennella M. A.,  Appelhoff R. J., Giedroc D. P., Robinson N. J., J. 
Biol. Chem., 2002, 277, 38441-38448. 
[39] Nguyen H. V., Zhao Z., Sallustrau A., Horswell S. L., Male L., Mulas A., Tucker J. H. 
R., Chem. Commun., 2012, 48, 12165-12167.  
[40] http://biophysics.idtdna.com/UVSpectrum.html, accessed on 10/10/2012. 
[41] http://www.basic.northwestern.edu/biotools/oligocalc.html, accessed on 10/10/2012. 
[42] Fairall L., Buttinelli M., Panetta G., DNA-Protein Interactions, Chapter 5: Bandshift, gel 
retardation or electrophoretic mobility shift assays, Oxford University Press, New York, 
2000, ISBN 978-0-19-963691-4. 
  
 
 
 
 
 
 
CHAPTER V: PRELIMINARY STUDIES ON 
SENSING AND NUCLEASE APPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 – Preliminary studies on sensing and nuclease applications 
 
221 
 
5.1 – Introduction 
5.1.1 – Sequence specific DNA sensors based on polypyridine and peptides 
Following the hypothesis by Lerman that aromatic compounds can intercalate DNA 
through non-covalent interactions,[1] Lippard and co-workers showed that the complex 
[Pt
II
(terpy)(SCH2CH2OH)]
+
 interacted with DNA in a similar fashion, and that this lead to an 
alteration in its photophysical properties.[2] The concepts of π interactions with nucleotide bp 
of DNA and shape recognition were later generalised to a broad variety of square-planar and 
octahedral metal complexes bearing aromatic ligands, from which new types of probes, 
diagnostic, and therapeutics agents were developed.[3] The design of complexes capable of 
sequence selective DNA intercalation based on matching shape and functionalities is 
challenging, though a few notable success have been reported.[4,5] An alternative strategy 
consists of covalently attaching metal complexes with moieties able to sequence selectively 
bind DNA such as urea,[6] or peptides.[7]   
Barton and co-workers reported a conjugate made of a [Rh
III
(phin)2(phen’)] complex 
(phin = 9,10-phenanthrenequinone diimine; phen’ = 5-(amidoglutaryl)-1,10-phenanthroline) 
and a 13 residue peptide, derived from the α3-helix from the phage P22 repressor, which, upon 
photoactivation (see section 5.1.2), specifically cleaves DNA at the adenosine nucleotide from 
5’-CCA-3’ consensus sites (see Figure 5.1A). A single mutation of a glutamate residue for 
lysine, glutamine, aspartate, or glutamate methyl ester, abolished sequence specific binding, 
as indicated by the loss of cleavage specificity.[8] Also relevant to this study are the work by 
Ogawa and co-workers who prepared a conjugate with [Ru
II
(bipy)2(phen-IA)]
2+
 (phen-IA = 
N-iodoacetyl-5-amino-1,10-phenanthroline) and GCN4bz peptide moieties, however the 
conjugate was unable to induce sequence specific photocleavage (see Figure 5.1B).[9] In both 
studies, the photophysical properties of the polyaromatic metal complexes peptide conjugates, 
and how these are affected by sequence-selective DNA binding were not investigated.  
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Figure 5.1 – (A) Model for the [RhIII(phin)2(phen’)] peptide conjugate binding to the 5’-
CCA-3’ DNA recognition site. The side-chain from the glutamate residue is shown forming a 
hydrogen bond with the 4- amino group from cytosine, reproduced with permission from 
reference 8. Copyright 1994 American Chemical Society. (B) Model for the 
[Ru
II
(bipy)2(phen-IA)]
2+
-GCN4bz conjugate binding to the AP1 DNA recognition site, 
reproduced with permission from reference 9. Copyright 2000 Elsevier. 
 
Many reports describe the luminescent properties of polypyridine metal 
complexes,[5,10-12] and peptide based DNA sensors (including non-aromatic metal 
complexes peptide conjugates).[13,14] To the best of our knowledge, there is only few reports 
where the luminescent output of polypyridine peptide conjugates allow to discriminate 
between different DNA sequences,[15,16] moreover the effects described are modest. 
Excitation of metal-free bipy and terpy ligands through their lower energy π→π* (λ = 
298 nm) results in contrasted fluorescence properties. In aprotic solvents, the very low 
fluorescence quantum yield observed for bipy (5x10
-4
 in ethanol, 298 K) was explained by 
efficient intersystem crossing to local triplet states.[17] In contrast, these deactivation 
processes are less efficient for terpy, consistent with the higher fluorescence quantum yield 
(0.09 in ethanol, 300 K).[18] As for absorbance properties, the emission properties of bipy 
and terpy in aqueous media are largely pH-dependent. In short both ligands were previously 
shown to display fluorescence in basic media similar to those recorded in aprotic media (bipy: 
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ФF n.d., terpy: ФF 0.11). In contrast, emission profiles recorded at lower pH, associated with 
monoprotonated bipy and diprotonated terpy display more intense fluorescence ([bipyH]
+
: 
ФF n.d., [terpyH2]
2+: ФF 0.61) with the emission peak centred at 340 (bipy), or 345 and 350 
nm (terpy).[18,19]  
Metal-ion complexation can again have contrasted effects on the fluorescence spectra of 
polypyridine ligands. For example, Zn(II) complexation of bipy and terpy results in 
fluorescence enhancement, and the resulting complexes have higher fluorescence quantum 
yields than the mono- and diprotonated species, respectively ([bipyZn
II
]
2+: ФF 0.36, 
[terpyZn
II
]
2+: ФF > 0.65).[20-22] In contrast, coordination of Cu(II) results in quasi-total 
quenching of the fluorescence.[22] Previous studies by Pu and co-workers have shown that, 
unlike the free-ligand, the complex terpy:Cu(II) was able to efficiently sense the Zn(II) cation 
among other transition metal ions by displacement of Cu(II), (see Figure 5.2A and B),[22] but 
also histidine among other amino-acids and imidazole derivatives without Cu(II) 
displacement (see Figure 5.2C).[23] In the latter case, it was hypothesised that histidine was 
able to coordinate the metal from terpy:Cu(II), through vacant orbitals, completing its 
coordination sphere. 
 
Figure 5.2 – Bar charts displaying relative fluorescence intensity (λexc. = 298 nm) in the 
presence of metal ions and amino-acids, by terpy:Cu(II) complexes. (A) Relative 
fluorescence intensity (λem. = 338 nm) measured upon addition of 2 eq. metal-ions to 20 μM 
terpy (I1). (B) Relative fluorescence intensity (λem. = 351 nm) upon addition of 50 eq. metal-
ion to 20 μM terpy:Cu(II) solution (I2). (C) Relative fluorescence intensity (λem. = 352 nm) 
upon addition of 5 eq. amino-acids or imidazole derivatives to a solution containing 20 μM 
terpy:Cu(II) solution (I2); (Cys)2 stands for cystine, N-MI for 1-methyl-1H-imidazole, and 2-
MI for 2-methyl-1H-imidazole; adapted with permissions from references 22 and 23. 
Copyright 2012 Royal Society of Chemistry. 
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5.1.2 – Polypyridine peptide conjugates as sequence specific nuclease agents 
Following the discovery and study of the DNA cleavage ability of bleomycin metal 
complexes in the presence of oxygen,[24,25] Sigman and co-workers introduced the first 
artificial DNA cleavage agent based on Cu(I)-(phen) complexes.[26] The complex binds 
DNA through the minor groove and produces reactive oxygen species (ROS) through Fenton-
type reactions between O2 and Cu(I), which are able to abstract protons from the sugar 
backbone leading to phosphodiester bond cleavage (see Figure 5.3A).[27] Many metal 
complexes with similar nucleolytic activity were subsequently studied,[28] including Ru(II) 
and Rh(III) complexes the excited states of which were shown to present suitable redox 
properties for oxidation by oxygen and ROS production.[3] For most of the Cu(I/II) and 
Fe(II/III) complexes, the presence of a reducing agent is required for in situ reduction from 
Cu(II) and Fe(III) to Cu(I) and Fe(II), a pre-requisite for DNA cleavage.[27] However, some 
complexes are able to cleave DNA in the absence of a reducing agent.[29,30] 
Similarly, the discovery of restriction enzyme functionality[31] has driven considerable 
interest towards the preparation of artificial molecules able to catalyse DNA phosphoester 
bond hydrolysis (see Figure 5.3B).[32] More efficient hydrolytic agents based on dinuclear 
metal complexes have appeared over the decades.[33,34] Various bipy or terpy complexes of 
Cu(I/II)[35-37] and Zn(II)[38,39] have been shown to cleave DNA through oxidative and 
hydrolytic pathways, respectively. 
 
Figure 5.3 – Schemes representing either (A) a proposed mechanism for oxidative DNA 
cleavage following the H-1’ abstraction by CuI(phen), where B represents any bp;[27] or (B) 
a consensus catalytic cycle for the hydrolysis of phosphoester bonds from the DNA backbone 
promoted by metal ions.[40] 
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Preceding the design of binary species with Rh(III) complexes and sequence-specific 
peptide moities (see section 5.1.1), Sigman and co-workers covalently linked Cu(I)-(phen-
IA) with the tryptophan repressor trp, thus obtaining an artificial restriction enzyme of high-
specificity (7 bp recognition site). Interestingly, DNA cleavage occurs only in the presence of 
tryptophan, which is a condition for DNA binding of the natural repressor protein.[41] These 
led to the development of numerous selective artificial nucleases, based on the combination of 
metal complexes and sequence-specific peptides, capable of cleaving DNA through 
oxidative,[42-45] but also hydrolytic pathways.[46,47] It is worth mentioning the GCN4bz-
Fe(II)(EDTA) conjugates (complex is coupled to the N-termini) prepared by Dervan and co-
workers, the sequence specific cleavage pattern of which allowed for a better understanding 
of the protein binding mode, ca that the N-termini of the GCN4bz peptide dimer are located in 
close proximity of the DNA major groove and separated from each other by 9-10 bp.[48] 
5.1.3 – Aims of the chapter 
This chapter describes the fluorescence properties of the polypyridine peptide 
conjugates and the corresponding Cu(II) complexes and the preparation of new Ru(II) 
containing polypyridine metal complexes with interesting photophysical properties with 
respect to sequence selective DNA sensing. The second objective was to test some of the 
polypyridine peptide conjugates for their ability to perform sequence selective DNA cleavage. 
Preliminary results are presented. 
 
5.2 – Results and discussion 
5.2.1 – Polypyridine-peptide conjugates as sensors 
5.2.1.1 – Polypyridine ligand fluorescence applied to DNA sensing 
As an extension of the work on polypyridine peptide conjugates complexed with Cu(II) 
or Zn(II), their fluorescence properties were investigated both in the absence or presence of 
DNA with specific or non-specific sequences. As a starting point, the emission spectra of 
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model compounds were evaluated in the absence or presence of CuCl2. Upon excitation at 298 
nm, the emission spectra of solutions containing 20 μM bipy-GS2 or terpy-GS2 in 20 mM 
phosphate pH 7.4 display bands centred at 350 nm and 334 nm (bipy-GS2: I350 nm 17.6 a.u.; 
I334 16.1 a.u.), or 351 nm (terpy-GS2: I351 nm 317.3 a.u.). Upon addition of CuCl2, the intensity 
of the emission bands decrease and the weak band observed for bipy-GS2 is almost not 
distinguishable after one equivalent of CuCl2 has been added (bipy-GS2: I350 nm 17.6 → 6.8 
a.u.; I334 nm 16.1 → 4.8 a.u.). In contrast, it is possible to observe that the more intense 
emission band of terpy-GS2 retains ~23 % of its intensity after one equivalent of CuCl2 has 
been added (terpy-GS2: I351 nm 317.3 → 74.3 a.u.), however, this further decreases to 2 % 
upon addition of a second equivalent CuCl2 (terpy-GS2: I351 nm 74.3 → 7.2 a.u.) (see Figure 
5.4). 
 
Figure 5.4 – Emission profile (λexc. = 298 nm) recorded for 20 μM bipy-GS2 (A), or terpy-
GS2 (B) solutions in 20 mM phosphate buffer pH 7.4, recorded in the absence (▬), or 
presence of CuCl2, either 1 (▬), or 2 eq. (▬●▬). 
 
The emission profile recorded for bipy-GS2 at pH 7.4, which is expected to 
predominantly exist as the trans- conformation, displays a very weak emission band, 
consistent with previous studies of bipy fluorescence.[17] Even though the proportion of 
monoprotonated (cis-trans-) over basic form (trans-trans-) is expected to be low at this 
pH,[49] the emission profile of terpy-GS2 at pH 7.4 displays much more intense emission 
bands compared to bipy-GS2, which is consistent with previous reports for terpy at neutral 
pH.[18,23]  Interestingly, the decrease in fluorescence of terpy-GS2 upon CuCl2 addition, 
correlates with the expected amount of unbound terpy-GS2 under these conditions (1 eq. Cu : 
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12-29 %, 2 eq. Cu : 1-9 %), calculated from the two binding constants extracted from the UV 
titration data (see Chapter 3). Emission spectroscopy therefore represents an alternative 
method by which to estimate the CuCl2 affinity of terpy-GS2 and related terpy ligands. 
Histidine was previously hypothesised to bind terpyCu(II) through the vacant metal 
orbitals, thus explaining the significant increase observed in fluorescence.[23] These vacant 
orbitals might also be accessible to donor atoms from DNA or peptide, when 
terpy(GCN4bd2)2Cu(II) is complexed with specific rather than non-specific DNA due to 
structural constraints, and these could result in contrasted fluorescent properties. The emission 
profile of 10 μM solutions of terpy(GCN4bd2)2 in 10 mM phosphate pH 7.4, recorded in the 
absence or presence of 10 μM DNA containing either NON or CRE sites, all display a band 
centred around 338 nm of differing intensities (alone: I338 nm 305.9, NON: I342 nm 109.4, CRE: 
I342 nm 140.2). Upon addition of CuCl2, the emission bands all decrease in intensity (see Figure 
5.5). 
 
Figure 5.5 – Emission profile (λexc. = 298 nm) of 10 μM terpy(GCN4bd2)2 solutions in 10 
mM phosphate buffer pH 7.4, recorded in the absence (A), or presence of 10 μM duplex 
DNA, containing either the NON (B), or CRE site (C). CuCl2 was titrated into each solution: 
0 eq. (▬), between 0 and 1 eq. (▬ ▬), 1 eq. (▬), more than 1 eq. CuCl2 added (▬●▬). 
 
Plots of emission intensity at 338 nm versus Cu(II) equivalence are largely consistent 
with formation of the 1:1 complexes previously described, in the absence of DNA or in the 
presence of DNA containing the CRE target site (see Figure 5.6A and C). However, the 
number of data points recorded are not sufficient to conclude for spectra recorded in the 
presence of DNA bearing the non-specific site (see Figure 5.6B). 
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Figure 5.6 – Plot of emission intensity at 338 nm (λexc. = 298 nm) as a function of Cu(II) 
equivalence for the Cu(II) titration of solutions containing 10 μM terpy(GCN4bd2)2 in 10 
mM phosphate buffer pH 7.4, recorded in the absence (A), or presence of 10 μM duplex DNA 
containing either the NON (B), or the CRE target site (C). 
 
Solutions containing 20 μM terpy-GS2, or 10 μM terpy(GCN4bd2)2 display similar 
emission profiles with peaks of similar intensity but shifted by 10 nm. In contrast, the 
intensity is greatly reduced when terpy(GCN4bd2)2 is recorded in the presence of DNA, 
regardless of the sequence. Considering the different concentrations used, it seems the 
presence of positively charged peptide moieties results in an increase of the fluorescence 
intensity, whereas it decreases upon complexation with negatively charged DNA. In all cases, 
addition of CuCl2 results in quenching of the fluorescence and do not allow for a satisfactory 
discrimination between the DNA sequences of interest. However, profiles recorded are 
consistent with the affinity measured in the absence or presence of DNA by UV spectroscopy, 
and fluorescence data might therefore be used to independently confirm the affinity 
calculations. 
 
5.2.1.2 – Attempts at synthesising [RuII(bipy)3]
2+
 peptide conjugates and investigating 
their phosphorescent properties 
The preparation of some GCN4bd2 conjugates dimerised through a [Ru
II
(bipy)3]
2+
 
linker was envisioned, the phosphorescence of which might be able to discriminate between 
specific versus non-specific DNA. In contrast, Ru(terpy)2 complexes usually display weak 
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emission signals at room temperature,[50] and therefore preparation of related peptide 
conjugates was not attempted. 
Despite previous reports which describe coupling between [Ru
II
(bipy)3]
2+
 and peptides 
(see Figure 5.7, route A),[51-54] a methodology that involved the bipy-peptide conjugates 
previously prepared would involve minimum synthetic steps (see Figure 5.7, routes B and C). 
In a recent report, McLaughlin and co-workers report the preparation of [Ru
II
(bipy)3]
2+
-
oligonucleotide conjugates by refluxing bipy-oligo conjugates with [Ru
II
(bipy)2Cl2] in an 
ethanol:100 mM phosphate pH 7 (2:3) solvent mixture.[55] This strategy was applied to the 
preparation of [Ru
II
(bipy)3]
2+
-peptide conjugates (see Figure 5.7, route C). 
 
 
Figure 5.7 – Scheme representing the different potential strategies for the preparation of 
[Ru
II
(bipy)2(cys2bipy)]
2+
 complex from Ru
II
(bipy)2Cl2. Route A (▬) is an adaptation of the 
Millet et al. method,[52] route B (▬) remains to be investigated, and route C (▬) from the 
McLaughlin et al. method.[55] 
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The preparation of the conjugate [Ru
II
(bipy)2(cys2bipy)]
2+
 was first attempted, in order 
to investigate the chemistry. After refluxing cys2bipy and Ru
II
(bipy)2Cl2 in ethanol:10 mM 
phosphate pH 7.4 (2:3) for 3.5 hours, and subsequent purification by semi-preparative HPLC 
(eluted with water (0.05% TFA)/methanol gradients), the conjugate [Ru
II
(bipy)2(cys2bipy)]
2+
 
was obtained as a salt, and characterised by 
1
H NMR spectroscopy (see Figure 5.8). A new 
spectrum recorded after 10 days displayed small peaks in the aliphatic region, and integral 
values for H
7
, H
8
 and H
9
 decreased in intensity, consistent with degradation of the conjugate 
complex possibly associated with a loss of the L-cystenyl moieties. 
 
Figure 5.8 – Comparison of 1H NMR spectra for cys2bipy (A) or [Ru
II
(bipy)2(cys2bipy)]
2+
 
complex recorded at 300 MHz in D2O (pD ~1) directly (B) and 10 days after preparation (C); 
dioxane was added as internal standard (δ = 3.75 ppm). 
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The absorption spectra of 6.7 μM RuII(bipy)2Cl2 recorded in  ethanol:10 mM phosphate 
pH 7.4 (2:3), display peaks at 517 (ε517 nm 3,238 M
-1
 cm
-1
, 
1
MLCT), 365 (ε365 nm 3,253 M
-1
 cm
-
1
, 
1
MLCT), 296 (ε296 nm 23,238 M
-1
 cm
-1, π→π*) and 250 nm (ε250 nm 7,451 M
-1
 cm
-1, π→π*). 
In contrast, the absorption spectra of [Ru
II
(bipy)2(cys2bipy)]
2+
 recorded under similar 
conditions displays peaks at 429 (ε429 nm 3,427 M
-1
 cm
-1
, 
1
MLCT), 289 (ε289 nm 41,829 M
-1
 cm
-
1, π→π*) and 244 nm (ε244 nm 24,776 M
-1
 cm
-1, π→π*) (assignments based on references 56-
58) (see Figure 5.9A). Upon excitation at 456 nm, the emission spectra of a 50 μM 
Ru
II
(bipy)2Cl2 solution displays a weak band centred at 533 nm (I533 nm 8.8 a.u.). In contrast, 
the emission spectra of [Ru
II
(bipy)2(cys2bipy)]
2+
 recorded under identical conditions displays 
two intense peaks at 618 (I618 nm 198.6 a.u.), and 526 nm (I526 nm 97.4 a.u.) (see Figure 5.9B).  
Figure 5.9 – Comparison of absorption (A), and emission spectra (B) of RuII(bipy)2Cl2 (▬), 
and [Ru
II
(bipy)2(cys2bipy)]
2+
 (▬) recorded in an ethanol:10 mM phosphate pH 7.4 (2:3) 
mixture. Concentration of complexes were either 6.7 μM (A), or 50 μM (B); λexc = 456 nm. 
 
Absorption and emission (λexc = 456 nm) spectra recorded for [Ru
II
(bipy)2(cys2bipy)]
2+
 
compared to those of Ru
II
(bipy)2Cl2 are consistent with coordination of an additional bipy 
unit to the metal center.[59,60] The contrast between the two emission spectra provides an 
efficient way to monitor the formation of [Ru
II
(bipy)2((peptide)2bipy)]
2+
 complexes, 
specifically using HPLC coupled to a fluorescence detector. 
The preparation of the conjugate [Ru
II
(bipy)2(bipy(GCN4bd2)2)]
2+
 was attempted 
following a similar experimental methodology, but no evidence suggested formation of the 
desired product. The reaction was then attempted starting from bipy(GCN4bd2)2 and 
[Ru
II
(bipy)2(acetone)2]
2+
 which is already charged and might be more reactive towards a 
strained bipy unit, however this was also unsuccessful. At this stage, it remains unclear 
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whether the complex [Ru
II
(bipy)2(bipy(GCN4bd2)2)]
2+
 is easier to prepare by a peptide-bipy 
coupling step followed by complexation (see Figure 5.7, route C), or by synthesis of the intact 
ruthenium linker and subsequent coupling to the peptides (see Figure 5.7, routes A or B). 
5.2.2 – Polypyridine-GCN4bd peptides as sequence-specific nuclease agents 
5.2.2.1 – Modelling of GCN4bd peptide conjugates 
Metal-based nuclease agents cleave DNA either through hydrolysis or oxidative 
mechanisms. DNA cleavage through hydrolysis involves coordination of the metal center to 
oxygen from the DNA backbone, thus facilitating cleavage/hydrolysis of a phosphoester bond 
(-P-O-).[61] In contrast, DNA cleavage through oxidative mechanisms involve production of 
ROS that can diffuse and abstract protons from sugar [27] or nucleobases [62] (see Figure 
5.10), ultimately leading to DNA cleavage through rearrangement reactions. The efficiency is 
highly dependent on “target” hydrogens accessibility to the ROS.[27] As an indication, OH· 
radicals generated by Cu
I
-phen complexes were estimated to diffuse and cleave DNA over a 
15 Å radius,[63] however diffusion is prevented in the presence of radical quenchers such as 
glycerol.[64] 
 
Figure 5.10 – (A) Cartoon representation of the DNA double helix and localisation of the 
minor and major groove: zoom and chemdraw representation of two bp, and potential 
oxidation sites are marked by arrows (blue = sugar oxidation; green = base oxidation). (B) 
Chemdraw representation of DNA deoxyribose, showing the accessibility of the proton 
(potential oxidation sites) from the minor (red) or major groove (blue); adapted from 
reference 65. 
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Simple models generated from the DNA bound GCN4 crystal structure (pdb code 
1YSA[66]), indicate that metal-ions coordinated to polypyridine linkers of bipy(GCN4bd1)2 
or bipy(GCN4bd2)2 complexes would be located up to 28-30, or 11-12 Å away from the 
nearest backbone oxygen, respectively (see Figure 5.11). These represent distances which are 
too long for direct coordination of the metal to DNA oxygens, therefore, both conjugates are 
not expected to be able to cleave DNA through a hydrolytic process. However, 11-12 Å is a 
suitable distance for oxidative cleavage and production of ROS by the shorter GCN4bd2 
conjugates, which might therefore be able to cleave DNA, consistent with previous designs of 
sequence-specific nuclease agents.[42] 
 
Figure 5.11 – Cartoons showing distances separating polypyridine linker nitrogen from the 
closest oxygens from the DNA backbone in the bipy(GCN4bd1)2:AP1 (A), and 
bipy(GCN4bd2)2:AP1 complexes (B). Cartoons were obtained by qualitative modification of 
pdb file 1YSA [66] using pymol, without energy minimisation. The glycine-glycine-cysteine 
domain in (A) is represented as an unfolded domain (consistent with our CD measurements) 
and therefore fully extended.  
 
5.2.2.2 – Cleavage studies of supercoiled plasmid containing specific site by 
Cu:bipy(GCN4bd2)2 
In order to study sequence specific oxidative cleavage, a procedure similar to that 
reported by Giovannangeli and co-workers was used.[67] A plasmid vector pUC57 (> 95 % 
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supercoiled) consisting of 2,710 bp, plus 20 bp oligonucleotide CRE duplex inserted at the 
EcoRV site by blunt end ligase was purchased from Genscript (see Figure 5.12). This artificial 
construct contains only one 5’-TGACGTCA-3’ repeat, which is a target site of 
bipy(GCN4bd)2 (see Chapter 5). 
 
 
Figure 5.12 – (A) Diagram representing the different domains and restriction sites in the 
pUC57 artificial vector, for which bp numbering is indicated, reproduced from Genscript.[68] 
(B) Full sequence display for the Multiple Cloning Site (MCS) domain of pUC57 (396-476): 
CRE 20 bp duplex was inserted at EcoRV site (marked by an arrow). 
 
 
The supercoiled plasmid pUC57-CRE was incubated at 310 K either alone, or in the 
presence of the restriction enzyme AatII, which cleaves 5’-GACGTC-3’ sites including AatII 
(see Figure 5.12) and CRE sites, thus affording two linear fragments of 513 and 2,217 bp, or 
in the presence of Cu(II), 3-mercaptopropionic acid (MPA), and increasing amount of 
bipy(GCN4bd2)2 this would result in a 2,730 bp linear fragment if cleavage occurs at CRE. 
The different solutions were resolved by horizontal electrophoresis, and visualised by UV 
transillumination following staining with ethidium bromide. 
The gel radiogram obtained indicates that plasmid pUC57-CRE alone elutes as two 
bands: a more intense fast-migrating band attributed to supercoiled content, and a weaker 
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slow-migrating band consistent with the presence of circular plasmid (see Figure 5.13 lane 1). 
Following co-incubation with AatII at 310 K for 1 hour, pUC57-CRE eluted as a single band 
with retention different from that of DNA alone and consistent with the expected ~2,200 bp 
linear fragment (see Figure 5.13 lane 2). The short fragment (513 bp) would not be expected 
to be retained on the gel under the conditions used. After incubation at 310 K for 2 hours in 
the presence of 25 μM Cu(II) and 100 μM MPA,  pUC57-CRE still elutes as two bands with 
retentions similar to the plasmid alone, but the intensity of the slow- and fast-migrating band 
increases and decreases respectively, consistent with single-strand cleavage (see Figure 5.13 
lane 3). In contrast, elution indicates the presence of a third band when increasing amounts of 
bipy(GCN4bd2)2 (1-5 μM) were also present during incubation (see Figure 5.13 lane 4-8). 
The new band, consistent with a linear 2,730 bp fragment associated with a double-strand cut, 
has intermediary retention and its intensity increases with bipy(GCN4bd2)2 concentration, 
accompanied by a decrease of the fast-migrating band intensity, whereas the slow-migrating 
band remains unchanged. Finally, a pUC57-CRE solution incubated with 5 μM 
bipy(GCN4bd2)2 and 100 μM MPA, but in the absence of Cu(II), displays an elution profile 
similar to that of pUC57-CRE alone (see Figure 5.13 lane 9). 
 
Figure 5.13 – Gel radiogram recorded after electro-elution of solutions containing 150 ng 
pUC57-CRE either alone (lane 1), in the presence of AatII enzyme (lane 2), in the presence of 
100 μM MPA, 25 μM CuCl2, buffer, and increasing amounts of bipy(GCN4bd2)2 (lanes 3 to 
8), or in the presence of 100 μM MPA, buffer, and 5 μM bipy(GCN4bd2)2 (lane 9). 
Concentration of bipy(GCN4bd2)2 was 0, 1, 2, 3, 4 and 5 μM (lane 3, 4, 5, 6, 7 and 8 
respectively), in 20 mM phosphate buffer pH 7.4 and 20 mM NaCl. 
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The short linear fragment observed upon co-incubation of pUC57-CRE with AatII is 
consistent with the insertion of the CRE duplex in the Eco-RV site. The gel indicates that 
Cu(II) promotes DNA cleavage, but that only in the presence of bipy(GCN4bd2)2 are double-
strand breaks observed.  
In order to investigate the specificity of cleavage attributed to the 
Cu(II):bipy(GCN4bd2)2 complex, the linear fragments obtained were post-treated with a 
restriction enzyme in order to establish the initial cleavage site based on the size of the 
different fragments,[41,67] using NdeI enzyme (see Figure 5.14A). Supercoiled pUC57-CRE 
plasmid was incubated at 310 K with: (1) 5 μM bipy(GCN4bd2)2 , 10 μM CuCl2, 100 μM 
MPA for 2 hours followed by (2) NdeI enzyme for 0.5 hours. A 1 kilobase DNA ladder, and 
the pUC57-CRE solutions prior to and post-treatment with NdeI were loaded on to the gel and 
eluted. The radiogram confirms that incubation with Cu(II):bipy(GCN4bd2)2 results in the 
formation of circular and linearised fragments of ~2,900 bp (see Figure 5.14B, compare lanes 
1 and 2). However, only the ~2,900 bp linear fragment is observed upon post-treatment with 
NdeI (see Figure 5.14B, compare lane 1 and 3). 
 
Figure 5.14 – (A) Scheme representing the strategy used to establish pUC57-CRE cleavage 
specificity towards CRE sites using NdeI enzyme. Following post-treatment with NdeI, the 
2,730 bp linear fragment would be converted to 2,491 and 239 bp fragments. (B) Radiogram 
for 150 ng of pUC57-CRE incubated with 100 μM MPA, 10 μM CuCl2, 5 μM 
bipy(GCN4bd2)2, 20 mM phosphate pH 7.4 and 20 mM NaCl at 310 K for 2 hours: 1 kb 
DNA ladder (lane 1), pUC57-CRE prior to (lane 2) and post-treatment with NdeI (lane 3). 
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Successive treatment of pUC57-CRE with Cu(II):bipy(GCN4bd2)2 and NdeI did not 
result in the appearance of a band corresponding to the ~2,500 bp fragment, suggesting that 
DNA cleavage by Cu(II):bipy(GCN4bd2)2 occurring under these conditions was not specific 
towards the introduced CRE site. This constitutes a preliminary negative result, and no further 
cleavage conditions have been tested for Cu(II):bipy(GCN4bd2)2. As an example, the 
sequence-specific cleavage reported by Giovannangeli et al. involved incubation of plasmid at 
310 K for 17 hours in the presence of 3 mM MPA. However, the supercoiled pUC57-CRE 
was quantitatively converted to the linear form when exposed to similar conditions (15 hours 
at 310 K, 3 mM MPA). 
 
5.3 – Summary 
Preliminary fluorescence studies on polypyridine peptide conjugates indicate that unlike 
bipy conjugates, metal free terpy conjugates display an intense emission band upon 
excitation at 298 nm. Addition of Cu(II) to terpy-GS2 or terpy(GCN4bd2)2 results in 
fluorescence quenching, which is largely independent of the sequence of the DNA present. 
Any differences were attributed to different metal affinities previously estimated, rather than 
second-sphere coordination. In an extension of this study, the model conjugate 
[Ru
II
(bipy)2(cys2bipy)]
2+
 was prepared, the optical properties of which are shown to be 
consistent with [Ru
II
(bipy)3]
2+
 type complexes. However, following the same synthetic 
approach, the conjugate [Ru
II
(bipy)2(bipy(GCN4bd2)2)]
2+
 could not be obtained. 
The ability of the Cu(II):bipy(GCN4bd2)2 complex to cleave supercoiled DNA at an 
inserted CRE recognition site was investigated by horizontal electrophoresis. Our results 
indicate that in the presence of excess Cu(II) and reducing agent the conjugate is able to 
induce double-strand breaks which are not directed specifically towards the recognition site, 
as shown by post-treatment and fragment size analysis. However, the nuclease ability of 
terpy(GCN4bd2)2 was not investigated, and more studies are required in order to conclude 
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on the potential of polypyridine:Cu(II) GCN4bd peptide conjugates to find applications as 
sequence specific oxidative nuclease agents. 
5.4 – Experimental 
5.4.1 – Equipment and reagents 
Mono- and dihydrogen potassium phosphate salts, sodium chloride, lithium chloride, 
ethanol (EtOH), agarose, and ultrapure or DNA grade water were all obtained from Fisher 
Scientific. Copper chloride (CuCl2), glycerol, 5,5’-dimethyl-2,2’-bipyridine, 2,2’-bipyridine, 
silver nitrate, and 3-mercaptopropionic acid (MPA) were obtained from Sigma-Aldrich. 
Deuterated solvents (DMSO-d6 and D2O) were obtained from Cambridge Isotope Laboratory 
Inc. Dimethylformamide (DMF) was obtained from AGTC Bioproducts and acetone from 
VWR. RuCl3 hydrate was obtained from Alfa Aesar and ammonium hexafluorophosphate 
from Strem Chemicals. NdeI and AatII enzyme, 10x restriction buffer, and 1 kb DNA ladder 
were obtained from New Englands Biolab. The pUC57 vector > 95 % supercoiled content 
(SC grade) with 5’-ACGAGATGACGTCATCTCCA-3’ oligonucleotide and its 
complementary strand inserted by blunt end ligase at EcoRV cloning site, was obtained as a 1 
μg μL-1 solution in distilled deionised water from Genscript and used directly. 
HRES and ES-TOF MS were recorded on a Microwaters LCT TOF spectrometer 
equipped with a 3000 V capillary voltage, and a cone voltage of 35 V. UV-visible spectra 
were recorded in a 1 cm pathlength quartz cuvette at 298 K on a CARY50 spectrometer. 
Wavelengths are given in nm, and extinction coefficients in M
-1
 cm
-1
. Emission spectra were 
recorded on a Shimadzu RF-5301PC spectrophotometer with excitation and emission slit 
width both set at 5 nm, and using 1 mL quartz cuvette with 1 cm pathlength. Wavelengths are 
given in nm and intensity in arbitrary unit (a. u.). All 
1
H NMR spectra were collected on 
AVIII300 (300 MHz 
1
H, T = 293 K), and 
13
C NMR on AVIII400 (400 MHz 
1
H, 100 MHz 
13
C, T = 298 K) spectrometer, both equipped with a 5 mm probe. Solvent residual signal, 
DMSO quintet (δ = 2.50 ppm), was used as an internal reference. As an exception, dioxane 
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was used as an internal standard (δ = 3.75 ppm) for all experiments recorded in D2O. For pD 
measurement, pH paper was used. Chemical shifts (δ) are given in parts per million (ppm) to 
higher frequency compare to the methyl signal of either trimethylsilane (organic solvent), or 
the sodium salt of 3-(trimethylsilyl)propanesulfonicacid (D2O) at 0 ppm.[69] Data were 
processed using Bruker Topspin version 2.1 (300 and 400 MHz) or 1.3 (500 MHz) and 
Mestrenova Lite version 5.2.5. For the electrophoresis experiments, gel were visualised using 
an Uvitec Cambridge imager. 
 
5.4.2 – Synthetic procedure and characterisation 
Synthesis of Ru
II
(bipy)2Cl2: cis-bis-(2,2’-bipyridine)dichlororuthenium(II) dihydrate 
[70,71] 
 
In a round-bottom flask, trichlororuthenium(III) hydrate (79.3 mg, 298 μmol), lithium 
chloride (84.8 mg, 2 mmol), 2,2’-bipyridine (93.6 mg, 0.6 mmol) and DMF (25 mL) were 
refluxed for 12 hours under a N2 atmosphere. After the suspension cooled to room 
temperature, acetone (200 mL) was added and it was stored at 253 K overnight, filtered in 
vacuo using a glass sintered funnel, washed with water (3x5 mL) and diethylether (3x5 mL) 
and dried in vacuo, affording a black solid (72 mg, 46 %). 
1
H NMR (300 MHz, DMSO-d6): 
9.97 (d, 
3
JH6b-H5b = 7.5 Hz, 2H, H
6b
), 8.64 (d, 
3
JH3b-H4b = 7.5 Hz, 2H, H
3b
), 8.49 (d, 
3
JH3a-H4a = 
7.5 Hz, 2H, H
3a
), 8.08 (td, 
3
JH4b-H5b = 
3
JH4b-H3b = 7.5 Hz, 
4
JH4b-H6b = 1.4 Hz, 2H, H
4b
), 7.78 (td, 
3
J = 6.6 Hz, 
4
JH5b-H3b = 1.1 Hz, 2H, H
5b
), 7.69 (td, 
3
J = 7.8 Hz,
 4
JH4a-H6a = 1.2 Hz, 2H, H
4a
), 
7.51 (d, 
3
JH6a-H5a = 5.2 Hz, 2H, H
6a
), 7.11 (td, 
3
JH5a-H6a = 
3
JH5a-H4a = 6.6 Hz, 
4
JH5a-H3a = 1.1 Hz, 
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2H, H
5a
); 
13
C NMR 
1
H decoupled (100 MHz, DMSO-d6): 160.3 (C
2a
), 158.1 (C
2b
), 153.1 
(C
6b
), 152.1 (C
6a
), 134.6 (C
4b
), 133.5 (C
4a
), 125.3 (C
5b
), 125.2 (C
5a
), 122.7 (C
3a
), 122.5 (C
3b
); 
UV-vis (EtOH/100 mM phosphate pH 7.4 (2/3)): 517 (3,238), 365 (3,253), 296 (23,238), 250 
(7,451); Emission (EtOH/100 mM phosphate pH 7.4 (2/3), λexc = 456 nm): 533 (8.8). 
 
Synthesis of [Ru
II
(bipy)2(Me2bipy)](PF6)2: cis-bis-(2,2’-bipyridine)(5,5’-dimethyl-2,2’-
bipyridine)ruthenium(II) hexafluorophosphate 
 
 
In a round-bottom flask, cis-bis-(2,2’-bipyridine)dichlororuthenium(II) dihydrate (15 
mg, 28.9 μmol) and 5,5’-dimethyl-2,2’-bipyridine (5.3 mg, 28.9 μmol) were dissolved in 
EtOH (5 mL) and refluxed for 4 hours, after which the solution was dried in vacuo. Upon 
addition of water (2 mL) and a saturated solution of NH4PF6 (5 mL), an orange solid 
precipitated and was filtered out, washed with diethylether (2x5 mL), collected and dried in 
vacuo, yielding the compound together with excess NH4PF6 salts (50.3 mg). 
1
H NMR (300 
MHz, DMSO-d6): 8.83 (d, 
3
JH3a/b-H4a/b = 8.2 Hz, 2H, H
3a/b
), 8.82 (d, 
3
JH3a/b-H4a/b = 8.1 Hz, 2H, 
H
3a/b
),8.69 (d, 
3
JH3-H4 = 8.4 Hz, 2H, H
3
), 8.20-8.12 (m, 4H, H
4a+b
), 7.99 (d, 
3
JH4-H3 = 8.4 Hz, 
2H, H
4
), 7.71 (d, 
3
JH6a/b-H5a/b = 6.1 Hz, 2H, H
6a/b
), 7.68 (d, 
3
JH6a/b-H5a/b = 6.2 Hz, 2H, H
6a/b
), 
7.55 (t, 
3
JH5a/b-H6a/b = 
3
JH5a/b-H4a/b = 6.9 Hz, 2H, H
5a/b
), 7.50 (d, 
3
JH5a/b-H6a/b = 
3
JH5a/b-H4a/b = 6.4 
Hz, 2H, H
5a/b
), 7.47 (s, 2H, H
6
); 
13
C NMR 
1
H decoupled (100 MHz, DMSO-d6): 156.6 (C
2a/b
), 
156.6 (C
2a/b
), 154.1 (C
2
), 151.2 (C
6a/b
), 151.1 (C
6a/b
), 150.6 (C
6
), 138.6 (C
4
), 137.8 (C
4a+b
), 
127.8 (C
5a+b
), 124.5 (C
3a/b
), 124.4 (C
3a/b
), 123.5 (C
3
), 18.1 (C
7
), C
5
 was not observed; HRES-
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TOF (CH2Cl2) calculated exact mass for C32H28N6F6P
102
Ru: 743.1061; measured: 743.1064. 
ES-TOF: m/z = 743.5 ([M+PF6]
+
, 33 %), 375.1 (47 %), 299.2 ([M]
2+
, 100 %), 219.1 (46 %). 
 
Synthesis of [Ru
II
(bipy)2(cys2bipy)](CF3COO)4: bis-(2,2’-bipyridine)[5,5’-bis(methyl-S-
cysteinyl)-2,2’-bipyridine]ruthenium(II) tetra-(trifluoroacetate) 
 
 
In a round-bottom flask, were added cis-bis-(2,2’-bipyridine)dichlororuthenium(II) 
dihydrate (3.0 mg, 5.8 μmol), a 5,5’-bis(methyl-S-cysteinyl)-2,2’-bipyridine aqueous solution 
(18.9 mM, 305 μL, 5.8 μmol), EtOH (2 mL), 100 mM phosphate buffer pH 7.4 (0.3 mL), and 
water (2.4 mL). The suspension was refluxed for 3.5 hours, and the solvent was removed in 
vacuo to yield a brown solid which was purified by semi-preparative RP-HPLC (C18 
Phenomenex, monitoring absorbance at 210 and 450 nm) using a 0 to 22.5 % gradient 
methanol in water (containing 0.05 % TFA) over 36 min. The solvent was evaporated in 
vacuo to yield pure bis-(2,2’-bipyridine)[5,5’-bis(methyl-S-cysteinyl)-2,2’-
bipyridine]ruthenium(II), as a yellow solid (2.5 mg, 52 %). 
1
H NMR (300 MHz, D2O, pD~1): 
8.55 (d, 
3
JH3a/b-H4a/b = 8.1 Hz, 4H, H
3a+b
), 8.48 (d, 
3
JH3-H4 = 8.4 Hz, 2H, H
3
), 8.05 (m, 6H, 
H
4+4a+b
), 7.85 (m, 4H, H
6a+b
), 7.69 (d, 
5
JH6-H4 = 1.6 Hz, 1H, H
6
), 7.68 (d, 
5
JH6-H4 = 1.6 Hz, 1H, 
H
6
), 7.37 (m, 4H, H
5a+b
), 3.88 (m, 2H, H
9
), 3.66 (m, 4H, H
7
), 2.69 (m, 4H, H
8
); ES-TOF 
(MeOH): calculated mass for C38H38N8O4
102
RuS2: 836.15; measured: m/z = 871.5 ([M+Cl]
+
, 
28 %), 835.5 ([M+H]
+
, 40 %), 481.2 ([Ru(bipy)2Cl(MeOH)]
+
, 42 %), 449.2 ([Ru(bipy)2Cl]
+
, 
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30 %), 423.3 ([cys2bipy+H]
+
, 22 %), 418.2 ([M]
2+
, 100 %); UV-vis (EtOH/100 mM 
phosphate pH 7.4 (2/3)): 429 (3,427), 289 (41,829), 244 (24,776); Emission (EtOH/100 mM 
phosphate pH 7.4 (2/3), λexc = 456 nm): 618 (198.6), 526 (97.4). 
 
Attempts to synthesise [Ru
II
(bipy)2(bipy(GCN4bd2)2)](CF3COO)n: bis-(2,2’-
bipyridine)[5,5’-bis(methyl-S-GCN4bd2)-2,2’-bipyridine]ruthenium(II) trifluoroacetate: 
2 different approaches were followed (A) and (B). 
 
 
(A) A solution of cis-bis-(2,2’-bipyridine)dichlororuthenium(II) dihydrate (8.66 mM, 20 
μL, 0.176 μmol) in ethanol was added to a round-bottom flask containing an aqueous 
bipy(GCN4bd2)2 solution (130 μM, 1.35 mL, 0.176 μmol), ethanol (980 μL) and 100 mM 
phosphate buffer pH 7.4 (150 μL). The resulting suspension was degased with N2(g) for 10 
minutes and then refluxed for 4 days. In order to monitor the reaction, a small fraction was 
analysed by analytical C18 RP-HPLC (water +0.05 % TFA/ methanol gradients) after 5 
hours, 2 days, and 3 days refluxing and the different fractions were collected, the mass 
spectrometry analysis of which did not show peaks at expected values.  
(B) In a round-bottom flask, cis-bis-(2,2’-bipyridine)dichlororuthenium(II) dihydrate 
(1.4 mg, 2.7 μmol), AgNO3 (0.9 mg, 5.4 μmol) and acetone (1 mL) were stirred at room 
temperature in the dark for 13 hours, after which the solution turned green and a dark 
precipitate formed. The suspension was transferred to an eppendorf and centrifuged, and the 
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green supernatant was collected. UV-vis (water): 645 (1,420), 435 (1,573), 285 (76,800); 
(adapted from reference 72). A small fraction of the supernatant (22 μL) was added to a 
round-bottom flask containing an aqueous bipy(GCN4bd2)2 solution (130 μM, 0.5 mL, 65 
nmol) and acetone (478 μL). The suspension refluxed for 3 days and, again, analytical C18 
RP-HPLC and mass spectrometry did not indicate the formation of the desired product. 
 
5.4.3 – Analytical procedures 
5.4.3.1 – Polypyridine ligand fluorescence (related to section 5.2.1) 
Prior to recording the fluorescence profile of model compounds, emission spectra of 20 
mM phosphate buffer pH 7.4 solutions (1 mL) were acquired (λexc. = 298 nm; slits width 
excitation and emission = 5 nm). Aliquots of model compound stock solutions (either bipy-
GS2 (6.2 mM, 3.2 μL), or terpy-GS2 (7.1 mM, 2.8 μL)) were then added to the cuvette such 
that their final concentrations were equal to 20 μM, and new spectra were recorded. Aliquots 
of a 1 mM CuCl2 stock solution were then added, and again new spectra recorded. Spectra 
recorded for the buffer were subtracted from spectra of model compounds recorded in the 
absence or presence of CuCl2. Fluorescence spectra of terpy-(GCN4bd2)2 recorded in the 
absence or presence of DNA were recorded following a similar methodology, however, the 
blank solution now contains 10 μM duplex DNA (either CRE or NON) if present (50 μM, 200 
μL) and 10 mM phosphate buffer pH 7.4, furthermore, only 10 μM terpy-(GCN4bd2)2 (600 
μM, 16.7 μL) were added for each measurement. 
5.4.3.2 – Nuclease activity of bipy-(GCN4bd2)2 (related to section 5.2.2) 
For the DNA cleavage assay, binding solution (Vtotal = 5 μL) were prepared by 
successive addition of pUC57-CRE (100 ng μL-1, 150 ng, 1.5 μL), and 5× buffer or buffer-
Cu(II) mixture (1 μL) containing 100 μM phosphate pH 7.4, 100 μM NaCl, and 125 μM 
CuCl2 (if present). Gradient of bipy-(GCN4bd2)2 were prepared from 10 and 25 μM stock 
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solutions and the volume adjusted up to 4.5 μL with ultrapure water. Cleavage were initiated 
by addition of MPA (1 mM, 0.5 nmol, 0.5 μL), and solutions were vortexed, centrifuged and 
incubated at 310 K for 2 hours. The DNA blank solution contained only pUC57-CRE (100 ng 
μL-1, 150 ng, 1.5 μL), and water (3.5 μL) and was incubated at 277 K. AatII control contained 
pUC57-CRE (100 ng μL-1, 150 ng, 1.5 μL), 10x restriction buffer (0.5 μL), AatII restriction 
enzyme (10 unit μL-1, 1 unit, 0.1 μL), water (2.9 μL), and was incubated at 310 K for 1 hour. 
All eppendorf, tips, and solutions used (except for MPA and bipy(GCN4bd2)2 stock and 
restriction solution) were autoclaved prior to use. 
Following incubation, a dye solution (1 μL) prepared in 5x TBE loading buffer and 
containing 25% glycerol, was added to each eppendorf, and the solutions were stored at 277 K 
for 10 minutes. 5 μL of each solution was subsequently loaded on a 0.8 % agarose gel soaked 
in 1× TBE, and electrophoresed horizontally at 7 V cm
-1
 for 3 hours. The gel was then stained 
in 0.5 μg mL-1 aqueous ethidium bromide solution for 45 minutes, destained in deionised 
water for 15 min, and visualised on a UV transilluminator. 
The gel used to confirm the cleavage specificity was run with a similar method. 
However, the volumes used were three times higher (Vtotal = 15 μL), and CuCl2 was not 
present in the buffer but added separately (150 μM, 0.15 nmol, 1 μL). Following incubation at 
310 K for 2 hours, the solution was divided equally over 3 eppendorfs. To one of these, 10× 
restriction buffer (0.5 μL) and NdeI restriction enzyme (10 unit μL-1, 1 unit, 0.1 μL) were 
added, and the solution incubated at 310 K for a further 30 minutes, affording the post-treated 
solution. Remaining steps were carried out as previously described, except for volume of 1 kb 
ladder loaded (1 μL), and electro-elution performed at 90 V for 2.3 hours. 
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6.1 - Summary 
This thesis reports the design and study of polypyridine units as peptide dimerisation 
domains suitable for artificial regulation of biomolecular activity based on conformational 
transitions. The regulation potential of an allosteric ineffective bipy linker was compared with 
that of an allosteric-effective terpy (based on the respective positions of their substituents). 
Chapter 2 describes the synthesis and study of low molecular weight artificial regulation 
sites based on polypyridine conjugates, for which conformational and coordination studies 
were attempted. The preparation of small dimeric conjugates based on L-glutathione moieties 
were more straightforward than their smaller counterparts based on L-cysteine moieties 
consistent with the reaction being driven by the solubility of the resulting product in water. 
The coordination studies strongly support the hypothesis that both bipy and terpy linkers 
bind Cu(II) and Zn(II) mainly in a 1:1 ratio at low concentrations (millimolar range) 
regardless of the peptide substituents, however CD studies suggests the successive formation 
of different complexes upon addition of Cu(II) to model conjugates (observed at 100-350 
μM). The conformation of metal bound and unbound states could not be studied in detail due 
to the complexity of the NMR spectra, due to quadrupolar relaxation, second-order effects and 
dynamic effects. However, Cu(II) and Zn(II) addition monitored by UV spectroscopy is 
consistent with the expected trans-to-cis conformational transition proposed, and hence 
justify their interest as regulation sites. This represents one of the most complete studies of the 
conformation of bipy, and more importantly terpy conjugates, in aqueous solution. 
Chapter 3 describes the preparation of larger peptides based on the GCN4 transcription 
factor, their dimerisation via the bipy and terpy linkers, and studies of Cu(II) and Zn(II) 
coordination to the resulting conjugates. Two peptides with N- and C- termini capped 
incorporating either 17 or 25 residues from GCN4 (both including the entire bd) and with 
different flexibility in the C-terminal regions were designed, prepared and dimerised with the 
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polypyridine linkers. The conjugates of the longer peptides were not obtained in satisfactory 
purity, and metal titrations monitored by UV spectroscopy display behaviour different from 
the model conjugates (only a moderate shift of the bands). In contrast, the dimer conjugates 
made of the shorter peptides could be obtained in high purity. The addition of Cu(II) and 
Zn(II) results in coordination similar to the models, however, metal addition monitored by CD 
did not result in induced signals in contrast to the models. Differences could be due to 
capping of the N- and C- termini which might otherwise contribute to the coordination sphere.  
Chapter 4 describes the DNA binding studies of the designed GCN4bd polypyridine 
conjugates. The dimer conjugates based on the long peptides display both increased helicity 
and bandshifts in the presence of DNA bearing a target site of native GCN4 (CRE), moreover, 
the estimated peptide-DNA dissociation constant (~10 nM) is consistent with previous 
reports. However, the addition of metal ions did not significantly affect DNA binding 
probably due to a high degree of flexibility in the dimerisation region. In contrast, the dimer 
conjugates based on the short peptides did not display any bandshift, however the folding into 
helices in the presence of CRE DNA (associated with DNA binding) was generally improved 
upon metal ion addition. Interestingly, the addition of either Cu(II) or Zn(II) increased the 
helicity of bipy(GCN4bd2)2 and terpy(GCN4bd2)2 conjugates to opposite extents only in 
the presence of DNA with the CRE site. However, only the helicity of the terpy(GCN4bd2)2 
conjugate was affected by Cu(II) or Zn(II) addition in the presence of DNA bearing the AP1 
site, which is also targeted by native GCN4 but lacks a central bp compared to CRE. This 
result is consistent with both our design and previous reports, which indicate that the 
sequence specificity of GCN4bd dimers is affected by the bulkiness of their linkers. 
Chapter 5 presents initial work directed towards studying the potential application of 
GCN4bd polypyridine conjugates as DNA sensors or nuclease agents. Our initial 
measurements which are consistent with previous photochemical reports on polypyridines, 
indicate that terpy displays a more intense fluorescence than bipy at room temperature. In all 
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cases, the polypyridine fluorescence decreases upon addition of Cu(II) and binding curves are 
consistent with an increase of Cu(II):terpy(GCN4bd2)2 affinity in the presence of DNA 
bearing the CRE binding site. The preparation of conjugates in which GCN4bd peptides are 
dimerised with a Ru
II
(bipy)3
2+
 linker have not been successful so far, however, the model 
conjugate [Ru
II
(bipy)2(cys2bipy)]
2+
 was prepared and studied, displaying intense 
phosphorescence. Cu(II) and Zn(II) complexes, including polypyridine complexes, have 
previously been shown to promote DNA strand cleavage, though different mechanisms and 
intermediates can be involved. Based on qualitative distance estimation using models of the 
peptide conjugates complexed with their DNA target sites, the DNA cleavage is more likely 
to occur via the production of diffusible reactive species, hence the choice of Cu which 
possesses several oxidation states. However, our initial results indicate that cleavage of a 2.7 
kilobase supercoiled plasmid, attributed to the conjugate bipy(GCN4bd2)2:Cu(I/II) (present 
in large excess), is not specifically directed towards the CRE target site. 
Together, these results indicate that peptide dimerisation with disubstituted 
polypyridines allows for regulation of biomolecular activity based on the conformational 
transition resulting from metal coordination. Potential applications could include species 
using these to impact gene regulation either by occupying or denaturing (cleavage) the 
recognition site in vivo. 
 
6.2 – Future work 
6.2.1 – Preparation of new linkers and related models 
The preparation of new polypyridine linkers suitable for incorporation within large 
peptide dimer scaffolds might be envisioned, in which case conjugates based on L-glutathione 
moieties could again be prepared as suitable model ligands. However, capping of the N- and 
C- termini might be necessary to prevent them contributing to metal coordination. Altering 
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the positioning of linkages on the pyridinyl rings might allow for the increase in the linker 
affinity for metal ions. Terpy linkers can also be prepared which would deactivate DNA 
binding upon metal coordination (see Figure 6.1A).[1] This design may allow for the 
preparation of conjugates for which DNA binding would trigger the release of a selected 
metal-ion which could be accompanied by an increase in fluorescence. Alternatively, the 
preparation of polypyridines containing additional substituents able to hinder the pyridine 
rotation, might stabilise particular conformations and facilitate their assignments using NMR 
spectroscopy (see Figure 6.1B and C).[2,3,4] 
 
Figure 6.1 – Scheme representing (A) the 3,6’’-dimethyl-2,2’,6’,2’’-terpyridine linker the 
substituent realignment of which would promote the mixed cis-trans conformation and the 
release of a metal-ion (M
n+
), (B) the annulated bipy: ethyl bridge 2,2’-bipyridium salt, or 
terpy (C) and bipy (D) bearing hydroxyl groups at positions 3 and/or 5, thus stabilising the 
trans-trans- and trans- conformations, respectively. 
 
A logical extension of the coordination studies reported here, would involve 
investigating the interactions of model compounds with different metal ions, notably Fe(II) 
which preferentially forms 3bipy:1Fe(II) and 2terpy:1Fe(II) complexes,  thus contrasting 
with the results obtained with Cu(II) and Zn(II). However, initial work involving the addition 
of Fe(II) salts to the bipy-GS2 conjugates resulted in formation of an unidentified species 
which is poorly soluble in water at physiological pH. 
The first attempts to couple Ru
II
(bipy)2Cl2 or [Ru
II
(bipy)2(acetone)2]
2+
 complexes with 
the bipy(GCN4bd2)2 conjugate were unsuccessful. However, there exist alternative synthetic 
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strategies such as the complexation of a Ru
II
(DMSO)4Cl2 salt with bipy(GCN4bd2)2 
followed by coordination with two additional bipy ligands.[5] Considering the low stability of 
the precursor complex [Ru
II
(bipy)2(cys2bipy)]
2+
 in D2O, one may consider attaching bipy to 
the GCN4bd peptide using more robust bonds, such as amide linkages.[6,7] Aside from the 
synthetic aspects, it is possible to enhance the changes in photophysical properties 
experienced by the peptide conjugate upon binding to DNA. For example, an electron 
acceptor incorporated towards the N-terminus of a GCN4bd peptide conjugate could quench 
the luminescence of a C-terminal luminophore in the absence of a particular structural 
organisation. In contrast, the luminescence of the peptide conjugate might be restored upon 
binding to DNA and stabilisation of the α-helix, by similarity with a previous study involving 
a target antibody (see Figure 6.2).[8] 
 
Figure 6.2 – Scheme illustrating a peptide beacon bearing a Ru(bipy)2(phen-IA) luminescent 
moiety and a 4,4-bipyridinium quencher either (A) unbound or (B) bound  to the target 
antibody; adapted with permission from reference 8. Copyright 2007 American Chemical 
Society. 
 
By extension, one can imagine incorporating artificial regulation sites based on 
molecular machines within peptide.[9,10] However, highly hydrophobic molecules can be 
challenging to incorporate within peptides. 
 
Chapter 6 – Conclusions and future work 
 
255 
 
6.2.2 – Design of new peptides and conjugates 
From the DNA binding results, one can envision the design of a new peptide similar to 
our short GCN4bd peptide, bearing more residues conserved from GCN4 in order to achieve 
tighter DNA binding and formation of a more stable peptide dimer conjugate-DNA complex. 
This would allow us to establish the important relationship between compromising strong 
DNA binding and the ability to perturb this on switching. Based on literature reports, this can 
be achieved upon retention of three additional C-terminal residues from GCN4 
(approximately one α-helical turn).[11,12] Moreover, the majority of reports on artificial 
GCN4bd dimers include a C-terminal dimerisation domain, whereas this could alternatively 
be inserted at the middle of the sequence and followed by a tail made of residues retained 
from GCN4 or with a high propensity to form helices and/or interact specifically.  
As for model conjugates, dimerisation with conformationally restrained linkers and 
chelation with different metal ions would give more information on the role of the linker 
conformation in the interaction of the conjugate with the DNA target site. Moreover, DNA 
binding studies conducted on GCN4-polypyridine monomeric conjugates might allow to 
account for the peptide assembly with coordination bonds and metal promoting DNA binding, 
by formation of dimers assembled with coordination bonds. A possible extension of this work 
would involve testing the activity of peptide conjugates in vivo as metal-dependent inhibitors 
of AP1 transcription factors.[13] 
The linkers developed in this thesis could be applied to other DNA binding peptides 
such as MyoD,[14] or different well-studied biomolecular recognition events such as the 
hydrolase activity of HN1 artificial enzyme.[15] The insertion of polypyridine in the peptide 
backbone could alternatively allow for the regulation of pore formation by cyclic peptides 
(such as gramycidin), or regulate the formation of α-hairpins or single-chain coiled coils 
important for biomolecular recognition. 
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A.1 – Spectroscopic techniques 
A.1.1 – Electronic absorption or UV-visible spectroscopy 
Spectroscopy is the study of the interactions between light and matter, and electronic 
absorption spectroscopy measures the fraction of light absorbed by a molecule, termed 
absorbance (A) (see Equation A.1). Molecules absorb photons of specific energies which 
correspond to the energetic difference between two energetic states of the electrons (from a 
stable to a less stable state). The absorption of light by molecules often corresponds to 
electromagnetic radiation from the far-ultraviolet, ultraviolet or visible energetic domains the 
energy of which is related to the wavelength (λ) (see Equation A.2). By correlation, it is 
possible to obtain information on the nature of the chemical bonds (type or electronic density) 
based on the absorbance wavelength. The most frequent transitions, which correspond to the 
movement of electrons from the highest occupied molecular orbital (HOMO) to the lowest 
unoccupied molecular orbital (LUMO) (see Figure A.1A), result in the most intense peaks in 
the absorption spectrum. The absorbance depends on the transition probability, which follow 
orbital (l), spin (S) and magnetic (ML) selection rules (Δl = ±1, ΔS = 0, ΔML = 0, ±1) and the 
concentration of molecules responsible for this transition (based on Equation A.3, defined as 
the Beer-Lambert law). [1,2] 
     (
 
  
) (A.1) 
       
   
 
 (A.2) 
         (A.3) 
A corresponds to the absorbance, I0 and I the intensity of the radiation before and after 
passing through the sample respectively, E the energy, ν the frequency and λ the wavelength 
associated with the radiation, h is the Planck constant (            m2 kg s-1), c the speed 
of light in vacuo (          m s-1), ε is the molar absorption coefficient for a given 
compound, c its concentration, and l the pathlength of the material which is crossed by light. 
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Figure A.1 – (A) Scheme illustrating the absorption of a photon with a wavelength of 111 nm 
resulting in an electronic transition from the HOMO to the LUMO orbital; adapted from 
reference 3. (B) Scheme illustrating the reaction between Ellman’s reagent (5,5’-dithiobis-(2-
nitrobenzoic acid)) and a thiol, resulting in the formation of the 2-nitro-5-thiobenzoate dye; 
(C) Example of the UV-visible spectra obtained for a L-glutathione solution following 
Ellman’s test procedure. The thiol concentration can be estimated based on the absorbance at 
412 nm and the known pathlength of the sample and absorption coefficient for the dye 
formed. 
 
 
Proteins display an intense band in the range 185-200 nm attributed to amide π→π* 
transitions.[4] Moreover, proteins containing dithiol linkages (cystine), or aromatic residues 
(tyrosine, phenylalanine and most notably tryptophan) display intense bands in the UV range 
(200-400 nm). For this reason, the absorbance at 280 nm is sometimes used to calculate the 
concentration of a protein for which the sequence is known and includes aromatic residues 
(based on a calculated absorption coefficient value [5]). This can alternatively be achieved 
using the Ellman’s assay if the protein contains a known number of available cysteine 
residues (the only thiol containing proteinogenic amino-acid). In this procedure, free thiols 
react with 5,5’-dithiobis-(2-nitrobenzoic acid), generating chromophoric 2-nitro-5-
thiobenzoate radicals (see Figure A.1B).[6] The absorbance properties of this radical species, 
are known (ε 412 nm = 14,150 M
-1
 cm
-1 [
7]), and so can be readily quantified by UV-visible 
spectroscopy (see Figure A.1C), giving an approximation of the available thiol concentration. 
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A.1.2 – Circular dichroism spectroscopy 
Dichroism is the property of certain materials to absorb light to different extents 
depending on its polarisation. Circular dichroism (CD) is the difference of absorptivity 
between left-handed and right-handed circularly polarised light, expressed as molar ellipticity 
(see equations A.4 and A.5), as a function of the wavelength. CD is a variant of electronic 
absorption spectroscopy which accounts for the chirality of molecular orbitals which can 
either be intrisic or induced by bound molecules.[1,8] The CD spectra of chromophoric chiral 
molecules will display characteristic signals at wavelengths near an absorbance maximum 
(λmax) called cotton effects. A positive cotton effect produces a positive CD signal at a 
wavelength higher than the λmax, which crosses the wavelength axis at λmax, and which 
produces a negative signal at a wavelength lower than λmax. In contrast, the reverse is 
observed for a negative cotton effect (see Figure A.2A). 
           (A.4) 
[ ]              (A.5) 
εL and εR correspond to the absorptivity of left and right-handed circularly polarized 
light, respectively, and [Ф] the molar ellipticity. The conversion value (3298.2) is obtained 
upon removal of the concentration dependence from the expression of ellipticity. 
Figure A.2 – (A) CD signal defined as either a positive (top), or negative cotton effect 
(bottom). (B) CD spectra of proteins with either a high α-helix (red), β-sheet (blue), or 
polyproline content (yellow). ε represents the molar absorption coefficient, Δε the difference 
of absorptivity between left and right circularly polarised light, and [Ф]MRE the molar 
ellipticity per residue in deg dmol
-1
 cm
2
 res
-1
 and λ the wavelength in nm; adapted with 
permission from reference 9 and 10. Copyright 2010 and 2006 Royal Society of Chemistry. 
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This technique is particularly useful for studying the structures of polymeric 
biomolecules (e.g. DNA and proteins). The region from 260 to 190 nm of a CD spectrum is 
the most relevant to the study of peptide structures as it contains both the π → π* and the n → 
π* transitions (215-230 nm), with the latter being electronically forbidden but magnetically 
allowed.[4] CD spectra displaying two negative minima around 208 and 222 nm and a 
positive maximum around 190 nm, are associated with a high degree of α-helical content, 
whereas typical β-sheet spectra display only one negative minima and one positive maximum, 
which are less intense and centred at a slightly higher wavelength compared to those for the α-
helix. In contrast, unstructured (random coil) and polyproline containing peptide strands, both 
display intense negative minima around 200 nm, and small positive maxima around 210 nm 
(see Figure A.2B). A first approximation involves estimating the α-helix content of a peptide 
based on the [Ф] value at 222 nm, a region where the α-helical domains contribute most to the 
ellipticity.[11] On a side note, CD data tends to be recorded as ellipticities (Ф), which can 
readily be converted to the more conventional molar ellipticity ([Ф]) and residual molar 
ellipticity ([Ф]MRE) following Equation A.6: 
[ ]     
[ ]
 
  
     
     
 (A.6) 
n corresponds to the number of residues in the protein, c its concentration, and l to the 
cell pathlength. 
 
A.1.3 – Emission spectroscopy 
Excited states are usually unstable and are therefore characterised by short lifetimes. 
Following electronic excitation by light, there exist several pathways (both intra- and 
intermolecular) by which the electron can return to its original ground-state, each associated 
with different probabilities or quantum yields (Ф). Electronic decay transitions are classified 
as either fluorescent, phosphorescent, internal conversion or intersystem, depending on 
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whether energy loss is converted into luminescent radiation or not, and if the transition occurs 
between two states of the same or different spin multiplicity (ΔS ≠ 0, spin-forbidden 
transition) (see Table A.1). Each pathway involves a number of such electronic transitions 
coupled with vibrational decay, thus fluorescence radiation occurs at a lower energy 
compared to the excitation wavelength (see Figure A.3). Spin-forbidden transitions are 
usually associated with long-lived or metastable excited states and slow rates of decay, which 
were the original definition for phosphorescence. Quenching commonly refers to 
intermolecular processes which result in a decrease in the fluorescence quantum yield (energy 
transfer, reactions, complex formation or collisions).[12] 
 
Table A.1– Summary of the different types of electronic transition decays, and their 
associated quantum yields (Q.Y.) 
Type Definition Q.Y. 
phosphorescence Radiative decay between two states with different spin multiplicities ФP 
fluorescence Radiative decay between two states with the same spin multiplicity ФF 
intersystem crossing Non-radiative decay between two states with different spin multiplicity ФISC 
internal conversion Non-radiative decay between two states with the same spin multiplicity ФIC 
 
 
Figure A.3 – Jablonski diagram representing the electronic excitation, the different types of 
electronic transition decay, and the contribution from vibrational relaxation (not to scale). S 
corresponds to singlet, T triplet, and S0 the ground state. The quantum yield for each pathway 
of electronic decay are defined as ФF + ФP + ФIC + ФISC = 1; adapted with permission from 
reference 13. Copyright 2005 Springer. 
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A.1.4 – Nuclear Magnetic Resonance spectroscopy 
Nuclear magnetic resonance (NMR) is a spectroscopic technique which involves 
measuring transitions between different spin levels of nuclei (I) in the presence of a magnetic 
field. Any nuclei possessing an even number of both protons and neutrons (such as   
  ) have 
a nuclear spin I = 0, associated with a single energy state (2I+1 = 1), and are NMR-silent. In 
contrast, other nuclei possess more than one spin nuclei state, separated by energies relative to 
the magnetic field applied and the intrinsic magnetic properties of the nucleus (see Equation 
A.7). For example, a nucleus with I = ½ (such as 
1
H or 
13
C) has two spin states which 
correspond to the parallel and antiparallel alignment of the spin with respect to the magnetic 
field orientation (see Figure A.4A). Since the electron cloud surrounding a nucleus shields it 
partially from the applied magnetic field B0, while being itself affected by the nuclei in its 
close environment, all non-equivalent nuclei will resonate at slightly different frequencies. 
The extent of shielding is denoted as the chemical shift (δ), which is independent of the 
strength of the applied field (see Equation A.8), and is representative of the chemical 
environment. The indirect transmission of orientation from a spin nucleus to a neighbouring 
nucleus through chemical bonds (relayed by the electronic spin), is called scalar coupling and 
results in splitting of the peaks (see Figure A.4B). The resulting number of peaks observed is 
called the spin multiplicity and is representative of the number of non-equivalent nuclei in the 
neighbouring environment. The shift between the resulting peaks corresponds to the coupling 
constant (J), the frequency of which is independent of the field applied, and is representative 
of the number or types of bonds separating the two nuclei. In 
1
H NMR spectroscopy, coupling 
is usually observed if nuclei are separated by two (
2
J) to four (
4
J) chemical bonds. However, 
there are cases where the chemical shifts and coupling constants may not be extracted from 
the multiplet centers and line splitting, respectively (second-order effects). This occurs if the 
coupling between two nuclei is strong compared to the difference in their chemical shift (Δδ/J 
< 10) and can be, in some cases, circumvented by recording the spectra using a higher 
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magnetic field. Since the Fourier transform (FT) converts time-dependent functions into a 
frequency spectra (see Figure A.4C), FT-NMR spectrometers usually irradiate samples with 
the entire energetic range of interest at the same time (pulsed) instead of scanning through 
(continuous mode), thus allowing for considerable time savings. FT-NMR spectrometers are 
usually referred to by the frequency at which protons would resonate if placed in the 
instrument.  
    
      
   
 (A.7) 
  
      
    
 (A.8) 
ΔE is the energy difference between two spin nuclei states, h the Planck constant, γ the 
gyromagnetic ratio of the nuclei, and B0 the magnetic field applied. The frequency, ν, at 
which a given nucleus will change spin state, and νref represents the frequency at which the 
nucleus of interest will resonate (based on equations A.2 and A.7). 
 
Figure A.4 – Scheme illustrating (A) the absorption of radiation by a nucleus I = ½ resulting 
in a spin state transition associated with a change in the spin orientation with respect to the 
magnetic field applied (B0), (B) the scalar coupling between non-equivalent protons (H1, H2) 
and the triplet signal in 
1
H NMR spectroscopy associated with protons H1. (C) The NMR 
spectra measured upon irradiation of a sample at different frequencies either separately or 
together (pulse) and the conversion to a frequency spectrum by fourier transform; adapted 
from reference 14. 
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The direct coupling between nuclei, called cross-relaxation or Nuclear Overhauser 
Effect (NOE), is transmitted through space rather than chemical bonds, and can provide 
important information on distances separating nuclei. However, NOE are averaged to zero by 
molecular rotation (tumbling) and therefore do not result in peak splitting upon classic NMR 
acquisition. NOE spectroscopy (NOESY) uses phasing/dephasing pulse sequences associated 
with defined mixing times, thus allowing for detection of the NOE coupling between 
resonances.[2] 
Two protons from a CH2 group, the local environment of which includes a chiral center, 
are not symmetry related and have different resonances. For examples, the two β hydrogen 
atoms of a cysteine can be differentiated based on their orientation with respect to the α-
proton, and adopt different resonances (β1 and β2) which couple with each other (
2
J) and the 
α-proton (3J), resulting in an ABX pattern (see Figure A.5A). In some cases, the observed 
pattern might be complicated by second-order effects.  
Another phenomenon encountered in NMR and relevant to this work is the dynamic 
effect. Molecules can adopt different conformations or form complexes with other molecules, 
hence different species, which are linked by chemical equilibria, can be present in solution. A 
proton resonance changes depending on its environment, hence different resonances can be 
observed for the different species. However, the different species related to a given molecule 
have, in most cases, chemical exchange processes which occur faster than the measurement, 
and their resonances are averaged based on their percentage contribution, and a single signal 
is observed. However, for processes which occur slower than the NMR timescale (e.g. 
hindered rotation or complexation), the long lived conformations or species will give distinct 
signals (see Figure A.5B).  
If one neglect the magnetic inhomogeneity of the sample, the peak width in NMR is 
inversely proportional to the transverse relaxation time (T2). The spin of nuclei with I > ½ 
(such as 
2
H or 
14
N) which possess more than two spin states, have shorter T2 due to a 
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phenomenon called quadrupolar relaxation. Upon complexation of transition metal ions, the 
relaxation time T2 of the ligand nuclei might be shortened due to quadrupolar relaxation (due 
to the organisation of orbitals relative to the different spin levels), resulting in broadening of 
the spectra. If the metal ion is paramagnetic, the relaxation is very fast and the peaks are 
significantly broadened, often to the extent that they cannot be observed. 
 
Figure A.5 – (A) The 1H NMR signals of the two β hydrogens (Hβ) from L-cysteine in D2O 
at pD 7.4, 298 K and 500 MHz and a scheme illustrating the scalar coupling between the Hβ 
(blue, 
2
J) and Hα (red, 3J); adapted from reference 15. Scheme monitoring the formation of a 
complex, HG, upon addition of a guest molecule, G, to a solution containing a host molecule, 
H, consistent with either (B) a slow, (C) an intermediary, or (D) a fast process on the NMR 
timescale; adapted with permission from reference 16. Copyright 2013 Elsevier. 
 
A.1.5 – Mass Spectrometry 
Mass spectrometry (MS) is a gas-phase spectroscopic technique which involves ionising 
molecules in vacuo, separating them based on their mass over charge ratio (m/z), and their 
detection, thus allowing for deduction of the exact mass. Different techniques exist for 
ionisation and analysis/detection, and only those methods relevant to this work will be 
described. Electron impact (EI) is the oldest ionisation technique and involves bombarding the 
target molecule with a high energy electron beam resulting in loss of electrons and/or 
fragmentation of the molecule (species type M
+
 or M
●+
, where M is the compound of interest, 
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are usually obtained). In contrast, electrospray ionisation (ESI) involves passing a solution 
through a thin charged needle, resulting in the formation of ionised droplets which transit to 
the gas phase. This soft ionisation technique is particularly useful for measuring the mass of 
large macromolecules, and tends to result in several adducts with different charges (the most 
common are of the form [M+xH]
x+
, where M is the compound of interest, H hydrogen atoms, 
and x the number of hydrogen or charge) are usually obtained. Matrix-assisted laser 
desorption/ionisation (MALDI) involves co-crystallising the sample in the presence of a 
matrix material with strong UV absorption properties. The resulting analyte deposited on a 
plate is irradiated with a UV laser beam resulting in simultaneous desorption, vaporisation 
and ionisation of the analyte. Due to the protective role of the matrix, MALDI can be 
classified as a soft ionisation technique, which mainly produces single-charged adducts (of the 
type [M+H]
+
). The MS spectrometers used in this study were all equipped with a time-of-
flight (TOF) detector which allows for the measurement of the m/z of ionised molecules based 
on the time they require to cross a chamber and reach the detector.[2] 
A.2 – Electrophoretic techniques 
A.2.1 – Study of protein-DNA interactions 
Electrophoresis refers to the movement of particles in a solid (gel) across which an 
electric field is applied, and allows for the separation of macromolecules based on their size 
and/or charge, for both preparative and analytical purposes. The electrophoretic mobility shift 
assay (EMSA) is a technique suitable for the study of specific or non-specific interactions 
between proteins and DNA, if the complex formed is stable under the electrophoretic 
conditions. This is based on the different retention of DNA-protein complex from the DNA 
strands alone under the gel conditions (see Figure A.6A), the intensity of the resulting bands 
can be quantified and used to estimate the protein-DNA dissociation constant. If one 
considers the simple case of a protein binding a particular DNA site as a monomer, the 
dissociation constant is calculated following equations A.9-A.11: 
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[ ]  [ ] 
[  ]
 (A.9) 
[ ]   [ ]  [  ] (A.10) 
[ ]   [ ]  [  ] (A.11) 
KD represents the protein-DNA dissociation constant, [P]F and [P]T the DNA unbound 
and total concentration of the protein, [D]F and [D]T the protein unbound and total 
concentration of the DNA respectively, and [PD] the concentration of the protein-DNA 
complex. When [D]F << KD, then [P]F >> [PD] and one can write [P]T = [P]F thus obtaining 
Equation A.12: 
    
[ ]  [ ] 
[  ]
 (A.12) 
Therefore, the protein-DNA dissociation constant can be calculated experimentally if 
the proportion of free DNA over protein-DNA complex, and the total protein concentration, 
are known. When the concentration of free DNA is equal to the concentration of protein-DNA 
complex, the total protein concentration is equal to the protein-DNA dissociation 
constant.[17] 
 
Figure A.6 – Scheme illustrating (A) the use of EMSA to evaluate whether a protein binds to 
a specific DNA duplex, or (B) the use of DNase footprinting to locate the binding site of a 
protein within a DNA strand based on the enzymatic cleavage pattern; adapted from 
references 18 (with permission) and 19. Copyright 2001 Elsevier. 
Appendices – Experimental techniques 
 
269 
 
There exist alternative/complementary electrophoretic methods for the study of protein-
DNA interaction, including DNase footprinting, which is mentioned in this report. It involves 
comparing the electrophoretic profiles of DNA fragments resulting from enzymatic cleavage 
either in the absence of presence of the DNA binding protein, which can protect its binding 
site from cleavage (see Figure A.6B). Importantly, it allows for confirmation of the protein 
DNA binding site, even if the protein-DNA complex is not stable under the electrophoretic 
conditions. 
 
A.2.2 – Cleavage of supercoiled plasmid DNA 
As for proteins, DNA may adopt a large variety of structures. Plasmids are a type of 
non-chromosomal double-stranded DNA, consisting of several thousand bp, which are 
usually circular (the 5’- end of each strand is directly connected to its 3’- end). In their 
supercoiled form, the circular plasmids are twisted over themselves forming highly compact 
structures (see Figure A.7A). A cut to one of the DNA strands will promote the transition to 
the circular relaxed form, whereas a double stranded cut (or cuts to both strands within 12 bp) 
will promote formation of the linear form (see Figure A.7A). Supercoiled plasmid DNA is 
largely used to test the ability of a given molecule to cleave DNA, because DNA cleavage is 
thermodynamically favoured for the large compact form, moreover, the different forms of 
plasmid can easily be separated and quantified by electrophoresis. For a particular plasmid 
(sequence and size), the more compact is its form, the faster it migrates on a gel, hence 
supercoiled plasmid (form I) migrates faster than linear plasmid (form III), itself migrating 
faster than the relaxed form (form II) (see Figure A.7B). However if several double-stranded 
cuts occur, the shorter linear DNA strands might migrate quicker than the supercoiled form 
due to their lower molecular weight. In a typical DNA cleavage assay, the conversion of form 
I directly into form III indicates that DNA is cut through a double-strand, rather than a single-
strand cleavage mechanism.[20] 
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Figure A.7 – Scheme illustrating (A) the shape of the three forms of plasmid DNA and the 
transition between them promoted upon DNA cleavage, and (B) their theoretical retention in 
horizontal electrophoresis; reproduced with permission from reference 21. Copyright 2013 
Elsevier. 
 
A.3 – Miscellaneous methods 
A.3.1 – Solid-phase peptide synthesis (SPPS) 
Solid-phase synthesis is a process which involves assembling stepwise the different 
units of a polymeric molecule on a functionalised solid-support. For each unit, all but one 
chemical functions are protected, ensuring the coupling of a single unit per step. The excess of 
reagent, which remains in solution, can be separated from the support by filtration and 
washing. Then, a function is selectively deprotected to allow for the coupling of a new unit 
(Figure A.8). Following the last coupling, the polymer product is cleaved from the support. 
 
Figure A.8 – Scheme representing the multistep assembly of a polymer on a solid-support, 
where X and Y are residues, P a protecting group, n and n+1 the positions in the sequence. 
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Nowadays, SPPS is commonly used for the preparation of short peptides (~ 2-60 
residues). Proteinogenic amino-acids have two or three chemical functions, the protection of 
which has been achieved with a large variety of groups. The fluorenylmethyloxycarbonyl- 
(Fmoc) group is a chromophore commonly used in SPPS to protect amino-acids N-terminus 
(amine). Fmoc SPPS involves attaching the C-terminus (carboxylic acid) of such residues to 
the solid-support, then the Fmoc group is removed using a base affording the free amine to 
which a new Fmoc-protected residue can be coupled. The side-chains, which usually bear 
miscellaneous acid-sensitive protecting groups, remain protected during the chain elongation 
process. In this work, peptides are prepared by Fmoc SPPS on rink amide 4-
methylbenzhydrylamine (MBHA) resin. The peptide chain is elongated on an automated 
peptide synthesiser using (O-(benzotriazol-1-yl)-NN,N’,N’-tetramethyluronium) 
hexafluorophosphate (HBTU) and diisopropylethylamine (DIEA) as acid and amine 
activators, respectively, in order to increase the rates of coupling. Then, its N-termini is 
capped with an acetyl (Ac) group to avoid further coupling, and the peptide is simultaneously 
cleaved from the support and its side-chains deprotected with an acid (cleavage from Rink 
amide MBHA resin results in C-termini capping with –NH2).[22] 
 
A.3.2 – Reversed-phase high performance liquid chromatography 
Liquid chromatography involves eluting a mixture through an adsorbent material (static 
phase) for which the different components of the mixture display different affinities, using a 
liquid eluent (mobile phase) as a vector in order to separate the components of the mixture. 
Several types of static phases can be suitable depending on the properties of the components 
to be separated. In high-performance liquid chromatography (HPLC), migration through a 
static phase with small particle size and tightly packed in columns, is made possible by 
applying a high pressure to the system thus allowing for a better separation (or higher 
resolution) of mixtures. The content of the eluent leaving the column is usually monitored by 
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a non-destructive and in-flow spectroscopic technique (such as electronic absorption or 
emission), allowing for the analysis of the efficiency of the separation, and for recovery of the 
components. The process can be applied either on an analytical or preparative scale depending 
on the size of the column and the eluent flow, however resolution is generally greater on 
thinner columns. Reversed-phase HPLC (RP-HPLC) apparatus involves a nonpolar static 
phase and a moderately polar eluent and is well suited for the separation of peptides. Using 
this technique, less polar and low molecular weight components are retained less on the static 
phase and migrate faster than their nonpolar high molecular weight counterparts. The eluent 
often consists of a solvent mixture (usually two to four different constituents), and elution 
processes involving an eluent with constant composition are called isocratic, whereas the 
eluent composition is gradually varied in gradient processes.[23] 
 
A.3.3 – C H N analysis 
C H N analysis is a destructive analytical technique which involves combusting a 
known amount of a pure sample (ideally a single type of molecule) using an enriched oxygen 
atmosphere, collecting the different combustion products (typically carbon dioxide, water and 
nitric oxide), and quantifying them in order to determine the precise elemental carbon, 
hydrogen and nitrogen composition of the molecule.[24] 
 
A.4 - References 
                                                          
[1] Kobayashi N., Muranaka A., Circular dichroism and magnetic circular dichroism 
spectroscopy for organic chemists, Chapter 1: Theory of optical spectroscopy, Royal Society 
of Chemistry, Cambridge, 2011, ISBN 978-1-84755-869-5. 
[2] Harwood L. M., Claridge T. D. W., Introduction to organic spectroscopy, Oxford 
University Press, New York, 1997, ISBN 978-0-19-855755-5. 
Appendices – Experimental techniques 
 
273 
 
                                                                                                                                                                                     
[3]http://chemwiki.ucdavis.edu/Organic_Chemistry/Organic_Chemistry_With_a_Biological_
Emphasis/Chapter__4%3A_Structure_Determination_I/Section_4.3%3A_Ultraviolet_and_vis
ible_spectroscopy, accessed on 27/08/2013.  
[4] Woody R. W., Koslowski A., Biophys. Chem., 2002, 101-102, 535-551.  
[5] Pace C. N., Schmid F. X., Protein Structure, Chapter 10: How to determine the molar 
absorbance coefficient of a protein, Oxford University Press, New York, 1997, ISBN 0-19-
963618-4.  
[6] Ellman G. L., Arch. Biochem. Biophys., 1959, 82, 70-77. 
[7] Collier H. B., Anal. Biochem., 1973, 56, 310-311. 
[8] Wolf C., Bentley K. W., Chem. Soc. Rev., 2013, 42, 5408-5424. 
[9] Masiero S., Trotta R., Pieraccini S., DeTito S., Perone R., Randazzo A., Spada G. P., Org. 
Biomol. Chem., 2010, 8, 2683-2692. 
[10] Miles A. J., Wallace B. A., Chem. Soc. Rev., 2006, 35, 39-51.  
[11] Wallace B. A., Janes R. W., Modern techniques for circular dichroism and synchrotron 
radiation circular dichroism spectroscopy,  IOS press, Amsterdam, 2009, ISBN 1-60750-000-
1.  
[12] Wayne C. E., Wayne R. P., Photochemistry, Oxford University Press, New York, 1996, 
ISBN 0-19-855886-4.  
[13] Liu T., Sullivan J. P., Pressure and Temperature Sensitive Paints, Springer, Berlin, 2005, 
ISBN 978-3-540-22241-5. 
Lorenz M., Horbach T., Schulz A., Bauer H., J. Turbomach., 2013, 135, 031003.  
[14] http://www2.chemistry.msu.edu/faculty/reusch/virttxtjml/spectrpy/nmr/nmr2.htm, 
accessed on 27/08/2013.  
[15]http://www.bmrb.wisc.edu/metabolomics/mol_summary/spectrum_display.php?title=1D
%201H&mol_dir=L_cysteine&exp=1H&mol=L-cysteine&bmrbid=bmse000034&pH=7.4, 
accessed on 27/08/2013.  
Appendices – Experimental techniques 
 
274 
 
                                                                                                                                                                                     
[16] Kleckner I. R., Foster M. P., BBA Proteins Proteom., 2011, 1814, 942-968.  
[17] Fairall L., Buttinelli M., Panetta G., DNA-Protein Interactions, Chapter 5: Bandshift, gel 
retardation or electrophoretic mobility shift assays, Oxford University Press, New York, 
2000, ISBN 978-0-19-963691-4. 
[18] Rodgers J. S., Hocker J. R., Hanas R. J., Nwosu E. C., Hanas J. S., Biochem. Pharmacol., 
2001, 61, 1543-1550.  
[19] https://www.nationaldiagnostics.com/electrophoresis/article/dnase-i-footprinting, 
accessed on 28/08/2013. 
[20] Mancin F., Tecilla P., Metal-Complex DNA interactions, Chapter 13: Artificial 
restriction agents for DNA cleavage, John Wiley & Sons, Chichester, 2009, ISBN 978-1-
4051-7629-3.   
[21] Desbouis D., Troitsky I. P., Belousoff M. J., Spiccia L., Graham B., Coord. Chem. Rev., 
2012, 256, 897-937. 
[22] Chan, W. C., White, P. D., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, 
Oxford University Press, New York, 2000, ISBN 978-0199637249. 
[23] Ahuja S., Rasmussen H., HPLC method development for pharmaceuticals, Elsevier 
Academic Press, Amsterdam, 2007, ISBN 978-0-12-370540-2.   
[24] Dean J. A., Analytical chemistry handbook, section 17, McGraw-Hill, New York, 1995, 
ISBN 0-07-016197-6.  
